```
=> d his

     (FILE 'HOME' ENTERED AT 16:52:23 ON 14 JAN 2004)
               SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 16:52:38 ON 14 JAN 2004
L1             1 S US20020173051/PN
               SEL RN

     FILE 'REGISTRY' ENTERED AT 16:53:11 ON 14 JAN 2004
L2             7 S E1-E7
L3             3 S L2 AND C6/ES
L4             2 S L3 AND N/ELS

     FILE 'HCAPLUS' ENTERED AT 16:54:23 ON 14 JAN 2004
L5           937 S L4
L6           390 S L4 (L) (RACT OR RGT OR RCT)/RL
               E SOLID PHASE SYNTHESIS/CT
               E E3+ALL
L7             8 S E2+NT AND L5
               E COMBINATORIAL CHEMISTRY/CT
               E E3+ALL
L8          2498 S E1
               E E3+ALL
L9          2802 S E1
               E COMBINATOR/CT
               E E8+ALL
L10         7215 S E1+NT
               E E4+ALL
L11         4712 S E1+NT
               E HIGH THROUGHPUT/CT
               E E5+ALL
L12         2802 S E1
L13           12 S L5 AND L8-L12
L14            9 S L5 AND SOLID PHASE
L15           13 S L5 AND SOLID (L) SYNTHESIS
L16           19 S L7,L13-L15
               E RASMUSSEN J/AU
L17           88 S E3,E14
L18          115 S E78
               E KREPSKI L/AU
L19          101 S E4-E6
L20            1 S L17-L19 AND L5
L21           19 S L16,L20
L22            6 S L5 AND SOLID(L)SUPPORT?
L23           21 S L21,L22

     FILE 'HCAPLUS' ENTERED AT 16:59:36 ON 14 JAN 2004
               SET COST ON
```

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 16:59:36 ON 14 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 14 Jan 2004  VOL 140 ISS 3
FILE LAST UPDATED: 13 Jan 2004  (20040113/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> d all hitstr tot

L23  ANSWER 1 OF 21  HCAPLUS  COPYRIGHT 2004 ACS on STN
AN   2003:570979  HCAPLUS
DN   139:133464
ED   Entered STN:  25 Jul 2003
TI   Preparation of pyrrolidonecarboxamides as neuropeptide Y antagonists.
IN   Isler, Markus; Giller, Thomas; Schwalm, Guenter; Steger, Matthias;
     Hilpert, Kurt; Valdenaire, Oliver; Breu, Volker
PA   Axovan Ltd., Switz.
SO   PCT Int. Appl., 89 pp.
     CODEN: PIXXD2
DT   Patent
LA   German
IC   ICM  C07D401-14
     ICS  C07D401-12; C07D409-14; C07D405-14; C07D207-26; C07D403-12;
          C07C211-54; C07C211-56; A61K031-4015; A61K031-403; A61K031-4025;
          A61P003-04; A61P003-10
CC   27-10 (Heterocyclic Compounds (One Hetero Atom))
     Section cross-reference(s): 1
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2003059905      A1   20030724       WO 2002-CH725    20021227
         W:  AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
             FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
             MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SK,
             SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
             ZW, AM, AZ, BY
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
PRAI CH 2001-2381       A    20011231
     WO 2002-CH429      A    20020805
OS   MARPAT 139:133464
GI
```



I

Q1 =



AB Title compds. [I; R1 = (substituted) Ph, PhCH2, PhCH2CH2, α-hydroxyphenylethyl, naphthyl, naphthylmethyl, thienylalkyl, furylalkyl, pyridylalkyl, 1-alkylpyrrolidin-2-ylalkyl, pyrrolidinoalkyl, morpholinoalkyl, (benzo-fused) cycloalkyl; R2 = Q1, R5C6H4; X = CH2, CO, O, NR3; R3 = H, alkyl; R4 = H, alkoxy; R5 = Ph, heteroalkyl, aryloxy, alkoxy, alkanoyl, NR6R7; R6 = H, alkyl, aralkyl, cycloalkylalkyl, alkoxycarbonylalkyl; R7 = aryl, heteroaryl, alkyl, hydroxyalkyl, acyl], were prepared Thus, 5-oxo-1-phenylpyrrolidine-3-carboxylic acid in CH2Cl2/DMF was shaken 5 min. with **solid-supported** DCC; N,N-Dimethyl-p-phenylendiamine in CH2Cl2/DMF was added and the mixture was shaken overnight at room temperature The **solid** was filtered off, the filtrate was evaporated, the residue in CH2Cl2 was mixed with Me isocyanate-polystyrene and shaken for 12 h followed by filtration and shaking of the filtrate with tris(2-aminoethyl)amine-polystyrene for 12 h at room temperature followed by filtration and evaporation to give 5-oxo-1-phenylpyrrolidine-3-carboxylic acid (4-dimethylaminophenyl)amide. Tested I showed IC50 = 0.003-0.049 μM in a radioligand competition binding screen with mouse NPY-Y5 receptors.

ST arthritis diabetes eating disorder obesity treatment pyrrolidonecarboxamide prepn; neuropeptide Y receptor antagonist pyrrolidonecarboxamide prepn

IT Neuropeptide Y receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Y5, antagonists; preparation of pyrrolidonecarboxamides as neuropeptide Y antagonists)

IT Appetite
(disorder, treatment; preparation of pyrrolidonecarboxamides as neuropeptide Y antagonists)

IT Antiarthritics
Antidiabetic agents
Antiobesity agents
Human
(preparation of pyrrolidonecarboxamides as neuropeptide Y antagonists)

IT Arthritis
Diabetes mellitus
Obesity
(treatment; preparation of pyrrolidonecarboxamides as neuropeptide Y antagonists)

IT 302560-04-9P 330591-86-1P 402771-54-4P 566152-85-0P 566152-86-1P
566152-87-2P 566152-88-3P 566152-89-4P 566152-90-7P 566152-91-8P
566152-92-9P 566152-93-0P 566152-94-1P 566152-95-2P 566152-96-3P
566152-97-4P 566152-98-5P 566152-99-6P 566153-00-2P 566153-01-3P
566153-02-4P 566153-03-5P 566153-04-6P 566153-05-7P 566153-06-8P
566153-07-9P 566153-08-0P 566153-09-1P 566153-10-4P 566153-11-5P
566153-12-6P 566153-13-7P 566153-14-8P 566153-15-9P 566153-17-1P
566153-18-2P 566153-19-3P 566153-20-6P 566153-21-7P 566153-22-8P
566153-23-9P 566153-24-0P 566153-25-1P 566153-26-2P 566153-27-3P
566153-28-4P 566153-29-5P 566153-30-8P 566153-31-9P 566153-32-0P
566153-33-1P 566153-34-2P 566153-35-3P 566153-36-4P 566153-37-5P
566153-39-7P 566153-41-1P 566153-43-3P 566153-45-5P 566153-46-6P
566153-47-7P 566153-48-8P 566153-49-9P 566153-50-2P 566153-51-3P

566153-52-4P 566153-53-5P 566153-54-6P 566153-55-7P 566153-56-8P
566153-57-9P 566153-58-0P 566153-59-1P 566153-60-4P 566153-61-5P
566153-62-6P 566153-63-7P 566153-64-8P 566153-65-9P 566153-66-0P
566153-67-1P 566153-68-2P 566153-69-3P 566153-70-6P 566153-71-7P
566153-72-8P 566153-73-9P 566153-74-0P 566153-75-1P 566153-76-2P
566153-77-3P 566153-78-4P 566153-79-5P 566153-80-8P 566153-81-9P
566153-82-0P 566153-83-1P 566153-84-2P 566153-85-3P 566153-86-4P
566153-87-5P 566153-88-6P 566153-89-7P 566153-90-0P 566153-91-1P
566153-92-2P 566153-93-3P 566153-94-4P 566153-95-5P 566153-96-6P
566153-97-7P 566153-98-8P 566153-99-9P 566154-00-5P 566154-01-6P
566154-02-7P 566154-03-8P 566154-04-9P 566154-05-0P 566154-06-1P
566154-07-2P 566154-08-3P 566154-09-4P 566154-11-8P 566154-12-9P
566154-13-0P 566154-14-1P 566154-15-2P 566154-16-3P 566154-17-4P
566154-18-5P 566154-19-6P 566154-20-9P 566154-21-0P 566154-22-1P
566154-23-2P 566154-24-3P 566154-25-4P 566154-26-5P 566154-27-6P
566154-28-7P 566154-29-8P 566154-30-1P 566154-31-2P 566154-32-3P
566154-33-4P 566154-34-5P 566154-35-6P 566154-36-7P 566154-37-8P
566154-38-9P 566154-39-0P 566154-40-3P 566154-41-4P 566154-42-5P
566154-43-6P 566154-44-7P 566154-45-8P 566154-46-9P 566154-47-0P
566154-48-1P 566154-49-2P 566154-50-5P 566154-51-6P 566154-52-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolidonecarboxamides as neuropeptide Y antagonists)

IT 75-36-5, Acetyl chloride 89-97-4, 2-Chlorobenzylamine 92-65-9 92-67-1, 4-Aminobiphenyl 93-05-0, 4-Amino-N,N-diethylaniline 98-88-4, Benzoyl chloride 99-88-7, 4-Isopropylaniline 99-92-3, 4'-Aminoacetophenone 99-98-9, N,N-Dimethyl-p-phenylenediamine 100-01-6, p-Nitroaniline, reactions 100-07-2, 4-Methoxybenzoyl chloride 101-54-2, N-Phenyl-1,4-phenylenediamine 103-80-0, Phenylacetyl chloride 104-94-9, p-Methoxyaniline 105-36-2, Bromoacetic acid ethyl ester 108-12-3, Isovaleryl chloride 108-44-1, m-Toluidine, reactions 118-31-0, 1-Naphthylmethylamine 120-20-7, 2-(3,4-Dimethoxyphenyl)ethylamine 132-32-1 139-59-3, 4-Phenoxyaniline 153-78-6, 2-Aminofluorene 372-19-0, 3-Fluoroaniline 527-69-5, 2-Furoyl chloride 836-30-6, 4-Nitrodiphenylamine 1711-07-5, 3-Fluorobenzoyl chloride 2243-47-2, 3-Aminobiphenyl 3096-57-9, 2-Amino-9-fluorenone 3282-30-2, Pivaloyl chloride 4023-34-1, Cyclopropylcarbonyl chloride 5452-35-7, Cycloheptylamine 5834-17-3, 3-Amino-2-methoxydibenzofuran 6344-63-4, 9H-Fluoren-1-amine 7154-73-6, 1-(2-Aminoethyl)pyrrolidine **7568-93-6**, 2-Hydroxy-2-phenylethylamine 13744-88-2 20781-20-8, 2,4-Dimethoxybenzylamine 21615-34-9, 2-Methoxybenzoyl chloride 25054-53-9, Piperonyloyl chloride 30380-70-2 39629-86-2 51387-90-7, 2-(2-Aminoethyl)-1-methylpyrrolidine 51451-83-3 60559-31-1 63674-47-5 63674-68-0 63675-14-9 81261-93-0 91215-79-1 96449-92-2 101112-48-5 133747-57-6 175136-92-2 175136-93-3 220844-79-1 261363-53-5 304859-18-5 387358-43-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolidonecarboxamides as neuropeptide Y antagonists)

IT 3085-82-3P 5543-88-4P 5543-89-5P 56617-45-9P 63674-51-1P 175205-45-5P 304858-45-5P 331981-73-8P 346644-26-6P 407633-90-3P 566154-53-8P 566154-54-9P 566154-55-0P 566154-56-1P 566154-57-2P 566154-58-3P 566154-59-4P 566154-60-7P 566154-61-8P 566154-62-9P 566154-63-0P 566154-64-1P 566154-65-2P 566154-66-3P 566154-67-4P 566154-68-5P 566154-69-6P 566154-70-9P 566154-71-0P 566154-72-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolidonecarboxamides as neuropeptide Y antagonists)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Bayer Ag; GB 856452 A 1960 HCAPLUS
(2) Craig, D; WO 0107409 A 2001 HCAPLUS
(3) Merck & Co Inc; GB 2351733 A 2001 HCAPLUS

(4) Nichols, J; US 5281612 A 1994 HCAPLUS
(5) Otsuka Pharma Co Ltd; EP 0393607 A 1990 HCAPLUS
(6) Robert, B; WO 0185714 A 2001 HCAPLUS
IT **7568-93-6**, 2-Hydroxy-2-phenylethylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolidonecarboxamides as neuropeptide Y antagonists)
RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:60036 HCAPLUS
DN 138:237585
ED Entered STN: 27 Jan 2003
TI High-Throughput Manual Parallel Synthesis Using SynPhase Crowns and Lanterns
AU Gerritz, Samuel W.; Norman, Mark H.; Barger, Lee A.; Berman, Judd; Bigham, Eric C.; Bishop, Michael J.; Drewry, David H.; Garrison, Deanna T.; Heyer, Dennis; Hodson, Stephen J.; Kakel, Jennifer A.; Linn, James A.; Marron, Brian E.; Nanthakumar, Suganthini S.; Navas, Frank J., III
CS Department of Medicinal Chemistry, GlaxoSmithKline Inc., Research Triangle Park, NC, 27709, USA
SO Journal of Combinatorial Chemistry (2003), 5(2), 110-117
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
CC 21-2 (General Organic Chemistry)
Section cross-reference(s): 1
OS CASREACT 138:237585
AB The high-throughput manual **solid-phase** parallel **synthesis** of libraries comprising thousands of discrete samples using pellicular **supports** (i.e. SynPhase crowns and lanterns) and a suite of novel tools and techniques is described. Key aspects of this approach include the combination of a split-split-split **synthesis** strategy with spatial encoding to differentiate thousands of crowns, the rapid washing and filtration of up to 48 reaction vessels in parallel, the application of an inexpensive and environmentally friendly technique to remove trifluoroacetic acid from sixteen 96-well plates in parallel, and a high-throughput method for removing cleaved crowns from reusable pin racks. Tens of thousands of discrete samples have been produced using this conceptually and operationally straightforward strategy. One of these, 1-(2-hydroxy-2-phenylethyl)-2-benzoylaminobenzimidazole-5-carboxamide, had IC50 for NPY-5 receptor antagonism of 52 nM.
ST **solid phase** parallel **synthesis** SynPhase crown lantern; benzoylaminobenzimidazolecarboxamide hydroxyphenylethyl **solid phase synthesis** NPY5 receptor antagonist
IT **Combinatorial chemistry**
Combinatorial library
Solid phase synthesis
(high-throughput manual parallel **synthesis** using SynPhase crowns and lanterns)
IT 501936-68-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation by high-throughput manual parallel synthesis using SynPhase crowns and lanterns and NPY-5 antagonist activity of)

IT 501936-69-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation by high-throughput manual parallel synthesis using SynPhase crowns and lanterns and NPY-5 antagonist activity of)

IT 453-71-4, 4-Fluoro-3-nitrobenzoic acid 532-55-8, Benzoyl isothiocyanate **7568-93-6**, 2-Amino-1-phenylethanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of NPY-5 antagonist by high-throughput manual parallel synthesis using SynPhase crowns and lanterns)

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; 1997 Drug Discovery Technology Conference in Boston, 7th Japanese Combinatorial Chemistry Forum in Yokohama
(2) Bel-ArtScienceware; Commercial source for Vaccu-Pette:Catalog no F378760000, www.bel-art.com
(3) Bunin, B; The Combinatorial Index 1998
(4) Cargill, J; Curr Opin Chem Biol 1997, V1, P67 HCAPLUS
(5) Chemglass; Commercial source for six-pack bottles and mesh-equipped caps:Quote no J-12955
(6) Chiron And Novartis; RF-crown sorter
(7) Collins, J; J Med Chem 2002, V45, P1963 HCAPLUS
(8) Dorner, B; Fmoc Solid-Phase Peptide Synthesis 2000, P303 HCAPLUS
(9) Drewry, D; Tetrahedron Lett 1997, V38, P3377 HCAPLUS
(10) Furka, A; Int J Pept Protein Res 1991, V37, P487 HCAPLUS
(11) Garrison, D; Manuscript in preparation
(12) Geysen, H; Proc Natl Acad Sci U S A 1984, V81, P3998 HCAPLUS
(13) Giger, R; WO 9818550 1998 HCAPLUS
(14) Hall, S; Combinatorial Chemistry Molecular Diversity Drug Discovery 1998, P291 HCAPLUS
(15) Heyer, D; 222nd ACS National Meeting, Abstract MEDI-030 2001
(16) Hodson, S; 16th International Congress of Heterocyclic Chemistry, Abstract POI 81 1997
(17) Houghten, R; Nature 1991, V354, P84 HCAPLUS
(18) Houghten, R; Proc Natl Acad Sci U S A 1985, V82, P5131 HCAPLUS
(19) Irori; AutoSort-10K, www.irori.com
(20) Lam, K; Nature 1991, V354, P82 HCAPLUS
(21) Linn, J; Abstracts of Papers, 222nd ACS National Meeting, Abstract MEDI-027 2001
(22) Linn, J; Tetrahedron Lett 1999, V40, P2227 HCAPLUS
(23) Maeji, N; Pept Res 1995, V8, P33 HCAPLUS
(24) Maeji, N; React Polym 1994, V22, P203 HCAPLUS
(25) Marron, B; Second International Conference on Molecular Diversity 1998
(26) Matthews, J; Regul Peptides 1997, V72, P113 HCAPLUS
(27) Merrifield, R; J Am Chem Soc 1963, V85, P2149 HCAPLUS
(28) Meyers, H; Methods Mol Cell Biol 1996, V6, P1
(29) Mimotope; www.mimotopes.com
(30) Moran, E; J Am Chem Soc 1995, V117, P10787 HCAPLUS
(31) Nicoloau, K; Angew Chem, Int Ed 1995, V34, P2289
(32) Smith, J; J Comb Chem 1999, V1, P368 HCAPLUS
(33) Spectrum Laboratories; Commercial source for Teflon mesh:Catalog no 146443, www.spectrumlabs.com
(34) Tan, D; Curr Opin Drug Discovery Dev 2000, V3, P439 HCAPLUS
(35) Terrett, N; Combinatorial Chemistry 1998
(36) Thompson, L; Chem Rev 1996, V96, P555 HCAPLUS
(37) Wheaton Scientific Products; Commercial source for vial rack:Catalog no 868806, www.wheatonsci.com
(38) Xiao, X; Biotech Bioeng (Comb Chem) 2000, V71, P44 HCAPLUS

IT **7568-93-6**, 2-Amino-1-phenylethanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of NPY-5 antagonist by high-throughput manual parallel

synthesis using SynPhase crowns and lanterns)
RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:42245 HCAPLUS
DN 138:106689
ED Entered STN: 17 Jan 2003
TI Preparation of thiazolylamino benzamide derivatives as modulators of cell proliferation and inhibitors of protein kinases
IN Chu, Shao Song; Alegria, Larry Andrew; Bleckman, Ted Michael; Chong, Wesley K. M.; Duvadie, Rohit K.; Li, Lin; Reich, Siegfried H.; Romines, William H.; Wallace, Michael B.; Yang, Yi
PA Agouron Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 7
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003004467	A2	20030116	WO 2002-US21280	20020705
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003225147	A1	20031204	US 2002-190219	20020705
PRAI US 2001-303679P	P	20010706		
US 2001-305274P	P	20010713		

OS MARPAT 138:106689
GI



AB Aminothiazole compds. with mono-/di-substituted benzamides (shown as I; variables described below; e.g. 4-[[4-amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-morpholin-4-ylethyl)benzamide), and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs,

pharmaceutically active metabolites, and pharmaceutically acceptable salts of said metabolites are described. These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders. Inhibitory activities towards three cyclin complexes of protein kinases, phosphorylated FGF receptor and/or LCK tyrosine kinase and/or cytotoxicity towards the HCT-116 cancer cell line are reported for hundreds of I, many of which were prepared combinatorially. For I: R1 and R2 are each independently H, or an alkyl, alkenyl, alkynyl, heteroalkyl, alkoxy, aminoalkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group unsubstituted or substituted with ≥1 substituents listed in the claims, or R1 or R2, together with the N-C(O) and two adjacent C atoms of the Ph ring of I, forms a 5- or 6-membered ring structure fused to the Ph ring of I and unsubstituted or substituted with ≥1 substituents listed in the claims, or R1 and R2, taken together with the N atom to which they are bonded, form a monocyclic or fused or nonfused polycyclic structure which may contain 1-3 addnl. heteroatoms, the structure being unsubstituted or substituted with ≥1 substituents listed in the claims. R3 is an aryl, heteroaryl, alkyl, or cycloalkyl group, unsubstituted or substituted with ≥1 substituents listed in the claims. Y is H, alkyl, heteroalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, cycloalkyl, heterocycloalkyl, -NO2, -NH2, -N-OH, N-ORc, -CN, -(CH2)z-CN (z is 0-4), halogen, -OH, -O-Ra-O-, -ORb, -CO-R, -O-CO-Rc, -CO-ORc, -O-CO-OR, -O-OR, =O, =S, -NRdRe, -CO-NRdRe, -O-CO-NRdRe, -NRc-CO-Re, -NR-CO-OR, -CO-NRc-CO-Rd, -O-SO2-Re, -O-SO-R, -O-S-Re, -S-CO-Rc, -SO-CO-ORc, -SO-CO-OR, -O-SO3, -NRc-SRd, -NRc-SO-Rd, NRc-SO2-Rd, -CO-SRc, -CO-SO-Re, -CO-OSO2-Rc, -CS-Rc, -CSO-R, -CSO2-R,, -NRc-CS-Rd, -O-CS-Re, -O-CSO-Rc, -O-SO2-Re, -OS2-NRdRe, -SO-NRdRe, -S-NRdRe, -NRd-CSO2-Rd, - NRc-CSO-Rd, -NRc-CS-Rd, -SH, -S-Rb, and -PO2-ORc (Ra, etc. defined in claims). Although the methods of preparation are not claimed, .apprx.80 example prepns. of I are included and directions are given for combinatorial preparation of 396 I.

ST thiazolylamino benzamide prepn cell proliferation modulator protein kinase inhibitor

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(VEGF; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT Amides, preparation
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(aryl, thiazolylamino-substituted; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT Cyclins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(complexes with cyclin-dependent kinases, inhibitors; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT Nervous system, disease
(degeneration; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT Nervous system agents
(degenerative; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT Drug delivery systems
(for thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT Cell proliferation
(modulators; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT Cytotoxicity

(of thiazolylamino benzamide derivs.)

IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Antiviral agents
Autoimmune disease
Combinatorial library
Human
Immunomodulators
Neoplasm
(preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT Drug delivery systems
(prodrugs; for thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT Infection
(viral; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT 141349-86-2, CDK2 kinase 143375-65-9, CDK1 kinase 147014-97-9, CDK4 kinase 303014-92-8, CDK6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(and cyclin complexes, inhibitors; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT 486413-82-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-morpholin-4-ylethyl)benzamide 486413-83-6P 486413-84-7P 486413-86-9P 486413-87-0P 486413-88-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-isopropoxyethyl)benzamide 486413-91-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-phenylbenzamide 486413-93-8P 486413-95-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-benzylpiperidin-4-yl)benzamide 486414-07-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-[4-(2-hydroxyethyl)phenyl]benzamide 486416-20-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(acetylamino)phenyl)benzamide 486417-01-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(dimethylamino)ethyl)benzamide
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT 486415-57-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-propyl-N-(cyclopropylmethyl)benzamide 486415-58-1P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-methylpiperazino)methanone 486415-59-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-methyl-N-benzylbenzamide 486415-60-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-hydroxyethyl)-N-butylbenzamide 486415-61-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-methyl-N-(((dimethylamino)carbonyl)methyl)benzamide 486415-62-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(aminocarbonyl)phenyl)benzamide 486415-63-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-chloro-4-methylphenyl)benzamide 486415-64-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(cyanomethyl)-N-butylbenzamide 486415-65-0P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](morpholino)methanone 486415-66-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-methyl-N-(2-phenylethyl)benzamide 486415-67-2P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(3-hydroxypropyl)piperazino)methanone 486415-68-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-methyl-N-(2-methoxyethyl)benzamide 486415-69-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-hydroxy-4-methoxyphenyl)benzamide 486415-70-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-chloro-6-methylphenyl)benzamide

486415-71-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-ethoxyphenyl)benzamide 486415-72-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-methyl-N-(2-hydroxyethyl)benzamide 486415-73-0P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](2,6-dimethylmorpholino)methanone 486415-74-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2,2-dimethoxyethyl)-N-methylbenzamide 486415-75-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-methyl-N-((pyridin-3-yl)methyl)benzamide 486415-76-3P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(2-propenyl)piperazino)methanone 486415-77-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-methoxy-5-(trifluoromethyl)phenyl)benzamide 486415-78-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-methoxyphenyl)benzamide 486415-79-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(ethoxycarbonyl)phenyl)benzamide 486415-80-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-ethyl-N-(2-hydroxyethyl)benzamide 486415-81-0P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](thiomorpholino)methanone 486415-82-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-methyl-N-(2-propenyl)benzamide 486415-83-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-ethyl-N-((pyridin-4-yl)methyl)benzamide 486415-84-3P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl]((R)-3-(dimethylamino)pyrrolidino)methanone 486415-85-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(1,2,3-thiadiazol-4-yl)phenyl)benzamide 486415-86-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(methylthio)phenyl)benzamide 486415-87-6P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-((furan-2-yl)carbonyl)piperazino)methanone 486415-88-7P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](thiazolidin-3-yl)methanone 486415-89-8P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4,4-(ethylenedioxy)piperidino)methanone 486415-90-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(diethylamino)ethyl)-N-ethylbenzamide 486415-91-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N,N-bis(2-methoxyethyl)benzamide 486415-92-3P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl]((S)-3-(dimethylamino)pyrrolidino)methanone 486415-93-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-chloro-3-methylphenyl)benzamide 486415-94-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(methoxycarbonyl)phenyl)benzamide 486415-95-6P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](2,5-dihydro-1H-pyrrol-1-yl)methanone 486415-96-7P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](3-(aminocarbonyl)piperidino)methanone 486415-97-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((dioxolan-2-yl)methyl)-N-methylbenzamide 486415-98-9P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(aminocarbonyl)piperidino)methanone 486415-99-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-chloro-4-methylphenyl)benzamide 486416-00-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2,4-dimethoxyphenyl)benzamide 486416-01-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(ethoxycarbonyl)phenyl)benzamide 486416-02-8P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](pyrrolidino)methanone 486416-03-9P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](3-(hydroxymethyl)piperidino)methanone 486416-04-0P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](3-hydroxypiperidino)methanone 486416-05-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((methoxycarbonyl)methyl)-N-methylbenzamide 486416-06-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-isopropylphenyl)benzamide 486416-07-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(benzodioxol-5-yl)benzamide

486416-08-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(hydroxymethyl)phenyl)benzamide 486416-09-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-methoxyphenyl)benzamide 486416-10-8P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](3-hydroxypyrrolidino)methanone 486416-11-9P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-hydroxypiperidino)methanone 486416-12-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-methyl-N-(2-(pyridin-4-yl)ethyl)benzamide 486416-13-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-chloro-4-methoxyphenyl)benzamide 486416-14-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-cyanophenyl)benzamide 486416-15-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(methoxycarbonyl)phenyl)benzamide 486416-16-4P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-((benzodioxol-5-yl)methyl)piperazino)methanone 486416-17-5P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(2-hydroxyethyl)piperidino)methanone 486416-18-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(dimethylamino)propyl)-N-methylbenzamide 486416-19-7P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-acetylpiperazino)methanone 486416-21-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(quinolin-5-yl)benzamide 486416-22-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3,5-difluorophenyl)benzamide 486416-23-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-isopropylphenyl)benzamide 486416-24-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-benzyl-N-isopropylbenzamide 486416-25-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-methyl-N-(2-(pyridin-2-yl)ethyl)benzamide 486416-26-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-methyl-N-(2-methylpropyl)benzamide 486416-27-7P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](3-(acetylamino)pyrrolidino)methanone 486416-28-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-hydroxyphenyl)benzamide 486416-29-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(quinolin-6-yl)benzamide 486416-30-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-chlorophenyl)benzamide 486416-31-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-(methoxycarbonyl)-2-methylpropyl)-N-methylbenzamide 486416-32-4P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-formylpiperazino)methanone 486416-33-5P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](1,2,3,4-tetrahydroisoquinolin-2-yl)methanone 486416-34-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-cyclopentyl-N-methylbenzamide 486416-35-7P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-ethylpiperazino)methanone 486416-36-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(aminosulfonyl)phenyl)benzamide 486416-37-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(isoquinolin-5-yl)benzamide 486416-38-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3,4-dichlorophenyl)benzamide 486416-39-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(aminocarbonyl)phenyl)benzamide 486416-40-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3,5-dimethoxyphenyl)benzamide 486416-41-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(2-methylpyrimidin-4-yl)phenyl)benzamide 486416-42-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(2-oxopyrrolidino)propyl)benzamide 486416-43-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1,2-dimethylpropyl)benzamide 486416-44-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-ethylpentyl)benzamide 486416-45-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-phenylethyl)benzamide 486416-46-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(dimethylamino)propyl)benzamide 486416-47-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-

(dimethylamino)butyl)benzamide 486416-48-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(1-hydroxyethyl)phenyl)benzamide 486416-49-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(indan-1-yl)benzamide 486416-50-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-isopropylbenzamide 486416-51-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2,2-dimethoxyethyl)benzamide 486416-52-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-methoxypropyl)benzamide 486416-53-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(6-(dimethylamino)hexyl)benzamide 486416-54-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(benzothiazol-6-yl)benzamide 486416-55-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2,3-dihydro-1,1,3-trioxobenzoisothiazol-6-yl)benzamide 486416-56-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-(hydroxymethyl)-2-methylpropyl)benzamide 486416-57-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-methoxy-1-methylethyl)benzamide 486416-58-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-hydroxy-2-phenylethyl)benzamide 486416-59-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(4-aminophenyl)ethyl)benzamide 486416-60-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(methoxycarbonyl)phenyl)benzamide 486416-61-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-isopropyl-3-methylphenyl)benzamide 486416-62-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-(hydroxymethyl)-3-(methylthio)propyl)benzamide 486416-63-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-hydroxy-1-methylethyl)benzamide 486416-64-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-hydroxypropyl)benzamide 486416-65-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(4-methylphenyl)ethyl)benzamide 486416-66-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3,3,5-trimethylcyclohexyl)benzamide 486416-67-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-phenoxyethyl)benzamide 486416-68-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(2-(ethoxycarbonyl)ethenyl)phenyl)benzamide 486416-69-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1,1-dioxobenzothiophen-6-yl)benzamide 486416-70-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((tetrahydrofuran-2-yl)methyl)benzamide 486416-71-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2-(ethoxycarbonyl)-1-methylethyl)amino)benzamide 486416-72-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-phenylpropyl)benzamide 486416-73-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(dimethylamino)propyl)benzamide 486416-74-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1,1-dioxotetrahydrothiophen-3-yl)benzamide 486416-75-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-oxotetrahydrothiophen-3-yl)benzamide 486416-76-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-amino-4-methoxybenzoyl)benzamide 486416-77-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-cyclopropylbenzamide 486416-78-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-((1,3-dimethylbutyl)amino)benzamide 486416-79-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-methylpropyl)benzamide 486416-80-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(diethylamino)propyl)benzamide 486416-81-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(piperidino)propyl)benzamide 486416-82-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-2-oxotetrahydrofuran-3-yl)benzamide 486416-83-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-((ethoxycarbonyl)methyl)phenyl)benzamide 486416-84-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-cyclopentylbenzamide 486416-85-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(morpholino)propyl)benzamide 486416-86-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-

methyl-3-phenylpropyl)benzamide 486416-87-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-isopropoxypropyl)benzamide 486416-88-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-ethoxyethyl)benzamide 486416-89-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(aminocarbonyl)ethyl)benzamide 486416-90-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-methoxy-4-methylphenyl)benzamide 486416-91-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-cyclohexylbenzamide 486416-92-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(pyridin-2-yl)ethyl)benzamide 486416-93-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1,5-dimethylhexyl)benzamide 486416-94-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(acetylamino)ethyl)benzamide 486416-95-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(imidazol-1-yl)propyl)benzamide 486416-96-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(cyclopropylmethyl)benzamide 486416-97-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-methyl-2-methoxy-2-oxoethyl)benzamide 486416-98-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-morpholinophenyl)benzamide 486416-99-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(1-methylpyrrolidin-2-yl)ethyl)benzamide 486417-00-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-sec-butylbenzamide 486417-02-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1,2-diethylpyrazolidin-4-yl)benzamide 486417-03-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-phenylpropyl)benzamide 486417-04-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-(hydroxymethyl)-2-methylpropyl)benzamide 486417-05-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(oxazol-5-yl)phenyl)benzamide 486417-06-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-2-hydroxy-1-phenylethyl)benzamide 486417-07-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-(hydroxymethyl)propyl)benzamide 486417-08-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(diethylamino)ethyl)benzamide 486417-09-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(pyrrolidino)propyl)benzamide 486417-10-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-(methoxymethyl)propyl)benzamide 486417-11-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-2-hydroxy-1-phenylethyl)benzamide 486417-12-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-((methylamino)carbonyl)phenyl)benzamide 486417-13-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-phenylethyl)benzamide 486417-14-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-methylbutyl)benzamide 486417-15-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-methoxyethyl)benzamide 486417-16-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-propoxyethyl)benzamide 486417-17-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-1-phenylethyl)benzamide 486417-18-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-phenylethyl)benzamide 486417-19-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((4-methoxyphenyl)methyl)benzamide 486417-20-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2-methoxyphenyl)methyl)benzamide 486417-21-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-cyanoethyl)-N-butylbenzamide 486417-22-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((benzodioxol-5-yl)methyl)benzamide 486417-23-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(cyclohexylmethyl)benzamide 486417-24-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2,3-dihydroxypropyl)-N-methylbenzamide 486417-25-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-2-hydroxy-1-methylethyl)benzamide 486417-26-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-indan-1-yl)benzamide 486417-27-0P

, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(2-chlorophenyl)ethyl)benzamide 486417-28-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-cyanoethyl)-N-((tetrahydrofuran-2-yl)methyl)benzamide 486417-29-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((pyridin-2-yl)methyl)benzamide 486417-30-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-benzylbenzamide 486417-31-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-methyl-N-(2-methyl-2-propenyl)benzamide 486417-32-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-1-(hydroxymethyl)propyl)benzamide 486417-33-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-indan-1-yl)benzamide 486417-35-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(2-methoxyphenyl)ethyl)benzamide 486417-36-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-butylbenzamide 486417-37-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-cyclohexyl-N-methylbenzamide 486417-38-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((pyridin-3-yl)methyl)benzamide 486417-39-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-acetylphenyl)benzamide 486417-40-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(ethoxycarbonyl)phenyl)benzamide 486417-41-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-(aminocarbonyl)ethyl)benzamide 486417-42-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-((methylamino)carbonyl)ethyl)benzamide 486417-44-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(3-methoxyphenyl)ethyl)benzamide 486417-46-3P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-benzylpiperidino)methanone 486417-47-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(cyanomethyl)-N-methylbenzamide 486417-48-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(2,4-dichlorophenyl)ethyl)benzamide 486417-50-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-methylphenyl)benzamide 486417-52-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-(aminocarbonyl)-2-hydroxyethyl)benzamide 486417-54-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-2-oxotetrahydrofuran-3-yl)benzamide 486417-56-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-pentylbenzamide 486417-58-7P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(pyridin-2-yl)piperazino)methanone 486417-60-1P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-hydroxy-4-phenylpiperidino)methanone 486417-62-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(2,3-dihydro-1,4-benzodioxin-5-yl)ethyl)benzamide 486417-64-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-propylphenyl)benzamide 486417-66-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-butoxyphenyl)benzamide 486417-68-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(2-fluorophenyl)ethyl)benzamide 486417-70-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(2-hydroxyethyl)phenyl)benzamide 486417-72-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((4-(trifluoromethoxy)phenyl)methyl)benzamide 486417-73-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-benzyl-N-ethylbenzamide 486417-75-8P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(ethoxycarbonyl)piperidino)methanone 486417-77-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(3,4-dichlorophenyl)ethyl)benzamide 486417-79-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3,4-dimethoxyphenyl)benzamide 486417-81-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(isoxazol-3-yl)benzamide 486417-83-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-phenylpropyl)benzamide 486417-89-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(6-methoxypyridin-3-yl)benzamide 486417-91-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2,3-dichlorophenyl)methyl)benzamide 486417-93-0P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-benzylpiperazino)methanone

486417-95-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-butyl-N-methylbenzamide 486417-97-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-propenyl)benzamide 486417-99-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-methoxy-4-(methoxycarbonyl)phenyl)benzamide 486418-05-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2-fluorophenyl)methyl)benzamide 486418-07-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(1-hydroxyethyl)phenyl)benzamide 486418-09-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-methyl-2-propenyl)benzamide 486418-11-5P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](3-((diethylamino)carbonyl)piperidino)methanone 486418-13-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-hydroxy-2-phenylethyl)-N-methylbenzamide 486418-15-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-((ethyl)(3-methylphenyl)amino)ethyl)benzamide 486418-17-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(indol-5-yl)benzamide 486418-19-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2-chlorophenyl)methyl)benzamide 486418-21-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(2-oxoimidazolidino)ethyl)benzamide 486418-23-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(trifluoromethoxy)phenyl)benzamide 486418-25-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-(ethoxycarbonyl)piperidin-4-yl)benzamide 486418-27-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N,N-diethylbenzamide 486418-29-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-hydroxyethyl)-N-propylbenzamide 486418-35-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((3,4,5-trimethoxyphenyl)methyl)benzamide 486418-37-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-fluorophenyl)benzamide 486418-39-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2,4-dichlorophenyl)methyl)benzamide 486418-42-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(4-methoxyphenyl)ethyl)benzamide 486418-44-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(diethylamino)-1-methylbutyl)benzamide 486418-46-6P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(4-methoxyphenyl)piperazino)methanone 486418-48-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(3,4-dimethoxyphenyl)ethyl)benzamide 486418-50-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-((5-nitropyridin-2-yl)amino)ethyl)benzamide 486418-53-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-hydroxypropyl)-N-((pyridin-2-yl)methyl)benzamide 486418-55-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2-methylphenyl)methyl)benzamide
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT 486418-57-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-(4-methylphenyl)ethyl)benzamide 486418-59-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((3-methoxyphenyl)methyl)benzamide 486418-60-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-methylbutyl)benzamide 486418-62-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N,N-dipropylbenzamide 486418-64-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((furan-2-yl)methyl)benzamide 486418-67-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-ethyl-N-[2-(pyridin-2-yl)ethyl]benzamide 486418-69-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-((3-fluorophenyl)methyl)benzamide 486418-71-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((4-methylphenyl)methyl)benzamide 486418-73-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-

((2,4-dimethoxyphenyl)methyl)benzamide 486418-75-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(methylthio)phenyl)benzamide 486418-77-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-hydroxybutyl)benzamide 486418-79-5P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(2-hydroxyethyl)piperazino)methanone 486418-81-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((4-chlorophenyl)methyl)benzamide 486418-83-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2-chlorophenyl)methyl)-N-methylbenzamide 486418-85-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(diethylamino)propyl)-N-methylbenzamide 486418-87-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((4-(trifluoromethyl)phenyl)methyl)benzamide 486418-89-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((3,5-dimethoxyphenyl)methyl)benzamide 486418-91-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-hydroxy-2,2-dimethylpropyl)benzamide 486418-93-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(2-hydroxyethoxy)ethyl)benzamide 486418-95-5P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](2-(2-hydroxyethyl)piperidino)methanone 486418-97-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(4-chlorophenyl)ethyl)benzamide 486418-99-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-tert-butylcyclohexyl)benzamide 486419-01-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(pyridin-4-yl)ethyl)benzamide 486419-03-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2-(trifluoromethyl)phenyl)methyl)benzamide 486419-05-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((4-tert-butylphenyl)methyl)benzamide 486419-07-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(indol-3-yl)ethyl)benzamide 486419-09-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N,N-bis(2-propenyl)benzamide 486419-11-8P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](3,5-dimethylpiperidino)methanone 486419-13-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(5-hydroxypentyl)benzamide 486419-15-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((3-chloro-4-methylphenyl)methyl)benzamide 486419-17-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(3-(trifluoromethyl)phenyl)ethyl)benzamide 486419-19-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((pyridin-4-yl)methyl)benzamide 486419-21-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2-chloro-4-fluorophenyl)methyl)benzamide 486419-23-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2,3-dihydroxypropyl)benzamide 486419-25-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-methylphenyl)benzamide 486419-27-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(6-chloropyridin-3-yl)benzamide 486419-30-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-methyl-N-(2-propynyl)benzamide 486419-32-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-ethylthioethyl)benzamide 486419-34-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-fluoro-4-methylphenyl)benzamide 486419-36-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2-ethoxyphenyl)methyl)benzamide 486419-38-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2,5-dichlorophenyl)methyl)benzamide 486419-40-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-bromophenyl)benzamide 486419-42-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-chlorophenyl)benzamide 486419-44-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-fluorophenyl)benzamide 486419-46-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-ethyl-N-methylbenzamide 486419-48-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-phenylbutyl)benzamide 486419-50-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(trifluoromethoxy)phenyl)benzamide 486419-52-7P, 4-[[4-Amino-5-(2,6-

difluorobenzoyl)thiazol-2-yl]amino]-N-((3-(trifluoromethyl)phenyl)methyl)benzamide 486419-54-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2,3-dimethylphenyl)methyl)benzamide 486419-56-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3,4,5-trimethoxyphenyl)benzamide 486419-58-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-cyanoethyl)-N-methylbenzamide 486419-59-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3,5-dimethylphenyl)benzamide 486419-60-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(diethylamino)ethyl)-N-methylbenzamide 486419-61-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-hydroxyethyl)-N-(2-methylbutyl)benzamide 486419-62-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-1-cyclohexylethyl)benzamide 486419-64-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2,4-difluorophenyl)methyl)benzamide 486419-66-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((4-fluoro-3-(trifluoromethyl)phenyl)methyl)benzamide 486419-67-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(2-methylpiperidino)propyl)benzamide 486419-69-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-cyanoethyl)-N-(phenylmethyl)benzamide 486419-70-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(phenylamino)phenyl)benzamide 486419-71-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-benzyl-N-butylbenzamide 486419-72-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((furan-2-yl)methyl)-N-methylbenzamide 486419-73-2P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](3-methyl-4-(3-methylphenyl)piperazino)methanone 486419-74-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2,5-difluorophenyl)methyl)benzamide 486419-75-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-acetylphenyl)benzamide 486419-76-5P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(pyridin-4-yl)piperazino)methanone 486419-77-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-cyclohexyl-N-ethylbenzamide 486419-78-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-ethoxyphenyl)benzamide 486419-79-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N,N-dibutylbenzamide 486419-80-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-methyl-N-((6-methylpyridin-2-yl)methyl)benzamide 486419-81-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-cyanoethyl)-N-((pyridin-3-yl)methyl)benzamide 486419-82-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((3,4-difluorophenyl)methyl)benzamide 486419-83-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-benzyl-2-hydroxyethyl)benzamide 486419-84-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(2,5-dimethoxyphenyl)ethyl)benzamide 486419-85-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-cyclohexyl-N-(2-propenyl)benzamide 486419-86-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(cyanomethyl)phenyl)benzamide 486419-87-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-propyl-N-(2-(pyridin-2-yl)ethyl)benzamide 486419-88-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-((2-cyanoethyl)thio)phenyl)benzamide 486419-89-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((3-chlorophenyl)methyl)benzamide 486419-90-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-phenylpropyl)benzamide 486419-91-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-hydroxyethyl)benzamide 486419-92-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S,S)-1-(hydroxymethyl)-2-methylbutyl)benzamide 486419-93-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-(hydroxymethyl)pentyl)benzamide 486419-94-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-fluoro-3-methylphenyl)benzamide 486419-95-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-((butyl)(ethyl)amino)ethyl)benzamide 486419-96-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-

N-((2,3-dimethoxyphenyl)methyl)benzamide 486419-97-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-(hydroxymethyl)-3-methylbutyl)benzamide 486419-98-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-hydroxypropyl)benzamide 486419-99-2P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(((isopropylamino)carbonyl)methyl)piperazino)methanone 486420-00-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((3,4-dichlorophenyl)methyl)benzamide 486420-01-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(cyclohex-1-enyl)ethyl)benzamide 486420-02-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((3,4-dimethylphenyl)methyl)benzamide 486420-03-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(bis(2-hydroxyethyl)amino)propyl)benzamide 486420-04-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-butyl-N-(4-hydroxybutyl)benzamide 486420-05-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-chloro-2-(hydroxymethyl)phenyl)benzamide 486420-06-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(dioxolan-2-yl)ethyl)benzamide 486420-08-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(pyridin-3-yl)ethyl)benzamide 486420-10-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2,2-diethoxyethyl)benzamide 486420-12-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((3,4-dimethoxyphenyl)methyl)benzamide 486420-13-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(trans-4-hydroxycyclohexyl)benzamide 486420-14-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-fluoro-4-methoxyphenyl)benzamide 486420-15-9P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](3-((acetyl)(methyl)amino)pyrrolidino)methanone 486420-16-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(3-fluorophenyl)ethyl)benzamide 486420-17-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(((1S,2R)-2-hydroxycyclohexyl)methyl)benzamide 486420-18-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-benzyl-N-(4-hydroxybutyl)benzamide 486420-19-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(5-methylpyridin-2-yl)benzamide 486420-20-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-benzylpyrrolidin-3-yl)benzamide 486420-21-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(methoxycarbonyl)-2-methylphenyl)benzamide 486420-22-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(4-fluorophenyl)ethyl)benzamide 486420-23-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-propyl-N-(1-methylpropyl)benzamide 486420-24-0P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(3-(dimethylamino)propyl)piperazino)methanone 486420-25-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(6-hydroxyhexyl)benzamide 486420-26-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-(cyclohexylmethyl)-2-hydroxyethyl)benzamide 486420-27-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((3-methylphenyl)methyl)benzamide 486420-28-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(3,4-dimethoxyphenyl)ethyl)-N-methylbenzamide 486420-29-5P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(2-methoxyethyl)piperazino)methanone 486420-30-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-((methyl)(phenyl)amino)propyl)benzamide 486420-31-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-cyanoethyl)-N-propylbenzamide 486420-32-0P 486420-33-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-((2-hydroxyethyl)thio)ethyl)benzamide 486420-34-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)benzamide 486420-35-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-(trifluoromethyl)phenyl)benzamide 486420-36-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(1,3,4-oxadiazol-2-yl)phenyl)benzamide 486420-37-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-hydroxy-3-

phenylpropyl)-N-methylbenzamide 486420-38-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-(trifluoromethyl)phenyl)benzamide 486420-39-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(2,6-dichlorophenyl)ethyl)benzamide 486420-40-0P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl]((R)-3-(acetylamino)pyrrolidino)methanone 486420-41-1P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(2-(diethylamino)ethyl)piperazino)methanone 486420-42-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-2-phenylpropyl)benzamide 486420-43-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((1S,2R)-2-hydroxyindan-1-yl)benzamide 486420-44-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-((trifluoromethyl)thio)phenyl)benzamide 486420-45-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-hydroxyphenyl)benzamide 486420-46-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-benzyl-N-(2-hydroxyethyl)benzamide 486420-47-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(2-ethoxyphenyl)ethyl)benzamide 486420-48-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-benzylpyrrolidin-3-yl)benzamide 486420-49-9P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(2-(dimethylamino)ethyl)piperazino)methanone 486420-50-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-1-((benzylthio)methyl)-2-hydroxyethyl)benzamide 486420-51-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((2-aminophenyl)methyl)benzamide 486420-52-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-ethyl-N-(4-hydroxybutyl)benzamide 486420-53-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-(hydroxymethyl)-3-(methylthio)propyl)benzamide 486420-54-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(dioxolan-2-yl)ethyl)-N-methylbenzamide 486420-55-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-cyclohexylethyl)benzamide 486420-56-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-isopropylphenyl)benzamide 486420-57-9P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl](4-(hydroxymethyl)piperidino)methanone 486420-58-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-2-hydroxy-2-phenylethyl)benzamide 486420-59-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4,4-diethoxybutyl)benzamide 486420-60-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(5-methylisoxazol-3-yl)benzamide 486420-61-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(3-chloro-4-hydroxyphenyl)benzamide 486420-62-6P, [4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]phenyl][4-[2-(thien-2-yl)ethyl]piperazino]methanone 486420-63-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-hydroxy-5-methylphenyl)benzamide
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT 486413-89-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-pyrrolidin-2-ylmethyl)benzamide 486414-71-5P, 4-[[4-Amino-5-[1-(4-methylpyridin-3-yl)methanoyl]thiazol-2-yl]amino]-N-((S)-1-methylpyrrolidin-2-ylmethyl)benzamide 486415-22-9P, 4-[[4-Amino-5-(2-methylsulfonylbenzoyl)thiazol-2-yl]amino]benzoic Acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT 486413-85-8P 486413-92-7P, 4-[[(S)-4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-Acetylpyrrolidin-2-ylmethyl)benzamide 486413-94-9P 486413-96-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-[2-(4-hydroxyphenyl)ethyl]benzamide

486413-97-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-piperidin-1-ylethyl)benzamide 486413-98-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-dimethylaminophenyl)benzamide 486413-99-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2,3-dihydrobenzo[1,4]dioxin-6-yl)benzamide 486414-01-1P, 4-[[4-Amino-5-[1-(2,6-difluorophenyl)methanoyl]thiazol-2-yl]amino]-N-(2-methyl-2-methylaminopropyl)benzamide diacetate 486414-02-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(5-methoxy-2-methylphenyl)benzamide 486414-03-3P 486414-04-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-morpholin-4-ylphenyl)benzamide 486414-05-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-indan-2-ylbenzamide 486414-06-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-diisopropylaminoethyl)benzamide 486414-08-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-[4-[acetyl(methyl)amino]phenyl]benzamide 486414-09-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-thiophen-2-ylethyl)benzamide 486414-10-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(pyridin-3-yl)benzamide 486414-11-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(4-cyanomethylbenzyl)benzamide 486414-12-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-pyridin-4-ylethyl)benzamide 486414-13-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-1-methylpyrrolidin-3-yl)benzamide 486414-15-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-methylpyrrolidin-2-ylmethyl)benzamide Dihydrochloride 486414-17-9P 486414-20-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(piperidin-2-ylmethyl)benzamide Trifluoroacetate 486414-22-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-1-methylpyrrolidin-2-ylmethyl)benzamide 486414-23-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-pyrrolidin-1-ylethyl)benzamide 486414-24-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-2-dimethylamino-1-methylethyl)-N-methylbenzamide 486414-26-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-2-dimethylamino-1-methylethyl)-N-methylbenzamide 486414-28-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-ethylpyrrolidin-2-ylmethyl)benzamide 486414-29-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-[2-[(cyclopropylmethyl)methylamino]-2-methylpropyl]benzamide 486414-32-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-2-dimethylamino-1-methylethyl)benzamide Dihydrochloride 486414-36-2P, 4-[[4-Amino-5-[(2,6-difluorophenyl)methanoyl]thiazol-2-yl]amino]-N-((S)-2-dimethylamino-1-methylethyl)benzamide 486414-37-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2S-dimethylaminopropyl)benzamide 486414-40-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-methylpiperidin-2-ylmethyl)benzamide 486414-42-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2R-dimethylaminopropyl)benzamide 486414-44-2P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-[2-(2,5-dihydropyrrol-1-yl)ethyl]benzamide Dihydrochloride 486414-47-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-1-methyl-2-(piperidino)ethyl)benzamide 486414-48-6P 486414-50-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-1-dimethylaminomethyl-2-methylpropyl)benzamide 486414-52-2P 486414-54-4P 486414-55-5P 486414-56-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-[2-(cis-2,6-dimethylpiperidin-1-yl)ethyl]benzamide 486414-57-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-methyl-2-piperidin-1-ylpropyl)benzamide 486414-58-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-[2-(2,2,6,6-tetramethylpiperidin-1-yl)ethyl]benzamide 486414-59-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-[((2S,4R)-4-hydroxy-1-methylpyrrolidin-2-yl)methyl]benzamide 486414-60-2P 486414-61-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2,2,5,5-tetramethylpyrrolidin-3-ylmethyl)benzamide Dihydrochloride

486414-63-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-[2-(cis-3,5-dimethylpiperazin-1-yl)ethyl]benzamide 486414-66-8P, 4-[[5-(1-Adamantan-1-ylmethanoyl)-4-aminothiazol-2-yl]amino]-N-(2-dimethylaminoethyl)benzamide 486414-67-9P, 4-[[4-Amino-5-[1-(4-methylpyridin-3-yl)methanoyl]thiazol-2-yl]amino]-N-(((S)-1-methylpyrrolidin-2-yl)methyl)benzamide dihydrochloride 486414-72-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-dimethylamino-1-methylethyl)-2-methoxybenzamide 486414-73-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-dimethylamino-1,1-dimethylethyl)benzamide Dihydrochloride 486414-74-8P, 4-[[4-Amino-5-[(3-methylthien-2-yl)carbonyl]thiazol-2-yl]amino]-N-((R)-2-(dimethylamino)-1-methylethyl)benzamide 486414-75-9P 486414-82-8P 486414-85-1P 486414-88-4P 486414-91-9P 486414-95-3P, 4-[[4-Amino-5-(2-fluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-methylpyrrolidin-2-ylmethyl)benzamide bis(trifluoroacetate) 486414-97-5P, 4-[[4-Amino-5-(2,6-difluoro-4-methylbenzoyl)thiazol-2-yl]amino]-N-((S)-1-methylpyrrolidin-2-ylmethyl)benzamide 486415-08-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-[(S)-1-((S)-1-methylpyrrolidin-2-yl)ethyl]benzamide 486415-12-7P, 4-[[4-Amino-5-[1-(3-methylthiophen-2-yl)methanoyl]thiazol-2-yl]amino]-N-((S)-1-methylpyrrolidin-2-ylmethyl)benzamide 486415-13-8P, 4-[[4-Amino-5-(2-chloro-6-fluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-methylpyrrolidin-2-ylmethyl)benzamide 486415-16-1P, 4-[[5-(2-Acetylaminobenzoyl)-4-aminothiazol-2-yl]amino]-N-((S)-1-methylpyrrolidin-2-ylmethyl)benzamide 486415-20-7P 486415-24-1P 486415-28-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-methylazetidin-3-ylmethyl)benzamide 486415-30-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-methyl-2-azabicyclo[2.2.1]hept-3-endo-ylmethyl)benzamide 486415-35-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)-1,3-thiazol-2-yl]amino]-N-[[1-(dimethylamino)cyclopentyl]methyl]benzamide 486415-36-5P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)-1,3-thiazol-2-yl]amino]-N-[[1-(dimethylamino)cyclobutyl]methyl]benzamide 486415-39-8P, 4-[[4-Amino-5-(2,6-dichlorobenzoyl)thiazol-2-yl]amino]-N-carbamoylmethylbenzamide 486415-40-1P, 4-[[4-Amino-5-(2,6-dichlorobenzoyl)thiazol-2-yl]amino]-N-(2-hydroxyethyl)benzamide 486415-41-2P, 4-[[4-Amino-5-(2,6-dichlorobenzoyl)thiazol-2-yl]amino]-N-(2,3-dihydroxypropyl)benzamide 486415-42-3P, 4-[[4-Amino-5-(2,6-dichlorobenzoyl)thiazol-2-yl]amino]-N-(2-dimethylaminoethyl)benzamide 486415-43-4P, 4-[[4-Amino-5-(2,6-dichlorobenzoyl)thiazol-2-yl]amino]-N-[2-(2-hydroxyethoxy)ethyl]benzamide 486415-46-7P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-2-chloro-N-(2-dimethylaminoethyl)benzamide 486415-48-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-2-hydroxy-N-(2-phenylaminoethyl)benzamide 486415-49-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-dimethylamino-1-methylethyl)-2-hydroxybenzamide 486415-52-5P, 5-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-2-(2-dimethylaminoethyl)isoindole-1,3-dione 486415-56-9P, 3-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-methylaminoethyl)benzamide 486420-65-9P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(dimethylamino)-1-methylethyl)benzamide 486420-66-0P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-(2,5-dihydropyrrol-1-yl)ethyl)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT 144378-32-5, Cyclin B-CDK1 kinase 146279-88-1, Cdk2-cyclin A kinase 149371-07-3, Cdk4 kinase-cyclin d complex
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of thiazolylamino benzamide derivs. as modulators

of cell proliferation and inhibitors of protein kinases)
IT 114051-78-4, LCK kinase 125149-26-0, FGF receptor kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)
IT 55-81-2, (2-(4-Methoxyphenyl)ethyl)amine 61-54-1, (2-(Indol-3-yl)ethyl)amine 62-53-3, (Phenyl)amine, reactions 63-74-1, (4-(Aminosulfonyl)phenyl)amine 64-04-0, (2-Phenylethyl)amine 75-31-0, (Isopropyl)amine, reactions 78-81-9, (2-Methylpropyl)amine 78-96-6, (2-Hydroxypropyl)amine 87-25-2, (2-(Ethoxycarbonyl)phenyl)amine 87-63-8, (2-Chloro-6-methylphenyl)amine 89-93-0, ((2-Methylphenyl)methyl)amine 89-97-4, ((2-Chlorophenyl)methyl)amine 89-99-6, ((2-Fluorophenyl)methyl)amine 90-04-0, (2-Methoxyphenyl)amine 91-21-4, 1,2,3,4-Tetrahydroisoquinoline 94-09-7, (4-(Ethoxycarbonyl)phenyl)amine 94-64-4, Methyl((2-chlorophenyl)methyl)amine 95-00-1, ((2,4-Dichlorophenyl)methyl)amine 95-74-9, (3-Chloro-4-methylphenyl)amine 95-76-1, (3,4-Dichlorophenyl)amine 95-84-1, (2-Hydroxy-5-methylphenyl)amine 96-20-8, (1-(Hydroxymethyl)propyl)amine 98-16-8, (3-(Trifluoromethyl)phenyl)amine 99-03-6, (3-Acetylphenyl)amine 99-88-7, (4-Isopropylphenyl)amine 99-92-3, (4-Acetylphenyl)amine 100-36-7, (2-(Diethylamino)ethyl)amine 100-60-7, Methyl(cyclohexyl)amine 100-81-2, ((3-Methylphenyl)methyl)amine 100-82-3, ((3-Fluorophenyl)methyl)amine 101-54-2, (4-(Phenylamino)phenyl)amine 102-48-7, ((3,4-Dimethylphenyl)methyl)amine 102-49-8, ((3,4-Dichlorophenyl)methyl)amine 102-97-6, Isopropyl(benzyl)amine 103-67-3 103-76-4, 1-Piperazineethanol 104-10-9, (4-(2-Hydroxyethyl)phenyl)amine 104-63-2, Benzyl(2-hydroxyethyl)amine 104-78-9, (3-(Diethylamino)propyl)amine 104-79-0, Methyl(2-(diethylamino)ethyl)amine 104-84-7, ((4-Methylphenyl)methyl)amine 104-86-9, ((4-Chlorophenyl)methyl)amine 104-94-9, (4-Methoxyphenyl)amine 104-96-1, (4-(Methylthio)phenyl)amine 105-04-4, Ethyl(2-(diethylamino)ethyl)amine 106-47-8, (4-Chlorophenyl)amine, reactions 106-49-0, (4-Methylphenyl)amine, reactions 107-11-9, (2-Propenyl)amine 107-85-7, (3-Methylbutyl)amine 108-00-9, N,N-Dimethylethylenediamine 108-09-8, (1,3-Dimethylbutyl)amine 108-42-9, (3-Chlorophenyl)amine 108-44-1, (3-Methylphenyl)amine, reactions 108-69-0, (3,5-Dimethylphenyl)amine 108-91-8, (Cyclohexyl)amine, reactions 109-01-3 109-55-7, (3-(Dimethylamino)propyl)amine 109-73-9, (Butyl)amine, reactions 109-83-1, Methyl(2-hydroxyethyl)amine 109-85-3, (2-Methoxyethyl)amine 109-89-7, Diethylamine, reactions 110-58-7, (Pentyl)amine 110-68-9, Methyl(butyl)amine 110-73-6 110-76-9, (2-Ethoxyethyl)amine 110-91-8, Morpholine, reactions 111-75-1, 2-Hydroxyethyl(butyl)amine 111-92-2, Dibutylamine 111-95-5 120-20-7, (2-(3,4-Dimethoxyphenyl)ethyl)amine 122-07-6, Methyl(2,2-dimethoxyethyl)amine 122-80-5, (4-(Acetylamino)phenyl)amine 123-00-2, (3-(Morpholino)propyl)amine 123-30-8, (4-Hydroxyphenyl)amine 123-75-1, Pyrrolidine, reactions 123-90-0, Thiomorpholine 124-02-7, Diallylamine 134-20-3, (2-(Methoxycarbonyl)phenyl)amine 140-80-7, (4-(Diethylamino)-1-methylbutyl)amine 141-43-5, (2-Hydroxyethyl)amine, reactions 141-91-3, 2,6-Dimethylmorpholine 142-25-6, Methyl(2-(dimethylamino)ethyl)amine 142-84-7, Dipropylamine 156-41-2, (2-(4-Chlorophenyl)ethyl)amine 156-43-4, (4-Ethoxyphenyl)amine 156-87-6, (3-Hydroxypropyl)amine 177-11-7, 4,4-(Ethylenedioxy)piperidine 348-54-9, (2-Fluorophenyl)amine 349-65-5, (2-Methoxy-5-(trifluoromethyl)phenyl)amine 366-99-4, (3-Fluoro-4-methoxyphenyl)amine 369-68-6, (3-((Trifluoromethyl)thio)phenyl)amine 372-19-0, (3-Fluorophenyl)amine 372-39-4, (3,5-Difluorophenyl)amine 372-66-7, (5-Hydroxy-1,5-dimethylhexyl)amine 404-70-6, (2-(3-Fluorophenyl)ethyl)amine 452-69-7, (4-Fluoro-3-methylphenyl)amine 452-80-2, (2-Fluoro-4-methylphenyl)amine 455-14-1, (4-(Trifluoromethyl)phenyl)amine 461-82-5, (4-(Trifluoromethoxy)phenyl)amine 502-83-0, (1-(Hydroxymethyl)-3-(methylthio)propyl)amine 504-78-9, Thiazolidine 533-30-2,

(Benzothiazol-6-yl)amine 543-82-8, (1,5-Dimethylhexyl)amine 580-15-4, (Quinolin-6-yl)amine 582-22-9, (2-Phenylpropyl)amine 582-33-2, (3-(Ethoxycarbonyl)phenyl)amine 591-19-5, (3-Bromophenyl)amine 591-27-5, (3-Hydroxyphenyl)amine 598-74-3, (1,2-Dimethylpropyl)amine 611-34-7, (Quinolin-5-yl)amine 615-65-6, (2-Chloro-4-methylphenyl)amine 616-30-8, (2,3-Dihydroxypropyl)amine 617-89-0, ((Furan-2-yl)methyl)amine 618-36-0, (1-Phenylethyl)amine 619-45-4, (4-(Methoxycarbonyl)phenyl)amine 621-33-0, (3-Ethoxyphenyl)amine 622-26-4, 4-(2-Hydroxyethyl)piperidine 624-78-2, Methyl(ethyl)amine 625-43-4, Methyl(2-methylpropyl)amine 627-37-2 643-28-7, (2-Isopropylphenyl)amine 645-36-3, (2,2-Diethoxyethyl)amine 693-05-0, Methyl(2-cyanoethyl)amine 693-51-6, Butyl(2-Cyanoethyl)amine 706-03-6, (2-Cyanoethyl)(Phenylmethyl)amine 765-30-0, (Cyclopropyl)amine 877-96-3, 4-(3-(Dimethylamino)propyl)piperazine 929-06-6, (2-(2-Hydroxyethoxy)ethyl)amine 1001-53-2, (2-(Acetylamino)ethyl)amine 1003-03-8, (Cyclopentyl)amine 1008-91-9, 4-(Pyridin-4-yl)piperazine 1072-67-9, (5-Methylisoxazol-3-yl)amine 1125-60-6, (Isoquinolin-5-yl)amine 1126-09-6, 4-(Ethoxycarbonyl)piperidine 1484-84-0, 2-(2-Hydroxyethyl)piperidine 1535-73-5, (3-(Trifluoromethoxy)phenyl)amine 1583-88-6, (2-(4-Fluorophenyl)ethyl)amine 1603-41-4, (5-Methylpyridin-2-yl)amine 1664-40-0, N-Phenylethylenediamine 1687-53-2, (3-Hydroxy-4-methoxyphenyl)amine 1750-42-1, (Isoxazol-3-yl)amine 1758-46-9, (2-Phenoxyethyl)amine 1857-20-1, Methyl(((dimethylamino)carbonyl)methyl)amine 1938-58-5, (6-(Dimethylamino)hexyl)amine 2026-48-4, ((S)-1-(Hydroxymethyl)-2-methylpropyl)amine 2038-03-1, (2-(Morpholino)ethyl)amine 2038-57-5, (3-Phenylpropyl)amine 2039-67-0, (2-(3-Methoxyphenyl)ethyl)amine 2045-79-6, (2-(2-Methoxyphenyl)ethyl)amine 2185-02-6, ((S)-2-Oxotetrahydrofuran-3-yl)amine 2237-30-1, (3-Cyanophenyl)amine 2393-23-9, ((4-Methoxyphenyl)methyl)amine 2403-22-7, Butyl(benzyl)amine 2439-56-7, Methyl(cyclopentyl)amine 2454-37-7, (3-(1-Hydroxyethyl)phenyl)amine 2508-29-4, (5-Hydroxypentyl)amine 2516-47-4, (Cyclopropylmethyl)amine 2555-03-5, Methyl(2-methyl-2-propenyl)amine 2620-50-0, ((Benzodioxol-5-yl)methyl)amine 2627-86-3, ((S)-1-Phenylethyl)amine 2696-84-6, (4-Propylphenyl)amine 2706-56-1, (2-(Pyridin-2-yl)ethyl)amine 2735-04-8, (2,4-Dimethoxyphenyl)amine 2740-83-2, ((3-(Trifluoromethyl)phenyl)methyl)amine 2759-28-6, 4-Benzylpiperazine 2835-68-9, (4-(Aminocarbonyl)phenyl)amine 2878-14-0, (2-Methyl-2-propenyl)amine 2899-37-8, ((S)-1-(Hydroxymethyl)-3-(methylthio)propyl)amine 2906-12-9, (3-Isopropoxypropyl)amine 2941-20-0, (1-Phenylpropyl)amine 2987-53-3, (2-(Methylthio)phenyl)amine 3010-04-6, (Cyanomethyl)(butyl)amine 3048-01-9, ((2-(Trifluoromethyl)phenyl)methyl)amine 3182-95-4, ((S)-1-Benzyl-2-hydroxyethyl)amine 3218-02-8, Cyclohexanemethanamine 3261-62-9, (2-(4-Methylphenyl)ethyl)amine 3300-51-4, ((4-(Trifluoromethyl)phenyl)methyl)amine 3367-95-1, 3-((Diethylamino)carbonyl)piperidine 3399-73-3, (2-(Cyclohex-1-enyl)ethyl)amine 3490-06-0, Methyl(2-(3,4-dimethoxyphenyl)ethyl)amine 3529-08-6, (3-(Piperidino)propyl)amine 3529-10-0, (4-(Dimethylamino)butyl)amine 3544-24-9, (3-(Aminocarbonyl)phenyl)amine 3544-25-0, (4-(Cyanomethyl)phenyl)amine 3600-86-0, (2-(2,5-Dimethoxyphenyl)ethyl)amine 3644-18-6, 4-(2-(Dimethylamino)ethyl)piperazine 3731-51-9, ((Pyridin-2-yl)methyl)amine 3731-52-0, ((Pyridin-3-yl)methyl)amine 3731-53-1, ((Pyridin-4-yl)methyl)amine 3789-59-1, ((S)-1-Phenylpropyl)amine 3886-69-9, ((R)-1-Phenylethyl)amine 3964-52-1, (3-Chloro-4-hydroxyphenyl)amine 4038-92-0, 4-(2-(Diethylamino)ethyl)piperazine 4048-33-3, (6-Hydroxyhexyl)amine 4138-26-5, 3-(Aminocarbonyl)piperidine 4141-08-6, (2-((Methylamino)carbonyl)phenyl)amine 4152-90-3, ((3-Chlorophenyl)methyl)amine 4327-52-0, (2-((2-Cyanoethyl)thio)phenyl)amine 4344-55-2, (4-Butoxyphenyl)amine 4379-15-1, (3-Hydroxy-1-isopropylpropyl)amine 4393-09-3, ((2,3-Dimethoxyphenyl)methyl)amine 4403-69-4, ((2-

Aminophenyl)methyl)amine 4442-59-5, ((2,3-Dihydro-1,4-benzodioxin-2-yl)methyl)amine 4518-10-9, (3-(Methoxycarbonyl)phenyl)amine 4534-10-5, (4-Isopropyl-3-methylphenyl)amine 4543-95-7, Butyl(4-hydroxybutyl)amine 4543-96-8, Methyl(3-(dimethylamino)propyl)amine 4606-65-9, 3-(Hydroxymethyl)piperidine 4726-85-6, (2-(Aminocarbonyl)ethyl)amine 4753-75-7, Methyl((furan-2-yl)methyl)amine 4795-29-3, ((Tetrahydrofuran-2-yl)methyl)amine 4985-85-7, (3-(Bis(2-hydroxyethyl)amino)propyl)amine 5036-48-6, (3-(Imidazol-1-yl)propyl)amine 5048-82-8, (4-(2-(Ethoxycarbonyl)ethenyl)phenyl)amine 5071-96-5, ((3-Methoxyphenyl)methyl)amine 5192-03-0, (Indol-5-yl)amine 5303-65-1, (2-(Ethoxycarbonyl)-1-methylethyl)amine 5308-25-8 5317-32-8, 4-(3-Hydroxypropyl)piperazine 5332-73-0, (3-Methoxypropyl)amine 5339-85-5, (2-(2-Hydroxyethyl)phenyl)amine 5344-90-1, (2-(Hydroxymethyl)phenyl)amine 5345-54-0, (3-Chloro-4-methoxyphenyl)amine 5350-93-6, (6-Chloropyridin-3-yl)amine 5369-16-4, (3-Isopropylphenyl)amine 5378-35-8, (3-(1,3,4-Oxadiazol-2-yl)phenyl)amine 5382-16-1, 4-Hydroxypiperidine 5400-88-4, (4-tert-Butylcyclohexyl)amine 5438-70-0, (4-((Ethoxycarbonyl)methyl)phenyl)amine 5459-93-8 5459-95-0, Methyl(3-(diethylamino)propyl)amine 5473-12-1, Methyl((methoxycarbonyl)methyl)amine 5585-33-1, (2-Morpholinophenyl)amine 5616-32-0, Methyl(cyanomethyl)amine 5638-76-6, Methyl(2-(pyridin-2-yl)ethyl)amine 5754-35-8, (2-(Dioxolan-2-yl)ethyl)amine 5763-61-1, ((3,4-Dimethoxyphenyl)methyl)amine
RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)
(preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT 5856-63-3, ((R)-1-(Hydroxymethyl)propyl)amine 5913-13-3, ((R)-1-Cyclohexylethyl)amine 6168-72-5, (2-Hydroxy-1-methylethyl)amine 6281-42-1, (2-(2-Oxoimidazolidino)ethyl)amine 6304-26-3, Ethyl(2-(pyridin-2-yl)ethyl)amine 6315-89-5, (3,4-Dimethoxyphenyl)amine 6338-70-1, (1,1-Dioxotetrahydrothiophen-3-yl)amine 6346-09-4, (4,4-Diethoxybutyl)amine 6457-49-4, 4-(Hydroxymethyl)piperidine 6589-55-5, Methyl(2-hydroxy-2-phenylethyl)amine 6628-00-8, Cyclohexyl(2-propenyl)amine 6628-77-9, (6-Methoxypyridin-3-yl)amine 6791-49-7, ((S)-1-(Aminocarbonyl)-2-hydroxyethyl)amine 6850-57-3, ((2-Methoxyphenyl)methyl)amine 6859-99-0, 3-Hydroxypiperidine 6950-99-8, ((Pyridin-2-yl)methyl)(3-hydroxypropyl)amine 6971-57-9, Methyl((6-methylpyridin-2-yl)methyl)amine 7149-75-9, (4-Chloro-3-methylphenyl)amine 7249-87-8, Propyl(2-cyanoethyl)amine 7324-05-2, ((S)-1-(Aminocarbonyl)ethyl)amine 7533-40-6, ((S)-1-(Hydroxymethyl)-3-methylbutyl)amine **7568-93-6**, (2-Hydroxy-2-phenylethyl)amine 7663-77-6, (3-(2-Oxopyrrolidino)propyl)amine 7755-92-2, 4-Formylpiperazine 10065-72-2, ((S)-1-Methyl-2-methoxy-2-oxoethyl)amine 10272-07-8, (3,5-Dimethoxyphenyl)amine 10277-74-4, ((R)-Indan-1-yl)amine 10541-69-2, ((2,5-Dichlorophenyl)methyl)amine 10593-85-8, (2-Oxotetrahydrothiophen-3-yl)amine 13078-80-3, (2-(2-Chlorophenyl)ethyl)amine 13214-66-9, (4-Phenylbutyl)amine 13258-63-4, (2-(Pyridin-4-yl)ethyl)amine 13325-10-5, (4-Hydroxybutyl)amine 13472-00-9, (2-(4-Aminophenyl)ethyl)amine 13484-40-7, 4-(2-Methoxyethyl)piperazine 13889-98-0, 4-Acetylpiperazine 13952-84-6, (sec-Butyl)amine 13961-36-9, 4-(2-Propenyl)piperazine 14003-16-8, ((5-Methylfuran-2-yl)methyl)amine 14268-66-7, (Benzodioxol-5-yl)amine 14321-27-8, Ethyl(benzyl)amine 14572-89-5, (4-(1-Hydroxyethyl)phenyl)amine 14573-23-0, (2-(2,6-Dichlorophenyl)ethyl)amine 15205-11-5, ((2-Chloro-4-fluorophenyl)methyl)amine 15404-06-5, (2-((Butyl)(ethyl)amino)ethyl)amine 15901-42-5, (3,3,5-Trimethylcyclohexyl)amine 16369-21-4, Propyl(2-hydroxyethyl)amine 16397-19-6, (1-(Hydroxymethyl)pentyl)amine 16452-01-0, (3-Methoxy-4-methylphenyl)amine 17430-98-7, ((S)-1-Cyclohexylethyl)amine 17481-27-5, (3-Amino-4-methoxybenzoyl)amine

18471-40-4, (1-Benzylpyrrolidin-3-yl)amine 18595-14-7, (4-(Methoxycarbonyl)-2-methylphenyl)amine 18638-99-8, ((3,4,5-Trimethoxyphenyl)methyl)amine 19248-13-6, (2-((Ethyl)(3-methylphenyl)amino)ethyl)amine 19764-58-0, (2-(Dimethylamino)propyl)amine 20173-04-0, Methyl((pyridin-3-yl)methyl)amine 20173-24-4, (2-(Pyridin-3-yl)ethyl)amine 20503-40-6, (1,1-Dioxobenzothiophen-6-yl)amine 20781-20-8, ((2,4-Dimethoxyphenyl)methyl)amine 20989-17-7, ((S)-2-Hydroxy-1-phenylethyl)amine 21581-45-3, (2-(3,4-Dichlorophenyl)ethyl)amine 22094-62-8, (2,3-Dihydro-1,1,3-trioxobenzoisothiazol-6-yl)amine 22374-89-6, (1-Methyl-3-phenylpropyl)amine 22483-09-6, (2,2-Dimethoxyethyl)amine 23159-07-1, (3-(Pyrrolidino)propyl)amine 24304-84-5, (2-((2-Hydroxyethyl)thio)ethyl)amine 24313-88-0, (3,4,5-Trimethoxyphenyl)amine 24629-25-2, ((S,S)-1-(Hydroxymethyl)-2-methylbutyl)amine 25560-00-3, (3-(2-Methylpiperidino)propyl)amine 26116-12-1, ((1-Ethylpyrrolidin-2-yl)methyl)amine 26389-60-6, Propyl(cyclopropylmethyl)amine 26734-09-8, (3-Hydroxy-2,2-dimethylpropyl)amine 27298-98-2, ((S)-1-(4-Methylphenyl)ethyl)amine 27489-62-9, (trans-4-Hydroxycyclohexyl)amine 27492-84-8, 4-Amino-2-methoxybenzoic acid methyl ester 28163-64-6, ((R)-2-Phenylpropyl)amine 28292-42-4, (1-Ethylpentyl)amine 29602-39-9, (2-((5-Nitropyridin-2-yl)amino)ethyl)amine 31252-42-3, 4-Benzylpiperidine 32231-06-4, 4-((Benzodioxol-5-yl)methyl)piperazine 33194-35-3, ((S)-1-((Methylamino)carbonyl)ethyl)amine 33403-97-3, Ethyl((pyridin-4-yl)methyl)amine 33611-48-2, ((Pyridin-3-yl)methyl)(2-cyanoethyl)amine 34698-41-4, (Indan-1-yl)amine 34803-66-2 34967-24-3, ((3,5-Dimethoxyphenyl)methyl)amine 35016-37-6, Methyl((S)-1-(methoxycarbonyl)-2-methylpropyl)amine 35161-71-8, Methyl(2-propynyl)amine 35320-23-1, ((R)-2-Hydroxy-1-methylethyl)amine 35794-11-7, 3,5-Dimethylpiperidine 35947-10-5, 3-Methyl-4-(3-methylphenyl)piperazine 36489-03-9, (2-Ethylthioethyl)amine 37143-54-7, (2-Methoxy-1-methylethyl)amine 37585-25-4, (4-Chloro-2-(hydroxymethyl)phenyl)amine 37806-29-4, ((2-Ethoxyphenyl)methyl)amine 38212-30-5, 4-(4-Methoxyphenyl)piperazine 38256-93-8, Methyl(2-methoxyethyl)amine 39190-67-5, Propyl(sec-butyl)amine 39216-86-9, Ethyl(4-hydroxybutyl)amine 39226-95-4, ((2,3-Dichlorophenyl)methyl)amine 39546-32-2, 4-(Aminocarbonyl)piperidine 39590-27-7, (2-(2-Ethoxyphenyl)ethyl)amine 39890-42-1, 4-(((Isopropylamino)carbonyl)methyl)piperazine 39895-55-1, ((4-tert-Butylphenyl)methyl)amine 40137-22-2, Methyl(2,3-dihydroxypropyl)amine 40172-95-0, 4-((Furan-2-yl)carbonyl)piperazine 40499-83-0, 3-Hydroxypyrrolidine 40807-61-2, 4-Hydroxy-4-phenylpiperidine 42142-52-9, Methyl(3-hydroxy-3-phenylpropyl)amine 42185-03-5, (2-Propoxyethyl)amine 50541-93-0, (1-Benzylpiperidin-4-yl)amine 51387-90-7, (2-(1-Methylpyrrolidin-2-yl)ethyl)amine 51586-20-0, ((2,3-Dimethylphenyl)methyl)amine 51744-82-2, ((R)-2-Oxotetrahydrofuran-3-yl)amine 52516-13-9, (2-(2,4-Dichlorophenyl)ethyl)amine 52516-30-0, (2-(3-(Trifluoromethyl)phenyl)ethyl)amine 52721-69-4, (2-(2-Fluorophenyl)ethyl)amine 53485-07-7, (3-((Methyl)(phenyl)amino)propyl)amine 55496-55-4, Methyl(2-(pyridin-4-yl)ethyl)amine 55496-57-6, Propyl(2-(pyridin-2-yl)ethyl)amine 55755-16-3, Methyl(2-phenylethyl)amine 56613-80-0, ((R)-2-Hydroxy-1-phenylethyl)amine 56613-81-1, ((S)-2-Hydroxy-2-phenylethyl)amine 57366-77-5, Methyl((dioxolan-2-yl)methyl)amine 58859-46-4, (1-(Ethoxycarbonyl)piperidin-4-yl)amine 59578-63-1, Benzyl(4-hydroxybutyl)amine 61341-86-4, ((S)-Indan-1-yl)amine 63448-63-5, (1-(Methoxymethyl)propyl)amine 63493-28-7, (1-Methylbutyl)amine 67515-74-6, ((4-Fluoro-3-(trifluoromethyl)phenyl)methyl)amine 67952-93-6, ((3-Chloro-4-methylphenyl)methyl)amine 70180-92-6, (1,2-Diethylpyrazolidin-4-yl)amine 71172-58-2 72235-52-0, ((2,4-Difluorophenyl)methyl)amine 72235-53-1, ((3,4-Difluorophenyl)methyl)amine 79286-74-1, 3-(Acetylamino)pyrrolidine

79286-87-6, 3-((Acetyl)(methyl)amino)pyrrolidine 81731-43-3, (2-Isopropoxyethyl)amine 85118-06-5, ((2,5-Difluorophenyl)methyl)amine 85803-43-6, ((R)-1-((Benzylthio)methyl)-2-hydroxyethyl)amine 90322-18-2, ((Tetrahydrofuran-2-yl)methyl)(2-cyanoethyl)amine 93919-56-3, ((4-(Trifluoromethoxy)phenyl)methyl)amine 114715-38-7, ((S)-1-Benzylpyrrolidin-3-yl)amine 114715-39-8, ((R)-1-Benzylpyrrolidin-3-yl)amine 121180-51-6, (4-(1,2,3-Thiadiazol-4-yl)phenyl)amine 126456-43-7 131288-67-0, ((S)-1-(Cyclohexylmethyl)-2-hydroxyethyl)amine 131900-62-4, (R)-3-(Acetylamino)pyrrolidine 132883-44-4, (S)-3-(Dimethylamino)pyrrolidine 132958-72-6, (R)-3-(Dimethylamino)pyrrolidine 133269-86-0, (((1S,2R)-2-Hydroxycyclohexyl)methyl)amine 142753-10-4, Methyl(2-(dioxolan-2-yl)ethyl)amine 157837-31-5, (3-(Oxazol-5-yl)phenyl)amine 175201-90-8, (3-(2-Methylpyrimidin-4-yl)phenyl)amine 261633-75-4, (2-(2,3-Dihydro-1,4-benzodioxin-5-yl)ethyl)amine 461046-73-1, 4-(2-(Thien-2-yl)ethyl)piperazine
RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)
(preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT 486413-81-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]benzoic Acid
RL: CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT 75-77-4, Chlorotrimethylsilane, reactions 75-86-5, 2-Hydroxy-2-methylpropionitrile 108-15-6, N1,N1-Dimethylpropane-1,2-diamine 109-96-6, 2,5-Dihydro-1H-pyrrole 110-89-4, Piperidine, reactions 133-11-9, 4-Amino-2-hydroxybenzoic acid phenyl ester 461-96-1, 1-Bromo-3,5-difluorobenzene 551-93-9, 2'-Aminoacetophenone 766-17-6, cis-2,6-Dimethylpiperidine 768-66-1, 2,2,6,6-Tetramethylpiperidine 1142-20-7, 2S-Benzyloxycarbonylaminopropionic acid 1205-06-7, 4-Ethoxycarbonylphenyl isothiocyanate 2273-39-4, 2-Methyl-2-methylaminopropionitrile 2457-76-3, 4-Amino-2-chlorobenzoic acid 3317-61-1, 5,5-Dimethyl-1-pyrroline N-oxide 3430-22-6, 3-Bromo-4-methylpyridine 4530-20-5, N-tert-Butoxycarbonylglycine 5122-82-7, 1-Adamantyl bromomethyl ketone 5466-84-2, 4-Nitrophthalic anhydride 5739-10-6, 2-Imidazol-1-ylethylamine 7764-95-6, 2R-tert-Butoxycarbonylaminopropionic acid 10200-59-6, 2-Thiazolecarboxaldehyde 13504-85-3, (2S,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 13670-99-0, 2',6'-Difluoroacetophenone 13750-81-7, 1-Methyl-2-imidazolecarboxaldehyde 15761-38-3, N-(tert-Butoxycarbonyl)-L-alanine 18144-47-3, tert-Butyl 4-aminobenzoate 18977-45-2, (Cyclopropylmethyl)methylamine 21655-48-1, cis-3,5-Dimethylpiperazine 22795-99-9, S-(-)-2-Aminomethyl-1-ethylpyrrolidine 22838-58-0, N-tert-Butoxycarbonyl D-valine 26250-84-0, (S)-(-)-1-(tert-Butoxycarbonyl)-2-piperidinecarboxylic acid 26607-51-2, N-Benzyloxycarbonyl-D-alanine 33208-99-0, (S)-2-Aminopropionamide hydrochloride 35320-22-0 36476-78-5, Azetidine-3-carboxylic acid 40637-81-8, 1-Methylimidazole-5-carboxamide 54606-49-4, 3-Aminomethyl-2,2,5,5-tetramethyl-1-pyrrolidinyloxy 59531-86-1, D-Alanine tert-butyl ester hydrochloride 62466-11-9, 2-Bromoacetyl-3-methylthiophene 63399-73-5, (S)-2-Methylpyrrolidine-2-carboxylic acid hydrobromide 66411-53-8, [((R)-1-Methylpyrrolidin-2-yl)methyl]amine 66411-54-9, [((S)-1-Methylpyrrolidin-2-yl)methyl]amine 76936-44-2, 2,N2,N2-Trimethylpropane-1,2-diamine 81547-72-0, 2-Bromo-2',6'-dichloroacetophenone 89379-40-8, 2,N1,N1-Trimethylpropane-1,2-diamine 92146-82-2, tert-Butyl 3-aminobenzoate 97674-02-7, Tributyl(1-ethyloxyvinyl)stannane 119020-01-8, (S)-2-Aminomethylpyrrolidine-1-carboxylic acid tert-butyl ester 122536-77-0, 3R-(t-Boc-amino)pyrrolidine 152294-81-0, 5-Amino-2-(2-

dimethylaminoethyl)isoindole-1,3-dione 164642-21-1, 1-(Aminomethyl)-N,N-dimethylcyclopentanamine 166735-47-3, 3-endo-2-Azabicyclo[2.2.1]hept-5-ene-3-carboxylic acid ethyl ester 176445-78-6, 1-(Aminomethyl)-N,N-dimethylcyclobutanamine 243983-21-3, (S)-2-[(S)-1-(Benzylhydroxyamino)ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester 370069-31-1, 2-Aminomethylpiperidine-1-carboxylic acid tert-butyl ester 486415-11-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT 655-15-2P, 2-Bromo-2'-fluoroacetophenone 828-55-7P, 1-(2-Aminoethyl)-2,2,6,6-tetramethylpiperidine 1788-35-8P, cis-1-(2-Aminoethyl)-2,6-dimethylpiperidine 3323-76-0P, 1-(2-Methanesulfonylphenyl)ethanone 4688-64-6P, N-[2-(2-Bromoacetyl)phenyl]acetamide 5234-26-4P, N-(2-Acetylphenyl)acetamide 20062-62-8P, 1-Methyl-1H-imidazole-2-carboxaldehyde oxime 51227-30-6P, 1-(4-Methylpyridin-3-yl)ethanone 54151-73-4P, 1-(2-Amino-1,1-dimethylethyl)piperidine 55661-33-1P, C-Thiazol-2-ylmethylamine 56159-89-8P, 2-Bromo-2',6'-difluoroacetophenone 78058-41-0P, (S)-2-Carbamoylpiperidine-1-carboxylic acid tert-butyl ester 82105-48-4P, (S)-N,N-Dimethylpropane-1,2-diamine dihydrochloride 96807-37-3P, 2-(2-Dimethylaminoethyl)-5-nitroisoindole-1,3-dione 99513-18-5P, 2-Bromo-1-(2-methanesulfonylphenyl)ethanone 114358-07-5P, (4R,2S)-2-Carbamoyl-4-hydroxypyrrolidine-1-carboxylic Acid Benzyl Ester 116577-09-4P, 2,N2-Dimethylpropane-1,2-diamine 124312-73-8P, C-(1-Methyl-1H-imidazol-2-yl)methylamine 125218-78-2P, ((S)-1-Dimethylcarbamoylethyl)carbamic acid tert-butyl ester 129993-47-1P, 1-Methyl-1H-imidazole-4-carboxylic acid amide 134618-04-5P, (5S,3R)-5-Aminomethyl-1-methylpyrrolidin-3-ol 142253-55-2P 157359-99-4P, 2-Bromo-1-(2-chloro-6-fluorophenyl)ethanone 184910-20-1P, (4-Bromo-2,6-difluorophenyl)trimethylsilane 220594-95-6P, 5-Aminomethyl-2,2-dimethylpyrrolidin-1-ol 223786-78-5P, 4-[[4-Amino-5-(2,6-dichlorobenzoyl)thiazol-2-yl]amino]benzoic acid 300578-46-5P, 2-(2,5-Dihydropyrrol-1-yl)ethylamine Dihydrochloride 346691-01-8P, ((R)-1-Methylpyrrolidin-3-yl)carbamic acid tert-butyl ester 352439-94-2P, 2-Hydroxy-4-isothiocyanato-benzoic Acid Phenyl Ester 403712-75-4P, (R)-N,N-Dimethylpropane-1,2-diamine dihydrochloride 435273-53-3P, 2-Bromo-1-(4-methylpyridin-3-yl)ethanone Hydrobromide 486413-80-3P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]benzoic acid Ethyl Ester 486413-90-5P, 2S-[[[1-[4-[[4-Amino-5-[1-(2,6-difluorophenyl)methanoyl]thiazol-2-yl]amino]phenyl]methanoyl]amino]methyl]pyrrolidine-1-carboxylic acid tert-butyl ester 486414-14-6P, (R)-1-Methylpyrrolidin-3-ylamine trifluoroacetic acid salt 486414-16-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((S)-1-methylpyrrolidin-2-ylmethyl)benzamide 486414-18-0P, (S)-1-Methylpyrrolidin-3-ylamine trifluoroacetic acid salt 486414-21-5P, 2-[[[1-[4-[[4-Amino-5-[1-(2,6-difluorophenyl)methanoyl]thiazol-2-yl]amino]phenyl]methanoyl]amino]methyl]piperidine-1-carboxylic acid tert-butyl ester 486414-25-9P, (S)-N1,N1,N2-Trimethylpropane-1,2-diamine 486414-27-1P, (R)-N1,N1,N2-Trimethylpropane-1,2-diamine 486414-30-6P, 2-[(Cyclopropylmethyl)methylamino]-2-methylpropionitrile 486414-31-7P, N2-Cyclopropylmethyl-2,N2-dimethylpropane-1,2-diamine 486414-33-9P, (1R-Dimethylcarbamoylethyl)carbamic acid Benzyl Ester 486414-34-0P, ((R)-2-Dimethylamino-1-methylethyl)carbamic acid Benzyl Ester 486414-35-1P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-2-dimethylamino-1-methylethyl)benzamide 486414-38-4P, (S)-2-Dimethylaminopropionamide Hydrochloride 486414-39-5P, (S)-N2,N2-Dimethylpropane-1,2-diamine Dihydrochloride 486414-41-9P, [((S)-1-Methylpiperidin-2-yl)methyl]amine 486414-43-1P, (R)-N2,N2-Dimethylpropane-1,2-diamine hydrochloride 486414-45-3P, [2-(2,5-Dihydropyrrol-1-yl)-2-oxoethyl]carbamic acid tert-Butyl Ester 486414-46-4P, 2-Amino-1-(2,5-dihydropyrrol-1-yl)ethanone 486414-49-7P, 1R-Methyl-2-piperidin-1-ylethylamine 486414-51-1P, (R)-3,N1,N1-Trimethylbutane-1,2-diamine 486414-53-3P, 4-[[4-Amino-5-(2,6-

difluorobenzoyl)thiazol-2-yl]amino]-N-(1-hydroxy-5,5-dimethylpyrrolidin-2-ylmethyl)benzamide 486414-62-4P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(1-hydroxy-2,2,5,5-tetramethylpyrrolidin-3-ylmethyl)benzamide 486414-64-6P, cis-3,5-Dimethylpiperazine-1-carbonitrile 486414-65-7P, 2-(cis-3,5-Dimethylpiperazin-1-yl)ethylamine 486414-68-0P, 3-(1-Ethoxyvinyl)-4-methylpyridine 486414-69-1P, 4-[[4-Amino-5-[1-(4-methylpyridin-3-yl)methanoyl]thiazol-2-yl]amino]benzoic Acid 486414-70-4P, 4-[[4-Amino-5-[1-(4-methylpyridin-3-yl)methanoyl]thiazol-2-yl]amino]benzoic acid Ethyl Ester 486414-76-0P, 4-[[4-Amino-5-[1-(3-methylthiophen-2-yl)methanoyl]thiazol-2-yl]amino]benzoic Acid Ethyl Ester 486414-78-2P, 4-[[4-Amino-5-[1-(3-methylthiophen-2-yl)methanoyl]thiazol-2-yl]amino]benzoic Acid 486414-83-9P, C-(1-Methyl-1H-imidazol-4-yl)methylamine 486414-86-2P, C-(3-Methyl-3H-imidazol-4-yl)methylamine 486414-89-5P, 2R-[[4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]benzoyl]amino]propionic acid tert-Butyl Ester 486414-92-0P, 4-[[4-Amino-5-(2-fluorobenzoyl)thiazol-2-yl]amino]benzoic Acid Ethyl Ester 486414-93-1P, 4-[[4-Amino-5-(2-fluorobenzoyl)thiazol-2-yl]amino]benzoic Acid 486414-99-7P, (2,6-Difluoro-4-methylphenyl)trimethylsilane 486415-01-4P, 2,6-Difluoro-4-methylacetophenone 486415-03-6P, 2-Bromo-2',6'-difluoro-4'-methylacetophenone 486415-05-8P, 4-[[4-Amino-5-(2,6-difluoro-4-methylbenzoyl)thiazol-2-yl]amino]benzoic Acid 486415-07-0P, 4-[[4-Amino-5-(2,6-difluoro-4-methylbenzoyl)thiazol-2-yl]amino]benzoic acid ethyl ester 486415-09-2P, (S)-2-((S)-1-Aminoethyl)pyrrolidine-1-carboxylic Acid tert-Butyl Ester 486415-10-5P 486415-14-9P, 4-[[4-Amino-5-(2-chloro-6-fluorobenzoyl)thiazol-2-yl]amino]benzoic Acid Ethyl Ester 486415-15-0P, 4-[[4-Amino-5-(2-chloro-6-fluorobenzoyl)thiazol-2-yl]amino]benzoic Acid 486415-17-2P, 4-[[5-(2-Acetylaminobenzoyl)-4-aminothiazol-2-yl]amino]benzoic Acid Ethyl Ester 486415-18-3P, 4-[[5-(2-Acetylaminobenzoyl)-4-aminothiazol-2-yl]amino]benzoic Acid 486415-21-8P, 4-[[4-Amino-5-(2-methanesulfonylbenzoyl)thiazol-2-yl]amino]benzoic Acid Ethyl Ester 486415-25-2P, (S)-2-Methylpyrrolidine-1,2-dicarboxylic Acid 1-tert-Butyl Ester 486415-26-3P, (S)-2-Carbamoyl-2-methylpyrrolidine-1-carboxylic Acid tert-Butyl Ester 486415-27-4P, C-((2S)-1,2-Dimethylpyrrolidin-2-yl)methylamine 486415-29-6P, 3-Carbamoylazetidine-1-carboxylic Acid tert-Butyl Ester 486415-31-0P, 3-endo-2-(tert-Butoxycarbonyl)-2-azabicyclo[2.2.1]hept-5-ene-3-carboxylic acid Ethyl Ester 486415-32-1P, 3-endo-2-(tert-Butoxycarbonyl)-2-azabicyclo[2.2.1]heptane-3-carboxylic Acid 486415-33-2P, 3-endo-2-(tert-Butoxycarbonyl)-2-azabicyclo[2.2.1]hept-5-ene-3-carboxylic acid 486415-34-3P, 3-endo-Carbamoyl-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-Butyl Ester 486415-37-6P, 4-Isothiocyanatobenzoic Acid tert-Butyl Ester 486415-38-7P, 4-[[4-Amino-5-(2,6-dichlorobenzoyl)thiazol-2-yl]amino]benzoic Acid tert-Butyl Ester 486415-44-5P, 2-Chloro-4-isothiocyanatobenzoic Acid 486415-45-6P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-2-chlorobenzoic acid 486415-47-8P, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-2-hydroxybenzoic acid Phenyl Ester 486415-50-3P, 5-Amino-2-(2-dimethylaminoethyl)isoindole-1,3-dione hydrochloride 486415-51-4P, 2-(2-Dimethylaminoethyl)-5-isothiocyanato-isoindole-1,3-dione 486415-53-6P, 3-Isothiocyanatobenzoic Acid tert-Butyl Ester 486415-54-7P, 3-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]benzoic acid tert-Butyl Ester 486415-55-8P, 3-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]benzoic Acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

IT **7568-93-6**, (2-Hydroxy-2-phenylethyl)amine
RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)
(preparation of thiazolylamino benzamide derivs. as modulators of cell

proliferation and inhibitors of protein kinases)
RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 4 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:858108 HCAPLUS
DN 138:237942
ED Entered STN: 13 Nov 2002
TI Enantioselective **synthesis** of aziridines using asymmetric transfer hydrogenation as a precursor for chiral derivatives used as bonding agent for rocket **solid** propellants
AU Kawamoto, Aparecida M.; Wills, Martin
CS Div. Quimica, Inst. Aeronautica Espaco, Centro Tecnico Aeroespacial, Sao Jose dos Campos, 12228-904, Brazil
SO Quimica Nova (2002), 25(6), 921-925
CODEN: QUNODK; ISSN: 0100-4042
PB Sociedade Brasileira de Quimica
DT Journal
LA English
CC 27-3 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 50
OS CASREACT 138:237942
AB A rapid, expedient, and enantioselective method for the **synthesis** of β-hydroxy amines and monosubstituted aziridines in up to 99% e.e., via asym. transfer hydrogenation of α-amino ketones and cyclization through treatment with tosyl chloride and base, is described. (1R,2R)-N-(para-toluenesulfonyl)-1,2-ethylenediamine with formic acid has been utilized as a ligand for the ruthenium(II) catalyzed enantioselective transfer hydrogenation of the ketones. The chiral 2-methylaziridine, which is a potentially more efficient bonding agent for rocket **solid** propellant, has been successfully achieved.
ST asym transfer hydrogenation amido ketone; bonding agent rocket solid propellant chiral aziridine
IT Asymmetric **synthesis** and induction
(enantioselective preparation of aziridines using asym. transfer hydrogenation of α-amido ketone and cyclization as a precursor for chiral derivs. used as bonding agent for rocket **solid** propellants)
IT Cyclization
(enantioselective preparation of aziridines using asym. transfer hydrogenation of α-amido ketones and cyclization as a precursor for chiral derivs. used as bonding agent for rocket solid propellants)
IT Propellants (fuels)
(solid; enantioselective preparation of aziridines using asym. transfer hydrogenation of α-amido ketones and cyclization as a precursor for chiral derivs. used as bonding agent for rocket solid propellants)
IT Hydrogenation
(transfer, stereoselective; enantioselective preparation of aziridines using asym. transfer hydrogenation of α-amido ketones and cyclization as a precursor for chiral derivs. used as bonding agent for rocket solid propellants)
IT Hydrogenation catalysts
(transfer, stereoselective; ruthenium(II) catalyzed enantioselective preparation of aziridines using asym. transfer hydrogenation of α-amido ketones and cyclization as a precursor for chiral derivs. used as bonding agent for rocket solid propellants)

IT Ketones, preparation
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(α-amido; enantioselective preparation of aziridines using asym. transfer hydrogenation of α-amido ketones and cyclization as a precursor for chiral derivs. used as bonding agent for rocket solid propellants)
IT 57-39-6P, MAPO 7652-64-4P, HX 752
RL: PNU (Preparation, unclassified); PREP (Preparation)
(chiral derivative or analog; enantioselective preparation of aziridines using asym. transfer hydrogenation of α-amido ketones and cyclization as a precursor for chiral derivs. used as bonding agent for rocket solid propellants)
IT 52462-29-0 144222-34-4
RL: CAT (Catalyst use); USES (Uses)
(enantioselective preparation of aziridines using asym. transfer hydrogenation of α-amido ketones and cyclization as a precursor for chiral derivs. used as bonding agent for rocket solid propellants)
IT 78-96-6 **7568-93-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(enantioselective preparation of aziridines using asym. transfer hydrogenation of α-amido ketones and cyclization as a precursor for chiral derivs. used as bonding agent for rocket solid propellants)
IT 67341-07-5P 76477-26-4P 95656-86-3P 167938-56-9P 170384-29-9P 281670-47-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(enantioselective preparation of aziridines using asym. transfer hydrogenation of α-amido ketones and cyclization as a precursor for chiral derivs. used as bonding agent for rocket solid propellants)
IT 129319-71-7P 129319-91-1P 197020-64-7P 313657-44-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(enantioselective preparation of aziridines using asym. transfer hydrogenation of α-amido ketones and cyclization as a precursor for chiral derivs. used as bonding agent for rocket solid propellants)
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Allen, H; US 3745074 1973 HCAPLUS
(2) Atkinson, R; J Chem Soc, Chem Commun 1987, P1362 HCAPLUS
(3) Azman, A; J Am Chem Soc 1970, V101, P1107
(4) Bardos, T; J Surg Oncol 1971, V3, P431 MEDLINE
(5) Belgrad, R; Int J Radiat Oncol Biol Phys 1982, V8, P1219 MEDLINE
(6) Evans, D; J Am Chem Soc 1993, V115, P5328 HCAPLUS
(7) Evans, D; J Org Chem 1991, V113, P726 HCAPLUS
(8) Fletcher, D; J Chem Inf Comput Sci 1996, V36, P746 HCAPLUS
(9) Fujii, A; J Am Chem Soc 1996, V118, P2521 HCAPLUS
(10) Haddadin, M; Small Ring Heterocycles 1985, part 3, P283
(11) Hasegawa, K; AIAA Papers 1983, V83, P1199
(12) Hashiguchi, S; J Am Chem Soc 1995, V117, P7562 HCAPLUS
(13) Hori, K; Propellants, Explos, Pyrotech 1990, V15, P99 HCAPLUS
(14) Kawamoto, A; Tetrahedron: Asymmetry 2000, V11, P3257 HCAPLUS
(15) Kemp, J; Comprehensive Organic Synthesis 1991, V7, P470
(16) Kenny, J; Chem Commun 2000, P99 HCAPLUS
(17) Kenny, J; Synlett 1999, P1615 HCAPLUS
(18) King, R; Inorg Chem 1974, V13, P2449 HCAPLUS
(19) Kori, K; Propellants, Explos, Pyrotech 1985, V10, P176
(20) Li, Z; J Am Chem Soc 1993, V115, P5326 HCAPLUS
(21) Mashima, K; Chem Lett 1998, P1199 HCAPLUS
(22) Mashima, K; Chem Lett 1998, P1201 HCAPLUS
(23) Murata, K; J Org Chem 1999, V64, P2186 HCAPLUS
(24) Palmer, M; J Org Chem 1997, V62, P5226 HCAPLUS
(25) Palmer, M; Tetrahedron: Asymmetry 1999, V10, P2045 HCAPLUS

(26) Paredes, R; Tetrahedron 1988, V44, P6821 HCAPLUS
(27) Perlman, M; J Org Chem 1988, V53, P1761 HCAPLUS
(28) Puntener, K; Tetrahedron Lett 1996, V37, P8165
(29) Rauf, A; J Am Oil Chem Soc 1984, V61, P959 HCAPLUS
(30) Smith, A; Tetrahedron: Asymmetry 1999, V10, P3267 HCAPLUS
(31) Wampler, G; Cancer Chemother Pharmacol 1980, V4, P49 MEDLINE
(32) Wessig, P; Synlett 1997, P893 HCAPLUS
(33) Wills, M; J Mol Catal A 1999, V146, P139 HCAPLUS
(34) Wills, M; Molecules 2000, V5, P1

IT **7568-93-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(enantioselective preparation of aziridines using asym. transfer hydrogenation of α-amido ketones and cyclization as a precursor for chiral derivs. used as bonding agent for rocket solid propellants)
RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:793502 HCAPLUS
DN 137:310454
ED Entered STN: 18 Oct 2002
TI **Solid phase synthesis supports** and methods
IN **Rasmussen, Jerald K.; Krepski, Larry R.**
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM B01J019-00
CC 21-2 (General Organic Chemistry)
Section cross-reference(s): 33, 34
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002081078	A2	20021017	WO 2002-US6367	20020228
	WO 2002081078	A3	20030327		
	W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002173051	A1	20021121	US 2001-827107	20010405
	EP 1373167	A2	20040102	EP 2002-715021	20020228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2001-827107	A	20010405		
	WO 2002-US6367	W	20020228		

AB A method for preparation of azlactone-linker-functionalized **support** of formula SS-[CO-NH-CR5R6-(CH2)n-CO-NH-[CR1R2]p-CR3R4OR7]m [SS represents a **support** material; CO-NH-CR5R6-(CH2)n-CO is derived from an

azlactone group; R5 and R6 = each independently an organic group and n = 0, 1; NH-(CR1R2)p-CR3R4OR7is the linker; R1, R2, R3, and R4 = each independently H or an organic group, and at least one of R3 and R4 = an aromatic group; R7 = H, a protecting group, or an organic group capable of being derivatized, and p = at least 1; and m = 1 to the resin capacity of the **support** material] for **solid phase synthesis** of derivatized organic compds. is developed. The examples include the coupling of 2-amino-1-phenylethanol, 2-amino-1-(4-methoxyphenyl)ethanol, or 3-formylindol-1-ylacetic acid to EMPHAZE AB 1 beads.

ST **solid phase synthesis** org compd azlactone linker functionalized **support**; coupling linker azlactone functionalized **support** bead membrane; combinatorial chem library **solid phase** polypeptide polynucleotide

IT Spheres
(beads; preparation of azlactone-linker-functionalized support by coupling of linker to EMPHAZE AB 1 beads)

IT **Solid phase synthesis**
(combinatorial; **solid phase synthesis** of derivatized organic compds. as building blocks for combinatorial libraries on prepared azlactone-linker-functionalized **support**)

IT Coupling reaction
Linking agents
Polymer-supported reagents
(preparation of azlactone-linker-functionalized support by coupling of linker to azlactone-functionalized support)

IT **Combinatorial library**
(**solid phase synthesis** of derivatized organic compds. as building blocks for combinatorial libraries on prepared azlactone-linker-functionalized **support**)

IT Membranes, nonbiological
(**solid phase synthesis** of derivatized organic compds. on prepared azlactone-linker-functionalized **support** as membrane)

IT Polynucleotides
RL: CPN (Combinatorial preparation); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation)
(**solid phase synthesis** of polynucleotides on azlactone-linker-functionalized **support**)

IT Peptides, preparation
RL: CPN (Combinatorial preparation); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation)
(**solid phase synthesis** of polypeptides on azlactone-linker-functionalized **support**)

IT **Combinatorial chemistry**
(**solid-phase; solid phase synthesis** of derivatized organic compds. as building blocks for combinatorial libraries on prepared azlactone-linker-functionalized **support**)

IT 129825-50-9
RL: NUU (Other use, unclassified); RCT (Reactant); RACT (Reactant or reagent); USES (Uses)
(preparation of azlactone-linker-functionalized support by coupling of linker to azlactone-functionalized support)

IT 65-85-0, Benzoic acid, reactions 107-15-3, Ethylenediamine, reactions **7568-93-6**, 2-Amino-1-phenylethanol **55275-61-1**, 2-Amino-1-(4-methoxyphenyl)ethanol 117870-93-6, Indolyl 138423-98-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of azlactone-linker-functionalized support by coupling of linker to azlactone-functionalized support)

IT **7568-93-6**, 2-Amino-1-phenylethanol **55275-61-1**, 2-Amino-1-(4-methoxyphenyl)ethanol

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of azlactone-linker-functionalized support by coupling of linker to azlactone-functionalized support)
RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 55275-61-1 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-methoxy- (9CI) (CA INDEX NAME)



L23 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:256222 HCAPLUS
DN 136:294651
ED Entered STN: 05 Apr 2002
TI Preparation of aryl-substituted N-hydroxy amides with amide linkages as HDAC inhibitors for treatment of proliferative conditions
IN Watkins, Clare J.; Romero-Martin, Maria-Rosario; Moore, Kathryn G.; Ritchie, James; Finn, Paul W.; Kalvinsh, Ivars; Loza, Einars; Starchenkov, Igor; Dikovska, Klara; Bokaldere, Rasma Melita; Gailite, Vija; Vorona, Maxim; Andrianov, Victor; Lolya, Daina; Semenikhina, Valentina; Amolins, Andris; Harris, C. John; Duffy, James E. S.
PA Prolifix Limited, UK
SO PCT Int. Appl., 346 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C233-03
ICS C07C233-05; C07C233-09; C07C233-08; C07D207-40; C07D213-06; C07D209-14; C07D235-24; C07D307-34; C07D333-24; C07D333-60; A61P035-00
CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 34
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002026696	A1	20020404	WO 2001-GB4329	20010927
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001090134	A5	20020408	AU 2001-90134	20010927
EP 1335898	A1	20030820	EP 2001-970014	20010927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI GB 2000-23985 A 20000929
US 2001-297785P P 20010614
WO 2001-GB4329 W 20010927
OS MARPAT 136:294651
AB The title compds. AQ1JQ2CONHOH [I; wherein A = aryl group; Q1 = aryl leader group having a backbone of at least 2 C atoms; J = NR1CO or CONR1; R1 = amido substituent; Q2 = acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemical protected forms, and prodrugs thereof] were prepared via solution phase and **solid phase** synthetic methods as histone deacetylase (HDAC) inhibitors for treatment of proliferative conditions, such as cancer and psoriasis. For example, 6-aminocaproic acid Me ester•HCl was coupled with 2-naphthoyl chloride in the presence of diisopropyl ethylamine in DMF to give the amide. Deesterification (79%), followed by conversion to the N-hydroxyamide using HONH2•HCl in the presence of 1,1'-carbonyldiimidazole in THF, afforded naphthalene-2-carboxylic acid (5-hydroxycarbamoylpentyl)amide II (PX105687) in 40% yield. The latter inhibited recombinant HDAC1 and HDAC2 with IC50 values of 33 nM and 29 nM, resp., and inhibited cell proliferation against the human cervical adenocarcinoma (HeLa) cell line using cell proliferation reagent WST-1 with IC50 of 1.1 nM. Structure-activity relationship studies showed superior activity for I when (1) the backbone of Q1 had > 1 carbon atoms, and (2) the alkylene group Q2 had > 5 carbon atoms.
ST aryl hydroxyamide amide prepn histone deacetylase inhibitor; arylcarboxylic acid hydroxycarbamoylalkylamide prepn antiproliferative anticancer psoriasis treatment
IT Structure-activity relationship
(HDAC; preparation of N-hydroxy amides with amide linkages as HDAC inhibitors for treatment of proliferative conditions)
IT Antitumor agents
Cytotoxic agents
Human
Solid phase synthesis
(preparation of N-hydroxy amides with amide linkages as HDAC inhibitors for treatment of proliferative conditions)
IT Psoriasis
(treatment; preparation of N-hydroxy amides with amide linkages as HDAC inhibitors for treatment of proliferative conditions)
IT 85594-22-5P, PX 083449 149647-93-8P, PX 117418 193551-00-7P, PX 089274 251456-56-1P, PX 082531 251456-73-2P, PX 089276 251456-77-6P, PX 106495 408324-89-0P, PX 083447 408324-97-0P, PX 083448 408324-98-1P, PX 083803 408325-02-0P, PX 083804 408325-08-6P, PX 083806 408325-11-1P, PX 083807 408325-13-3P, PX 089283 408325-14-4P, PX 105552 408325-15-5P, PX 105553 408326-76-1P, PX 099268 408327-00-4P, PX 105668 408327-26-4P, PX 105669 408327-50-4P, PX 105670 408327-69-5P, PX 105554 408327-86-6P, PX 106513 408329-73-7P, PX 105830 408329-74-8P, PX 105829 408329-75-9P, PX 105847 408329-76-0P, PX 105831 408329-79-3P, PX 105848 408329-80-6P, PX 105849 408329-93-1P, PX 105850 408329-96-4P, PX 105851 408329-98-6P, PX 106518 408330-01-8P, PX 106520 408330-02-9P, PX 106524 408330-05-2P, PX 106525 408330-08-5P, PX 106526 408330-10-9P, PX 106527 408330-12-1P, PX 106516 408330-13-2P, PX 106517 408330-15-4P, PX 106521 408330-17-6P, PX 106528 408330-18-7P, PX 106491 408330-19-8P, PX 082546 408330-20-1P, PX 082548 408330-36-9P, PX 082549 408330-70-1P, PX 082530 408330-96-1P, PX 082533 408331-29-3P, PX 082534 408331-52-2P, PX 089275 408331-68-0P, PX 083808 408331-68-0P, PX 083808 408332-51-4P, PX 089048 408349-39-3P, PX 089049 408349-74-6P, PX 082532 408350-43-6P, PX 117711 408350-74-3P, PX 117706 408350-93-6P, PX 117707 408351-09-7P, PX 116212 408351-31-5P, PX 117232 408351-49-5P, PX 117231 408351-68-8P, PX 116246 408351-87-1P, PX 116244 408352-98-7P, PX 105845 408353-19-5P, PX 105816 408353-69-5P, PX 105846 408353-91-3P, PX 105832 408354-00-7P,

PX 106519 408354-01-8P, PX 106210 408354-02-9P, PX 106232 408354-03-0P, PX 117237 408354-04-1P, PX 116235 408354-05-2P, PX 117224 408354-06-3P, PX 117254 408354-07-4P, PX 117239 408354-08-5P, PX 116211 408354-09-6P, PX 117255 408354-10-9P, PX 117430 408354-11-0P, PX 117436 408354-12-1P, PX 117437 408354-13-2P, PX 117451 408354-14-3P, PX 117454 408354-15-4P, PX 117737 408354-21-2P, PX 117738 408354-22-3P, PX 117456 408354-24-5P, PX 116231 408354-25-6P, PX 116234 408354-26-7P, PX 116214 408354-28-9P, PX 116215 408354-29-0P, PX 106494 408354-30-3P, PX 106496 408354-31-4P, PX 106497 408354-32-5P, PX 116219 408354-33-6P, PX 116220 408354-34-7P, PX 116221 408354-35-8P, PX 117247 408354-43-8P, PX 117415 408354-65-4P, PX 117421 408354-89-2P, PX 117441 408355-10-2P, PX 117442 408355-31-7P, PX 117721 408355-66-8P, PX 117729 408355-89-5P, PX 117722 408356-18-3P, PX 117261 408356-36-5P, PX 117444 408356-74-1P, PX 117797 408356-88-7P, PX 105687 408356-93-4P, PX 106492 408356-94-5P, PX 106493 408356-95-6P, PX 106515 408356-96-7P, PX 117458 408356-97-8P, PX 117717 408356-98-9P, PX 117718 408356-99-0P, PX 117719 408357-29-9P, PX 116213 408357-30-2P, PX 105824 408357-31-3P, PX 105826 408357-32-4P, PX 105827 408357-33-5P, PX 105828 408357-34-6P, PX 106488 408357-35-7P, PX 106489 408357-36-8P, PX 116216 408357-37-9P, PX 116217 408357-38-0P, PX 116224 408357-39-1P, PX 116226 408357-40-4P, PX 117249 408357-41-5P, PX 117416 408357-43-7P, PX 117419 408357-44-8P, PX 117420 408357-49-3P, PX 117408 408357-61-9P, PX 116218 408357-69-7P, PX 116223 408357-70-0P, PX 117417 408357-71-1P, PX 117461 408357-72-2P, PX 117720 408357-73-3P, PX 117459 408357-76-6P, PX 116241 408357-81-3P, PX 117407 408357-82-4P, PX 117406 408357-83-5P, PX 117767 408357-84-6P, PX 117783 408357-85-7P, PX 117785
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(HDAC inhibitor; preparation of N-hydroxy amides with amide linkages as HDAC inhibitors for treatment of proliferative conditions)

IT 110-94-1DP, Pentanedioic acid, resin-bound 956-09-2P, 6-Benzoylaminohexanoic acid 1608-36-2P, 3-(4-Nitrophenyl)acrylic acid methyl ester 3303-84-2DP, resin-bound 3303-84-2P, N-tert-Butoxycarbonyl-β-alanine 6404-29-1DP, resin-bound 18496-54-3P, 4-Phenylbutyryl chloride 22834-47-5P, 6-(4-Methoxybenzoylamino)hexanoic acid 26930-49-4P, 3-Benzo[1,3]dioxol-5-ylacryloyl chloride 27219-07-4DP, resin-bound 56374-47-1P, Naphthalene-2-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester 57294-38-9DP, resin-bound 59378-98-2P, Mono-tert-butyl monomethyl glutarate 60722-88-5P, 4-Benzyloxycarbonylaminobutyric acid 2,5-dioxopyrrolidin-1-yl ester 63128-51-8DP, resin-bound 63128-51-8P, Mono-tert-butyl glutarate 65198-02-9P, 3-(4-Aminophenyl)acrylic acid methyl ester 75930-73-3P, 6-(4-Nitrobenzoylamino)hexanoic acid methyl ester 78121-46-7P, 6-Diphenylacetylaminohexanoic acid 86432-33-9P, (S)-3-(1H-Indol-3-yl)-2-(4-phenylbutyrylamino)propionic acid 88556-26-7P, 4-Phenylbutyric acid 2,5-dioxopyrrolidin-1-yl ester 94476-64-9DP, resin-bound 94476-72-9DP, resin-bound 100636-30-4P, 5-Phenyl-(2E,4E)-pentadienoyl chloride 107326-34-1DP, resin-bound 118528-55-5P, 6-[(Naphthalene-1-carbonyl)amino]hexanoic acid 119516-39-1P, 6-[(Naphthalene-2-carbonyl)amino]hexanoic acid 172333-10-7P, Naphthalen-2-ylacetic acid 2,5-dioxopyrrolidin-1-yl ester 177653-67-7P, 3-(4-Benzoylaminophenyl)acrylic acid 193550-99-1P, 6-(4-Dimethylaminobenzoylamino)hexanoic acid 202060-10-4DP, resin-bound 251304-83-3P, 6-(4-Dimethylaminobenzoylamino)hexanoic acid methyl ester 251456-57-2DP, resin-bound 251456-91-4P, 6-(4-Methoxybenzoylamino)hexanoic acid methyl ester 313267-03-7P, 6-[(Furan-2-carbonyl)amino]hexanoic acid 384807-63-0P, 6-[(3,4-Dimethoxybenzoyl)amino]hexanoic acid methyl ester 406725-10-8P, 4-[(2E)(4E)-5-Phenylpenta-2,4-dienoylamino]butyric acid methyl ester 406725-11-9P 406725-12-0P, 6-[(2E)(4E)-5-Phenylpenta-2,4-

dienoylamino]hexanoic acid methyl ester 406725-13-1P 406725-14-2P, (2E,4E)-6-[5-(2-Nitrophenyl)penta-2,4-dienoylamino]hexanoic acid methyl ester 406725-16-4P, (2E,4E)-6-(4-Methyl-5-phenylpenta-2,4-dienoylamino)hexanoic acid methyl ester 406725-17-5P, (2E,4E)-6-[5-(4-Nitrophenyl)penta-2,4-dienoylamino]hexanoic acid methyl ester 406725-18-6P, (E)-6-(3-Benzo[1,3]dioxol-5-ylacryloylamino)hexanoic acid methyl ester 406725-19-7P, (2E,4E)-6-(5-Biphenyl-4-ylpenta-2,4-dienoylamino)hexanoic acid methyl ester 406725-20-0P, (2Z,4E)-6-[5-(4-Chlorophenyl)penta-2,4-dienoylamino]hexanoic acid methyl ester 406725-21-1P, (2E,4E)-6-[5-(4-Chlorophenyl)penta-2,4-dienoylamino]hexanoic acid methyl ester 406725-22-2P, (2E,4E)-8-(5-Phenylpenta-2,4-dienoylamino)octanoic acid methyl ester 406725-23-3P, (2E,4E)-7-(5-Phenylpenta-2,4-dienoylamino)heptanoic acid methyl ester 406725-24-4P, (2E,4E)-6-(2-Methyl-5-phenylpenta-2,4-dienoylamino)hexanoic acid methyl ester 406725-25-5P, (2E,4E)-6-[5-(4-Methoxyphenyl)penta-2,4-dienoylamino]hexanoic acid methyl ester 406725-26-6P, (E)-6-(5-Phenylpent-2-en-4-ynoylamino)hexanoic acid methyl ester 406725-27-7P, (2E,4E)-6-(3-Methyl-5-phenylpenta-2,4-dienoylamino)hexanoic acid methyl ester 406725-28-8P, (2E,4E)-6-[5-(4-Dimethylaminophenyl)penta-2,4-dienoylamino]hexanoic acid methyl ester 406725-29-9P, Methyl 6-[(3-phenylpropanoyl)amino]hexanoate 406725-30-2P, Methyl 6-[((E)-3-phenyl-2-propenoyl)amino]hexanoate 406725-31-3P, (E)-6-(3-Pyridin-4-ylacryloylamino)hexanoic acid methyl ester 406725-32-4P, (E)-6-(3-Pyridin-2-ylacryloylamino)hexanoic acid methyl ester 406725-33-5P, 6-[[(E)-3-(2-Furyl)-2-propenoyl]amino]hexanoate 406725-34-6DP, resin-bound 406725-35-7P, 3-[3-[[(E)-3-(1,3-Benzodioxol-5-yl)-1-oxo-2-propenyl]amino]phenyl]-(E)-2-propenoic acid methyl ester 406725-36-8P, 3-[3-[[(E)-3-(1,3-Benzodioxol-5-yl)-1-oxo-2-propenyl]amino]phenyl]-(E)-2-propenoic acid 406725-38-0P, 3-[3-[[(2E,4E)-1-Oxo-5-phenyl-2,4-pentadienyl]amino]phenyl]-(2E)-propenoic acid methyl ester 406725-40-4P, 3-[3-[[(2E,4E)-1-Oxo-5-phenyl-2,4-pentadienyl]amino]phenyl]-(2E)-propenoic acid 406725-42-6P, 5-Phenyl-4-methyl-(2E,4E)-pentadienoyl chloride 406725-45-9P, 3-[3-[[(2E,4E)-4-Methyl-1-oxo-5-phenyl-2,4-pentadienyl]amino]phenyl]-(2E)-propenoic acid methyl ester 406725-47-1P, 3-[3-[[(2E,4E)-4-Methyl-1-oxo-5-phenyl-2,4-pentadienyl]amino]phenyl]-(2E)-propenoic acid 406725-49-3P, 3-[3-(4-Phenylbutyrylamino)phenyl]acrylic acid methyl ester 406725-53-9P, 3-(4-Benzoylaminophenyl)acrylic acid methyl ester 406725-56-2P, 3-(4-Benzoylaminophenyl)propionic acid 406725-58-4P, 3-[4-[(Naphthalene-2-carbonyl)amino]phenyl]acrylic acid methyl ester 406725-59-5P, 3-[4-[(Naphthalene-2-carbonyl)amino]phenyl]acrylic acid 406725-60-8P, 3-[4-(2-Naphthalen-1-ylacetylamino)phenyl]acrylic acid methyl ester 406725-64-2P, 3-[4-(2-Naphthalen-1-ylacetylamino)phenyl]acrylic acid 406725-67-5P, 4-[(2E)(4E)-5-(4-Chlorophenyl)penta-2,4-dienoylamino]butyric acid methyl ester 406725-70-0P, 4-[(2E)(4E)-5-(4-Bromophenyl)penta-2,4-dienoylamino]butyric acid methyl ester 406725-73-3P, 4-[(2Z)(4E)-5-(4-Bromophenyl)penta-2,4-dienoylamino]butyric acid methyl ester 406725-77-7P, 5-[(2E)(4E)-5-Phenylpenta-2,4-dienoylamino]pentanoic acid methyl ester 406725-79-9P, 6-[(4-Aminofurazan-3-carbonyl)amino]hexanoic acid methyl ester 406725-81-3P, 6-(4-Phenylbutyrylamino)hexanoic acid methyl ester 406725-83-5P, 6-((E)-3-Naphthalen-2-ylacryloylamino)hexanoic acid methyl ester 406725-85-7P, 6-[(2E)(4E)-5-Naphthalen-1-ylpenta-2,4-dienoylamino]hexanoic acid methyl ester 406725-87-9P 406725-91-5P, 6-[3-[5-(3,5-Bis-trifluoromethylphenyl)furan-2-yl]acryloylamino]hexanoic acid methyl ester 406725-94-8P 406725-95-9P 406725-96-0P 406725-97-1P 406725-98-2P 406725-99-3P 406726-00-9P, (2E)-6-(5,5-Diphenylpenta-2,4-dienoylamino)hexanoic acid methyl ester 406726-01-0P, 6-((E)-2-Methyl-5-phenylpent-2-en-4-ynoylamino)hexanoic acid methyl ester 406726-02-1P 406726-03-2P 406726-04-3P 406726-05-4P, 6-(2-Fluoren-9-ylideneacetylamino)hexanoic acid methyl ester 406726-06-5P 406726-07-6P 406726-08-7P 406726-09-8P, 6-(4-Bromobenzoylamino)hexanoic acid methyl ester 406726-10-1P,

6-(4-Iodobenzoylamino)hexanoic acid methyl ester 406726-11-2P, 6-(4-tert-Butylbenzoylamino)hexanoic acid methyl ester 406726-12-3P, 6-(4-Cyano-benzoylamino)hexanoic acid methyl ester 406726-13-4P, 6-[(Furan-3-carbonyl)amino]hexanoic acid methyl ester 406726-14-5P 406726-15-6P, 6-[(5-Bromofuran-2-carbonyl)amino]hexanoic acid methyl ester 406726-16-7P, 6-(3-Thiophen-2-ylacryloylamino)hexanoic acid methyl ester 406726-17-8P, 6-(3-Phenylpropynoylamino)hexanoic acid methyl ester 406726-18-9P, 6-(4-Isopropylbenzoylamino)hexanoic acid methyl ester 406726-19-0P, 6-(3-Naphthalen-1-ylacryloylamino)hexanoic acid methyl ester 406726-20-3P, 6-(2-Benzo[b]thiophen-3-ylacetylamino)hexanoic acid methyl ester 406726-21-4P, 6-[2-[1-(4-Fluorobenzyl)-1H-indol-3-yl]acetylamino]hexanoic acid methyl ester 406726-22-5P 406726-24-7P, 6-[2-(4-Chlorophenyl)-2-methylpropionylamino]hexanoic acid methyl ester 406726-25-8P, 6-(5-Phenylpentanoylamino)hexanoic acid methyl ester 406726-26-9P 406726-27-0P, 6-(5-Phenylpent-4E-enoylamino)hexanoic acid methyl ester 406726-28-1P, 6-[(Naphthalene-2-carbonyl)amino]hexanoic acid methyl ester 406726-29-2P, 5-[(Naphthalene-2-carbonyl)amino]pentanoic acid methyl ester 406726-30-5P, 7-[(Naphthalene-2-carbonyl)amino]heptanoic acid methyl ester 406726-31-6P, 8-[(Naphthalene-2-carbonyl)amino]octanoic acid methyl ester 406726-32-7P, 6-(4-Phenylbut-3-enoylamino)hexanoic acid methyl ester 406726-33-8P, 6-[2-(4-Dimethylaminophenyl)acetylamino]hexanoic acid methyl ester 406726-34-9P, 6-[3-(4-Trifluoromethylphenyl)acryloylamino]hexanoic acid methyl ester 406726-35-0P, 6-[3-(3-Trifluoromethoxyphenyl)acryloylamino]hexanoic acid methyl ester 406726-36-1P, 6-[3-(4-Chloro-2-fluorophenyl)acryloylamino]hexanoic acid methyl ester 406726-37-2P, 5-[[[4-(Dimethylamino)-1-naphthalenyl]carbonyl]amino]pentanoic acid methyl ester 406726-38-3P, 6-[[[4-(Dimethylamino)-1-naphthalenyl]carbonyl]amino]hexanoic acid methyl ester 406726-39-4P, Methyl 6-[(1H-benzimidazol-2-ylcarbonyl)amino]hexanoate 406726-40-7P, 6-[(1H-Benzimidazol-2-ylcarbonyl)amino]hexanoic acid 406726-41-8P, N-[6-[(Benzyloxy)amino]-6-oxohexyl]-1H-benzimidazole-2-carboxamide 406726-42-9P, 6-[(Furan-2-carbonyl)amino]hexanoic acid methyl ester 406726-43-0P, 6-[(Furan-2-carbonyl)amino]hexanoic acid benzyloxyamide 406726-44-1P, 6-(3-Furan-2-ylpropionylamino)hexanoic acid methyl ester 406726-45-2P, 6-(3-Furan-2-ylpropionylamino)hexanoic acid 406726-46-3P, 6-(3-Furan-2-ylpropionylamino)hexanoic acid benzyloxyamide 406726-47-4P, 6-[(Naphthalene-1-carbonyl)amino]hexanoic acid methyl ester 406726-48-5P, 6-[(Naphthalene-1-carbonyl)amino]hexanoic acid benzyloxyamide 406726-49-6P, 6-(2-Biphenyl-4-ylacetylamino)hexanoic acid methyl ester 406726-50-9P, 6-(2-Biphenyl-4-ylacetylamino)hexanoic acid 406726-51-0P, 6-(2-Biphenyl-4-ylacetylamino)hexanoic acid benzyloxyamide 406726-52-1P, 6-Diphenylacetylaminohexanoic acid methyl ester 406726-53-2P, 6-Diphenylacetylaminohexanoic acid benzyloxyamide 406726-54-3P, 7-[2-(1H-Indol-3-yl)ethylcarbamoyl]heptanoic acid methyl ester 406726-55-4P, 5-[2-(1H-Indol-3-yl)ethylcarbamoyl]pentanoic acid methyl ester 406726-56-5P, 7-(2-Naphthalen-1-ylethylcarbamoyl)heptanoic acid methyl ester 406726-57-6P, 7-(2-Hydroxy-2-phenylethylcarbamoyl)heptanoic acid methyl ester 406726-58-7P, 7-(2,2-Diphenylethylcarbamoyl)heptanoic acid methyl ester 406726-59-8P, 7-(3-Phenylallylcarbamoyl)heptanoic acid methyl ester 406726-60-1P, 7-Benzylcarbamoylheptanoic acid methyl ester 406726-61-2P, 7-Phenethylcarbamoylheptanoic acid methyl ester 406726-62-3P, 7-(3-Phenylpropylcarbamoyl)heptanoic acid methyl ester 406726-63-4P, 6-[2-(1H-Indol-3-yl)ethyl]carbamoylhexanoic acid ethyl ester 406726-64-5P, 7-(Naphthalen-1-ylcarbamoyl)heptanoic acid methyl ester 406726-65-6P, 7-(Naphthalen-2-ylcarbamoyl)heptanoic acid methyl ester 406726-66-7P, 7-(Benzhydrylcarbamoyl)heptanoic acid methyl ester 406726-67-8P, 6-(Naphthalen-2-ylcarbamoyl)hexanoic acid ethyl ester 406726-68-9P, 7-(Biphenyl-4-ylcarbamoyl)heptanoic acid ethyl ester 406726-69-0P, 7-[(Naphthalen-1-ylmethyl)carbamoyl]heptanoic acid methyl ester 406726-70-3P, 7-[2-(1H-Benzimidazol-2-yl)ethylcarbamoyl]heptanoic acid methyl ester 406726-71-4P, 7-[2-(1H-Benzimidazol-2-

yl)ethylcarbamoyl]heptanoic acid 406726-72-5P, Octanedioic acid [2-(1H-benzimidazol-2-yl)ethyl]amide benzyloxyamide 406726-73-6P, (S)-6-[3-(1H-Indol-3-yl)-2-(4-phenylbutyrylamino)propionylamino]hexanoic acid 2,5-dioxopyrrolidin-1-yl ester 406726-74-7P, (S)-3-(1H-Indol-3-yl)-2-(2-naphthalen-2-ylacetylamino)propionic acid 406726-75-8P, (S)-6-[3-(1H-Indol-3-yl)-2-(2-naphthalen-2-ylacetylamino)propionylamino]hexanoic acid 2,5-dioxopyrrolidin-1-yl ester 406726-76-9P, 4-(1H-Indol-3-yl)butyric acid 2,5-dioxopyrrolidin-1-yl ester 406726-77-0P, (S)-3-(1H-Indol-3-yl)-2-(4-1H-indol-3-ylbutyrylamino)propionic acid 406726-78-1P, (S)-6-[3-(1H-Indol-3-yl)-2-(4-1H-indol-3-ylbutyrylamino)propionylamino]hexanoic acid benzyloxyamide 406726-79-2P, (S)-3-(1H-Indol-3-yl)-2-[(naphthalene-2-carbonyl)amino]propionic acid 406726-80-5P, (S)-Naphthalene-2-carboxylic acid [1-(5-benzyloxycarbamoylpentylcarbamoyl)-2-(1H-indol-3-yl)ethyl]amide 406726-81-6P, (S)-2-(4-Benzyloxycarbonylaminobutyrylamino)-3-(1H-indol-3-yl)propionic acid 406726-82-7P, (S)-6-[2-(4-Benzyloxycarbonylaminobutyrylamino)-3-(1H-indol-3-yl)propionylamino]hexanoic acid 2,5-dioxopyrrolidin-1-yl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of N-hydroxy amides with amide linkages as HDAC inhibitors for treatment of proliferative conditions)

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of N-hydroxy amides with amide linkages as HDAC inhibitors for treatment of proliferative conditions)

IT 60-32-2, 6-Aminocaproic acid 61-54-1, 2-(1H-Indol-3-yl)ethylamine 62-23-7, 4-Nitrobenzoic acid 64-04-0, Phenethylamine 73-22-3, L-Tryptophan, reactions 86-55-5, Naphthalene-1-carboxylic acid 87-51-4, (1H-Indol-3-yl)acetic acid, reactions 88-14-2, Furan-2-carboxylic acid 91-00-9, Diphenylmethylamine 91-59-8, Naphthalen-2-ylamine 92-67-1, Biphenyl-4-ylamine 93-09-4, Naphthalene-2-carboxylic acid 98-73-7, 4-tert-Butylbenzoic acid 99-88-7, 4-Isopropylaniline 100-09-4, 4-Methoxybenzoic acid 102-92-1 104-94-9, p-Anisidine 117-34-0, Diphenylacetic acid 118-31-0, 1-Naphthylmethylamine 133-32-4, 4-(1H-Indol-3-yl)butyric acid 134-32-7, Naphthalen-1-ylamine 140-10-3, trans-Cinnamic acid, reactions 488-93-7, Furan-3-carboxylic acid 501-52-0, 3-Phenylpropanoic acid 536-66-3, 4-Isopropylbenzoic acid 539-47-9, 3-Furyl-2-acrylic acid 581-96-4, Naphthalen-2-ylacetic acid 585-70-6, 5-Bromofuran-2-carboxylic acid 586-76-5, 4-Bromobenzoic acid 606-84-8, 3,3-Diphenylacrylic acid 619-58-9, 4-Iodobenzoic acid 619-65-8, 4-Cyanobenzoic acid 619-84-1, 4-Dimethylaminobenzoic acid 619-89-6, 4-Nitrocinnamic acid 627-91-8, Adipic acid monomethyl ester 637-44-5, Phenylpropynoic acid 704-80-3 708-83-8 935-13-7, 3-Furan-2-ylpropionic acid 1124-65-8, 3-Thiophen-2-ylacrylic acid 1126-74-5, 3-Pyridin-3-ylacrylic acid 1131-09-5, Benzo[b]thiophen-3-ylacetic acid 1204-06-4, 3-(1H-Indol-3-yl)acrylic acid 1501-27-5, Monomethyl glutarate 1552-94-9, 5-Phenylpenta-2,4-dienoic acid 1552-96-1, 4-Dimethylaminocinnamic acid 1821-12-1, 4-Phenylbutyric acid 1914-58-5 1926-80-3, 6-(Amino)hexanoic acid methyl ester hydrochloride 2038-57-5, 3-Phenylpropylamine 2062-26-2, 4-Trifluoromethylcinnamic acid 2243-83-6, 2-Naphthalenecarbonyl chloride 2270-20-4, 5-Phenylpentanoic acid 2373-80-0, 3-Benzo[1,3]dioxol-5-ylacrylic acid 2687-43-6, O-Benzylhydroxylamine hydrochloride 2849-93-6, 1H-Benzimidazole-2-carboxylic acid 3946-32-5, Suberic acid monomethyl ester 3963-62-0, 2,2-Diphenylethylamine 4360-51-4 4425-73-4, Fluoren-9-ylideneacetic acid 4735-50-6, 2-Naphthalen-1-ylethylamine 5105-78-2, 4-Benzyloxycarbonylaminobutyric acid 5121-00-6, 1-Naphthaleneacetyl chloride 5728-52-9, Biphenyl-4-ylacetic acid 6258-30-6, 2-(4-Chlorophenyl)-2-methylpropionic acid 6315-89-5, 4-Aminoveratrole 6404-29-1 7498-88-6, 4,4-Diphenylbut-3-enoic acid **7568-93-6**, 2-Amino-1-phenylethanol 13026-12-5, 3-Naphthalen-1-ylacrylic acid

13031-60-2, Methyl 4-aminobutyrate hydrochloride 15542-32-2
15542-34-4, (2E,4E)-5-(4-Chlorophenyl)-2,4-pentadienoic acid 15542-35-5
15542-37-7, (2E,4E)-5-(4-Methoxyphenyl)-2,4-pentadienoic acid
15542-38-8, (2E,4E)-5-[4-(Dimethylamino)phenyl]-2,4-pentadienoic acid
15542-39-9, (2E,4E)-5-[1,1'-Biphenyl]-4-yl-2,4-pentadienoic acid
17078-28-3, 4-Dimethylaminophenylacetic acid 17920-83-1 17994-94-4,
Methyl 7-aminoheptanoate hydrochloride 20414-94-2, (2E,4E)-2-Methyl-5-phenyl-2,4-pentadienoic acid 20430-13-1, (2E,4E)-3-Methyl-5-phenyl-2,4-pentadienoic acid 27219-07-4, 5-(tert-Butoxycarbonylamino)valeric acid
27655-93-2, (2E,4E)-4-Methyl-5-phenyl-2,4-pentadienoic acid 27948-28-3,
(E)-5-Phenyl-2-penten-4-ynoic acid 28010-12-0, (2E,4E)-5-Phenyl-2,4-pentadienoic acid 28010-14-2, (2Z,4E)-5-(4-Chlorophenyl)-2,4-pentadienoic acid 29275-88-5 29518-68-1, 2-(1H-Benzimidazol-2-yl)ethylamine 29840-56-0, Methyl 5-aminopentanoate hydrochloride
33018-91-6, Pimelic acid monoethyl ester 38489-76-8,
(E)-3-(1,3-Benzodioxol-5-yl)-2-propenoic acid 51485-76-8,
3-(1-Methyl-1H-pyrrol-2-yl)acrylic acid 51557-26-7, 3-Naphthalen-2-ylacrylic acid 54495-51-1, (E)-3-(2-Pyridinyl)-2-propenoic acid
56427-17-9 57294-38-9 58186-45-1 58550-29-1 60773-92-4,
4-Phenylbut-3-enoyl chloride 73850-25-6 77420-98-5, Methyl 8-amino octanoate hydrochloride 78062-03-0, 4-Dimethylaminonaphthalene-1-carboxylic acid 78350-50-2, 4-Aminofurazan-3-carboxylic acid
83106-03-0, 3-(3-Phenoxyphenyl)acrylic acid 84228-93-3,
(E)-3-(4-Pyridinyl)-2-propenoic acid 92356-78-0, (2E,4E)-5-(4-Nitrophenyl)-2,4-pentadienoic acid 120553-18-6 154024-74-5
168833-80-5, 3-(3-Trifluoromethoxyphenyl)acrylic acid 169184-42-3,
Methyl 6-aminooctanoate hydrochloride 176204-51-6, [1-(4-Fluorobenzyl)-1H-indol-3-yl]acetic acid 202982-65-8, 3-(4-Chloro-2-fluorophenyl)acrylic acid 406725-15-3, (2E,4E)-5-(2-Nitrophenyl)penta-2,4-dienoic acid 406725-75-5 406725-86-8 406725-89-1,
3-[1-(4-Chlorophenyl)-1H-pyrrol-2-yl]acrylic acid 406725-93-7,
3-[5-(3,5-Bis-trifluoromethylphenyl)furan-2-yl]acrylic acid 406726-23-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of N-hydroxy amides with amide linkages as HDAC inhibitors for treatment of proliferative conditions)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) American Cyanamid Co; WO 0044709 A 2000 HCAPLUS
(2) American Cyanamid Co; WO 0044713 A 2000 HCAPLUS
(3) Andrew, B; WO 9826773 A 1998 HCAPLUS
(4) Jung, M; BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 1997, V7(13), P1655 HCAPLUS
(5) Manfred, J; JOURNAL OF MEDICINAL CHEMISTRY 1999, V42(22), P4669
(6) Schmidt, K; ARCHIV DER PHARMAZIE 1999, V332(10), P353 HCAPLUS

IT **7568-93-6**, 2-Amino-1-phenylethanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of N-hydroxy amides with amide linkages as HDAC inhibitors for treatment of proliferative conditions)

RN 7568-93-6 HCAPLUS

CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:72047 HCAPLUS

DN 136:134676

ED Entered STN: 25 Jan 2002

TI Preparation of cyclic amine phenyl β3 adrenergic receptor agonists

for treatment of metabolic disorders related to insulin resistance or hyperglycemia

IN Hu, Baihua; Sum, Fuk-Wah; Malamas, Michael Sotirios

PA American Home Products Corporation, USA

SO PCT Int. Appl., 235 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D211-58
ICS C07D401-10; C07D417-10; C07D417-14; C07D401-14; C07D401-12; C07D409-14; C07D413-14; C07D409-12; C07D405-14; C07D405-12; C07D223-12; C07D403-12; C07D401-10; C07D233-00; C07D211-00; C07D417-10; C07D277-00; C07D211-00

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 34

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002006232	A1	20020124	WO 2001-US22387	20010716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002028835	A1	20020307	US 2001-903754	20010712
US 6525202	B2	20030225		
EP 1301482	A1	20030416	EP 2001-984234	20010716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012522	A	20030624	BR 2001-12522	20010716
US 2003144326	A1	20030731	US 2002-330576	20021227
PRAI US 2000-218627P	P	20000717		
US 2001-903754	A3	20010712		
WO 2001-US22387	W	20010716		

OS MARPAT 136:134676

GI



I



II

AB Title compds. I [wherein A = (hetero)aryl or heterocyclyl; X = OCH2, SCH2, or a bond; T1 = (CH2)m; T2 = (CH2)n; m = 1-3; n = 1-3; T = a bond, (un)substituted alkyl or alkenyl, alkynyl, alkylthio, alkylamino, alkoxy(alkyl), alkylthioalkyl, acyl, or alkenylcarbonyl; R1, R2, and R3 = independently H, (cyclo)alkyl, OH, halo, CF3, alkoxy, benzyloxy, allyloxy, propargyloxy, acyloxy, CN, NO2, NH2, CONH2, (di)alkylamino, formamido, ureido, acylamino, alkylsulfonylamino, arylsulfonylamino, dialkyloxyphosphorylamino, dihydroxyphosphorylamino, alkoxycarbonyl, or (un)substituted aryl; R4 = H, alkyl, halo, OH, alkoxy, alkylthio, (alkyl)amino, carboxy, acyl, arylcarbonyl, alkoxycarbonyl, CONH2, alkylaminocarbonyl, alkylsulfonyl, or arylsulfonylamino; R5 = (un)substituted (di)oxoimidazolidinyl, (di)oxooxazolidinyl, (di)oxothiazolidinyl, dioxooxadiazolidinyl, tetrazolyl, oxopyrrolinyl, alkoxycarbonyl, aminocarbonyl, acyl, ureido, etc.; or a pharmaceutically acceptable salt thereof] were prepared by standard and combinatorial synthetic methods as β3 adrenergic receptor agonists. For example, acetic acid was added to a mixture of N-[5-[(1R)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide (preparation given), 2-[4-(4-oxo-1-piperidinyl)benzyl]-1,2,4-oxadiazolidine-3,5-dione, and DMF. Sodium triacetoxyborohydride was added and the mixture stirred at room temperature for 24 h to give (R)-I (71%). The latter bound to the β3 adrenergic receptor with EC50 of 20 μM, exhibited a maximal response activity equivalent to isoproterenol, and increased thermogenesis in β3 transgenic mice by 30 ± 8% compared to an increase of 16 ± 4% in β3 knockout mice. Thus, I are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension, frequent urination, and are particularly useful in the treatment or inhibition II diabetes.

ST cyclic amine prepn beta adrenergic receptor agonist; antidiabetic agent cyclic amine prepn

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of cyclic amine Ph β3 adrenergic receptor agonists for treatment of metabolic disorders related to insulin resistance or hyperglycemia)

IT Micturition
(frequent, treatment; preparation of cyclic amine Ph β3 adrenergic receptor agonists for treatment of metabolic disorders related to insulin resistance or hyperglycemia)

IT Anti-inflammatory agents
(neurogenetic; preparation of cyclic amine Ph β3 adrenergic receptor agonists for treatment of metabolic disorders related to insulin resistance or hyperglycemia)

IT Diabetes mellitus
(non-insulin-dependent, treatment; preparation of cyclic amine Ph β3 adrenergic receptor agonists for treatment of metabolic disorders related to insulin resistance or hyperglycemia)

IT Antidiabetic agents
Antiglaucoma agents
Antiobesity agents
Combinatorial library
Human
(preparation of cyclic amine Ph β3 adrenergic receptor agonists for treatment of metabolic disorders related to insulin resistance or hyperglycemia)

IT Digestive tract, disease
(treatment; preparation of cyclic amine Ph β3 adrenergic receptor agonists for treatment of metabolic disorders related to insulin resistance or hyperglycemia)

IT 421-52-3P 5577-42-4P, N-[4-(2-Bromoacetyl)phenyl]methanesulfonamide

13698-56-1P, N-[5-(2-Amino-1-hydroxyethyl)-2-hydroxyphenyl]methanesulfonamide 14336-30-2P, N-[2-Benzyloxy-5-(2-dibenzylamino-1-oxoethyl)phenyl]methanesulfonamide 54126-80-6P, 2-Methyl-5-(2-oxiranylmethoxy)pyridine 57743-42-7P, 3-(2-Oxiranylmethoxy)pyridine 62312-88-3P, N-Benzyl-N-(2-benzyloxy-5-oxiranylmethoxyphenyl)methanesulfonamide 71031-03-3P, (2S)-2-Phenoxymethyloxirane 74213-24-4P, Dibromoformaldoxime 76596-53-7P, 3-Bromo-5-acetylisoxazole 76596-54-8P, 3-Bromo-5-(bromoacetyl)isoxazole 79406-57-8P 79406-58-9P, N-(5-Acetyl-2-chlorophenyl)methanesulfonamide 79406-59-0P, N-(5-Bromoacetyl-2-chlorophenyl)methanesulfonamide 112243-65-9P, (2S)-1-Amino-3-phenoxypropan-2-ol 113732-55-1P, 2-Bromo-1-[2-(trifluoromethyl)-1,3-thiazole-4-yl]ethanone 119677-65-5P, (1R)-2-Bromo-1-(3-bromoisoxazole-5-yl)ethanol 129280-26-8P, N-[4-((1R)-2-Amino-1-hydroxyethyl)phenyl]methanesulfonamide 168203-91-6P, (1S)-2-Bromo-1-[2-(trifluoromethyl)-1,3-thiazole-4-yl]ethanol 169032-01-3P, (1R)-2-Amino-1-(3-chlorophenyl)ethanol hydrochloride 174060-40-3P, 3-((2R)-Oxiranyl)pyridine 197446-34-7P, 4-(4-Oxopiperidin-1-yl)benzoic acid 208459-22-7P, (2S)-1-Amino-3-(4-hydroxyphenoxy)propan-2-ol 218610-20-9P, 8-(2-Nitrophenyl)-1,4-dioxa-8-azaspiro[4.5]decane 300345-77-1P, N-[5-((1R)-2-Azido-1-hydroxyethyl)-2-benzyloxyphenyl]methanesulfonamide 300345-78-2P, N-[2-Benzyloxy-5-(2-amino-(1R)-1-hydroxyethyl)phenyl]methanesulfonamide 329281-07-4P, 3-((2S)-Oxiranyl)pyridine 340756-74-3P, 4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)benzoic acid 340756-75-4P, N-[5-(2-Amino-(1R)-1-hydroxyethyl)-2-hydroxyphenyl]methanesulfonamide 340756-77-6P, [4-(4-Oxopiperidin-1-yl)phenyl]acetic acid 340756-80-1P, (E)-3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]acrylic acid ethyl ester 340756-81-2P, (E)-3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]acrylic acid 340756-82-3P, (E)-3-[4-(4-Oxopiperidin-1-yl)phenyl]acrylic acid 340756-84-5P, [4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]methanol 340756-85-6P 340756-87-8P, 4-(4-Oxo-1-piperidin-1-yl)benzamide 340756-90-3P, Ethyl [[4-(4-oxo-1-piperidinyl)benzoyl]amino]acetate 340756-91-4P, 3-[4-(4-Oxopiperidin-1-yl)benzoylamino]propionic acid benzyl ester 340756-92-5P 340756-93-6P, 3-Methyl-(2S)-2-[4-(4-oxopiperidin-1-yl)benzoylamino]butyric acid ethyl ester 340756-94-7P, 4-Methyl-(2S)-2-[4-(4-oxopiperidin-1-yl)benzoylamino]pentanoic acid ethyl ester 340756-95-8P 340757-10-0P, 1-[4-(Butylamino)phenyl]-4-piperidinone 340757-11-1P, Ethyl 3-oxo-3-[4-(4-oxo-1-piperidinyl)anilino]propanoate 340757-12-2P 340809-44-1P, (2S)-2-[4-(4-Oxopiperidin-1-yl)benzoylamino]-3-phenylpropionic acid methyl ester 344604-91-7P, 5-[4-(4-Oxopiperidin-1-yl)benzyl]thiazolidine-2,4-dione 349636-57-3P, 1-[4-(2-Imino-4-oxothiazolidin-5-ylmethyl)phenyl]piperidin-4-one 349636-61-9P, tert-Butyl 2-[2,4-dioxo-5-[4-(4-oxo-1-piperidinyl)benzyl]-1,3-thiazolidin-3-yl]acetate 349636-63-1P, 4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)benzaldehyde oxime 349636-64-2P, 8-[4-[(Hydroxyamino)methyl]phenyl]-1,4-dioxa-8-azaspiro[4.5]decane 349636-66-4P, N-Hydroxy-N-[4-(4-oxo-1-piperidinyl)benzyl]urea 349636-68-6P, 2-[4-(4-Oxo-1-piperidinyl)benzyl]-1,2,4-oxadiazolidine-3,5-dione 349636-91-5P, 5-(3-Amino-(2S)-2-hydroxypropoxy)-8-hydroxy-3,4-dihydro-1H-quinolin-2-one 349636-95-9P, N-[5-((2S)-3-Amino-2-hydroxypropoxy)-2-hydroxyphenyl]methanesulfonamide 373359-46-7P 373359-50-3P 373359-51-4P, 4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)phenylamine 373359-52-5P, N-[4-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)phenylsulfamoyl]phenyl]acetamide 373359-53-6P, N-[4-[4-(4-Oxopiperidin-1-yl)phenylsulfamoyl]phenyl]acetamide 373359-54-7P 373359-55-8P 373359-56-9P, 5-Pyridin-2-ylthiophene-2-sulfonic acid [4-(4-oxopiperidin-1-yl)phenyl]amide 373359-57-0P, 3,4-Dimethoxy-N-[4-(4-oxopiperidin-1-yl)phenyl]benzenesulfonamide 373359-58-1P, Butane-1-sulfonic acid [4-(4-oxo-piperidin-1-yl)phenyl]amide 373359-59-2P, Octane-1-sulfonic acid [4-(4-oxo-1-piperidinyl)phenyl]amide 373359-60-5P, Pyridine-3-sulfonic acid [4-(4-oxopiperidin-1-yl)phenyl]amide 373359-61-6P 373359-62-7P, 3-[4-(4-Oxopiperidin-1-yl)phenylsulfamoyl]thiophene-2-carboxylic acid methyl ester 373359-63-8P

373359-64-9P, 4-[4-(4-Oxopiperidin-1-yl)phenylsulfamoyl]benzoic acid
373360-08-8P, (2S)-1-Amino-3-(4-benzyloxyphenoxy)propan-2-ol
391872-89-2P, 5-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)benzylidene]-2-thioxothiazolidin-4-one 391904-79-3P, Benzoic acid 4-benzyloxy-3-nitrophenyl ester 391904-80-6P 391904-81-7P, Benzoic acid 3-benzenesulfonylamino-4-benzyloxyphenyl ester 391904-82-8P
391904-83-9P, N-Benzyl-N-(2-benzyloxy-5-hydroxyphenyl)benzenesulfonamide
391904-84-0P 391904-85-1P, N-[5-(3-Amino-2-hydroxypropoxy)-2-hydroxyphenyl]benzenesulfonamide 391904-86-2P, N-[5-((1R)-2-Azido-1-hydroxyethyl)-2-chlorophenyl]methanesulfonamide 391904-87-3P
391904-88-4P, Propane-2-sulfonic acid [5-((1R)-2-amino-1-hydroxyethyl)-2-hydroxyphenyl]amide 391904-89-5P, N-(5-Acetyl-2-benzyloxyphenyl)benzenesulfonamide 391904-90-8P, N-(2-Benzyloxy-5-bromoacetylphenyl)benzenesulfonamide 391904-91-9P, N-[2-Benzyloxy-5-(2-bromo-1-hydroxyethyl)phenyl]benzenesulfonamide 391904-92-0P, N-[5-((1R)-2-Azido-1-hydroxyethyl)-2-benzyloxyphenyl]benzenesulfonamide
391904-93-1P, N-[5-((1R)-2-Amino-1-hydroxyethyl)-2-hydroxyphenyl]benzenesulfonamide 391904-94-2P, 1-[4-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)phenyl]piperidin-4-one 391904-95-3P, 5-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)benzylidene]thiazolidine-2,4-dione
391904-96-4P, 5-[4-(4-Oxopiperidin-1-yl)benzylidene]-thiazolidine-2,4-dione 391904-97-5P, 5-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)benzyl]thiazolidine-2,4-dione 391904-98-6P, 5-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)benzylidene]-imidazolidine-2,4-dione 391905-00-3P, 5-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)benzyl]imidazolidine-2,4-dione
391905-02-5P, 5-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)benzylidene]-2-iminothiazolidin-4-one 391905-03-6P, 5-[4-(4-Oxopiperidin-1-yl)benzylidene]-imidazolidine-2,4-dione 391905-05-8P,
1-[4-(2-Imino-4-oxothiazolidin-5-ylidenemethyl)phenyl]piperidin-4-one
391905-07-0P, 5-[4-(4-Oxopiperidin-1-yl)benzyl]imidazolidine-2,4-dione
391905-10-5P, 8-[4-(1H-Tetrazol-5-yl)phenyl]-1,4-dioxa-8-azaspiro[4.5]decane 391905-12-7P, 1-[4-(1H-Tetrazol-5-yl)phenyl]piperidin-4-one 391905-13-8P, Ethyl [5-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]-2H-tetrazol-2-yl]acetate 391905-14-9P, Ethyl [5-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]-1H-tetrazol-1-yl]acetate 391905-16-1P, Ethyl 2-[2,4-dioxo-5-[4-(4-oxo-1-piperidinyl)benzyl]-1,3-thiazolidin-3-yl]acetate 391905-17-2P,
N-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)benzyl]-N-hydroxyurea
391905-20-7P, 3-Bromo-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)benzaldehyde
391905-21-8P, 5-[3-Bromo-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)benzylidene]-thiazolidine-2,4-dione 391905-22-9P, 5-[3-Bromo-4-(4-oxopiperidin-1-yl)benzylidene]thiazolidine-2,4-dione 391905-24-1P, 4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorobenzaldehyde 391905-25-2P,
5-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorobenzylidene]thiazolidine-2,4-dione 391905-28-5P, 5-[3-Fluoro-4-(4-oxopiperidin-1-yl)benzyl]thiazolidine-2,4-dione 391905-30-9P, 5-[3-Fluoro-4-(4-oxopiperidin-1-yl)benzylidene]thiazolidine-2,4-dione 391905-89-8P,
4-((2S)-Oxiran-2-yl)-2-trifluoromethyl-1,3-thiazole 391905-90-1P,
(1S)-2-Amino-1-[(2-trifluoromethyl)-1,3-thiazole-4-yl]ethanol
391905-92-3P, (1S)-2-Bromo-1-[3-(3,4-dichlorophenyl)isoxazol-5-yl]ethanol
391905-93-4P, 3-(3,4-Dichlorophenyl)-5-((2S)-oxiran-2-yl)isoxazole
391905-94-5P, (1S)-2-Amino-1-[3-(3,4-dichlorophenyl)isoxazol-5-yl]ethanol
391905-96-7P, N-[4-((1R)-2-Bromo-1-hydroxyethyl)phenyl]methanesulfonamide
391905-97-8P, N-[4-((1R)-2-Azido-1-hydroxyethyl)phenyl]methanesulfonamide
391906-00-6P, 3-Bromo-5-((2S)-oxiran-2-yl)isoxazole 391906-01-7P,
(1S)-2-Amino-1-(3-bromoisoxazole-5-yl)ethanol 391906-03-9P,
(2S)-1-Amino-3-(3-pyridinyloxy)-2-propanol 391906-05-1P,
(2S)-1-Amino-3-[(6-methyl-3-pyridinyl)oxy]-2-propanol 391906-07-3P,
(1R)-2-Bromo-1-(3-pyridinyl)-1-ethanol 391906-08-4P,
(1S)-2-Amino-1-(3-pyridinyl)-1-ethanol 391906-10-8P,
(1R)-2-Amino-1-[1,2,3,4]tetrazolo[1,5-a]pyridin-6-yl-1-ethanol
391906-12-0P, 5-[4-[4-[[(2R)-2-Hydroxy-2-[1,2,3,4]tetrazolo[1,5-a]pyridin-6-ylethyl]amino]-1-piperidinyl]benzyl]-1,3-thiazolidine-2,4-dione

391906-13-1P, (1R)-2-Amino-1-(3-pyridinyl)-1-ethanol 391906-15-3P, N-[5-(2-Bromoacetyl)-2-pyridinyl]methanesulfonamide 391906-16-4P 391906-18-6P 391906-20-0P 391906-21-1P 391906-23-3P 391906-24-4P, 5-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]-1,2-dihydropyrazol-3-one 391906-25-5P, 1-[4-(5-Oxo-2,5-dihydro-1H-pyrazol-3-yl)phenyl]piperidin-4-one 391906-27-7P, 2-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)benzylidene]-malonic acid diethyl ester 391906-28-8P, 2-[4-(4-Oxopiperidin-1-yl)benzylidene]malonic acid diethyl ester 391906-29-9P, N-(Benzyloxy)-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)benzamide 391906-30-2P, N-(Benzyloxy)-4-(4-oxopiperidin-yl)benzamide 391906-31-3P, (2S)-2-[4-(4-Oxopiperidin-1-yl)benzoylamino]pentanedioic acid diethyl ester 391906-32-4P, 3-[4-(4-Oxopiperidin-1-yl)benzoylamino]propionic acid ethyl ester 391906-33-5P, Methyl [[4-(4-oxo-1-piperidinyl)benzoyl]amino]acetate 391906-34-6P, 4-Methyl-(2S)-2-[4-(4-oxopiperidin-1-yl)benzoylamino]pentanoic acid methyl ester 391906-35-7P, Methyl 1-[4-(4-oxopiperidin-1-yl)benzoylamino]cyclopropanecarboxylate 391906-36-8P, (E)-3-[4-(4-Oxopiperidin-1-yl)phenyl]acrylic acid ethyl ester 391906-37-9P, 4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]benzamide 391906-38-0P, N-[(1S)-1-(Hydroxymethyl)-3-methylbutyl]-4-(4-oxo-1-piperidinyl)benzamide 391906-39-1P 391906-40-4P, N-((3S)-2-Oxoazepanyl)-4-(4-oxo-1-piperidinyl)benzamide 391906-41-5P, N-Butyl-N-(cyanomethyl)-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)benzamide 391906-42-6P, N-Butyl-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-N-(1H-tetrazol-5-ylmethyl)benzamide 391906-43-7P, N-Butyl-4-(4-oxo-1-piperidinyl)-N-(1H-tetrazol-5-ylmethyl)benzamide 391906-50-6P 391906-68-6P, N-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]-4-methoxybenzenesulfonamide 391906-70-0P, 4-Methoxy-N-[4-(4-oxopiperidin-1-yl)phenyl]benzenesulfonamide 391906-73-3P, 2-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)phenylamine hydrochloride 391906-75-5P, N-[4-[2-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)phenylsulfamoyl]phenyl]acetamide 391906-77-7P, N-[4-[2-(4-Oxopiperidin-1-yl)phenylsulfamoyl]phenyl]acetamide 391906-79-9P, N-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]-4-(3-hexylureido)benzenesulfonamide 391906-82-4P, 1-(4-Aminophenyl)piperidin-4-one hydrochloride 391906-84-6P, 5-(5-Trifluoromethylpyridin-2-ylsulfonyl)thiophene-2-sulfonic acid [4-(4-oxopiperidin-1-yl)phenyl]amide 391906-85-7P, 4-(2,4-Dioxothiazolidin-5-ylmethyl)-N-[4-(4-oxopiperidin-1-yl)phenyl]benzenesulfonamide 391906-88-0P, 4-[4-(4-Oxopiperidin-1-yl)phenylsulfamoyl]benzoic acid ethyl ester 391906-93-7P, 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [4-(4-oxopiperidin-1-yl)phenyl]amide 391906-95-9P, 4-Cyano-N-[4-(4-oxopiperidin-1-yl)phenyl]benzenesulfonamide 391906-97-1P, 3-Bromo-5-chlorothiophene-2-sulfonic acid [4-(4-oxopiperidin-1-yl)phenyl]amide 391906-99-3P 391907-02-1P, 3,4-Dichloro-N-[4-(4-oxopiperidin-1-yl)phenyl]benzenesulfonamide 391907-05-4P, N-[4-(4-Oxopiperidin-1-yl)phenyl]-4-trifluoromethylbenzenesulfonamide 391907-07-6P, N-[4-(4-Oxopiperidin-1-yl)phenyl]-4-trifluoromethoxybenzenesulfonamide 391907-09-8P, 4-Chloro-N-[4-(4-oxopiperidin-1-yl)phenyl]benzenesulfonamide 391907-11-2P, 4-Butyl-N-[4-(4-oxopiperidin-1-yl)phenyl]benzenesulfonamide 391907-14-5P, 2,5-Dimethoxy-N-[4-(4-oxopiperidin-1-yl)phenyl]benzenesulfonamide 391907-16-7P, 3,5-Dichloro-N-[4-(4-oxopiperidin-1-yl)phenyl]benzenesulfonamide 391907-18-9P, 5-Bromo-2-methoxy-N-[4-(4-oxopiperidin-1-yl)phenyl]benzenesulfonamide 391907-20-3P 391907-22-5P, [(3,4-Dimethoxybenzenesulfonyl)-[4-(4-oxopiperidin-1-yl)phenyl]amino]acetic acid ethyl ester 391907-24-7P 391907-27-0P, [(3,4-Dimethoxybenzenesulfonyl)[4-(4-oxopiperidin-1-yl)phenyl]amino]acetic acid benzyl ester 391909-58-3P 391909-60-7P 391909-62-9P 391909-64-1P, N-[4-(4-Oxopiperidin-1-yl)phenyl]butyramide 391909-67-4P, 3,4-Dimethoxy-N-[4-(4-oxopiperidin-1-yl)phenyl]benzamide 391909-69-6P, 2-Chloro-N-[4-(4-oxopiperidin-1-yl)phenyl]acetamide 391909-78-7P 391909-80-1P 391910-20-6P, 1-Benzhydryl-3-(tert-butyldimethylsilanyloxy)azetidine 391910-22-8P, 1-(4-Nitrophenyl)azetidin-3-ol 391910-24-0P 391910-26-2P,

Benzyl[1-(4-nitrophenyl)azetidin-3-yl]amine 391910-28-4P,
(2S)-1-[Benzyl[1-(4-nitrophenyl)azetidin-3-yl]amino]-3-(9H-carbazol-4-yloxy)propan-2-ol 391910-31-9P 391910-33-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of cyclic amine Ph β3 adrenergic receptor agonists for treatment of metabolic disorders related to insulin resistance or hyperglycemia)

IT 51-41-2 97-31-4, DL-Normetanephrine 98-09-9, Phenylsulfonyl chloride 98-31-7, 3,4-Dichlorobenzene sulfonyl chloride 98-60-2, 4-Chlorobenzene sulfonyl chloride 98-68-0, 4-Methoxybenzenesulfonyl chloride 100-52-7, Benzaldehyde, reactions 103-49-1, Dibenzylamine 104-14-3, DL-Octopamine 105-36-2, Ethyl bromoacetate 105-53-3, Diethyl malonate 107-95-9, β-Alanine 108-94-1, Cyclohexanone, reactions 109-00-2, 3-Pyridinol 121-60-8, N-Acetylsulfanilyl chloride 123-72-8, Butyraldehyde 141-75-3, Butyryl chloride 177-11-7, 1,4-Dioxa-8-azaspiro[4.5]decane 298-12-4, Glyoxylic acid 350-46-9, 4-Fluoronitrobenzene 354-38-1, Trifluoroacetamide 461-72-3, Hydantoin 536-21-0, DL-Norphenylephrine 556-90-1, Pseudothiohydantoin 623-33-6, Glycine ethyl ester hydrochloride 623-48-3, Ethyl iodoacetate 705-21-5, 3,5-Dichlorobenzene sulfonyl chloride 1118-89-4, L-Glutamic acid diethyl ester hydrochloride 1121-78-4, 6-Methyl-3-pyridinol 1126-78-9, N-Butylaniline 1138-56-3, 4-Butoxybenzenesulfonyl chloride 1423-60-5, 3-Butyn-2-one 1483-28-9, 2,5-Dimethoxybenzene sulfonyl chloride 1493-27-2, 2-Fluoronitrobenzene 1821-36-9, N-Cyclohexylaniline 2133-40-6, L-Proline methyl ester hydrochloride 2295-31-0, 2,4-Thiazolidinedione 2386-60-9, 1-Butanesulfonyl chloride 2687-43-6, O-Benzylhydroxyamine hydrochloride 2743-40-0, L-Leucine ethyl ester hydrochloride 2791-84-6 2949-22-6, Ethyl isocyanatoacetate 2991-42-6, 4-(Trifluoromethyl)benzene sulfonyl chloride 3010-04-6, (n-Butylamino)acetonitrile 3182-83-0, N-Butylglycine ethyl ester 4244-84-2, β-Alanine ethyl ester hydrochloride 5002-93-7, 1-Amino-3-(4-methoxyphenoxy)propan-2-ol 5292-43-3, tert-Butyl bromoacetate 5437-45-6, Benzyl 2-bromoacetate 5465-65-6 5680-79-5, Glycine methyl ester hydrochloride 6305-43-7, 1,4-Dibromo-2,3-butanedione 7517-19-3, L-Leucine methyl ester hydrochloride 7524-50-7, L-Phenylalanine methyl ester hydrochloride **7568-93-6**, 2-Amino-1-phenylethanol 7598-91-6, Ethyl 5-hydroxy-2-methylindole-3-carboxylate 7795-95-1, 1-Octanesulfonyl chloride 10130-89-9, 4-(Chlorosulfonyl)benzoic acid 10147-37-2, Isopropylsulfonyl chloride 13985-43-8, Benzoic acid 4-hydroxy-3-nitrophenyl ester 14347-15-0, 1-(3-Amino-4-benzyloxyphenyl)ethanone 16133-25-8, 3-Pyridinesulfonyl chloride 17609-47-1, L-Valine ethyl ester hydrochloride 17694-68-7, 3-(2-Bromoacetyl)pyridine hydrobromide 18162-48-6, tert-Butyldimethylsilyl chloride 18621-17-5, 1-(Diphenylmethyl)-3-hydroxyazetidine 19828-20-7, 1-(6-Amino-3-pyridinyl)-1-ethanone 21568-87-6, L-α-Amino-ε-caprolactam 23095-05-8, 5-Bromo-2-methoxybenzene sulfonyl chloride 23499-01-6, 1-(4-Nitrophenyl)piperidin-4-one 25437-95-0, 1-(4-Ethoxycarbonylphenyl)-4-piperidone 27019-47-2 34036-07-2, 3,4-Difluorobenzaldehyde 36239-09-5, Ethyl 3-chloro-3-oxopropionate 54997-92-1, 4-n-Butylbenzene sulfonyl chloride 56077-78-2, (4-Chlorosulfonylphenoxy)acetic acid methyl ester 59337-92-7, 2-(Methoxycarbonyl)thiophene-3-sulfonyl chloride 59826-16-3, 8-Benzyloxy-5-hydroxy-3,4-dihydro-1H-quinolin-2-one 62312-86-1, N-Benzyl-N-(2-benzoxy-5-hydroxyphenyl)methanesulfonamide 62600-71-9, (1R)-2-(3-Chlorophenyl)oxirane 63131-29-3, Methyl 4-fluorobenzoyl acetate 72784-42-0, 1-Aminocyclopropane-1-carboxylic acid methyl ester hydrochloride 77771-02-9, 3-Bromo-4-fluorobenzaldehyde 79421-38-8, 4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)benzoic acid ethyl ester 79421-39-9, 4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)benzonitrile 79421-40-2, 4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)benzaldehyde 79421-41-3, 1-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]ethanone 79421-42-4, 8-(4-Nitrophenyl)-1,4-dioxa-8-azaspiro[4.5]decane

94108-56-2, 4-(Trifluoromethoxy)benzene sulfonyl chloride 95093-95-1, (2S)-3-(9H-Carbazol-4-yloxy)methyloxirane 101544-49-4, 5-(2-Amino-1-hydroxyethyl)-1H-indole-7-carboxamide 115314-14-2, (2S)-(+)Glycidyl 3-nitrobenzenesulfonate 121652-86-6, (1R)-2-Amino-1-(3-chlorophenyl)ethanol 122797-04-0, (2S)-2-(4-Benzyloxyphenoxymethyl)oxirane 123787-99-5, 6-((2R)-Oxiranyl)[1,2,3,4]tetrazolo[1,5-a]pyridine 125758-75-0, 4-(2,4-Dioxothiazolidin-5-ylmethyl)benzenesulfonyl chloride 138872-44-3, 2-(Benzoylaminomethyl)thiophene-5-sulfonyl chloride 143412-40-2, (2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropylamine 151858-64-9, 5-Pyridin-2-ylthiophene-2-sulfonyl chloride 159215-13-1 166740-83-6, 4-((2S)-3-Amino-2-hydroxypropoxy)-1,3-dihydrobenzoimidazol-2-one 170011-70-8, 1-(4-Aminophenyl)piperidin-4-one 173901-02-5, 4-(3-Hexylureido)benzenesulfonyl chloride 175135-06-5, 4-(2-Chloro-4-nitrophenoxy)-3,5-dichlorobenzenesulfonyl chloride 175202-87-6, 5-(5-Trifluoromethylpyridin-2-ylsulfonyl)thiophene-2-sulfonyl chloride 175277-38-0, 5-(Bromoacetyl)-3-(3,4-dichlorophenyl)isoxazole 182251-92-9 246262-39-5, N-[2-Benzyloxy-5-[2-iodo-(1R)-1-[(triethylsilyl)oxy]ethyl]phenyl]methanesulfonamide 327088-20-0, 2-Amino-1-(6-methylpyridin-3-yl)ethanol 338422-71-2, 4-(3-Chloro-5-trifluoromethyl-2-pyridyloxy)benzenesulfonyl chloride 373359-49-0, N-[2-Benzyloxy-5-(2-chloro-1-oxoethyl)phenyl]methanesulfonamide 373360-07-7 373360-12-4, 2-Amino-1-(2,4-dihydroxyphenyl)ethanol 391872-88-1, N-[2-Benzyloxy-5-(2-bromo-1-hydroxyethyl)phenyl]methanesulfonamide 391906-57-3 391908-36-4, [4-[4-(4-Oxopiperidin-1-yl)phenylsulfamoyl]phenyl]acetic acid methyl ester 391908-43-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of cyclic amine Ph β3 adrenergic receptor agonists for treatment of metabolic disorders related to insulin resistance or hyperglycemia)

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance; preparation of cyclic amine Ph β3 adrenergic receptor agonists for treatment of metabolic disorders related to insulin resistance or hyperglycemia)

IT 340756-96-9P, Ethyl [[4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]benzoyl]amino]acetate 340756-97-0P 340756-98-1P 340757-00-8P 340757-13-3P, Ethyl 3-[4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]anilino]-3-oxopropanoate 344605-02-3P 373360-02-2P, Methyl 3-[[4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]anilino]sulfonyl]-2-thiophenecarboxylate 391905-31-0P 391905-67-2P 391905-86-5P, Ethyl [5-[4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]-1H-tetrazol-1-yl]acetate 391906-46-0P 391908-97-7P 391909-84-5P, Ethyl [[[4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]anilino]carbonyl]amino]acetate 391909-88-9P 391910-35-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(β3 agonist; preparation of cyclic amine Ph β3 adrenergic receptor agonists for treatment of metabolic disorders related to insulin resistance or hyperglycemia)

IT 329280-02-6P, 4-[4-[(2S)-2-Hydroxy-3-(2-oxo-2,3-dihydro-1H-benzimidazole-4-yloxy)propyl]amino]piperidin-1-yl]benzoic acid ethyl ester 340756-76-5P 340756-78-7P 340756-83-4P 340756-86-7P 340756-88-9P 340756-99-2P 340757-01-9P, [[4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]benzoyl]amino]acetic acid 340757-02-0P 340757-03-1P 340757-04-2P 340757-05-3P 340757-06-4P 340757-07-5P, (2S)-2-[[4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]benzoyl]amino]pentanedioic acid 340757-08-6P 340757-14-4P 340757-15-5P,

3-[4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]anilino]-3-oxopropanoic acid 340757-17-7P 344604-93-9P 344604-95-1P 344604-97-3P 344604-98-4P 349636-59-5P 349636-62-0P 349636-69-7P, N-[5-[(1R)-2-[1-[4-(3,5-Dioxo-[1,2,4]oxadiazolidin-2-ylmethyl)phenyl]piperidin-4-ylamino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide 373359-66-1P 373359-67-2P 373359-68-3P, N-[4-[[4-[4-[((2S)-2-Hydroxy-3-phenoxypropyl)amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetamide 373359-69-4P, N-[4-[[4-[4-[[(2S)-2-Hydroxy-3-(4-hydroxyphenoxy)propyl]amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetamide 373359-70-7P, N-[4-[[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetamide 373359-71-8P, N-[4-[[4-[4-[[(2S)-2-Hydroxy-3-[(8-hydroxy-2-oxo-1,2,3,4-tetrahydro-5-quinolinyl)oxy]propyl]amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetamide 373359-72-9P, N-[4-[[4-[4-[[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetamide 373359-73-0P, 4-[4-[(Hexylamino)carbonyl]amino]-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 373359-74-1P, 4-[4-(3-Cyclopentylpropyl)-5-oxo-4,5-dihydro-1H-tetrazol-1-yl]-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 373359-75-2P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-5-(2-pyridinyl)-2-thiophenesulfonamide 373359-76-3P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-3,4-dimethoxybenzenesulfonamide 373359-77-4P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-1-butanesulfonamide 373359-78-5P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-1-octanesulfonamide 373359-79-6P 373359-80-9P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(8-hydroxy-2-oxo-1,2,3,4-tetrahydro-5-quinolinyl)oxy]propyl]amino]-1-piperidinyl]phenyl]-3,4-dimethoxybenzenesulfonamide 373359-81-0P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(8-hydroxy-2-oxo-1,2,3,4-tetrahydro-5-quinolinyl)oxy]propyl]amino]-1-piperidinyl]phenyl]-1-butanesulfonamide 373359-82-1P 373359-83-2P 373359-84-3P, N-[4-[[4-[4-[[2-Hydroxy-2-(4-hydroxyphenyl)ethyl]amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetamide 373359-85-4P, N-[4-[[4-[4-[[(2R)-2-(3,4-Dihydroxyphenyl)-2-hydroxyethyl]amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetamide 373359-86-5P, N-[4-[[4-[4-[[2-(2,4-Dihydroxyphenyl)-2-hydroxyethyl]amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetamide 373359-87-6P, N-[4-[[4-[4-[[2-Hydroxy-2-(4-hydroxy-3-methoxyphenyl)ethyl]amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetamide 373359-88-7P, 5-[2-[[1-[4-[[[4-(Acetylamino)phenyl]sulfonyl]amino]phenyl]-4-piperidinyl]amino]-1-hydroxyethyl]-1H-indole-7-carboxamide 373359-90-1P 373359-91-2P, 4-[[(Hexylamino)carbonyl]amino]-N-[4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 373359-93-4P 373359-94-5P, N-[4-[4-[[2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]-5-(2-pyridinyl)-2-thiophenesulfonamide 373359-95-6P, N-[4-[4-[[2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]-3,4-dimethoxybenzenesulfonamide 373359-96-7P, N-[4-[4-[[2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]-1-butanesulfonamide 373359-97-8P, N-[4-[4-[[2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]-1-octanesulfonamide 373359-98-9P, N-[4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]-3-pyridinesulfonamide 373359-99-0P, 4-[[4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]anilino]sulfonyl]benzoic acid 373360-00-0P, Ethyl 4-[[4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]eth

yl]amino]-1-piperidinyl]anilino]sulfonyl]benzoate 373360-03-3P, 3-[[4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]anilino]sulfonyl]-2-thiophenecarboxylic acid 373360-04-4P, Benzyl [[4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]anilino]sulfonyl]acetate 373360-05-5P, [[4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]anilino]sulfonyl]acetic acid 373360-06-6P, Methyl [4-[[4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]anilino]sulfonyl]phenoxy]acetate 391905-34-3P, 5-[[4-[4-[[(R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]methyl]-2,4-dioxo-3-thiazolidineacetic acid ethyl ester 391905-35-4P 391905-39-8P 391905-40-1P 391905-41-2P 391905-42-3P 391905-43-4P 391905-44-5P 391905-46-7P 391905-48-9P 391905-51-4P 391905-54-7P 391905-56-9P 391905-58-1P 391905-61-6P 391905-64-9P 391905-65-0P 391905-68-3P 391905-70-7P 391905-72-9P 391905-76-3P 391905-78-5P 391905-80-9P 391905-81-0P 391905-82-1P 391905-83-2P 391905-84-3P 391905-85-4P 391905-87-6P, [5-[4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]-1H-tetrazol-1-yl]acetic acid 391905-88-7P, [5-[4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]-2H-tetrazol-2-yl]acetic acid 391905-91-2P, 5-[4-[4-[[(2S)-2-Hydroxy-2-[2-(trifluoromethyl)-1,3-thiazol-4-yl]ethyl]amino]piperidine-1-yl]benzyl]-1,3-thiazolidine-2,4-dione 391905-95-6P, 5-[4-[4-[[(2S)-2-[3-(3,4-Dichlorophenyl)isoxazol-5-yl]-2-hydroxyethyl]amino]piperidin-1-yl]benzyl]-1,3-thiazole-2,4-dione 391905-98-9P, N-[4-[(1R)-2-[[1-[4-[(2,4-Dioxo-1,3-thiazolidin-5-yl)methyl]phenyl]piperidine-4-yl]amino]-1-hydroxyethyl]phenyl]methanesulfonamide 391906-02-8P, 5-[4-[4-[4-[(2S)-2-(3-Bromoisoxazol-5-yl)-2-hydroxyethyl]amino]piperidine-1-yl]benzyl]-1,3-thiazolidine-2,4-dione 391906-04-0P 391906-06-2P 391906-09-5P, 5-[4-[4-((2S)-2-Hydroxy-2-pyridin-3-ylethylamino)piperidin-1-yl]benzyl]thiazolidine-2,4-dione 391906-11-9P 391906-14-2P, 5-[4-[4-((2R)-2-Hydroxy-2-pyridin-3-ylethylamino)piperidin-1-yl]benzyl]thiazolidine-2,4-dione 391906-17-5P 391906-19-7P 391906-22-2P 391906-26-6P, N-[(2R)-2-Hydroxy-5-[1-hydroxy-2-[1-[4-(5-oxo-2,5-dihydro-1H-pyrazol-3-yl)phenyl]piperidin-4-ylamino]ethyl]phenyl]methanesulfonamide 391906-44-8P 391906-45-9P 391906-47-1P 391906-48-2P 391906-49-3P 391906-51-7P 391906-52-8P, Diethyl (2S)-2-[[4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]benzoyl]amino]pentanedioate 391906-53-9P, Ethyl 3-[[4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]benzoyl]amino]propanoate 391906-54-0P 391906-55-1P, Methyl [[4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]benzoyl]amino]acetate 391906-56-2P 391906-58-4P 391906-59-5P, 4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]benzamide 391906-60-8P 391906-62-0P, N-Butyl-4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]-N-(1H-tetrazol-5-ylmethyl)benzamide 391907-29-2P, N-[4-[4-(2-Hydroxy-2-phenylethylamino)piperidin-1-yl]phenyl]-4-methoxybenzenesulfonamide 391907-31-6P 391907-37-2P, N-[4-[4-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-1-piperidinyl]phenyl]-4-methoxybenzenesulfonamide 391907-39-4P, N-[4-[4-[((2R)-2-Hydroxy-2-phenylethyl)amino]-1-piperidinyl]phenyl]-4-methoxybenzenesulfonamide 391907-41-8P, N-[4-[[4-[4-[[2-Hydroxy-3-(4-methoxyphenoxy)propyl]amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetamide 391907-44-1P, N-[4-[[2-[4-[[2-Hydroxy-2-(3-hydroxyphenyl)ethyl]amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetamide 391907-46-3P, N-[4-[[2-[4-[[(2R)-2-(3,4-Dihydroxyphenyl)-2-hydroxyethyl]amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetamide 391907-48-5P, N-[4-[4-[[(2R)-2-(3,4-Dihydroxyphenyl)-2-hydroxyethyl]amino]-1-

piperidinyl]phenyl]-4-methoxybenzenesulfonamide 391907-60-1P, N-[4-[[4-[4-[[2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetamide 391907-62-3P, 4-[[(Hexylamino)carbonyl]amino]-N-[4-[4-[[2-hydroxy-2-(6-methyl-3-pyridinyl)ethyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 391907-73-6P, N-[4-[4-[[(2S)-2-Hydroxy-3-(4-hydroxyphenoxy)propyl]amino]-1-piperidinyl]phenyl]-3,4-dimethoxybenzenesulfonamide 391907-82-7P, 5-Chloro-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-3-methyl-1-benzothiophene-2-sulfonamide 391907-84-9P, 4-Cyano-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 391907-86-1P, 4-Cyano-N-[(4-cyanophenyl)sulfonyl]-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 391907-88-3P, 3-Bromo-5-chloro-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-2-thiophenesulfonamide 391907-96-3P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-5-(3-isoxazolyl)-2-thiophenesulfonamide 391908-00-2P 391908-02-4P 391908-06-8P, N-[4-[4-[[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino]-1-piperidinyl]phenyl]-3,4-dimethoxybenzenesulfonamide 391908-08-0P, N-[4-[4-[[(2S)-2-Hydroxy-3-(4-hydroxyphenoxy)propyl]amino]-1-piperidinyl]phenyl]-5-(2-pyridinyl)-2-thiophenesulfonamide 391908-15-9P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-5-[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl]-2-thiophenesulfonamide 391908-17-1P, N-[4-[4-[[(2S)-2-Hydroxy-3-(4-hydroxyphenoxy)propyl]amino]-1-piperidinyl]phenyl]-5-[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl]-2-thiophenesulfonamide 391908-19-3P 391908-21-7P, 4-[(2,4-Dioxo-1,3-thiazolidin-5-yl)methyl]-N-[4-[4-[[2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 391908-23-9P, N-[4-[4-[[(2S)-2-Hydroxy-3-(4-hydroxyphenoxy)propyl]amino]-1-piperidinyl]phenyl]-1-octanesulfonamide 391908-26-2P, N-[4-[4-[[(2S)-2-Hydroxy-3-[4-hydroxy-3-[(methylsulfonyl)amino]phenoxy]propyl]amino]-1-piperidinyl]phenyl]-3,4-dimethoxybenzenesulfonamide 391908-28-4P, N-[4-[4-[[(2S)-2-Hydroxy-3-[4-hydroxy-3-[(methylsulfonyl)amino]phenoxy]propyl]amino]-1-piperidinyl]phenyl]-1-butanesulfonamide 391908-30-8P 391908-32-0P, N-[4-[4-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-1-piperidinyl]phenyl]-4-[[(hexylamino)carbonyl]amino]benzenesulfonamide 391908-34-2P, Ethyl [4-[[4-[4-[[(2S)-2-hydroxy-3-[4-hydroxy-3-[(methylsulfonyl)amino]phenoxy]propyl]amino]-1-piperidinyl]anilino]sulfonyl]phenyl]acetate 391908-39-7P, Methyl [4-[[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]anilino]sulfonyl]phenoxy]acetate 391908-41-1P, N-[5-[[(2S)-3-[[1-[4-[(Butylsulfonyl)amino]phenyl]-4-piperidinyl]amino]-2-hydroxypropyl]oxy]-2-hydroxyphenyl]benzenesulfonamide 391908-45-5P, N-[4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(isopropylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]-1-butanesulfonamide 391908-49-9P, Methyl [4-[[4-[4-[[(2R)-2-[4-chloro-3-[(methylsulfonyl)amino]phenyl]-2-hydroxyethyl]amino]-1-piperidinyl]anilino]sulfonyl]phenoxy]acetate 391908-59-1P, 3,4-Dichloro-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 391908-61-5P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide 391908-63-7P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-4-(trifluoromethoxy)benzenesulfonamide 391908-65-9P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-4-methoxybenzenesulfonamide 391908-67-1P, 4-Chloro-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]benzenesulfonamid

e 391908-69-3P, 4-Butyl-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 391908-71-7P, 3,5-Dichloro-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 391908-73-9P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-2,5-dimethoxybenzenesulfonamide 391908-76-2P, N-[4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]-2,5-dimethoxybenzenesulfonamide 391908-79-5P 391908-82-0P, 5-Bromo-N-[(5-bromo-2-methoxyphenyl)sulfonyl]-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-2-methoxybenzenesulfonamide 391908-85-3P, 5-Bromo-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-2-methoxybenzenesulfonamide 391908-88-6P 391908-91-1P 391908-94-4P 391909-04-9P 391909-09-4P 391909-12-9P 391909-15-2P, 4-[3-Chloro-5-(trifluoromethyl)-2-pyridinyl]oxy-N-[4-[4-[((2S)-2-hydroxy-3-phenoxypropyl)amino]-1-piperidinyl]phenyl]benzenesulfonamide 391909-20-9P, N-[[5-[[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]anilino]sulfonyl]-2-thienyl]methyl]benzamide 391909-25-4P, N-[[5-[[4-[4-[((2S)-2-Hydroxy-3-phenoxypropyl)amino]-1-piperidinyl]anilino]sulfonyl]-2-thienyl]methyl]benzamide 391909-27-6P, N-[[5-[[4-[4-[[2-Hydroxy-2-(3-hydroxyphenyl)ethyl]amino]-1-piperidinyl]anilino]sulfonyl]-2-thienyl]methyl]benzamide 391909-29-8P, 4-[[3-Chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 391909-31-2P, 4-[[3-Chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]-N-[4-[4-[[2-hydroxy-2-(3-hydroxyphenyl)ethyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 391909-33-4P, 3,5-Dichloro-4-(2-chloro-4-nitrophenoxy)-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 391909-36-7P, 3,5-Dichloro-4-(2-chloro-4-nitrophenoxy)-N-[4-[4-[((2S)-2-hydroxy-3-phenoxypropyl)amino]-1-piperidinyl]phenyl]benzenesulfonamide 391909-38-9P, 3,5-Dichloro-4-(2-chloro-4-nitrophenoxy)-N-[4-[4-[[2-hydroxy-2-(3-hydroxyphenyl)ethyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 391909-40-3P, N-[4-[4-[((2S)-2-Hydroxy-3-phenoxypropyl)amino]-1-piperidinyl]phenyl]-2-thiophenesulfonamide 391909-42-5P, 4-Butoxy-N-[4-[4-[((2S)-2-hydroxy-3-phenoxypropyl)amino]-1-piperidinyl]phenyl]benzenesulfonamide 391909-44-7P, N-[4-[4-[[(2S)-2-Hydroxy-2-(3-hydroxyphenyl)ethyl]amino]-1-piperidinyl]phenyl]-2-thiophenesulfonamide 391909-46-9P, 4-Butoxy-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 391909-49-2P, N-[4-[4-[((2S)-2-Hydroxy-3-phenoxypropyl)amino]-1-piperidinyl]phenyl]-3,4-dimethoxybenzenesulfonamide 391909-51-6P, N-[4-[4-[[2-Hydroxy-2-(3-hydroxyphenyl)ethyl]amino]-1-piperidinyl]phenyl]-3,4-dimethoxybenzenesulfonamide 391909-53-8P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-2-thiophenesulfonamide 391909-75-4P 391909-82-3P 391909-86-7P, [[[4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]anilino]carbonyl]amino]acetic acid 391909-90-3P 391909-92-5P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-3,4-dimethoxybenzamide 391909-94-7P, 2-Chloro-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]acetamide 391909-96-9P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-2-(4-morpholinyl)acetamide 391909-98-1P, 2-(Dimethylamino)-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]acetamide 391910-00-2P, N-[4-[4-[[2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]-

3,4-dimethoxybenzamide 391910-02-4P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]butanamide 391910-04-6P, N-[4-[4-[[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino]-1-piperidinyl]phenyl]butanamide 391910-06-8P, N-[4-[4-[[(2S)-2-Hydroxy-3-(4-hydroxyphenoxy)propyl]amino]-1-piperidinyl]phenyl]-3,4-dimethoxybenzamide 391910-08-0P, N-[4-[4-[[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino]-1-piperidinyl]phenyl]-3,4-dimethoxybenzamide 391910-10-4P, N-[4-[4-[[(2S)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]-1,3-benzodioxole-5-carboxamide 391910-12-6P, N-[4-[4-[[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino]-1-piperidinyl]phenyl]-1,3-benzodioxole-5-carboxamide 391910-14-8P, 3-Cyclopentyl-N-[4-[4-[[(2S)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl]amino]-1-piperidinyl]phenyl]propanamide 391910-16-0P, 3-Cyclopentyl-N-[4-[4-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]propanamide 391910-18-2P, N-[4-[4-[[(2R)-2-Hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]-1,3-benzodioxole-5-carboxamide 391910-38-6P 391910-41-1P, N-[4-[3-[Benzyl-[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]azetidin-1-yl]phenyl]acetamide 391910-44-4P, N-[4-[3-[Benzyl-[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]azetidin-1-yl]phenyl]-4-butoxybenzenesulfonamide 391910-47-7P, N-[4-[3-[Benzyl[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]azetidin-1-yl]phenyl]-3,4-dimethoxybenzenesulfonamide 391910-50-2P 391910-53-5P, N-[4-[3-[Benzyl-[3-(4-benzyloxyphenoxy)-2-hydroxypropyl]amino]azetidin-1-yl]phenyl]-3,4-dimethoxybenzenesulfonamide 391910-56-8P 391910-59-1P, N-Acetyl-N-[4-[3-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]-1-azetidinyl]phenyl]acetamide 391910-62-6P, 4-Butoxy-N-[4-[3-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]-1-azetidinyl]phenyl]benzenesulfonamide 391910-65-9P, N-[4-[3-[[(2S)-2-Hydroxy-3-(4-hydroxyphenoxy)propyl]amino]-1-azetidinyl]phenyl]-3,4-dimethoxybenzenesulfonamide 391910-68-2P, N-[4-[[4-[3-[[(2S)-2-Hydroxy-3-(4-hydroxyphenoxy)propyl]amino]-1-azetidinyl]anilino]sulfonyl]phenyl]acetamide 391910-71-7P, 4-Butoxy-N-[4-[3-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-1-azetidinyl]phenyl]benzenesulfonamide 391910-74-0P, N-[4-[3-[[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino]-1-azetidinyl]phenyl]acetamide 391910-77-3P, N-[4-[3-[[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino]-1-azetidinyl]phenyl]-3,4-dimethoxybenzenesulfonamide 391910-80-8P, N-[4-[[4-[3-[[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino]-1-azetidinyl]anilino]sulfonyl]phenyl]acetamide 391910-91-1P 391911-04-9P, 4-Butoxy-N-[4-[4-[[2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide 391911-04-9P 391911-11-8P, 4-Butoxy-N-[4-[4-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-1-piperidinyl]phenyl]benzenesulfonamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(β3 agonist; preparation of cyclic amine Ph β3 adrenergic receptor agonists for treatment of metabolic disorders related to insulin resistance or hyperglycemia)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Marsault, E; WO 9965895 A 1999 HCAPLUS
(2) Muehl, B; EP 0764640 A 1997 HCAPLUS
(3) Muehl, B; WO 9809625 A 1998 HCAPLUS
(4) Sanofi, S; WO 0117989 A 2001 HCAPLUS
(5) Sanofi, S; WO 0143744 A 2001 HCAPLUS
(6) Tokyo Tanabe Co; WO 9715549 A 1997 HCAPLUS
(7) Tokyo Tanabe Co; EP 0940387 A 1999 HCAPLUS

IT **7568-93-6**, 2-Amino-1-phenylethanol

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of cyclic amine Ph β3 adrenergic receptor agonists for treatment of metabolic disorders related to insulin resistance or hyperglycemia)
RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:33426 HCAPLUS
DN 136:340268
ED Entered STN: 13 Jan 2002
TI Transesterification of β-keto esters catalyzed by basic porous material
AU Kantam, M. Lakshmi; Sreekanth, P.
CS Inorganic Chemistry Division, Indian Institute of Chemical Technology, Hyderabad, 500 007, India
SO Catalysis Letters (2001), 77(4), 241-243
CODEN: CALEER; ISSN: 1011-372X
PB Kluwer Academic/Plenum Publishers
DT Journal
LA English
CC 21-2 (General Organic Chemistry)
AB β-Keto esters have been successfully transesterified with primary, secondary, tertiary, allylic, and alkynic alcs. in good yields using TBD anchored on MCM **support** for the first time. The hybrid **solid** base catalyst can be recycled several times with consistent activity.
ST transesterification keto ester solid base catalyst
IT Esters, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(keto; transesterification of β-keto esters catalyzed by basic porous material)
IT Transesterification
Transesterification catalysts
(transesterification of β-keto esters catalyzed by basic porous material)
IT Zeolite MCM-41
RL: RCT (Reactant); RACT (Reactant or reagent)
(transesterification of β-keto esters catalyzed by basic porous material)
IT 415949-65-4DP, MCM-41 bound
RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(transesterification of β-keto esters catalyzed by basic porous material)
IT 67-56-1, Methanol, reactions 71-36-3, 1-Butanol, reactions 100-51-6, Benzyl alcohol, reactions 106-24-1, Geranyl alcohol 107-19-7, Propargyl alcohol 111-27-3, 1-Hexanol, reactions 111-87-5, 1-Octanol, reactions 141-97-9, Ethyl acetoacetate 2530-83-8 5807-14-7 **7568-93-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(transesterification of β-keto esters catalyzed by basic porous material)
IT 105-45-3P, Methyl acetoacetate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(transesterification of β-keto esters catalyzed by basic porous material)
IT 591-60-6P, Butyl acetoacetate 5396-89-4P, Benzyl acetoacetate
10032-00-5P, Geranyl acetoacetate 13562-84-0P, Hexyl acetoacetate
16436-00-3P, Octyl acetoacetate 29816-99-7P, Propargyl acetoacetate
415949-64-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(transesterification of β-keto esters catalyzed by basic porous material)
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Angeletti, E; J Chem Soc Perkin Trans I 1989, P105 HCAPLUS
(2) Angeletti, E; Tetrahedron Lett 1988, V29, P226
(3) Balaji, B; Chem Commun 1996, P707 HCAPLUS
(4) Beck, J; J Am Chem Soc 1992, V114, P10834 HCAPLUS
(5) Billman, J; J Am Chem Soc 1947, V69, P2058 HCAPLUS
(6) Blandy, C; Catal Lett 1997, V43, P139 HCAPLUS
(7) Bleloch, A; Chem Commun 1999, P1907 HCAPLUS
(8) Brunel, D; J Org Chem 1997, V62, P749
(9) Choudary, B; J Mol Catal A 1999, V142, P361 HCAPLUS
(10) Choudary, B; J Mol Catal A 2000, V159, P411 HCAPLUS
(11) Corma, A; Chem Rev 1997, V97, P2373 HCAPLUS
(12) Engel, D; US 5350879 1994 HCAPLUS
(13) Lasperas, M; Stud Surf Sci Catal 1997, V108, P75 HCAPLUS
(14) Macquarrie, D; J Chem Soc Chem Commun 1997, P1781 HCAPLUS
(15) Osipow, L; J Am Oil Soc 1957, V34, P185 HCAPLUS
(16) Otera, J; J Org Chem 1991, V56, P5307 HCAPLUS
(17) Ponde, D; J Org Chem 1998, V63, P1058
(18) Posner, G; Tetrahedron Lett 1981, V22, P5003 HCAPLUS
(19) Rehberg, C; J Am Chem Soc 1944, V66, P1203 HCAPLUS
(20) Santaniello, E; Enzyme Microb Technol 1993, V15, P367 HCAPLUS
(21) Schuchardt, U; J Mol Catal A 1996, V109, P37 HCAPLUS
(22) Schwesinger, R; Chem Ber 1994, V127, P2435 HCAPLUS
(23) Seebach, D; Synthesis 1982, P138 HCAPLUS
(24) Subbrao, Y; Angew Chem Int Ed Engl 1997, V36, P2661
(25) Taft, R; J Am Chem Soc 1950, V721, P4511
(26) Tuel, A; Chem Mater 1996, V8, P114 HCAPLUS
IT **7568-93-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(transesterification of β-keto esters catalyzed by basic porous material)
RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:924420 HCAPLUS
DN 136:162487
ED Entered STN: 23 Dec 2001
TI Identification of Novel Ah Receptor Agonists Using a High-Throughput Green Fluorescent Protein-Based Recombinant Cell Bioassay
AU Nagy, Scott R.; Liu, Gang; Lam, Kit S.; Denison, Michael S.
CS Department of Environmental Toxicology, University of California, Davis, CA, 95616, USA
SO Biochemistry (2002), 41(3), 861-868
CODEN: BICHAW; ISSN: 0006-2960
PB American Chemical Society

DT Journal
LA English
CC 4-3 (Toxicology)
AB The Ah receptor is a ligand-dependent transcription factor that mediates the biol. and toxic effects of polycyclic aromatic hydrocarbons and halogenated aromatic hydrocarbons such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin). Recent evidence also suggests a role for the AhR in normal physiol. and development. Although a variety of structurally diverse chems. are reported to bind to and activate the AhR, the full spectrum of structural chemical classes that can interact with the AhR remains to be elucidated. Large-scale anal. of the ligand binding specificity of the AhR requires the use of a high-throughput AhR bioassay system for chemical screening. We have utilized a recombinant mouse hepatoma cell line (H1G1.1c3) containing a stably integrated TCDD- and AhR-responsive enhanced green fluorescent protein (EGFP) reporter gene to screen a 1,5-dialkylamino-2,4-dinitrobenzene combinatorial chemical library consisting of 155 parental amines and up to 12 090 combinatorial products in less than 7 days for novel AhR agonists. These analyses have identified numerous parental amines as relatively potent inducers of EGFP (with EC50s between 8 and 1000 μM) and also have revealed several novel products of the combinatorial chemical library synthesis with EC50s between 10 and 100 μM. Overall, these results have not only allowed the identification of novel activators of the AhR but also demonstrate the utility of the recombinant H1G1.1c3 cell bioassay for high-throughput chemical screening.
ST arom hydrocarbon receptor agonist diakylamino dinitrobenzene combinatorial library
IT Animal cell line
(H1G1.1c3; identification of novel Ah receptor agonists using high-throughput green fluorescent protein-based recombinant cell bioassay)
IT **Combinatorial library**
(dialkylamino dinitrobenzene; identification of novel Ah receptor agonists using high-throughput green fluorescent protein-based recombinant cell bioassay)
IT Aromatic hydrocarbon receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(identification of novel Ah receptor agonists using high-throughput green fluorescent protein-based recombinant cell bioassay)
IT Amines, biological studies
RL: BSU (Biological study, unclassified); CRT (Combinatorial reactant); RCT (Reactant); BIOL (Biological study); CMBI (Combinatorial study); RACT (Reactant or reagent)
(identification of novel Ah receptor agonists using high-throughput green fluorescent protein-based recombinant cell bioassay)
IT 99-65-0DP, Di(alkylamino) derivs. 396992-71-5P 396992-76-0P 396992-80-6P 396992-85-1P 396992-91-9P 396992-96-4P 396993-01-4P 396993-06-9P 396993-11-6P 396993-17-2P 396993-21-8P
RL: BSU (Biological study, unclassified); CPN (Combinatorial preparation); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)
(identification of novel Ah receptor agonists using high-throughput green fluorescent protein-based recombinant cell bioassay)
IT 91-21-4, 1,2,3,4-Tetrahydroisoquinoline 95-51-2, 2-Chloroaniline 95-54-5, 1,2-Phenylenediamine, biological studies 100-46-9, Benzylamine, biological studies 134-32-7, 1-Aminonaphthalene 327-92-4, 1,5-Difluoro-2,4-dinitrobenzene 365-34-4, 2-(Trifluoromethyl)phenylhydrazine 479-27-6, 1,8-Diaminonaphthalene 615-43-0, 2-Iodoaniline 618-40-6, 1-Methyl-1-phenylhydrazine 694-83-7, 1,2-Diaminocyclohexane 1484-26-0, 3-Benzyloxyaniline 2217-40-5, 1,2,3,4-Tetrahydro-1-naphthylamine 2217-41-6, 5,6,7,8-Tetrahydro-1-naphthylamine 2243-62-1, 1,5-Diaminonaphthalene 2312-23-4, 3-Chlorophenylhydrazine hydrochloride 2620-50-0, Piperonylamine 2905-56-8, 1-Benzylpiperidine 2987-53-3, 2-(Methylmercapto)aniline 5345-54-0, 3-Chloro-p-anisidine 5913-13-3, (R)-(-)-1-

Cyclohexylethylamine 6967-12-0, 6-Aminoindazole **7568-93-6**, 2-Amino-1-phenylethanol 14268-66-7, 3,4-(Methylenedioxy)aniline 20570-96-1, Benzylhydrazine dihydrochloride 34967-24-3, 3,5-Dimethoxybenzylamine 126456-43-7, (1S,2R)-(-)-cis-1-Amino-2-indanol 133115-72-7, 4-(Trifluoromethoxy)phenylhydrazine hydrochloride
RL: BSU (Biological study, unclassified); CRT (Combinatorial reactant); RCT (Reactant); BIOL (Biological study); CMBI (Combinatorial study); RACT (Reactant or reagent)
(identification of novel Ah receptor agonists using high-throughput green fluorescent protein-based recombinant cell bioassay)

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Cheung, Y; Toxicology 1997, V118, P115 HCAPLUS
(2) de Vito, M; Dioxins and Health 1994, P139 HCAPLUS
(3) Degawa, M; Biochim Biophys Acta 1998, V1379, P391 HCAPLUS
(4) Denison, M; J Biol Chem 1986, V261, P3987 HCAPLUS
(5) Denison, M; J Biol Chem 1988, V263, P17221 HCAPLUS
(6) Denison, M; Molecular Biology Approaches to Toxicology 1998, P393
(7) Denison, M; Toxicant-Receptor Interactions 1998, P3 HCAPLUS
(8) Denison, M; Toxicol Appl Pharmacol 1998, V152, P406 HCAPLUS
(9) Fernandez-Salguero, P; Toxicol Appl Pharmacol 1996, V140, P173 HCAPLUS
(10) Garrison, P; Fundam Appl Toxicol 1996, V30, P194 HCAPLUS
(11) Gillner, M; Mol Pharmacol 1993, V44, P336 HCAPLUS
(12) Hahn, M; Aquat Toxicol 1993, V26, P185 HCAPLUS
(13) Heath-Pagliuso, S; Biochemistry 1998, V37, P11508 HCAPLUS
(14) Kafafi, S; Chem Res Toxicol 1993, V6, P328 HCAPLUS
(15) Kennedy, S; Anal Biochem 1993, V211, P102 HCAPLUS
(16) Liu, G; J Comb Chem 2000, V2, P467 HCAPLUS
(17) Lu, Y; Biochem Pharmacol 1996, V51, P1077 HCAPLUS
(18) McDougal, A; Breast Cancer Res Treat 2001, V66, P147 HCAPLUS
(19) McDougal, A; Cancer Res 2001, V61, P3902 HCAPLUS
(20) Nagy, S; Toxicol Sci in press 2001
(21) Okey, A; Toxicol Lett 1994, V70, P1 HCAPLUS
(22) Phelan, D; Arch Biochem Biophys 1998, V357, P155 HCAPLUS
(23) Poland, A; Ann N Y Acad Sci 1979, V320, P214 HCAPLUS
(24) Pollenz, R; Mol Pharmacol 1993, V45, P428
(25) Postlind, H; Toxicol Appl Pharmacol 1993, V118, P255 HCAPLUS
(26) Probst, M; Mol Pharmacol 1993, V44, P511 HCAPLUS
(27) Safe, S; Crit Rev Toxicol 1990, V21, P51 HCAPLUS
(28) Safe, S; Exp Opin Invest Drugs 1999, V8, P1385 HCAPLUS
(29) Safe, S; Pharmacol Ther 1995, V67, P247 HCAPLUS
(30) Safe, S; Toxicol Lett 1998, V102-103, P343 HCAPLUS
(31) Schaldach, C; Biochemistry 1999, V38, P7594 HCAPLUS
(32) Seidel, S; J Biochem Mol Toxicol 2001, V55, P107
(33) Sinal, C; Mol Pharmacol 1997, V52, P590 HCAPLUS
(34) Sogawa, M; Genes Cells 1997, V2, P645
(35) Waller, C; Chem Res Toxicol 1995, V8, P847 HCAPLUS
(36) Whitlock, J; Annu Rev Pharmacol Toxicol 1999, V39, P103 HCAPLUS

IT **7568-93-6**, 2-Amino-1-phenylethanol
RL: BSU (Biological study, unclassified); CRT (Combinatorial reactant); RCT (Reactant); BIOL (Biological study); CMBI (Combinatorial study); RACT (Reactant or reagent)
(identification of novel Ah receptor agonists using high-throughput green fluorescent protein-based recombinant cell bioassay)

RN 7568-93-6 HCAPLUS

CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:31473 HCAPLUS
DN 134:100864
ED Entered STN: 12 Jan 2001
TI Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
IN Kania, Robert Steven; Bender, Steven Lee; Borchardt, Allen J.; Braganza, John F.; Cripps, Stephan James; Hua, Ye; Johnson, Michael David; Johnson, Theodore Otto, Jr.; Luu, Hiep The; Palmer, Cynthia Louise; Reich, Siegfried Heinz; Tempczyk-russell, Anna Maria; Teng, Min; Thomas, Christine; Varney, Michael David; Wallace, Michael Brennan
PA Agouron Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 439 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D231-00
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 7, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002369	A2	20010111	WO 2000-US18263	20000630
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000012352	A	20020514	BR 2000-12352	20000630
	EP 1218348	A2	20020703	EP 2000-943375	20000630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003503481	T2	20030128	JP 2001-507809	20000630
	NZ 516676	A	20030926	NZ 2000-516676	20000630
	US 6531491	B1	20030311	US 2001-983786	20011025
	US 6534524	B1	20030318	US 2001-983783	20011025
	NO 2001005797	A	20020301	NO 2001-5797	20011128
	ZA 2001010061	A	20030206	ZA 2001-10061	20011206
	BG 106380	A	20020930	BG 2002-106380	20020201
PRAI	US 1999-142130P	P	19990702		
	US 2000-609335	B3	20000630		
	WO 2000-US18263	W	20000630		

OS MARPAT 134:100864
GI



I

AB Indazole compds. I [R1 = substituted or unsubstituted aryl or heteroaryl,

R3CH:CH, R3N:CH; R2 = substituted or unsubstituted aryl, heteroaryl, Y-X; R3 = substituted or unsubstituted alkyl alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; Y = O, S, C(:CH2), CO, SO, SO2, alkylidene, NH, N(C1-C8 alkyl); X = substituted or unsubstituted aryl, heteroaryl, NH(alkyl), NH(cycloalkyl), NH(heterocycloalkyl), NH(aryl), NH(heteroaryl), NH(alkoxy), NH(dialkylamide)] and their pharmaceutically acceptable prodrugs, active metabolites, and salts are disclosed. The compds. modulate and/or inhibit the activity of certain protein kinases. In particular, I and pharmaceutical compns. containing them are capable of mediating tyrosine kinase signal transduction, and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compns. containing such compds., and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amts. of such compds. E.g., I [R1 = (E)-3,4-(MeO)2C6H3CH:CH; R2 = 4-HO-3-MeOC6H3] (II) was prepared from 6-aminoindazole by diazotization and substitution with iodide, protection of the indazole nitrogen with 2,4,6-Me3C6H2SO2Cl, coupling of the regioisomeric mixture with 4-(methoxymethoxy)-3-methoxybenzeneboronic acid in the presence of dichlorobis(triphenylphosphine)palladium, and deprotection of the indazole moiety and iodination at the 3-position of the indazole. Treatment of the 3-indazolyl iodide with sec-butyllithium, phenyllithium, and DMF, regioselective protection of the indazole with 2,4,6-Me3C6H2SO2Cl, olefination with 3,4-dimethoxybenzyltriphenylphosphonium bromide, deprotection of the indazole, deprotection of the methoxymethyl group, and equilibration of the double bond with iodine gave II. Biol. data on protein kinase inhibition, cell proliferation inhibition, neovascularization inhibition, and i.p. and oral bioavailability, are given.

ST indazole prepn protein kinase inhibitor; angiogenesis cellular proliferation inhibition indazole deriv

IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Cell proliferation
Combinatorial library
Drug bioavailability
(preparation of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT Vascular endothelial growth factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT Proliferation inhibition
(proliferation inhibitors; preparation of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 319461-13-7P 319461-26-2P 319461-33-1P 319461-51-3P 319461-63-7P 319462-35-6P 319463-19-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 319460-65-6P 319460-66-7P 319460-67-8P 319460-68-9P 319460-69-0P 319460-70-3P 319460-71-4P 319460-72-5P 319460-73-6P 319460-74-7P 319460-75-8P 319460-76-9P 319460-77-0P 319460-78-1P 319460-79-2P

319460-80-5P 319460-81-6P 319460-82-7P 319460-83-8P 319460-84-9P
319460-85-0P 319460-86-1P 319460-87-2P 319460-88-3P 319460-89-4P
319460-90-7P 319460-91-8P 319460-92-9P 319460-93-0P 319460-94-1P
319460-95-2P 319460-96-3P 319460-97-4P 319460-98-5P 319461-00-2P
319461-01-3P 319461-02-4P 319461-03-5P 319461-04-6P 319461-05-7P
319461-06-8P 319461-07-9P 319461-08-0P 319461-09-1P 319461-10-4P
319461-11-5P 319461-12-6P 319461-14-8P 319461-15-9P 319461-16-0P
319461-17-1P 319461-18-2P 319461-19-3P 319461-20-6P 319461-21-7P
319461-22-8P 319461-23-9P 319461-24-0P 319461-25-1P 319461-27-3P
319461-28-4P 319461-29-5P 319461-30-8P 319461-31-9P 319461-32-0P
319461-34-2P 319461-35-3P 319461-36-4P 319461-37-5P 319461-38-6P
319461-39-7P 319461-40-0P 319461-41-1P 319461-42-2P 319461-43-3P
319461-44-4P 319461-45-5P 319461-46-6P 319461-47-7P 319461-48-8P
319461-49-9P 319461-50-2P 319461-52-4P 319461-53-5P 319461-54-6P
319461-55-7P 319461-56-8P 319461-57-9P 319461-58-0P 319461-59-1P
319461-60-4P 319461-61-5P 319461-62-6P 319461-64-8P 319461-65-9P
319461-66-0P 319461-67-1P 319461-68-2P 319461-69-3P 319461-70-6P
319461-71-7P 319461-72-8P 319461-73-9P 319461-74-0P 319461-75-1P
319461-76-2P 319461-77-3P 319461-78-4P 319461-79-5P 319461-80-8P
319461-81-9P 319461-82-0P 319461-83-1P 319461-84-2P 319461-85-3P
319461-86-4P 319461-87-5P 319461-88-6P 319461-89-7P 319461-90-0P
319461-91-1P 319461-92-2P 319461-93-3P 319461-94-4P 319461-95-5P
319461-96-6P 319461-97-7P 319461-98-8P 319461-99-9P 319462-00-5P
319462-01-6P 319462-02-7P 319462-03-8P 319462-04-9P 319462-05-0P
319462-06-1P 319462-07-2P 319462-08-3P 319462-09-4P 319462-10-7P
319462-11-8P 319462-12-9P 319462-13-0P 319462-14-1P 319462-15-2P
319462-16-3P 319462-17-4P 319462-18-5P 319462-19-6P 319462-20-9P
319462-21-0P 319462-22-1P 319462-23-2P 319462-24-3P 319462-25-4P
319462-26-5P 319462-27-6P 319462-28-7P 319462-29-8P 319462-30-1P
319462-31-2P 319462-32-3P 319462-33-4P 319462-36-7P 319462-37-8P
319462-38-9P 319462-39-0P 319462-40-3P 319462-41-4P 319462-42-5P
319462-43-6P 319462-44-7P 319462-45-8P 319462-46-9P 319462-47-0P
319462-48-1P 319462-49-2P 319462-50-5P 319462-51-6P 319462-52-7P
319462-53-8P 319462-54-9P 319462-55-0P 319462-56-1P 319462-57-2P
319462-58-3P 319462-59-4P 319462-60-7P 319462-61-8P 319462-62-9P
319462-63-0P 319462-64-1P 319462-65-2P 319462-66-3P 319462-67-4P
319462-68-5P 319462-69-6P 319462-70-9P 319462-71-0P 319462-72-1P
319462-73-2P 319462-74-3P 319462-75-4P 319462-76-5P 319462-77-6P
319462-78-7P 319462-79-8P 319462-80-1P 319462-81-2P 319462-82-3P
319462-83-4P 319462-84-5P 319462-85-6P 319462-86-7P 319462-87-8P
319462-88-9P 319462-89-0P 319462-90-3P 319462-91-4P 319462-92-5P
319462-93-6P 319462-94-7P 319462-95-8P 319462-96-9P 319462-97-0P
319462-98-1P 319462-99-2P 319463-00-8P 319463-01-9P 319463-02-0P
319463-03-1P 319463-04-2P 319463-05-3P 319463-06-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 319463-07-5P 319463-08-6P 319463-09-7P 319463-10-0P 319463-11-1P
319463-12-2P 319463-13-3P 319463-14-4P 319463-15-5P 319463-16-6P
319463-17-7P 319463-18-8P 319463-20-2P 319463-21-3P 319463-22-4P
319463-23-5P 319463-24-6P 319463-25-7P 319463-26-8P 319463-27-9P
319463-28-0P 319463-29-1P 319463-30-4P 319463-31-5P 319463-32-6P
319463-33-7P 319463-34-8P 319463-35-9P 319463-36-0P 319463-37-1P
319463-38-2P 319463-39-3P 319463-40-6P 319463-41-7P 319463-42-8P
319463-43-9P 319463-44-0P 319463-45-1P 319463-46-2P 319463-47-3P
319463-48-4P 319463-49-5P 319463-50-8P 319463-51-9P 319472-71-4P
319474-32-3P 319474-49-2P 319474-59-4P 319480-79-0P 319480-80-3P
319480-81-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 9001-88-1, Phosphorylase kinase 9026-43-1, Protein kinase 80449-02-1, Tyrosine kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 114051-78-4, Lck tyrosine kinase 125149-26-0, FGF receptor kinase 141349-86-2, Cdk2 kinase 141350-03-0, Flt-1 VEGF receptor tyrosine kinase
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(preparation of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 54-96-6, 3,4-Diaminopyridine 55-22-1, Isonicotinic acid, reactions 62-53-3, Aniline, reactions 75-31-0, Isopropylamine, reactions 79-30-1, Isobutyryl chloride 89-99-6, 2-Fluorobenzylamine 95-54-5, 1,2-Diaminobenzene, reactions 95-83-0, 4-Chloro-1,2-phenylenediamine 98-73-7, 4-tert-Butylbenzoic acid 98-80-6, Phenylboronic acid 98-81-7, 1-Bromostyrene 98-88-4, Benzoyl chloride 98-98-6, 2-Pyridinecarboxylic acid 100-52-7, Benzaldehyde, reactions 100-82-3, 3-Fluorobenzylamine 102-51-2, 4-Methoxy-1,2-phenylenediamine 107-11-9, Allylamine 107-30-2, Methoxymethyl chloride 108-23-6, Isopropyl chloroformate 108-42-9, 3-Chloroaniline 108-86-1, Bromobenzene, reactions 108-98-5, Thiophenol, reactions 109-81-9, N-Methylethylenediamine 110-76-9, 2-Ethoxyethylamine 122-52-1, Triethyl phosphite 123-30-8, 4-Aminophenol 155-09-9, trans-2-Phenylcyclopropylamine 271-89-6, Benzofuran 288-32-4, Imidazole, reactions 349-01-9 367-31-7, 4-Fluoro-1,2-phenylenediamine 368-71-8, 4-(Trifluoromethyl)-1,2-phenylenediamine 369-36-8, 2-Fluoro-5-nitroaniline 399-95-1, 3-Fluoro-4-aminophenol 402-61-9 452-58-4, 2,3-Diaminopyridine 501-53-1 501-94-0, 2-(4-Hydroxyphenyl)ethanol 541-47-9, 3,3-Dimethylacrylic acid 580-13-2, 2-Bromonaphthalene 583-70-0, 2,4-Dimethylbromobenzene 584-13-4, 4-Amino-1,2,4-triazole 586-38-9, 3-Methoxybenzoic acid 588-72-7, (E)-2-Bromostyrene 591-20-8, 3-Bromophenol 591-27-5, 3-Aminophenol 606-18-8, 2-Amino-3-nitrobenzoic acid 615-74-7, 2-Chloro-5-methylphenol 617-89-0, 2-(Aminomethyl)furan 619-05-6, 3,4-Diaminobenzoic acid 622-33-3, O-Benzylhydroxylamine 645-00-1 713-68-8, 3-Phenoxyphenol 765-30-0, Cyclopropylamine 765-39-9, 1-Aminopyrrole 771-97-1, 2,3-Naphthalenediamine 938-25-0, 1,2-Naphthalenediamine 940-62-5, trans-4-Chlorocinnamic acid 1003-29-8, 1H-Pyrrole-2-carboxaldehyde 1013-88-3, Benzophenone imine 1121-60-4, 2-Pyridinecarboxaldehyde 1670-82-2, 1H-Indole-6-carboxylic acid 1692-15-5, 4-Pyridineboronic acid 1692-25-7, 3-Pyridineboronic acid 1759-53-1, Cyclopropanecarboxylic acid 1885-14-9, Phenyl chloroformate 2014-83-7, 2,6-Dichlorobenzyl chloride 2038-03-1, 4-(2-Aminoethyl)morpholine 2124-55-2, 1H-Indole-4-carboxylic acid 2360-20-5, 3,4-Diaminobenzenesulfonamide 2361-27-5 2393-23-9, 4-Methoxybenzylamine 2450-71-7, Propargylamine 2516-34-9, Cyclobutylamine 2516-47-4, Cyclopropylmethylamine 2675-79-8 2835-99-6, 3-Methyl-4-aminophenol 2878-14-0, 2-Methylallylamine 2973-59-3, 2-Bromo-5-hydroxy-4-methoxybenzaldehyde 3096-69-3, 2,3-Dimethyl-4-aminophenol 3973-70-4 4066-41-5 4403-71-8, 4-Aminobenzyl amine 4427-29-6, O-Isopropyl hydroxylamine 4684-94-0, 6-Chloro-2-pyridinecarboxylic acid 4857-42-5, 3-Methyl-5-isoxazolecarboxylic acid 4892-02-8, Methyl thiosalicylate 4930-98-7, 2-Hydrazinopyridine 5071-96-5, 3-Methoxybenzylamine 5348-42-5, 4,5-Dichloro-1,2-phenylenediamine 5470-22-4, 4-Chloro-2-

pyridinecarboxylic acid 5682-75-7, 3-Chloro-2-cyclohexen-1-one
5720-07-0, 4-Methoxybenzeneboronic acid 5744-56-9 5744-59-2
5792-43-8, O-n-Propyl hydroxylamine 6202-94-4 6313-54-8,
2-Chloroisonicotinic acid 6542-54-7, O-Allyl hydroxylamine 6783-05-7
6967-12-0, 6-Aminoindazole 7368-78-7, 4-Bromo-2-methoxyphenol
7463-51-6, 4-Bromo-3,5-dimethylphenol 7597-18-4, 6-Nitro-1H-indazole
7658-80-2 10365-98-7, 3-Methoxybenzeneboronic acid 13115-43-0,
Pyridin-2-yl-acetic acid 13471-68-6 13472-85-0, 5-Bromo-2-
methoxypyridine 13750-81-7, 1-Methyl-2-imidazolecarboxaldehyde
13922-41-3, 1-Naphthaleneboronic acid 14472-14-1, 4-Bromo-3-methylphenol
14533-84-7, Pentafluorophenyl trifluoroacetate 15855-06-8 15962-46-6
17082-09-6, trans-Cinnamoyl chloride 20485-43-2 21169-71-1,
Isoxazole-5-carboxylic acid 23020-15-7 24065-33-6,
5-Chloro-2-thiophenecarboxylic acid 25462-85-5 25503-90-6 26308-42-9
27841-33-4, 4,5-Dimethoxy-1,2-phenylenediamine 30418-59-8,
3-Aminophenylboronic acid 30433-91-1, 2-(2-Aminoethyl)thiophene
30925-08-7 31406-95-8, 4-Bromo-2-ethoxyphenol 31591-86-3 38608-07-0,
4,5-Methylenedioxy-1,2-phenylenediamine 38700-15-1, 2-
Picolyltriphenylphosphonium chloride 39658-16-7 40248-84-8,
3-Hydroxythiophenol 40992-09-4, 4-Bromo-2-methoxy-5-methylphenol
41927-01-9, 3,4-Dimethyl-1,2-phenylenediamine 50920-65-5 50920-68-8
54998-08-2 55052-28-3 57433-93-9, 4-(Methoxymethoxy)phenol
59483-54-4, 3-Chloro-2-nitroaniline 60166-86-1 61291-21-2 63485-67-6
65079-19-8, 6-Amino-2-methylquinoline 68176-57-8, 4-tert-Butyl-1,2-
phenylenediamine 68622-14-0 69076-67-1 70219-09-9,
3,4-Dimethoxybenzyltriphenylphosphonium bromide 73186-06-8 75647-90-4
76179-40-3, 4,5-Difluoro-1,2-phenylenediamine 76513-69-4 80149-80-0
80500-27-2, 4-Methyl-3-nitrophenylboronic acid 85545-58-0 88275-88-1,
3-Bromo-2-methoxyphenol 89790-89-6 101226-37-3 102127-34-4,
4-Bromo-3-methoxyphenol 105184-38-1, 3,5-Difluorophenylacetic acid
105425-65-8, 5-Methyl-2-furanamine 113398-02-0 122775-35-3,
3,4-Dimethoxyphenylboronic acid 175277-11-9 175402-68-3 220194-02-5
220465-43-0 261953-36-0 319474-46-9 319474-47-0 319474-48-1
319474-50-5 319474-51-6 319474-52-7 319474-53-8 319474-54-9
319474-55-0 319474-56-1 319474-57-2 319474-58-3 319474-60-7
319474-61-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aryl-substituted indazole derivs. as modulators and
inhibitors of protein kinases in the treatment of tumor growth,
cellular proliferation, and angiogenesis)

IT 2836-00-2P 3463-03-4P 22237-12-3P 29274-28-0P 55499-44-0P
61063-12-5P 63909-56-8P 70315-70-7P 95602-71-4P 99873-30-0P
101226-33-9P 109806-79-3P 129486-90-4P 132532-64-0P 141922-20-5P
144205-37-8P 156478-73-8P 263400-66-4P 303047-16-7P 319472-52-1P
319472-53-2P 319472-55-4P 319472-56-5P 319472-57-6P 319472-58-7P
319472-59-8P 319472-60-1P 319472-61-2P 319472-62-3P 319472-63-4P
319472-64-5P 319472-65-6P 319472-66-7P 319472-67-8P 319472-68-9P
319472-69-0P 319472-70-3P 319472-72-5P 319472-73-6P 319472-74-7P
319472-75-8P 319472-76-9P 319472-77-0P 319472-78-1P 319472-79-2P
319472-81-6P 319472-82-7P 319472-83-8P 319472-84-9P 319472-85-0P
319472-86-1P 319472-87-2P 319472-88-3P 319472-89-4P 319472-90-7P
319472-91-8P 319472-92-9P 319472-93-0P 319472-94-1P 319472-95-2P
319472-96-3P 319472-97-4P 319472-98-5P 319472-99-6P 319473-00-2P
319473-01-3P 319473-02-4P 319473-03-5P 319473-04-6P 319473-05-7P
319473-06-8P 319473-07-9P 319473-08-0P 319473-09-1P 319473-10-4P
319473-11-5P 319473-12-6P 319473-14-8P 319473-16-0P 319473-17-1P
319473-19-3P 319473-21-7P 319473-23-9P 319473-24-0P 319473-25-1P
319473-26-2P 319473-28-4P 319473-30-8P 319473-32-0P 319473-36-4P
319473-38-6P 319473-40-0P 319473-42-2P 319473-44-4P 319473-47-7P
319473-49-9P 319473-51-3P 319473-53-5P 319473-55-7P 319473-57-9P
319473-59-1P 319473-61-5P 319473-63-7P 319473-65-9P 319473-67-1P
319473-70-6P 319473-72-8P 319473-74-0P 319473-76-2P 319473-78-4P
319473-80-8P 319473-82-0P 319473-84-2P 319473-86-4P 319473-87-5P

319473-88-6P 319473-89-7P 319473-90-0P 319473-91-1P 319473-92-2P
319473-93-3P 319473-94-4P 319473-95-5P 319473-96-6P 319473-97-7P
319473-98-8P 319473-99-9P 319474-00-5P 319474-01-6P 319474-02-7P
319474-04-9P 319474-05-0P 319474-06-1P 319474-07-2P 319474-08-3P
319474-09-4P 319474-10-7P 319474-11-8P 319474-12-9P 319474-13-0P
319474-14-1P 319474-15-2P 319474-16-3P 319474-17-4P 319474-18-5P
319474-19-6P 319474-20-9P 319474-21-0P 319474-22-1P 319474-23-2P
319474-24-3P 319474-25-4P 319474-26-5P 319474-27-6P 319474-28-7P
319474-29-8P 319474-30-1P 319474-31-2P 319474-33-4P 319474-34-5P
319474-35-6P 319474-36-7P 319474-37-8P 319474-38-9P 319474-39-0P
319474-40-3P 319474-41-4P 319474-42-5P 319474-43-6P 319474-44-7P
319474-45-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 319472-54-3P 319472-80-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 319463-52-0P 319463-53-1P 319463-54-2P 319463-55-3P 319463-56-4P
319463-57-5P 319463-58-6P 319463-59-7P 319463-60-0P 319463-61-1P
319463-62-2P 319463-63-3P 319463-64-4P 319463-65-5P 319463-66-6P
319463-67-7P 319463-68-8P 319463-69-9P 319463-70-2P 319463-71-3P
319463-72-4P 319463-73-5P 319463-74-6P 319463-75-7P 319463-76-8P
319463-77-9P 319463-78-0P 319463-79-1P 319463-80-4P 319463-81-5P
319463-82-6P 319463-83-7P 319463-84-8P 319463-85-9P 319463-86-0P
319463-87-1P 319463-88-2P 319463-89-3P 319463-90-6P 319463-91-7P
319463-92-8P 319463-93-9P 319463-94-0P 319463-95-1P 319463-96-2P
319463-97-3P 319463-98-4P 319463-99-5P 319464-00-1P 319464-01-2P
319464-02-3P 319464-03-4P 319464-04-5P 319464-05-6P 319464-06-7P
319464-07-8P 319464-08-9P 319464-09-0P 319464-10-3P 319464-11-4P
319464-12-5P 319464-13-6P 319464-14-7P 319464-15-8P 319464-16-9P
319464-17-0P 319464-18-1P 319464-19-2P 319464-20-5P 319464-21-6P
319464-22-7P 319464-23-8P 319464-24-9P 319464-25-0P 319464-26-1P
319464-27-2P 319464-28-3P 319464-29-4P 319464-30-7P 319464-31-8P
319464-32-9P 319464-33-0P 319464-34-1P 319464-35-2P 319464-36-3P
319464-37-4P 319464-38-5P 319464-39-6P 319464-41-0P 319464-43-2P
319464-44-3P 319464-45-4P 319464-46-5P 319464-47-6P 319464-48-7P
319464-49-8P 319464-50-1P 319464-51-2P 319464-52-3P 319464-53-4P
319464-54-5P 319464-55-6P 319464-56-7P 319464-57-8P 319464-58-9P
319464-59-0P 319464-60-3P 319464-61-4P 319464-63-6P 319464-64-7P
319464-66-9P 319464-67-0P 319464-69-2P 319464-71-6P 319464-72-7P
319464-73-8P 319464-74-9P 319464-75-0P 319464-76-1P 319464-77-2P
319464-78-3P 319464-79-4P 319464-80-7P 319464-81-8P 319464-82-9P
319464-83-0P 319464-84-1P 319464-85-2P 319464-86-3P 319464-88-5P
319464-89-6P 319464-90-9P 319464-91-0P 319464-92-1P 319464-93-2P
319464-94-3P 319464-95-4P 319464-96-5P 319464-97-6P 319464-98-7P
319464-99-8P 319465-00-4P 319465-01-5P 319465-02-6P 319465-03-7P
319465-04-8P 319465-05-9P 319465-06-0P 319465-07-1P 319465-08-2P
319465-09-3P 319465-10-6P 319465-11-7P 319465-12-8P 319465-13-9P
319465-14-0P 319465-15-1P 319465-16-2P 319465-17-3P 319465-18-4P
319465-19-5P 319465-20-8P 319465-21-9P 319465-22-0P 319465-23-1P
319465-24-2P 319465-25-3P 319465-26-4P 319465-27-5P 319465-28-6P
319465-29-7P 319465-30-0P 319465-31-1P 319465-32-2P 319465-33-3P
319465-34-4P 319465-35-5P 319465-36-6P 319465-37-7P 319465-38-8P
319465-39-9P 319465-40-2P 319465-41-3P 319465-42-4P 319465-43-5P
319465-44-6P 319465-45-7P 319465-46-8P 319465-47-9P 319465-48-0P
319465-49-1P 319465-50-4P 319465-51-5P 319465-52-6P 319465-53-7P
319465-54-8P 319465-55-9P 319465-56-0P 319465-57-1P 319465-58-2P
319465-59-3P 319465-60-6P 319465-61-7P 319465-62-8P 319465-63-9P

319465-64-0P 319465-65-1P 319465-66-2P 319465-67-3P 319465-68-4P
319465-69-5P 319465-70-8P 319465-71-9P 319465-72-0P 319465-73-1P
319465-74-2P 319465-75-3P 319465-76-4P 319465-77-5P 319465-78-6P
319465-79-7P 319465-80-0P 319465-81-1P 319465-82-2P 319465-83-3P
319465-84-4P 319465-85-5P 319465-86-6P 319465-87-7P 319465-88-8P
319465-89-9P 319465-90-2P 319465-92-4P 319465-94-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 319465-95-7P 319465-97-9P 319465-99-1P 319466-01-8P 319466-03-0P
319466-05-2P 319466-06-3P 319466-07-4P 319466-08-5P 319466-09-6P
319466-10-9P 319466-11-0P 319466-12-1P 319466-13-2P 319466-14-3P
319466-16-5P 319466-17-6P 319466-18-7P 319466-19-8P 319466-20-1P
319466-21-2P 319466-22-3P 319466-23-4P 319466-24-5P 319466-25-6P
319466-26-7P 319466-27-8P 319466-28-9P 319466-29-0P 319466-30-3P
319466-31-4P 319466-32-5P 319466-33-6P 319466-34-7P 319466-35-8P
319466-36-9P 319466-37-0P 319466-38-1P 319466-39-2P 319466-40-5P
319466-41-6P 319466-42-7P 319466-43-8P 319466-44-9P 319466-45-0P
319466-46-1P 319466-47-2P 319466-48-3P 319466-49-4P 319466-50-7P
319466-51-8P 319466-52-9P 319466-53-0P 319466-54-1P 319466-55-2P
319466-56-3P 319466-57-4P 319466-58-5P 319466-59-6P 319466-60-9P
319466-61-0P 319466-62-1P 319466-63-2P 319466-64-3P 319466-65-4P
319466-66-5P 319466-67-6P 319466-68-7P 319466-69-8P 319466-70-1P
319466-71-2P 319466-72-3P 319466-73-4P 319466-74-5P 319466-75-6P
319466-76-7P 319466-77-8P 319466-78-9P 319466-79-0P 319466-80-3P
319466-81-4P 319466-82-5P 319466-83-6P 319466-84-7P 319466-85-8P
319466-86-9P 319466-87-0P 319466-88-1P 319466-89-2P 319466-90-5P
319466-91-6P 319466-92-7P 319466-93-8P 319466-94-9P 319466-95-0P
319466-96-1P 319466-97-2P 319466-98-3P 319466-99-4P 319467-00-0P
319467-01-1P 319467-02-2P 319467-03-3P 319467-04-4P 319467-05-5P
319467-06-6P 319467-07-7P 319467-08-8P 319467-09-9P 319467-10-2P
319467-11-3P 319467-12-4P 319467-13-5P 319467-14-6P 319467-15-7P
319467-16-8P 319467-17-9P 319467-18-0P 319467-19-1P 319467-20-4P
319467-21-5P 319467-22-6P 319467-23-7P 319467-24-8P 319467-25-9P
319467-26-0P 319467-27-1P 319467-28-2P 319467-29-3P 319467-30-6P
319467-31-7P 319467-32-8P 319467-33-9P 319467-34-0P 319467-35-1P
319467-36-2P 319467-37-3P 319467-38-4P 319467-39-5P 319467-40-8P
319467-41-9P 319467-42-0P 319467-43-1P 319467-44-2P 319467-45-3P
319467-46-4P 319467-47-5P 319467-48-6P 319467-49-7P 319467-50-0P
319467-51-1P 319467-52-2P 319467-53-3P 319467-54-4P 319467-55-5P
319467-56-6P 319467-57-7P 319467-58-8P 319467-59-9P 319467-60-2P
319467-61-3P 319467-62-4P 319467-63-5P 319467-64-6P 319467-65-7P
319467-66-8P 319467-67-9P 319467-68-0P 319467-69-1P 319467-70-4P
319467-71-5P 319467-72-6P 319467-73-7P 319467-74-8P 319467-75-9P
319467-76-0P 319467-77-1P 319467-78-2P 319467-79-3P 319467-80-6P
319467-81-7P 319467-82-8P 319467-83-9P 319467-84-0P 319467-85-1P
319467-86-2P 319467-87-3P 319467-88-4P 319467-89-5P 319467-90-8P
319467-91-9P 319467-92-0P 319467-93-1P 319467-94-2P 319467-95-3P
319467-96-4P 319467-97-5P 319467-98-6P 319467-99-7P 319468-00-3P
319468-01-4P 319468-02-5P 319468-03-6P 319468-04-7P 319468-05-8P
319468-06-9P 319468-07-0P 319468-08-1P 319468-09-2P 319468-10-5P
319468-11-6P 319468-12-7P 319468-13-8P 319468-14-9P 319468-15-0P
319468-16-1P 319468-17-2P 319468-18-3P 319468-19-4P 319468-20-7P
319468-21-8P 319468-22-9P 319468-23-0P 319468-24-1P 319468-25-2P
319468-26-3P 319468-27-4P 319468-28-5P 319468-29-6P 319468-30-9P
319468-31-0P 319468-32-1P 319468-33-2P 319468-34-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of combinatorial libraries of aryl-substituted indazole derivs.

as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 319468-35-4P 319468-36-5P 319468-37-6P 319468-38-7P 319468-39-8P
319468-40-1P 319468-41-2P 319468-42-3P 319468-43-4P 319468-44-5P
319468-45-6P 319468-46-7P 319468-47-8P 319468-48-9P 319468-49-0P
319468-50-3P 319468-51-4P 319468-52-5P 319468-53-6P 319468-54-7P
319468-55-8P 319468-56-9P 319468-57-0P 319468-58-1P 319468-59-2P
319468-60-5P 319468-61-6P 319468-62-7P 319468-63-8P 319468-64-9P
319468-65-0P 319468-66-1P 319468-67-2P 319468-68-3P 319468-69-4P
319468-70-7P 319468-71-8P 319468-72-9P 319468-73-0P 319468-74-1P
319468-75-2P 319468-76-3P 319468-77-4P 319468-78-5P 319468-79-6P
319468-80-9P 319468-81-0P 319468-82-1P 319468-83-2P 319468-84-3P
319468-85-4P 319468-86-5P 319468-87-6P 319468-88-7P 319468-89-8P
319468-90-1P 319468-91-2P 319468-92-3P 319468-93-4P 319468-94-5P
319468-95-6P 319468-96-7P 319468-97-8P 319468-98-9P 319468-99-0P
319469-00-6P 319469-01-7P 319469-02-8P 319469-03-9P 319469-04-0P
319469-05-1P 319469-06-2P 319469-07-3P 319469-08-4P 319469-09-5P
319469-10-8P 319469-11-9P 319469-12-0P 319469-13-1P 319469-14-2P
319469-15-3P 319469-16-4P 319469-17-5P 319469-18-6P 319469-19-7P
319469-20-0P 319469-21-1P 319469-22-2P 319469-23-3P 319469-24-4P
319469-25-5P 319469-26-6P 319469-27-7P 319469-28-8P 319469-29-9P
319469-30-2P 319469-31-3P 319469-32-4P 319469-33-5P 319469-34-6P
319469-35-7P 319469-36-8P 319469-37-9P 319469-38-0P 319469-39-1P
319469-40-4P 319469-41-5P 319469-42-6P 319469-43-7P 319469-44-8P
319469-45-9P 319469-46-0P 319469-47-1P 319469-48-2P 319469-49-3P
319469-50-6P 319469-51-7P 319469-52-8P 319469-53-9P 319469-54-0P
319469-55-1P 319469-56-2P 319469-57-3P 319469-58-4P 319469-59-5P
319469-60-8P 319469-61-9P 319469-63-1P 319469-65-3P 319469-67-5P
319469-69-7P 319469-71-1P 319469-73-3P 319469-75-5P 319469-77-7P
319469-79-9P 319469-81-3P 319469-84-6P 319469-86-8P 319469-90-4P
319469-92-6P 319469-96-0P 319469-99-3P 319470-01-4P 319470-02-5P
319470-04-7P 319470-06-9P 319470-08-1P 319470-10-5P 319470-13-8P
319470-16-1P 319470-18-3P 319470-20-7P 319470-22-9P 319470-24-1P
319470-27-4P 319470-28-5P 319470-29-6P 319470-30-9P 319470-31-0P
319470-32-1P 319470-33-2P 319470-34-3P 319470-35-4P 319470-36-5P
319470-37-6P 319470-38-7P 319470-39-8P 319470-40-1P 319470-41-2P
319470-42-3P 319470-43-4P 319470-44-5P 319470-45-6P 319470-46-7P
319470-47-8P 319470-48-9P 319470-49-0P 319470-50-3P 319470-51-4P
319470-52-5P 319470-53-6P 319470-54-7P 319470-55-8P 319470-56-9P
319470-57-0P 319470-58-1P 319470-59-2P 319470-60-5P 319470-61-6P
319470-62-7P 319470-63-8P 319470-64-9P 319470-65-0P 319470-66-1P
319470-67-2P 319470-68-3P 319470-69-4P 319470-70-7P 319470-71-8P
319470-72-9P 319470-73-0P 319470-74-1P 319470-75-2P 319470-76-3P
319470-77-4P 319470-78-5P 319470-79-6P 319470-80-9P 319470-81-0P
319470-82-1P 319470-83-2P 319470-84-3P 319470-85-4P 319470-86-5P
319470-87-6P 319470-88-7P 319470-89-8P 319470-90-1P 319470-91-2P
319470-92-3P 319470-93-4P 319470-94-5P 319470-95-6P 319470-96-7P
319470-97-8P 319470-98-9P 319470-99-0P 319471-00-6P 319471-01-7P
319471-03-9P 319471-05-1P 319471-06-2P 319471-07-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 319471-08-4P 319471-09-5P 319471-10-8P 319471-11-9P 319471-12-0P
319471-13-1P 319471-14-2P 319471-15-3P 319471-16-4P 319471-17-5P
319471-18-6P 319471-19-7P 319471-20-0P 319471-21-1P 319471-22-2P
319471-23-3P 319471-24-4P 319471-25-5P 319471-26-6P 319471-27-7P
319471-28-8P 319471-29-9P 319471-30-2P 319471-31-3P 319471-32-4P
319471-33-5P 319471-34-6P 319471-35-7P 319471-36-8P 319471-37-9P
319471-38-0P 319471-39-1P 319471-40-4P 319471-41-5P 319471-42-6P
319471-43-7P 319471-44-8P 319471-45-9P 319471-46-0P 319471-47-1P

319471-48-2P 319471-49-3P 319471-50-6P 319471-51-7P 319471-52-8P
319471-53-9P 319471-54-0P 319471-55-1P 319471-56-2P 319471-57-3P
319471-58-4P 319471-59-5P 319471-60-8P 319471-61-9P 319471-63-1P
319471-65-3P 319471-66-4P 319471-67-5P 319471-68-6P 319471-69-7P
319471-70-0P 319471-71-1P 319471-72-2P 319471-73-3P 319471-74-4P
319471-75-5P 319471-76-6P 319471-77-7P 319471-78-8P 319471-79-9P
319471-80-2P 319471-81-3P 319471-82-4P 319471-83-5P 319471-84-6P
319471-85-7P 319471-86-8P 319471-87-9P 319471-88-0P 319471-89-1P
319471-90-4P 319471-91-5P 319471-92-6P 319471-93-7P 319471-94-8P
319471-95-9P 319471-96-0P 319471-97-1P 319471-98-2P 319471-99-3P
319472-00-9P 319472-01-0P 319472-02-1P 319472-03-2P 319472-04-3P
319472-05-4P 319472-06-5P 319472-07-6P 319472-08-7P 319472-09-8P
319472-10-1P 319472-11-2P 319472-12-3P 319472-13-4P 319472-14-5P
319472-15-6P 319472-16-7P 319472-17-8P 319472-18-9P 319472-19-0P
319472-20-3P 319472-21-4P 319472-22-5P 319472-23-6P 319472-24-7P
319472-25-8P 319472-26-9P 319472-27-0P 319472-28-1P 319472-29-2P
319472-30-5P 319472-31-6P 319472-32-7P 319472-33-8P 319472-34-9P
319472-35-0P 319472-36-1P 319472-37-2P 319472-38-3P 319472-39-4P
319472-40-7P 319472-41-8P 319472-42-9P 319472-44-1P 319472-46-3P
319472-47-4P 319472-48-5P 319472-49-6P 319472-50-9P 319472-51-0P
319929-27-6P 319929-28-7P 319929-29-8P 319929-30-1P 319929-31-2P
319929-32-3P 319929-33-4P 319929-34-5P 319929-35-6P 319929-36-7P
319929-37-8P 319929-38-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 51-45-6, 1H-Imidazole-4-ethanamine, reactions 55-81-2 55-85-6
56-12-2, reactions 56-40-6, Glycine, reactions 61-54-1,
1H-Indole-3-ethanamine 61-82-5, 1H-1,2,4-Triazol-3-amine 64-04-0,
Benzeneethanamine 65-86-1 73-24-5, 1H-Purin-6-amine, reactions
74-89-5, Methanamine, reactions 75-64-9, reactions 77-86-1 78-81-9
78-96-6 79-31-2 79-91-4 80-59-1 83-55-6 86-97-5 87-25-2
87-60-5 87-62-7 88-05-1 88-68-6 89-50-9 89-93-0 89-97-4
90-04-0 90-41-5, [1,1'-Biphenyl]-2-amine 90-64-2 93-05-0 94-09-7
95-02-3 95-03-4 95-23-8 95-51-2 95-53-4, reactions 95-55-6
95-68-1 95-74-9 95-76-1 95-79-4 95-82-9 95-84-1 95-85-2
96-15-1 96-20-8 96-50-4, 2-Thiazolamine 98-16-8 99-03-6 99-88-7
99-92-3 99-98-9 100-36-7 100-46-9, Benzenemethanamine, reactions
100-63-0 100-81-2 102-28-3 102-48-7 102-50-1 102-56-7 102-83-0
104-10-9 104-13-2 104-75-6 104-78-9 104-84-7 104-86-9 104-94-9
104-96-1 106-47-8, reactions 106-49-0, reactions 107-35-7 107-45-9
107-85-7 107-93-7 107-95-9, β-Alanine 108-00-9 108-09-8
108-15-6 108-33-8 108-44-1, reactions 108-69-0 108-91-8,
Cyclohexanamine, reactions 109-55-7 109-73-9, 1-Butanamine, reactions
109-85-3 110-58-7, 1-Pentanamine 111-26-2, 1-Hexanamine 111-68-2,
1-Heptanamine 111-86-4, 1-Octanamine 115-69-5 115-70-8 118-31-0,
1-Naphthalenemethanamine 118-46-7 120-20-7 121-05-1 121-66-4
122-80-5 123-00-2, 4-Morpholinepropanamine 123-82-0, 2-Heptanamine
124-68-5 134-20-3 134-32-7, 1-Naphthalenamine 136-95-8,
2-Benzothiazolamine 138-39-6 138-59-0 140-31-8, 1-
Piperazineethanamine 140-75-0 140-80-7 141-43-5, reactions
155-10-2 156-06-9 156-41-2 156-43-4 156-87-6 329-89-5 348-54-9
349-55-3 353-07-1 360-97-4 363-51-9 366-99-4 367-29-3 371-40-4
372-19-0 372-39-4 372-66-7 399-96-2 403-40-7 404-70-6 422-03-7
452-69-7 452-71-1 452-80-2 452-84-6 455-14-1 459-73-4
462-08-8, 3-Pyridinamine 492-41-1 498-36-2 499-04-7 499-05-8
500-05-0 501-81-5, 3-Pyridineacetic acid 502-83-0 504-24-5,
4-Pyridinamine 504-29-0, 2-Pyridinamine 533-30-2, 6-Benzothiazolamine
534-03-2 536-90-3 540-61-4 543-82-8 551-93-9 553-53-7 556-90-1
578-66-5, 8-Quinolinamine 579-66-8 580-15-4, 6-Quinolinamine

580-17-6, 3-Quinolinamine 580-22-3, 2-Quinolinamine 582-22-9
582-33-2 585-32-0 591-54-8, 4-Pyrimidinamine 594-39-8 598-41-4
598-74-3 608-31-1 611-34-7, 5-Quinolinamine 612-19-1 616-24-0,
3-Pentanamine 616-30-8 618-36-0 618-40-6 619-45-4 621-33-0
623-04-1 625-38-7, 3-Butenoic acid 626-43-7 643-28-7 644-42-8
645-36-3 693-11-8 693-16-3, 2-Octanamine 695-34-1 753-90-2
768-94-5, Tricyclo[3.3.1.13,7]decan-1-amine 769-92-6 772-15-6
811-93-8 816-66-0 873-83-6 874-61-3 929-06-6 931-15-7
934-32-7, 1H-Benzimidazol-2-amine 936-02-7 937-39-3 1001-53-2
1003-03-8, Cyclopentanamine 1011-54-7 1066-51-9 1072-67-9
1072-98-6 1074-79-9 1120-99-6, 1,2,4-Triazin-3-amine 1125-60-6,
5-Isoquinolinamine 1192-20-7 1195-12-6 1199-46-8 1200-27-7
1452-63-7 1477-42-5 1505-50-6 1532-84-9, 1-Isoquinolinamine
1535-73-5 1583-88-6 1603-40-3 1603-41-4 1603-91-4 1622-57-7
1664-40-0 1670-83-3, 1H-Indole-7-carboxylic acid 1687-53-2
1750-42-1, 3-Isoxazolamine 1758-46-9 1783-81-9 1798-09-0
1820-80-0, 1H-Pyrazol-3-amine 1824-81-3 1877-77-6 1938-58-5
2026-48-4 2038-57-5, Benzenepropanamine 2039-67-0 2045-79-6
2213-43-6, 1-Piperidinamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 2217-40-5 2217-41-6 2243-47-2, [1,1'-Biphenyl]-3-amine 2246-44-8
2380-63-4, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine 2438-04-2 2454-37-7
2508-29-4 2524-81-4 2536-91-6 2549-14-6 2587-02-2 2620-50-0,
1,3-Benzodioxole-5-methanamine 2625-49-2 2627-86-3 2672-88-0
2696-84-6 2706-56-1, 2-Pyridineethanamine 2734-70-5 2799-16-8
2834-90-4 2835-68-9 2835-95-2 2835-97-4 2906-12-9 2941-20-0
2975-41-9 2987-53-3 3060-69-3 3082-62-0 3182-95-4 3197-06-6
3218-02-8, Cyclohexanemethanamine 3261-62-9 3325-11-9,
1H-Benzotriazol-5-amine 3326-71-4 3399-73-3, 1-Cyclohexene-1-ethanamine 3405-77-4 3437-33-0 3524-32-1 3528-58-3 3529-08-6,
1-Piperidinepropanamine 3529-09-7 3529-10-0 3544-24-9 3544-25-0
3676-85-5 3731-51-9, 2-Pyridinemethanamine 3731-52-0,
3-Pyridinemethanamine 3731-53-1, 4-Pyridinemethanamine 3863-11-4
3886-69-9 3886-70-2 3906-16-9 3963-62-0 3964-52-1 4000-72-0
4007-01-6 4042-36-8 4048-33-3 4083-57-2 4104-45-4 4152-90-3
4214-74-8 4276-09-9 4319-49-7, 4-Morpholinamine 4344-55-2
4388-97-0, 1,3-Dioxolane-2-methanamine 4393-09-3 4395-73-7 4403-69-4
4442-59-5 4512-32-7 4534-10-5 4572-03-6 4726-85-6 4760-34-3
4781-76-4 4795-29-3 4836-52-6 4846-21-3 4923-01-7 4985-85-7
5001-36-5 5036-48-6, 1H-Imidazole-1-propanamine 5049-61-6,
Pyrazinamine 5098-11-3 5117-88-4 5192-03-0, 1H-Indol-5-amine
5266-85-3 5267-64-1 5332-73-0 5339-85-5 5344-90-1 5345-54-0
5350-93-6 5369-16-4 5369-19-7 5378-35-8 5400-88-4 5407-87-4
5417-63-0 5442-24-0 5452-37-9, Cyclooctanamine 5469-69-2 5470-49-5
5472-41-3 5509-65-9 5754-35-8, 1,3-Dioxolane-2-ethanamine 5763-61-1
5813-64-9 5913-13-3 5988-53-4 6025-60-1 6168-72-5 6246-48-6
6281-42-1 6283-14-3, [1,1'-Bicyclohexyl]-2-amine 6291-85-6 6294-89-9
6298-19-7 6299-02-1 6315-89-5 6321-23-9 6338-70-1 6346-09-4
6373-50-8 6628-77-9 6791-49-7 6850-35-7 6850-38-0 6850-57-3
6928-85-4 6994-25-8 7149-75-9 7154-73-6, 1-Pyrrolidineethanamine
7175-81-7 7202-43-9 7305-71-7 7480-35-5 7533-40-6
7568-93-6 7593-47-7 7663-77-6 7664-66-6 10272-07-8
10316-79-7 10420-89-0 10453-89-1 10593-85-8 13066-95-0
13078-79-0 13078-80-3 13214-66-9, Benzenebutanamine 13258-63-4,
4-Pyridineethanamine 13325-10-5 13472-00-9 13552-21-1 13881-91-9
13952-84-6, 2-Butanamine 14003-16-8 14268-66-7, 1,3-Benzodioxol-5-amine 14331-56-7 14496-27-6 14678-02-5 15205-11-5 15404-06-5
15641-58-4 15901-42-5 16200-53-6 16298-03-6 16369-05-4
16369-14-5 16397-19-6 16499-88-0 16596-41-1, 1-Pyrrolidinamine
16748-73-5 16751-59-0, 4-Heptanamine 16867-03-1 16874-33-2

16957-70-3 17407-56-6 17430-98-7 17481-27-5 17502-28-2
17570-26-2 17584-12-2 17596-79-1 17609-80-2 17768-41-1,
Tricyclo[3.3.1.13,7]decane-1-methanamine 17965-82-1,
1,7-Naphthyridin-8-amine 18294-87-6, 1-Cyclohexene-1-acetic acid
18542-42-2 18595-14-7 18595-18-1 19060-15-2 19248-13-6
19293-58-4 19335-11-6, 1H-Indazol-5-amine 19406-86-1 19764-58-0
19947-75-2 20173-24-4, 3-Pyridineethanamine 20781-20-8 20781-22-0
20989-17-7 21277-16-7 21717-29-3 22013-33-8 22146-57-2
22195-47-7 22288-78-4 22356-89-4 22374-89-6 22483-09-6
22600-30-2 22795-97-7 22795-99-9 22889-78-7 23028-86-6
23159-07-1, 1-Pyrrolidinepropanamine 23590-02-5 23894-12-4
24297-59-4, 1H-Indole-1-acetic acid 24304-84-5 24340-76-9 24425-40-9
24544-04-5 24549-06-2 24717-01-9 25560-00-3 25660-70-2
25900-61-2 26116-12-1 26164-26-1 26371-07-3, 1-Piperidinepropanoic
acid 26734-09-8 27431-62-5 27489-62-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT 27578-60-5, 1-Piperidineethanamine 27757-71-7 27757-85-3,
2-Thiophenemethanamine 28020-37-3 28163-64-6 28292-42-4,
3-Heptanamine 28292-43-5 29555-02-0 30273-11-1 30389-18-5
30748-47-1 31002-73-0 31230-17-8 33184-16-6 33228-44-3
33252-32-3 33332-28-4 33913-58-5 34272-64-5 34272-83-8
34698-41-4 34967-24-3 35303-76-5 35320-23-1 36489-03-9
36768-62-4 37143-54-7 37477-16-0 37585-25-4 37806-29-4
38235-68-6 38291-82-6 39222-73-6 39590-27-7 39895-55-1
40535-14-6 40953-34-2 41365-75-7 41406-00-2 41458-65-5
41663-73-4 41977-04-2 41995-31-7 42185-03-5 42346-68-9
42712-64-1 50269-95-9 50541-93-0 50868-73-0 51387-90-7
51420-32-7 51586-20-0 52562-19-3 52721-69-4 53222-92-7
53369-71-4 53448-09-2 53485-07-7 53666-79-8 54898-73-6
55057-81-3 55745-74-9 55809-36-4 56311-39-8 56464-70-1
56613-80-0 56613-81-1 56820-19-0 57235-50-4 57260-73-8
57338-76-8 57390-38-2 58859-46-4 59331-96-3 59785-68-1
59983-39-0 60093-10-9 61341-86-4 63133-82-4 63435-16-5
63448-63-5 63493-28-7, 2-Pentanamine 63879-04-9 64353-29-3
67952-93-6 69338-35-8 70125-16-5 70180-92-6 70291-62-2
72235-52-0 72235-53-1 72748-99-3 73991-95-4 74370-93-7
74784-70-6 81731-43-3 81863-45-8 82039-90-5 82560-12-1
83846-66-6 84827-78-1 85068-27-5 85068-28-6 85118-06-5
87206-44-8 89260-46-8 89364-31-8 96799-03-0 98769-56-3
99799-10-7 100994-10-3 112245-09-7 112257-28-0 113349-34-1
118430-74-3 119364-52-2 132664-85-8 163733-96-8 175135-44-1
175277-93-7 179028-65-0 180624-79-7 205445-49-4 221647-72-9
244022-72-8 257932-29-9 319474-74-3 319474-87-8 319474-93-6
319475-00-8 319475-11-1 319476-05-6 319477-98-0 319479-97-5
319929-39-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

IT **7568-93-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:125936 HCAPLUS
DN 132:308590
ED Entered STN: 24 Feb 2000
TI Deoxyribonucleoside Cyclic N-Acylphosphoramidites as a New Class of Monomers for the Stereocontrolled Synthesis of Oligothymidylyl- and Oligodeoxycytidylyl- Phosphorothioates
AU Wilk, Andrzej; Grajkowski, Andrzej; Phillips, Lawrence R.; Beaucage, Serge L.
CS Division of Therapeutic Proteins Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, 20892, USA
SO Journal of the American Chemical Society (2000), 122(10), 2149-2156
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
CC 33-10 (Carbohydrates)
GI



I

AB A simple and straightforward **synthesis** of pyrimidine 2'-deoxyribonucleoside cyclic N-acylphosphoramidites I is described. Specifically, (±)-2-amino-1-phenylethanol was chemoselectively N-acylated by treatment with Et fluoroacetate followed by reaction with hexaethylphosphorus triamide to afford the cyclic N-acylphosphoramidite as a mixture of diastereomeric rotamers. Condensation of N4-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxycytidine with the cyclic N-acylphosphoramidite in the presence of 1H-tetrazole gave, after silica gel chromatog., pure (R)- and (S)-I. 31P NMR studies indicated that when (R)- or (S)-I is reacted with 3'-O-acetylthymidine and N,N,N',N'-tetramethylguanidine in CD3CN, the dinucleoside phosphotriester is formed in near quant. yield with total P-stereospecificity (δP 144.2 or 143.9 ppm). Sulfurization generated the P-stereodefined dinucleoside phosphorothioate (δP 71.0 or 71.2 ppm). The 2'-deoxycytidine cyclic N-acylphosphoramidite derivs.

(R)- and (S)-I were subsequently applied to the **solid-phase synthesis** of [Rp,Rp]- and [Sp,Sp]-trideoxycytidilyl diphosphorothioate d(CpsCpsC), and [Rp,Sp,Rp]-tetradeoxycytidilyl triphosphorothioate d(CpsCpsCpsC). Following deprotection, reversed-phase (RP) HPLC anal. of these oligonucleotide analogs showed a single peak for each oligomer. By comparison, RP-HPLC anal. of purified P-diastereomeric d(CpSCpSC) and d(CpSCpSCpSC) prepared from standard 2-cyanoethyl deoxyribonucleoside phosphoramidites exhibited 4 and 8 peaks, resp., each peak corresponding to a specific P-diastereomer. The thymidine cyclic N-acylphosphoramidite derivs. were also prepared, purified, and used successfully in the **solid-phase synthesis** of [Rp]11-d[(TpS)11T]. . Thus, the application of deoxyribonucleoside cyclic N-acyl phosphoramidites to P-stereocontrolled **synthesis** of oligodeoxyribonucleoside phosphorothioates may offer a compelling alternative to the methods currently used for such **syntheses.**

ST oligothymidylyl phosphorothioate stereochem prepn; oligodeoxyribonucleoside **solid phase synthesis** deoxycytidine cyclic acylphosphoramidite; deoxyribonucleoside cyclic acylphosphoramidite chemoselective prepn

IT Deoxyribonucleosides
RL: SPN (Synthetic preparation); PREP (Preparation)
(Cyclic N-Acylphosphoramidites; preparation of deoxyribonucleoside cyclic N-acylphosphoramidites as a new class of monomers for the stereocontrolled synthesis of oligothymidylyl and oligodeoxycytidylyl phosphorothioates)

IT Stereochemistry
(preparation of deoxyribonucleoside cyclic N-acylphosphoramidites as a new class of monomers for the stereocontrolled synthesis of oligothymidylyl and oligodeoxycytidylyl phosphorothioates)

IT 459-72-3, Ethyl fluoroacetate 6974-29-4 **7568-93-6** 21090-30-2 67219-55-0 74925-81-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of deoxyribonucleoside cyclic N-acylphosphoramidites as a new class of monomers for the stereocontrolled synthesis of oligothymidylyl and oligodeoxycytidylyl phosphorothioates)

IT 264881-16-5P 264881-21-2P 264881-24-5P 264881-27-8P 264881-35-8P 264881-36-9P 264881-39-2P 264881-40-5P 264881-45-0P 264881-60-9P 264881-61-0P 264881-63-2P 264881-66-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of deoxyribonucleoside cyclic N-acylphosphoramidites as a new class of monomers for the stereocontrolled synthesis of oligothymidylyl and oligodeoxycytidylyl phosphorothioates)

IT 92127-78-1P 92217-41-9P 92217-42-0P 92218-48-9P 163661-24-3P 173362-23-7P 264881-30-3P 264881-44-9P 264881-50-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of deoxyribonucleoside cyclic N-acylphosphoramidites as a new class of monomers for the stereocontrolled synthesis of oligothymidylyl and oligodeoxycytidylyl phosphorothioates)

RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Abraham, R; Proton and Carbon-13 NMR Spectroscopy - An Integrated Approach 1980, P171
(2) Adamiak, R; Tetrahedron Lett 1977, P1431 HCAPLUS
(3) Anon; Phosphor-Verbindungen II, Houben-Weyl - Methoden der organischen Chemie, Band E2 1982, P1125
(4) Beaucage, S; Am New York Acad Sci 1990, V616, P483
(5) Beaucage, S; Tetrahedron 1993, V49, P6123 HCAPLUS
(6) Boal, J; Nucleic Acids Res 1996, V24, P3115 HCAPLUS
(7) Brill, W; J Am Chem Soc 1991, V113, P3972 HCAPLUS
(8) Brown, D; J Chem Soc 1957, P2590 HCAPLUS
(9) Brown, T; J Chem Soc, Chem Commun 1989, P891 HCAPLUS

(10) Caruthers, M; Biophosphates and Their Analogues - Synthesis, Structure, Metabolism and Activity 1987, P3 HCAPLUS
(11) Chambers, R; Trans Faraday Soc 1970, V66, P1025 HCAPLUS
(12) Crooke, S; Annu Rev Pharmacol Toxical 1996, V36, P107 HCAPLUS
(13) Daub, G; J Am Chem Soc 1977, V99, P3526 HCAPLUS
(14) Edwards, O; Can J Chem 1992, V70, P1397 HCAPLUS
(15) Everett, T; Chemistry of Organic Fluorine Compounds II - A Critical Review, ACS Monograph 187 1995, P1037 HCAPLUS
(16) Guo, M; Bioorg Med Chem Lett 1998, V8, P2539 HCAPLUS
(17) Hilton, J; Prog Nucl Magn Reson Spectros 1975, V10, P27
(18) Ho, T; Chem Rev 1975, V75, P1 HCAPLUS
(19) Hoye, T; J Org Chem 1996, V61, P2056 HCAPLUS
(20) Hund, R; Phosphorus, Sulfur, Silicon 1992, V69, P119
(21) Iyer, R; J Org Chem 1990, V55, P4693 HCAPLUS
(22) Iyer, R; Tetrahedron Lett 1998, V39, P2491 HCAPLUS
(23) Jin, Y; J Org Chem 1998, V63, P3647 HCAPLUS
(24) Jin, Y; Tetrahedron Lett 1996, V37, P973 HCAPLUS
(25) Karwowski, B; Nucleosides Nucleotides 1998, V17, P1747 HCAPLUS
(26) Koziolkiewicz, M; Antisense Nucleic Acid Drug Dev 1997, V7, P43 HCAPLUS
(27) Mallory, F; J Am Chem Soc 1974, V96, P3536 HCAPLUS
(28) Mallory, F; J Am Chem Soc 1975, V97, P4770 HCAPLUS
(29) Mallory, F; J Org Chem 1985, V50, P457 HCAPLUS
(30) Matthews, R; Org Magn Reson 1980, V14, P258 HCAPLUS
(31) Matthews, R; Org Magn Reson 1982, V18, P226 HCAPLUS
(32) Miller, G; J Chem Phys 1969, V51, P3185 HCAPLUS
(33) Mizrakh, L; Zh Obshch Khim 1975, V45, P1469 HCAPLUS
(34) Mizrakh, L; Zh Obshch Khim 1975, V45, P549 HCAPLUS
(35) Pudovik, M; Zh Obshch Khim 1973, V43, P679 HCAPLUS
(36) Reese, C; Tetrahedron Lett 1978, P2727 HCAPLUS
(37) Regan, J; Org Prep Proced Int 1992, V24, P488 HCAPLUS
(38) Servis, K; J Am Chem Soc 1968, V90, P6712 HCAPLUS
(39) Stec, W; J Am Chem Soc 1995, V117, P12019 HCAPLUS
(40) Stec, W; J Am Chem Soc 1998, V120, P7156 HCAPLUS
(41) Stec, W; Nucleic Acids Res 1991, V19, P5883 HCAPLUS
(42) Tang, J; Nucleosides Nucleotides 1995, V14, P985 HCAPLUS
(43) van Boom, J; Tetrahedron Lett 1974, P3785 HCAPLUS
(44) Wang, J; Tetrahedron Lett 1997, V38, P3797 HCAPLUS
(45) Wang, J; Tetrahedron Lett 1997, V38, P705 HCAPLUS
(46) Wilk, A; Antisense Nucleic Acid Drug Dev 1999, V9, P361 HCAPLUS
(47) Wilk, A; J Org Chem 1997, V62, P6712 HCAPLUS
(48) Wilk, A; J Org Chem 1999, V64, P7515 HCAPLUS
(49) Wilk, A; Nucleic Acids Res 1995, V23, P530 HCAPLUS
(50) Wilk, A; Nucleic Acids Res Symp Ser No 24 1991, P63 HCAPLUS
(51) Wyrzykiewicz, T; Bioorg Chem 1995, V23, P33 HCAPLUS

IT **7568-93-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of deoxyribonucleoside cyclic N-acylphosphoramidites as a new class of monomers for the stereocontrolled synthesis of oligothymidylyl and oligodeoxycytidylyl phosphorothioates)

RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:255624 HCAPLUS
DN 131:31843
ED Entered STN: 27 Apr 1999

TI A Novel **Solid-Phase Synthesis** of Carboxypyrrolinones
AU Miller, Paula C.; Owen, Thomas J.; Molyneaux, John M.; Curtis, Jane M.; Jones, Claude R.
CS Monsanto Company, St. Louis, MO, 63167, USA
SO Journal of Combinatorial Chemistry (1999), 1(3), 223-234
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 23, 25
OS CASREACT 131:31843
AB A **solid-phase** organic **synthesis** method has been developed for the preparation of 3-carboxypyrrolinones. Treatment of polymer-bound malonic acid with amino alcs. afforded the malonamide resin products. Benzyl and alkyl amino alcs. were prepared in solution via a two-step procedure without purification and were coupled to the resin directly using a resin capture strategy. Polymer loadings and product conversions were determined by direct cleavage of resin-bound materials and anal. by 1H NMR spectroscopy with an internal standard Treatment of the polymer-bound malonamides with TFA released the malonamic acids, which underwent further reaction to afford the trifluoroacetate derivs. Secondary amides underwent an addnl. cyclization to afford oxazoles. The malonamide resins can be oxidized to the corresponding ketones by treatment with CrO2(O-t-Bu)2, which can in turn be cyclized in the presence of LDA or LHMDS to afford the resin-bound carboxypyrrolinones. TFA treatment releases the free 3-carboxypyrrolinones in 43-80% overall yield.
ST **solid phase synthesis** carboxypyrrolinone; pyrrolinone carboxy **solid phase synthesis**
IT **Solid phase synthesis**
(**solid-phase synthesis** of carboxypyrrolinones)
IT 67-64-1, 2-Propanone, reactions 97-96-1, 2-Ethylbutanal 100-52-7, Benzaldehyde, reactions 104-94-9, p-Anisidine 106-47-8, 4-Chloroaniline, reactions 106-88-7, 1,2-Epoxybutane 108-69-0, 3,5-Dimethylaniline 122-98-5 123-11-5, reactions 141-82-2D, Malonic acid, polymer bound 492-41-1 530-36-9, 2-Amino-1,2-diphenylethanol **7568-93-6** 23850-78-4 36239-09-5, Ethyl malonyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(**solid-phase synthesis** of carboxypyrrolinones)
IT 4164-21-0P 27159-30-4P 81316-56-5P 127757-04-4P 226879-73-8P 226879-74-9P 226879-75-0P 226879-76-1P 226879-77-2P 226879-78-3P 226879-79-4P 226879-80-7P 226879-81-8P 226879-82-9P 226879-83-0P 226879-84-1P 226879-85-2P 226879-86-3P 226879-87-4P 226879-88-5P 226879-89-6P 226879-90-9P 226879-91-0P 226879-92-1P 226879-93-2P 226879-94-3P 226879-95-4P 226879-96-5P 226879-97-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(**solid-phase synthesis** of carboxypyrrolinones)
IT 226879-98-7P 226879-99-8P 226880-00-8P 226880-01-9P 226880-02-0P 226880-03-1P 226880-04-2P 226880-05-3P 226880-06-4P 226880-07-5P 226880-08-6P 226880-09-7P 226880-10-0P 226880-11-1P 226880-12-2P 226880-13-3P 226880-14-4P 226880-15-5P 226880-16-6P 226880-17-7P 226880-18-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(**solid-phase synthesis** of carboxypyrrolinones)
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Abouelfida, A; Can J Chem 1992, V70, P14 HCAPLUS

(2) Abouelfida, A; Tetrahedron Lett 1991, V32, P2225 HCAPLUS
(3) Ackermann, J; Helv Chim Acta 1990, V73, P122 HCAPLUS
(4) Addor, R; ACS Symp Ser 1992, V504, P283 HCAPLUS
(5) Barluenga, J; Tetrahedron Lett 1993, V34, P7777 HCAPLUS
(6) Beebe, X; J Org Chem 1995, V60, P4196 HCAPLUS
(7) Blossey, E; J Org Chem 1990, V55, P4664 HCAPLUS
(8) Brown, D; J Org Chem 1994, V59, P2447 HCAPLUS
(9) Brown, R; Contemp Org Synth 1997, V4, P216 HCAPLUS
(10) Brown, R; Synth Commun 1988, V18, P1801 HCAPLUS
(11) Chan, T; J Chem Soc, Chem Commun 1985, P909 HCAPLUS
(12) Chen, C; J Am Chem Soc 1994, V116, P2661 HCAPLUS
(13) Dolle, R; Mol Diversity 1997, V2, P223 HCAPLUS
(14) Durr, D; US 4623378 1986 HCAPLUS
(15) Fecik, R; Med Res Rev 1998, V18, P149 HCAPLUS
(16) Fieser, L; Reagents for Organic Synthesis 1967, V1, P136
(17) Fujimoto, T; US 4345934 1982 HCAPLUS
(18) Gribble, G; Comprehensive Heterocyclic Chemistry II 1996, P207 HCAPLUS
(19) Hall, S; Annu Rep Comb Chem Mol Diversity 1997, V1, P30 HCAPLUS
(20) Hamper, B; J Org Chem 1998, V63, P708 HCAPLUS
(21) Hamper, B; Tetrahedron Lett 1998, V39, P2047 HCAPLUS
(22) Hogan, J; Nature (London) 1996, V384, P17 HCAPLUS
(23) Hunt, D; ACS Symp Ser 1998, V686, P1 HCAPLUS
(24) Iqbal, J; Tetrahedron Lett 1990, V31, P575 HCAPLUS
(25) James, I; Mol Diversity 1997, V2, P175 HCAPLUS
(26) Leznoff, C; Can J Chem 1977, V55, P1143 HCAPLUS
(27) Lynch, M; ACS Symp Ser 1992, V504, P200 HCAPLUS
(28) Marzinzik, A; J Org Chem 1998, V63, P723 HCAPLUS
(29) Montforts, F; Liebigs Ann Chem 1990, P1037 HCAPLUS
(30) Padwa, A; Tetrahedron Lett 1994, V35, P7159 HCAPLUS
(31) Patterson, D; US 5062880 1991 HCAPLUS
(32) Romof, T; Synlett 1998, P1341
(33) Schmidlin, T; Helv Chim Acta 1980, V63, P121 HCAPLUS
(34) Spaller, M; Curr Opin Chem Biol 1997, V1, P47 HCAPLUS
(35) Tschabold, E; Crop Sci 1988, V28, P583 HCAPLUS
(36) Van Der Maarel, H; Agro-Food-Ind Hi-Tech 1994, V5, P25 HCAPLUS
(37) Vedejs, E; J Org Chem 1982, V47, P1534 HCAPLUS
(38) Wang, S; J Am Chem Soc 1973, V95, P1328 HCAPLUS
(39) Woolard, F; WO 9007499 1990 HCAPLUS

IT **7568-93-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(solid-phase synthesis of carboxypyrrolinones)
RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 13 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:774131 HCAPLUS
DN 130:38707
ED Entered STN: 10 Dec 1998
TI Topologically segregated, encoded **solid phase** libraries
IN Lebl, Michal; Lam, Kit S.; Salmon, Sydney E.; Krchnak, Victor; Sepetov, Nikolai; Kocis, Peter
PA Selectide Corporation, USA
SO U.S., 63 pp., Cont.-in-part of U.S. Ser. No. 68,327, abandoned.
CODEN: USXXAM

DT Patent
LA English
IC ICM C12Q001-68
ICS G01N033-53; C07K017-02; C07H021-04
NCL 435006000
CC 34-3 (Amino Acids, Peptides, and Proteins)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5840485	A	19981124	US 1994-249830	19940526
	CA 2163637	AA	19941208	CA 1994-2163637	19940527
	WO 9428028	A1	19941208	WO 1994-US6078	19940527
	W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, UA, UZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9470486	A1	19941220	AU 1994-70486	19940527
	AU 686186	B2	19980205		
	EP 705279	A1	19960410	EP 1994-919294	19940527
	EP 705279	B1	20030219		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09501490	T2	19970210	JP 1995-501022	19940527
	JP 3394777	B2	20030407		
	AT 232882	E	20030315	AT 1994-919294	19940527
	EP 1310510	A2	20030514	EP 2003-3577	19940527
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI				
	US 6090912	A	20000718	US 1998-198209	19981123
PRAI	US 1993-68327	B2	19930527		
	US 1994-249830	A	19940526		
	EP 1994-919294	A3	19940527		
	WO 1994-US6078	W	19940527		

AB The invention relates to libraries of synthetic test compound attached to sep. phase synthesis supports that also contain coding mols. that encode the structure of the synthetic test compound The mols. may be polymers or multiple nonpolymeric mols. The synthetic test compound can have backbone structures with linkages such as amide, urea, carbamate (i.e., urethane), ester, amino, sulfide, disulfide, or carbon-carbon, such as alkane and alkene, or any combination thereof. Examples of subunits suited for the different linkage chemistries are provided. The synthetic test compound can also be a mol. scaffold having various substituents at defined positions, in which the scaffolds can be derivs. of monocyclic of bicyclic carbohydrates, steroids, sugars, heterocyclic structures, polyarom. structures, or other structures capable of acting as a scaffolding. Examples of suitable mol. scaffolds are provided. Preferably the library is one in which each synthetic test compound is non-sequenceable, i.e. not amenable to sequencing, and is paired with a unique coding mol., e.g., a peptide, whose sequence encodes the structure of the synthetic test compound attached to the same support and can be readily determined using traditional anal. techniques, e.g., Edman degradation The library is useful for identifying and analyzing a ligand of an acceptor of interest. The invention also relates to methods of synthesizing such libraries and the use of such libraries to identify and characterize mols. of interest from among the library of synthetic test compound

ST encoded **solid phase** library; peptide encoded library; ligand receptor

IT **Solid phase synthesis**
(peptide; preparation of topol. segregated, encoded **solid phase** libraries)

IT **Combinatorial chemistry**
(preparation of topol. segregated, encoded **solid phase** libraries)

IT Peptides, preparation

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of topol. segregated, encoded **solid phase** libraries)

IT 73-22-3D, L-Tryptophan, RAM-TentaGel-bound, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation; preparation of topol. segregated, encoded **solid phase** libraries)

IT 79-08-3D, Bromoacetic acid, TentaGel 130-bound
RL: RCT (Reactant); RACT (Reactant or reagent)
(amination; preparation of topol. segregated, encoded **solid phase** libraries)

IT 58822-25-6DP, 1-5-β-Neoendorphin (human), TentaGel AM resin-bound 140897-59-2DP, TentaGel AM resin-bound 167017-78-9DP, TentaGel AM resin-bound 216530-77-7DP, TentaGel AM resin-bound
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(binding to anti-β-endorphin and streptavidin monoclonal antibody; preparation of topol. segregated, encoded **solid phase** libraries)

IT 556-33-2DP, bound to TentaGel resin via safety-catch linker 1187-50-4DP, bound to TentaGel resin via safety-catch linker 4464-36-2DP, bound to TentaGel resin via safety-catch linker 10329-75-6DP, bound to TentaGel resin via safety-catch linker 19729-30-7DP, bound to TentaGel resin via safety-catch linker 20274-80-0DP, bound to TentaGel resin via safety-catch linker 32557-24-7DP, bound to TentaGel resin via safety-catch linker 54907-74-3DP, bound to TentaGel resin via safety-catch linker 92116-80-8DP, bound to TentaGel resin via safety-catch linker
RL: SPN (Synthetic preparation); PREP (Preparation)
(coding sequence; preparation of topol. segregated, encoded **solid phase** libraries)

IT 216530-82-4DP, TentaGel-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(model sequence; preparation of topol. segregated, encoded **solid phase** libraries)

IT 58822-25-6DP, 1-5-β-Neoendorphin (human), TentaGel-bound 116258-33-4P 170684-65-8DP, TentaGel-bound 170684-65-8DP, bound to "shaved" polyoxyethylene grafted polystyrene **solid phase support** 216530-80-2DP, TentaGel-bound 216530-80-2DP, bound to "shaved" polyoxyethylene grafted polystyrene **solid phase support** 216530-81-3DP, TentaGel-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(model sequence; preparation of topol. segregated, encoded **solid phase** libraries)

IT 167017-79-0DP, TentaGel AM resin-bound
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(polyglutamic acid staining and binding to anti-β-endorphin monoclonal antibody; preparation of topol. segregated, encoded **solid phase** libraries)

IT 51-67-2, Tyramine 55-22-1, Isonicotinic acid, reactions 62-53-3, Aniline, reactions 66-99-9, β-Naphthaldehyde 75-04-7, Ethanamine, reactions 75-31-0, Isopropylamine, reactions 75-64-9, tert-Butylamine, reactions 75-98-9, Pivalic acid 78-81-9, Isobutylamine 78-84-2, 2-Methylpropionaldehyde 78-96-6, 1-Amino-2-propanol 79-08-3, Bromoacetic acid 86-87-3, 1-Naphthaleneacetic acid 88-14-2, 2-Furoic acid 89-00-9, 2,3-Pyridinedicarboxylic acid 89-01-0, 2,3-Pyrazinedicarboxylic acid 90-02-8, reactions 91-00-9, Benzhydrylamine 93-97-0, Benzoic anhydride 96-17-3, 2-Methylbutyraldehyde 97-96-1, 2-Ethylbutyraldehyde 98-03-3,

2-Thiophenecarboxaldehyde 98-97-5, 2-Pyrazinecarboxylic acid 99-96-7, reactions 100-09-4, 4-Methoxybenzoic acid 100-10-7, 4-Dimethylaminobenzaldehyde 100-46-9, Benzylamine, reactions 100-52-7, Benzaldehyde, reactions 103-82-2, Phenylacetic acid, reactions 104-53-0, Hydrocinnamaldehyde 104-94-9, p-Anisidine 106-31-0, n-Butyric anhydride 106-49-0, p-Toluidine, reactions 107-15-3, Ethylenediamine, reactions 108-24-7 108-30-5, Succinic anhydride, reactions 108-55-4, Glutaric anhydride 108-91-8, Cyclohexylamine, reactions 109-73-9, 1-Butanamine, reactions 109-85-3, 2-Methoxyethylamine 117-34-0, Diphenylacetic acid 118-31-0, Naphthalene-1-methylamine 119-26-6, 2,4-Dinitrophenyl-hydrazine 121-33-5, Vanillin 122-59-8, Phenoxyacetic acid 122-78-1, Phenylacetaldehyde 123-08-0, 4-Hydroxybenzaldehyde 123-11-5, 4-Methoxybenzaldehyde, reactions 123-15-9, 2-Methylvaleraldehyde 123-72-8, Butyraldehyde 141-43-5, reactions 156-38-7, 4-Hydroxyphenylacetic acid 156-87-6, 3-Aminopropanol 407-25-0, Trifluoroacetic anhydride 447-61-0, α,α,α-Trifluoro-o-tolualdehyde 455-24-3, 4-Trifluoromethylbenzoic acid 463-00-3, γ-Guanidinobutyric acid 487-89-8, Indole-3-carboxaldehyde 529-20-4, 2-Tolualdehyde 555-16-8, 4-Nitrobenzaldehyde, reactions 584-93-0, α-Bromovaleric acid 590-86-3, Isovaleraldehyde 619-66-9, 4-Carboxybenzaldehyde 619-84-1, 4-Dimethylaminobenzoic acid 630-19-3, Trimethylacetaldehyde 634-97-9, 2-Pyrrolecarboxylic acid 638-32-4, Succinamic acid 645-65-8, 4-Imidazoleacetic acid 653-21-4, Pentafluorophenylacetic acid 822-98-0, 2-Amino-norbornane 830-79-5, 2,4,6-Trimethoxybenzaldehyde 872-85-5, Pyridine-4-carboxaldehyde 1003-03-8, Cyclopentylamine 1003-29-8, Pyrrole-2-carboxaldehyde 1138-80-3 1821-12-1, 4-Phenylbutyric acid 1877-73-2, 3-Nitrophenylacetic acid 1912-43-2, 2-Methyl-3-indoleacetic acid 2043-61-0, Cyclohexanecarboxaldehyde 2051-49-2, Caproic anhydride 2124-55-2, Indole-4-carboxylic acid 2213-43-6, 1-Aminopiperidine 2393-23-9, 4-Methoxy-benzylamine 2466-76-4, N-Acetylimidazole 2975-41-9, 2-Aminoindan 3218-36-8, 4-Phenylbenzaldehyde 3268-49-3, 3-Methylthiopropionaldehyde 3300-51-4, 4-(Trifluoromethyl)-benzylamine 3641-13-2 3978-80-1 4319-49-7, 4-Aminomorpholine 4363-93-3, Quinoline-4-carboxaldehyde 4530-20-5 4795-29-3, Tetrahydrofurfurylamine 4942-47-6, 1-Adamantaneacetic acid 4998-07-6, 2-Nitro-4,5-dimethoxybenzoic acid 5292-21-7, Cyclohexylacetic acid 5453-80-5, 5-Norbornene-2-carboxaldehyde 6232-88-8, 4-Bromomethylbenzoic acid 6928-85-4, 1-Methyl-4-aminopiperazine 6973-60-0, 1-Methyl-2-pyrrolecarboxylic acid 7536-58-5 **7568-93-6**, 2-Amino-1-phenyl-ethanol 10111-08-7, Imidazole-2-carboxaldehyde 10351-19-6, (4-Pyridylthio)acetic acid 13139-15-6 13734-36-6 15231-41-1, tert-Butyl β-Alaninate 16060-65-4, 4-Guanidinobenzoic acid 16136-58-6, 1-Methylindole-2-carboxylic acid 16935-04-9, 2-Methyl-4-nitro-1-imidazolepropionic acid 19293-58-4, 4-(Dimethylamino)-benzylamine 22106-33-8, 4-(Pyrrol-1-yl)benzoic acid 22282-72-0, 2-Hydroxyisonicotinic acid 24424-99-5, Di-tert-butyl dicarbonate 25173-72-2, 3-(3,4,5-Trimethoxyphenyl)propionic acid 29022-11-5, Fmoc-Gly-OH 34967-24-3, 3,5-Dimethoxy-benzylamine 35661-39-3 35661-40-6 35737-10-1 35737-15-6, Fmoc-Trp-OH 39508-07-1 39515-51-0, 3-Phenoxybenzaldehyde 47121-49-3, Ddz-Gly-OH 51317-25-0, Biphenylacetic acid 51387-90-7, 2-(2-Aminoethyl)-1-methylpyrrolidine 53218-34-1, 6-(2-Chlorobenzyloxycarbonylamino)caproic acid 53298-33-2, Fmoc-Cys(Bzl)-OH 60875-16-3, 4-(3-Methyl-5-oxo-2-pyrazolin-1-yl)benzoic acid 68858-20-8 71989-14-5 71989-16-7 71989-18-9 71989-20-3 71989-26-9 71989-31-6 71989-33-8 71989-35-0 71989-38-3 74141-18-7, (2-Amino-1-imidazolyl)acetic acid 76265-69-5, Fmoc-Lys(Tfa)-OH 76863-85-9, Fmoc-Lys(Npys)-OH 78081-87-5 79410-20-1, cis,cis-1,3,5-Trimethylcyclohexane-1,3,5-tricarboxylic acid 82911-69-1, 9-Fluorenylmethyl succinimidyl carbonate 84624-27-1 109425-51-6 109425-55-0 119043-62-8 119831-72-0 139551-73-8, Fmoc-D-Pen(Bzl)-OH 146982-27-6, Fmoc-Lys(Alloc)-OH 150629-67-7,

Fmoc-Lys(Dde)-OH 150629-67-7D, TentaGel-bound 152835-00-2, 2-(9-Fluorenylmethoxycarbonylamino)ethanethiol 158478-76-3 167017-73-4, 1,4-Dimethyl-2,3-pyrroledicarboxylic acid 167017-74-5D, bound to TentaGel resin via safety-catch linker 212567-95-8 216530-71-1, N-(2-Chlorobenzyloxycarbonyl)-β-alanine 216530-72-2 216530-74-4, Fmoc-Dab(Boc)-OH 216530-78-8, 1-Acetylindole-2-carboxaldehyde 216530-79-9, Boc-Dap(Fmoc)-OH 216530-85-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of topol. segregated, encoded **solid phase** libraries)

IT 56-40-6DP, Glycine, Sepharose-bound, preparation 29022-11-5DP, Fmoc-Gly-OH, Sepharose-bound 57260-73-8P 107271-36-3P 166410-28-2P, N-(tert-Butyloxycarbonyl)-N'-(9-fluorenylmethoxycarbonyl)ethylenediamine 166410-33-9P, N-(9-Fluorenylmethoxycarbonyl)ethylenediamine trifluoroacetate 167017-70-1P 167017-71-2P 167017-72-3P 216530-58-4DP, bound to TentaGel resin via safety-catch linker 216530-73-3DP, H-Gly-βAla-Gly-βAla-Gly-Lys(Tfa)-OH, bound to TentaGel resin via safety-catch linker 216530-83-5DP, TentaGel-bound 216530-84-6DP, TentaGel-bound 216530-86-8DP, TentaGel-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of topol. segregated, encoded **solid phase** libraries)

IT 152768-11-1P 152835-01-3P 153838-40-5P 216530-60-8DP, bound to TentaGel resin via safety-catch linker 216530-63-1DP, bound to TentaGel resin via safety-catch linker
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of topol. segregated, encoded **solid phase** libraries)

IT 56-40-6D, Glycine, RAM-TentaGel-bound, reactions 167017-80-3D, H-βAla-Gly-Trp-OH, RAM-TentaGel-bound
RL: RCT (Reactant); RACT (Reactant or reagent)
(reductive alkylation by aldehydes; preparation of topol. segregated, encoded **solid phase** libraries)

IT 167017-80-3D, H-βAla-Gly-Trp-OH, RAM-TentaGel S-bound
RL: RCT (Reactant); RACT (Reactant or reagent)
(reductive alkylation with aldehydes; preparation of topol. segregated, encoded **solid phase** libraries)

IT 216530-75-5P 216530-76-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(specific binding to anti-β-endorphin monoclonal antibody; preparation of topol. segregated, encoded **solid phase** libraries)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; WO 9119735 1991 HCAPLUS
(2) Anon; WO 9200091 1992 HCAPLUS
(3) Anon; WO 9306121 1993 HCAPLUS
(4) Anon; WO 9320242 1993 HCAPLUS
(5) Anon; WO 9408051 1994 HCAPLUS
(6) Anon; EP 0639584 A1 1995 HCAPLUS
(7) Baum; Solid-phase synthesis of benzodiazepines, Chemical and Engineering News 1993, V71, P33
(8) Brenner; Encoded combinatorial chemistry Proc Nat Acad Sci USA 1992, V89, P5381 HCAPLUS
(9) Bunin; J Am Chem Soc 1992, V114, P10997 HCAPLUS
(10) Ellman; US 5288514 1994 HCAPLUS
(11) Furka; Int J Pept Prot Res 1991, V37, P487 HCAPLUS
(12) Gallop; J Medicinal Chemistry 1994, V37(9), P1233 HCAPLUS
(13) Gordon; J Medicinal Chemistry 1994, V37(10), P1385 HCAPLUS
(14) Heubner; US 5182366 1993 HCAPLUS

(15) Kerr; J Am Chem Soc 1993, V115(6), P2529 HCAPLUS
(16) Lam; Bioorg Med Chem Lett 1993, V3, P419 HCAPLUS
(17) Lam; Immunomethods 1992, V1, P1
(18) Lam; Nature 1991, V354, P82 HCAPLUS
(19) Lebl; Techniques in Protein Chemistry 1994, VV, P541
(20) Needles; Generation and screening of an oligonucleotide-encoded synthetic peptide library, PNAS 1993, V90, P10700
(21) Nikolaiev; Peptide Research V6(3), P161 HCAPLUS
(22) Ohlmeyer; Complex synthetic chemical libraries indexed with molecular tags PNAS 1993, V90, P10922 HCAPLUS
(23) Simon; Peptoids:a modular approach todrug discovery, PNAS 1992, V89, P9367 HCAPLUS
(24) Vagner; "Innovationns and Perspectives in Solid Phase Synthesis and Related Technologies 1993

IT **7568-93-6**, 2-Amino-1-phenyl-ethanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of topol. segregated, encoded **solid phase** libraries)
RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 14 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:712381 HCAPLUS
DN 129:313134
ED Entered STN: 10 Nov 1998
TI Combinatorial libraries of peptidomimetic aminothioether acids
IN Mendel, David
PA Eli Lilly and Co., USA
SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C12Q001-00
ICS G01N033-53; G01N033-556; A01N001-02
CC 9-16 (Biochemical Methods)
Section cross-reference(s): 1, 6, 34
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9846786	A1	19981022	WO 1998-US7151	19980408
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9869620	A1	19981111	AU 1998-69620	19980408
	EP 973936	A1	20000126	EP 1998-915437	19980408
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	JP 2002504892	T2	20020212	JP 1998-544062	19980408
PRAI	US 1997-43496P	P	19970411		
	WO 1998-US7151	W	19980408		

OS MARPAT 129:313134
AB The present invention relates to a novel diverse library of aminothioether

compds. and derivs. thereof, and their possible use as lead compds. in drug development. Methods are presented for the preparation of these peptidomimetic compds. The general method used to prepare the diverse libraries of amino thioether acid compds. utilizes com. available or readily synthesized amino acids or amino alcs. and mercapto acids. An apparatus providing a readily accessible source of individual members of the library is also described. The apparatus can be used in assay kits and as a replaceable element in automated assay machines.

ST combinatorial chem library peptidomimetic aminothioether acid

IT Thioethers
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino, peptidomimetic compds.; combinatorial libraries of peptidomimetic aminothioether acids)

IT Peptides, biological studies
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(analogs, peptidomimetic aminothioether acid compds.; combinatorial libraries of peptidomimetic aminothioether acids)

IT **Combinatorial chemistry**
Combinatorial library
Drug screening
Drugs
Electrophiles
Microtiter plates
Peptide library
Test kits
(combinatorial libraries of peptidomimetic aminothioether acids)

IT Thiols (organic), biological studies
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinatorial libraries of peptidomimetic aminothioether acids)

IT Alcohols, biological studies
Aldehydes, biological studies
Amines, biological studies
Imines
Ketones, biological studies
RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(combinatorial libraries of peptidomimetic aminothioether acids)

IT Sulfonic acids, biological studies
RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(esters; combinatorial libraries of peptidomimetic aminothioether acids)

IT Halides
Isocyanates
Isothiocyanates
RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(organic; combinatorial libraries of peptidomimetic aminothioether acids)

IT Amines, biological studies
RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(primary; combinatorial libraries of peptidomimetic aminothioether acids)

IT Amines, biological studies
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(secondary; combinatorial libraries of peptidomimetic aminothioether acids)

IT Group VIA element compounds
Group VIA element compounds
Halides
Halides
RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(sulfur halides, organo-; combinatorial libraries of peptidomimetic aminothioether acids)

IT 71-43-2DP, Benzene, peptidomimetic derivative, biological studies
110-86-1DP, Pyridine, peptidomimetic derivative, biological studies
1925-79-7DP, peptidomimetic derivative 3641-05-2DP, peptidomimetic derivative
214709-24-7P 214838-48-9P 214838-49-0P 214838-50-3P 214838-51-4P
214838-52-5P 214838-53-6P 214838-54-7P 214838-55-8P 214838-56-9P
214838-57-0P 214838-58-1P 214838-59-2P 214838-60-5P 214838-61-6P
214838-62-7P 214838-63-8P 214838-64-9P 214838-65-0P 214838-66-1P
214838-67-2P 214838-68-3P 214838-69-4P 214838-70-7P 214838-71-8P
214838-72-9P 214838-73-0P 214838-74-1P 214838-75-2P 214838-76-3P
214838-77-4P 214838-78-5P 214838-79-6P 214838-80-9P 214838-81-0P
214838-82-1P 214838-83-2P 214838-84-3P 214838-85-4P 214838-86-5P
214838-87-6P 214838-88-7P 214838-89-8P 214838-90-1P 214838-91-2P
214838-92-3P 214838-93-4P 214838-94-5P 214838-95-6P 214838-96-7P
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinatorial libraries of peptidomimetic aminothioether acids)

IT 52-67-5, Penicillamine 68-11-1, reactions 79-42-5, Thiolactic acid
124-63-0, Methanesulfonyl chloride 2418-95-3 2749-11-3, L-Alaninol
2937-50-0, Allyl chloroformate 3374-22-9, Cysteine 4606-65-9,
3-Piperidinemethanol 7533-40-6, L-Leucinol **7568-93-6**,
2-Amino-1-phenylethanol 23680-31-1 24424-99-5, Boc-anhydride
28920-43-6 38521-46-9, 2-Mercaptonicotinic acid 79467-22-4,
2-[2-(Aminomethyl)phenylthio]benzyl alcohol 82911-69-1 214709-23-6
214838-32-1 214838-35-4 214838-36-5 214838-37-6 214838-38-7
214838-40-1 214838-42-3 214838-43-4 214838-44-5 214838-45-6
214838-47-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(combinatorial libraries of peptidomimetic aminothioether acids)

IT 104669-72-9P 116574-71-1P 127407-54-9P 127559-33-5P 162166-99-6P
214709-27-0P 214709-28-1P 214709-29-2P 214709-31-6P 214709-33-8P
214709-34-9P 214838-30-9P 214838-34-3P 214838-39-8P 214838-41-2P
214838-46-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinatorial libraries of peptidomimetic aminothioether acids)

IT 214709-30-5P 214709-32-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(combinatorial libraries of peptidomimetic aminothioether acids)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Horner; Liebigs Ann Chem 1985, 1, P22 HCAPLUS
(2) Richter Gedeon Vegyeszeti Gyar R T; EP 0177054 A1 1985 HCAPLUS
(3) Schwyer; Helvetica Chimica Acta 1984, V67, P1316
(4) Yamanouchi Pharmaceutical Co Ltd; EP 0181779 A1 1985 HCAPLUS

IT **7568-93-6**, 2-Amino-1-phenylethanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(combinatorial libraries of peptidomimetic aminothioether acids)

RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 15 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:303619 HCAPLUS
DN 129:40699
ED Entered STN: 23 May 1998
TI The use of high-throughput synthesis and purification in the preparation of a directed library of adrenergic agents
AU Siegel, Miles G.; Shuker, Athony J.; Droste, Christine A.; Hahn, Patrick J.; Jesudason, Cynthia D.; Mcdonald, John H., III; Matthews, Donald P.; Rito, Christopher J.; Thorpe, Andrew J.
CS Research Technology and Proteins, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA
SO Molecular Diversity (1998), Volume Date 1997-1998, 3(2), 113-116
CODEN: MODIF4; ISSN: 1381-1991
PB Kluwer Academic Publishers
DT Journal
LA English
CC 21-2 (General Organic Chemistry)
AB A library of potential agonists and antagonists for adrenergic receptors was prepared using high-throughput solution-phase parallel synthesis. Traditional solution-phase reductive amination reactions followed by rapid purification by ion exchange chromatog. yielded products with near-anal. purity. An array of ketones and amines, arranged in an 8 + 12 matrix, were combined to form 96 individual compds.
ST amine secondary high throughput prepn; reductive amination amine ketone; ion exchange chromatog rapid purifn product; combinatorial library secondary amine
IT **Combinatorial library**
Ion exchange chromatography
(preparation of a library of secondary amines as potential adrenergic agonists by reductive amination of ketones with primary amines and purified by ion-exchange chromatog.)
IT 1207-32-5P 3571-71-9P 4164-21-0P 6589-48-6P 6890-41-1P
6994-08-7P 7376-66-1P 7683-59-2P 18866-77-8P 23299-18-5P
26328-11-0P 41035-54-5P 57526-81-5P 69568-36-1P 97825-25-7P
105831-64-9P 106351-44-4P 113895-73-1P 118076-10-1P 118076-11-2P
130783-39-0P 143487-96-1P 162581-79-5P 208459-28-3P 208460-06-4P
208460-07-5P 208460-08-6P 208460-09-7P 208460-11-1P 208460-12-2P
208460-13-3P 208460-14-4P 208460-15-5P 208460-16-6P 208460-17-7P
208460-18-8P 208460-19-9P 208460-20-2P 208460-21-3P 208460-22-4P
208460-23-5P 208460-24-6P 208460-25-7P 208460-26-8P 208460-27-9P
208460-28-0P 208460-29-1P 208460-30-4P 208460-31-5P 208460-32-6P
208460-33-7P 208460-34-8P 208460-35-9P 208460-36-0P 208460-37-1P
208460-38-2P 208460-39-3P 208460-40-6P 208460-41-7P 208460-42-8P
208460-43-9P 208460-44-0P 208460-45-1P 208460-46-2P 208460-47-3P
208460-48-4P 208460-49-5P 208460-50-8P 208460-51-9P 208460-52-0P
208460-53-1P 208460-54-2P 208460-55-3P 208460-56-4P 208460-57-5P
208460-58-6P 208460-59-7P 208460-60-0P 208460-61-1P 208460-62-2P
208460-63-3P 208460-64-4P 208460-65-5P 208460-66-6P 208460-67-7P
208460-68-8P 208460-69-9P 208460-70-2P 208460-71-3P 208460-72-4P
208460-73-5P 208460-74-6P 208460-75-7P 208460-76-8P 208460-77-9P
208460-78-0P
RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(preparation of a library of secondary amines as potential adrenergic agonists by reductive amination of ketones with primary amines and purified by ion-exchange chromatog.)

IT 67-64-1, 2-Propanone, reactions 104-14-3 108-94-1, Cyclohexanone, reactions 120-92-3, Cyclopentanone 138-65-8 536-21-0 1072-72-6, 4-Tetrahydrothiopyranone 2550-26-7, 4-Phenyl-2-butanone 5471-51-2 **7568-93-6** 53360-89-7 74248-67-2 88965-93-9 112243-65-9 189119-64-0 208459-22-7 208459-24-9 208459-25-0 208459-26-1 208459-27-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of a library of secondary amines as potential adrenergic agonists by reductive amination of ketones with primary amines and purified by ion-exchange chromatog.)

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Astrup, A; Am J Clin Nutr 1992, V55, P246S MEDLINE
(2) Brittain, R; Proc R Soc Med 1972, V65, P759 HCAPLUS
(3) Cheng, S; J Am Chem Soc 1996, V118, P2567 HCAPLUS
(4) Chucholowski, A; Chimia 1996, V50, P525 HCAPLUS
(5) Gayo, L; Tetrahedron Lett 1997, V38, P513 HCAPLUS
(6) Hieble, J; J Med Chem 1996, V38, P3415
(7) Hieble, J; TiPS 1994, V15, P397 HCAPLUS
(8) Kaumann, A; Br J Pharmacol 1997, V120, P1187 HCAPLUS
(9) Lawrence, R; Synthesis 1997, P553 HCAPLUS
(10) Main, B; Comprehensive Medicinal Chemistry 1990, V3, P187
(11) Parlow, J; Tetrahedron Lett 1996, V37, P5257 HCAPLUS
(12) Ruffolo, R; J Med Chem 1996, V38, P3681
(13) Siegel, M; Tetrahedron Lett 1997, V38, P3357 HCAPLUS
(14) Strosberg, A; Obes Res 1995, V3, P501S HCAPLUS
(15) Strosberg, A; Psychopharmacol Ser 1993, V10, P9 HCAPLUS
(16) Wheeldon, N; Q J Med 1993, V86, P595 MEDLINE
(17) Zhao, J; Am J P-Cell 1994, V36, PC969

IT **7568-93-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of a library of secondary amines as potential adrenergic agonists by reductive amination of ketones with primary amines and purified by ion-exchange chromatog.)

RN 7568-93-6 HCAPLUS

CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 16 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:421310 HCAPLUS

DN 127:34144

ED Entered STN: 09 Jul 1997

TI Isoquinoline derivatives as biologically active compounds and isoquinoline combinatorial libraries

IN Kiely, John S.; Griffith, Michael C.

PA Torrey Pines Institute for Molecular Studies, USA

SO PCT Int. Appl., 171 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D217-26
ICS A61K031-47

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 9716428 A1 19970509 WO 1996-US16763 19961018
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM
CA 2234058 AA 19970509 CA 1996-2234058 19961018
AU 9674571 A1 19970522 AU 1996-74571 19961018
AU 705066 B2 19990513
EP 863877 A1 19980916 EP 1996-936720 19961018
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
CN 1202888 A 19981223 CN 1996-198438 19961018
JP 11514645 T2 19991214 JP 1996-517383 19961018
PRAI US 1995-545493 A 19951019
WO 1996-US16763 W 19961018
OS CASREACT 127:34144; MARPAT 127:34144
GI



I

AB Isoquinoline derivs. I [R1 = (un)substituted alkyl, alkenyl, etc.; R2 = H, (un)substituted alkyl, etc.; R3 - R6 = H, halo, etc.; X = OH, etc.; Y = CO2H, etc.] are prepared More specifically, this invention provides novel isoquinolines as well as novel libraries comprised of many such compds. This document also describes an initial screen of isoquinoline libraries in the δ-opioid receptor assay and the σ receptor assay.

ST isoquinoline prepn combinatorial library; opioid receptor assay isoquinoline combinatorial library; sigma receptor assay isoquinoline combinatorial library

IT **Combinatorial library**
Solid phase synthesis
(isoquinoline derivs. as biol. active compds. and isoquinoline combinatorial libraries)

IT Opioid receptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(σ-opioid; isoquinoline derivs. as biol. active compds. and isoquinoline combinatorial libraries with effect on σ receptors)

IT Opioid receptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(δ-opioid; isoquinoline derivs. as biol. active compds. and isoquinoline combinatorial libraries with effect on opioid receptors)

IT 190656-37-2P 190656-41-8P 190656-45-2P 190656-46-3P 190656-47-4P
190656-48-5P 190656-49-6P 190656-50-9P 190656-51-0P 190656-52-1P
190656-53-2P 190656-54-3P 190656-56-5P 190656-57-6P 190656-58-7P
190656-59-8P 190656-60-1P 190656-61-2P 190656-62-3P 190656-63-4P
190656-64-5P 190656-65-6P 190656-66-7P 190656-67-8P 190656-68-9P
190656-69-0P 190656-70-3P 190656-71-4P 190656-72-5P 190656-73-6P

190656-74-7P 190656-75-8P 190656-76-9P 190656-77-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(isoquinoline derivs. as biol. active compds. and isoquinoline combinatorial libraries)

IT 190656-78-1P 190656-79-2P
RL: BYP (Byproduct); PREP (Preparation)
(isoquinoline derivs. as biol. active compds. and isoquinoline combinatorial libraries)

IT 91-00-9D, resin-bound 55095-21-1D, resin-bound 117381-20-1, TentaGel
RL: NUU (Other use, unclassified); USES (Uses)
(isoquinoline derivs. as biol. active compds. and isoquinoline combinatorial libraries)

IT 51-45-6, Histamine, reactions 51-67-2, Tyramine 55-81-2, 4-Methoxyphenethylamine 56-40-6, Glycine, reactions 56-45-1, L-Serine, reactions 56-84-8, L-Aspartic acid, reactions 56-87-1, L-Lysine, reactions 56-91-7, 4-(Aminomethyl)benzoic acid 60-18-4, L-Tyrosine, reactions 61-54-1, Tryptamine 62-53-3, Benzenamine, reactions 64-04-0, Phenethylamine 66-77-3, 1-Naphthaldehyde 66-99-9, 2-Naphthaldehyde 67-36-7, 4-Phenoxybenzaldehyde 67-47-0, 5-(Hydroxymethyl)-2-furaldehyde 71-23-8, 1-Propanol, reactions 71-30-7, Cytosine 75-07-0, Acetaldehyde, reactions 75-31-0, Isopropylamine, reactions 77-86-1, Tris(hydroxymethyl)aminomethane 79-08-3, Bromoacetic acid 83-55-6 85-87-0, Pyridoxamine 87-25-2, 2-Carboethoxyaniline 87-59-2, 2,3-Dimethylaniline 87-60-5, 3-Chloro-2-methylaniline 88-17-5, 2-Trifluoromethylaniline 89-93-0, 2-Methylbenzylamine 89-97-4, 2-Chlorobenzylamine 90-02-8, 2-Hydroxybenzaldehyde, reactions 90-04-0, 2-Methoxyaniline 91-00-9, Aminodiphenylmethane 91-21-4, 1,2,3,4-Tetrahydroisoquinoline 91-59-8, 2-Aminonaphthalene 92-36-4, 2-(4-Aminophenyl)-6-methylbenzothiazole 92-54-6, 1-Phenylpiperazine 93-05-0, 4-(Diethylamino)aniline 94-09-7 94-70-2, 2-Ethoxyaniline 95-03-4, 5-Chloro-2-methoxyaniline 95-51-2, 2-Chloroaniline 95-53-4, 2-Methylaniline, reactions 95-55-6, 2-Hydroxyaniline 95-64-7, 3,4-Dimethylaniline 95-68-1, 2,4-Dimethylaniline 95-76-1, 3,4-Dichloroaniline 95-78-3, 2,5-Dimethylaniline 95-79-4, 5-Chloro-2-methylaniline 95-81-8, 2-Chloro-5-methylaniline 96-17-3 96-50-4, 2-Aminothiazole 98-01-1, 2-Furaldehyde, reactions 98-03-3, 2-Thiophenecarboxaldehyde 98-16-8, 3-Trifluoromethylaniline 99-59-2, 2-Methoxy-5-nitroaniline 99-61-6, 3-Nitrobenzaldehyde 99-88-7, 4-Isopropylaniline 99-98-9, 4-Dimethylaminoaniline 100-10-7, 4-(Dimethylamino)benzaldehyde 100-46-9, Benzylamine, reactions 100-52-7, Benzaldehyde, reactions 100-61-8, N-Methylaniline, reactions 100-81-2, 3-Methylbenzylamine 100-82-3, 3-Fluorobenzylamine 100-83-4, 3-Hydroxybenzaldehyde 102-49-8, 3,4-Dichlorobenzylamine 102-50-1, 4-Methoxy-2-methylaniline 102-56-7, 2,5-Dimethoxyaniline 103-67-3, N-Benzylmethylamine 103-76-4, 1-(2-Hydroxyethyl)piperazine 104-63-2, N-Benzylethanolamine 104-84-7, 4-Methylbenzylamine 104-86-9, 4-Chlorobenzylamine 104-87-0, 4-Methylbenzaldehyde 104-94-9, 4-Methoxyaniline 104-96-1 105-07-7, 4-Cyanobenzaldehyde 106-40-1, 4-Bromoaniline 106-47-8, 4-Chloroaniline, reactions 106-49-0, p-Toluidine, reactions 107-10-8, Propylamine, reactions 107-95-9, 3-Aminopropionic acid 108-00-9, N,N-Dimethylethylenediamine 108-42-9, 3-Chloroaniline 108-69-0, 3,5-Dimethylaniline 108-91-8, Cyclohexylamine, reactions 109-01-3, 1-Methylpiperazine 109-85-3, 2-Methoxyethylamine 109-89-7, Diethylamine, reactions 110-58-7, Amylamine 110-89-4, Piperidine, reactions 111-42-2, Diethanolamine, reactions 118-31-0, 1-Naphthalenemethylamine 120-57-0, 3,4-Methylenedioxybenzaldehyde 120-71-8, 2-Methoxy-5-methylaniline 122-03-2, 4-Isopropylbenzaldehyde 122-85-0, 4-Acetamidobenzaldehyde 123-08-0 123-11-5, 4-Methoxybenzaldehyde, reactions 123-30-8, 4-Hydroxyaniline 123-75-1, Pyrrolidine, reactions 124-02-7 135-02-4, 2-Methoxybenzaldehyde

136-95-8, 2-Aminobenzothiazole 139-59-3, 4-Phenoxyaniline 140-75-0, 4-Fluorobenzylamine 141-43-5, reactions 144-90-1, 3-Amino-2-methylpropionic acid 149-73-5, Trimethyl orthoformate 153-78-6, 2-Aminofluorene 155-09-9, trans-2-Phenylcyclopropylamine 156-41-2, 2-(4-Chlorophenyl)ethylamine 156-43-4, 4-Ethoxyaniline 348-40-3, 2-Amino-6-fluorobenzothiazole 348-54-9, 2-Fluoroaniline 351-54-2, 3-Fluoro-4-methoxybenzaldehyde 367-21-5, 3-Chloro-4-fluoroaniline 367-25-9, 2,4-Difluoroaniline 367-29-3, 5-Fluoro-2-methylaniline 371-40-4, 4-Fluoroaniline 372-19-0, 3-Fluoroaniline 387-45-1, 2-Chloro-6-fluorobenzaldehyde 401-95-6, 3,5-Bis(trifluoromethyl)benzaldehyde 404-70-6, 3-Fluorophenethylamine 437-81-0, 2,6-Difluorobenzaldehyde 446-52-6, 2-Fluorobenzaldehyde 452-80-2, 2-Fluoro-4-methylaniline 452-84-6, 2-Fluoro-5-methylaniline 454-89-7, 3-Trifluoromethylbenzaldehyde 455-14-1, 4-Trifluoromethylaniline 455-19-6, 4-(Trifluoromethyl)benzaldehyde 456-48-4, 3-Fluorobenzaldehyde 459-57-4, 4-Fluorobenzaldehyde 498-60-2, 3-Furaldehyde 498-62-4, 3-Thiophenecarboxaldehyde 500-22-1, 3-Pyridinecarboxaldehyde 503-29-7, Azetidine 504-24-5, 4-Aminopyridine 536-90-3, 3-Methoxyaniline 540-37-4, 4-Iodoaniline 555-16-8, 4-Nitrobenzaldehyde, reactions 582-33-2 583-68-6, 2-Bromo-4-methylaniline 583-75-5, 4-Bromo-2-methylaniline 591-19-5, 3-Bromoaniline 591-27-5, 3-Hydroxyaniline 591-31-1, 3-Methoxybenzaldehyde 608-22-0, 2,3-Dibromoaniline 608-27-5, 2,3-Dichloroaniline 615-36-1, 2-Bromoaniline 615-43-0, 2-Iodoaniline 615-55-4, 3,4-Dibromoaniline 616-30-8, 3-Amino-1,2-propanediol 617-89-0, Furfurylamine 618-36-0, α-Methylbenzylamine 619-21-6, 3-Carboxybenzaldehyde 619-66-9, 4-Carboxybenzaldehyde 620-02-0, 5-Methyl-2-furaldehyde 620-23-5, 3-Methylbenzaldehyde 621-33-0, 3-Ethoxyaniline 621-59-0, 3-Hydroxy-4-methoxybenzaldehyde 626-01-7, 3-Iodoaniline 660-88-8, 5-Aminopentanoic acid 695-34-1, 2-Amino-4-picoline 698-63-5, 5-Nitro-2-furaldehyde, reactions 703-59-3, Homophthalic anhydride 704-13-2, 3-Hydroxy-4-nitrobenzaldehyde 712-97-0, 3,4-Methylenedioxy-6-nitrobenzaldehyde 765-30-0, Cyclopropylamine 767-92-0, trans-Decahydroquinoline 768-94-5, 1-Adamantanamine 872-85-5, 4-Pyridinecarboxaldehyde 874-42-0, 2,4-Dichlorobenzaldehyde 929-17-9, 7-Aminoheptanoic acid 1003-03-8, Cyclopentylamine 1003-29-8, Pyrrole-2-carboxaldehyde 1121-60-4, 2-Pyridinecarboxaldehyde 1122-72-1, 6-Methyl-2-pyridinecarboxaldehyde 1122-91-4, 4-Bromobenzaldehyde 1192-58-1, 1-Methylpyrrole-2-carboxaldehyde 1197-18-8, trans-4-(Aminomethyl)cyclohexanecarboxylic acid 1484-26-0, 3-Benzyloxyaniline 1571-08-0, Methyl 4-formylbenzoate 1583-88-6, 4-Fluorophenethylamine 1668-84-4, 2,3-Methylenedioxyaniline 1738-68-7, Glycine benzyl ester 1745-07-9, 6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline 1747-60-0, 2-Amino-6-methoxybenzothiazole 1783-81-9, 3-(Methylmercapto)aniline 2038-57-5, Benzenepropanamine 2043-61-0, Cyclohexanecarboxaldehyde 2106-02-7, 2-Chloro-4-fluoroaniline 2213-43-6, 1-Aminopiperidine 2217-41-6, 1-Amino-5,6,7,8-tetrahydronaphthalene 2233-18-3, 3,5-Dimethyl-4-hydroxybenzaldehyde 2298-07-9 2393-23-9, 4-Methoxybenzylamine 2454-37-7, 3-(1-Hydroxyethyl)aniline 2516-47-4, (Aminomethyl)cyclopropane 2524-67-6, 4-Morpholinoaniline 2646-91-5, 2,3-Difluorobenzaldehyde 2688-84-8, 2-Phenoxyaniline 2696-84-6, 4-Propylaniline 2735-04-8, 2,4-Dimethoxyaniline 2740-83-2, 3-Trifluoromethylbenzylamine 2791-79-9 2834-92-6, 1-Amino-2-hydroxynaphthalene 2835-68-9 2836-03-5, 2-Dimethylaminoaniline 2836-04-6, 3-Dimethylaminoaniline 2973-76-4 2975-41-9, 2-Aminoindan 2987-53-3, 2-(Methylmercapto)aniline 3048-01-9, 2-Trifluoromethylbenzylamine 3132-99-8, 3-Bromobenzaldehyde 3213-28-3, 3,5-Dimethoxyphenethylamine 3218-36-8, 4-Biphenylcarboxaldehyde 3303-84-2 3446-89-7, 4-(Methylthio)benzaldehyde 3544-24-9 3586-12-7, 3-Phenoxyaniline 3731-51-9, 2-(Aminomethyl)pyridine 3731-52-0, 3-(Aminomethyl)pyridine 3731-53-1, 4-(Aminomethyl)pyridine 3863-11-4, 3,4-Difluoroaniline 3959-05-5, 2-Bromobenzylamine 3959-07-7, 4-Bromobenzylamine 3973-70-4,

1-Amino-4-(2-hydroxyethyl)piperazine 4319-49-7, 4-Aminomorpholine
4363-93-3, 4-Quinolinecarboxaldehyde 4393-09-3, 2,3-Dimethoxybenzylamine
4519-40-8, 2,3-Difluoroaniline 4530-20-5, N-(tert-Butoxycarbonyl)glycine
4684-12-2, 1-Amino-4-chloronaphthalene 4795-29-3,
Tetrahydrofurfurylamine 5036-48-6, 1-(3-Aminopropyl)imidazole
5345-54-0, 3-Chloro-4-methoxyaniline 5393-59-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(isoquinoline derivs. as biol. active compds. and isoquinoline
combinatorial libraries)

IT 5398-77-6, 4-Methylsulfonylbenzaldehyde 5447-02-9, 3,4-
Dibenzyloxybenzaldehyde 5452-35-7, Cycloheptylamine 5470-96-2,
2-Quinolinecarboxaldehyde 5736-85-6, 4-Propoxybenzaldehyde 5763-61-1,
3,4-Dimethoxybenzylamine 6238-14-8, 3-Aminoquinuclidine 6287-38-3,
3,4-Dichlorobenzaldehyde 6299-67-8, 2,3-Dimethoxyaniline 6315-89-5,
3,4-Dimethoxyaniline 6344-63-4, 1-Aminofluorene 6361-21-3,
2-Chloro-5-nitrobenzaldehyde 6373-46-2, 4-Benzyloxyaniline 6376-14-3,
4-Chloro-2-methoxy-5-methylaniline 6404-29-1 6530-09-2,
3-Aminoquinuclidine dihydrochloride 6589-55-5, α-
(Methylaminomethyl)benzyl alcohol 6630-33-7, 2-Bromobenzaldehyde
6635-20-7 6850-57-3, 2-Methoxybenzylamine 6928-85-4,
1-Amino-4-methylpiperazine 6933-10-4, 4-Bromo-3-methylaniline
6982-39-4, trans-2-Aminocyclohexanol 7154-73-6, 1-(2-
Aminoethyl)pyrrolidine 7175-81-7 7202-43-9 7242-92-4,
exo-2-Aminonorbornane 7311-34-4, 3,5-Dimethoxybenzaldehyde 7409-18-9,
3-Nitrobenzylamine 7409-30-5, 4-Nitrobenzylamine 7468-67-9,
2-Cyanobenzaldehyde **7568-93-6**, 2-Amino-1-phenylethanol
7570-45-8, 9-Ethyl-3-carbazolecarboxaldehyde 7745-91-7,
3-Bromo-4-methylaniline 7797-83-3, 2,3-Methylenedioxybenzaldehyde
10111-08-7, 2-Imidazolecarboxaldehyde 10200-59-6, 2-
Thiazolecarboxaldehyde 10203-08-4, 3,5-Dichlorobenzaldehyde 10256-43-6
10269-01-9, 3-Bromobenzylamine 10272-07-8, 3,5-Dimethoxyaniline
10343-99-4, cis-Decahydroquinoline 13078-79-0 13078-80-3,
2-(2-Chlorophenyl)ethylamine 13669-42-6, 3-Quinolinecarboxaldehyde
13679-70-4, 5-Methyl-2-thiophenecarboxaldehyde 14268-66-7,
3,4-Methylenedioxyaniline 14510-06-6, 8-Hydroxyquinoline-2-
carboxaldehyde 14615-72-6, 3,5-Dibenzyloxybenzaldehyde 15532-75-9
15761-38-3, N-(tert-Butoxycarbonyl)-L-alanine 15971-29-6,
4-Methoxy-1-naphthaldehyde 16588-34-4, 3-Nitro-4-chlorobenzaldehyde
16596-41-1, 1-Aminopyrrolidine 17768-41-1, 1-Adamantanemethylamine
18638-99-8, 3,4,5-Trimethoxybenzylamine 18791-75-8, 4-Bromo-2-
thiophenecarboxaldehyde 19012-03-4, 1-Methylindole-3-carboxaldehyde
19293-58-4, 4-(Dimethylamino)benzylamine 20781-20-8,
2,4-Dimethoxybenzylamine 22013-33-8, 1,4-Benzodioxan-6-amine
22374-89-6, 1-Methyl-3-phenylpropylamine 24313-88-0,
3,4,5-Trimethoxyaniline 24425-40-9 24458-14-8 24964-64-5,
3-Cyanobenzaldehyde 26153-38-8, 3,5-Dihydroxybenzaldehyde 26934-35-0,
4-(3-Dimethylaminopropoxy)benzaldehyde 27219-07-4 27687-14-5
28020-37-3, 3-Amino-2,6-dimethoxypyridine 28094-04-4 29022-11-5,
N-(9-Fluorenylmethoxycarbonyl)glycine 29668-44-8, 1,4-Benzodioxan-6-
carboxaldehyde 31002-73-0, endo-2-Aminonorbornane 32723-67-4,
3-Methyl-4-methoxybenzaldehyde 33228-44-3, 4-Pentylaniline 33233-67-9
34036-07-2, 3,4-Difluorobenzaldehyde 34803-66-2, 1-(2-Pyridyl)piperazine
35216-39-8, 3-Methylsulfonylaniline 35737-10-1 39515-51-0,
3-Phenoxybenzaldehyde 40499-83-0, 3-Pyrrolidinol 40807-61-2,
4-Hydroxy-4-phenylpiperidine 48067-24-9 52516-13-9 52721-69-4,
2-Fluorophenethylamine 52799-86-7 53460-46-1, 1,3,3-Trimethyl-6-
azabicyclo[3.2.1]octane 56961-75-2, 2,3,5-Trichlorobenzaldehyde
57294-38-9 59983-39-0 60142-89-4 61278-21-5 62373-80-2,
3-(4-Methoxyphenoxy)benzaldehyde 62414-68-0, (+)-3-Hydroxypiperidine
63149-33-7, 9-Formyl-8-hydroxyjulolidine 66211-46-9,
(+)-3-Amino-1,2-propanediol 69385-30-4, 2,6-Difluorobenzylamine
72235-52-0, 2,4-Difluorobenzylamine 72235-53-1, 3,4-Difluorobenzylamine
77771-02-9, 3-Bromo-4-fluorobenzaldehyde 79124-76-8,

3-(3,4-Dichlorophenoxy)benzaldehyde 84235-33-6, (+)-exo-2-Aminonorbornane 84624-27-1 85118-06-5, 2,5-Difluorobenzylamine 88574-06-5 116821-47-7 120570-05-0 122235-70-5 123536-15-2 130463-97-7 132696-45-8 134978-97-5 142929-49-5 161793-17-5, 2,3,4-Trifluorobenzaldehyde 190656-17-8 190656-34-9 190897-47-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(isoquinoline derivs. as biol. active compds. and isoquinoline combinatorial libraries)

IT **7568-93-6**, 2-Amino-1-phenylethanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(isoquinoline derivs. as biol. active compds. and isoquinoline combinatorial libraries)

RN 7568-93-6 HCAPLUS

CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 17 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:114374 HCAPLUS

DN 124:261653

ED Entered STN: 23 Feb 1996

TI **Solid phase synthesis** of hydantoins using a carbamate linker and a novel cyclization/cleavage step

AU Dressman, Bruce A.; Spangle, Larry A.; Kaldor, Stephen W.

CS Lilliy Res. Lab., Lilly Corporate Center, Indianapolis, IN, 46285, USA

SO Tetrahedron Letters (1996), 37(7), 937-40
CODEN: TELEAY; ISSN: 0040-4039

PB Elsevier

DT Journal

LA English

CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 28

AB An 800 compound hydantoin library has been constructed using a diverse set of 20 amino acids and over 80 primary amines. Amino acids were attached via their N-termini to (hydroxymethyl)polystyrene using a carbamate linker. Bound amino acids were converted to their corresponding amides and then cyclized under basic conditions to give hydantoins in high purities.

ST Merrifield synthesis hydantoin combinatorial library; amino acid primary amine cyclocondensation

IT **Combinatorial library**
Merrifield synthesis
(**solid phase synthesis** of hydantoins using a carbamate linker and a novel cyclization/cleavage step)

IT Amines, reactions
Amino acids, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(**solid phase synthesis** of hydantoins using a carbamate linker and a novel cyclization/cleavage step)

IT 52-52-8, 1-Aminocyclopentanecarboxylic acid 63-91-2, Phenylalanine, reactions 71-00-1, Histidine, reactions 73-22-3, Tryptophan, reactions 100-46-9, Benzylamine, reactions 103-01-5, N-Phenylglycine 502-32-9, Leucinol 3060-50-2, 2,2-Diphenylglycine 3731-53-1, 4-Aminomethylpyridine 3963-62-0, 2,2-Diphenylethylamine 5805-57-2, 2-Aminomethylbenzimidazole **7568-93-6**, 2-Amino-1-phenylethanol 7693-46-1, p-Nitrophenyl chloroformate 13211-31-9, Valine tert-butyl ester 18822-59-8, O-tert-Butyltyrosine 27431-62-5, N,N-Diethyl-1,4-butanediamine 67123-97-1, 1,2,3,4-Tetrahydroisoquinoline-

3-carboxylic acid 68076-36-8, N-tert-Butoxycarbonyl-1,4-butanediamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(**solid phase synthesis** of hydantoins
using a carbamate linker and a novel cyclization/cleavage step)
IT 7693-46-1DP, p-Nitrophenyl chloroformate, reaction products with (hydroxymethyl)polystyrene
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(**solid phase synthesis** of hydantoins
using a carbamate linker and a novel cyclization/cleavage step)
IT 461-72-3DP, Hydantoin, derivs. 2221-11-6P 34657-67-5P 34658-62-3P 80355-07-3P 110182-71-3P 175232-85-6P 175232-86-7P 175232-87-8P 175232-88-9P 175232-89-0P 175232-90-3P 175232-91-4P 175232-92-5P 175232-93-6P 175232-94-7P 175232-95-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(**solid phase synthesis** of hydantoins
using a carbamate linker and a novel cyclization/cleavage step)
IT **7568-93-6**, 2-Amino-1-phenylethanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(**solid phase synthesis** of hydantoins
using a carbamate linker and a novel cyclization/cleavage step)
RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 18 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:761505 HCAPLUS
DN 123:170192
ED Entered STN: 29 Aug 1995
TI Preparation of **solid phase** libraries of test compounds and their topologically separated coding molecules.
IN Lebl, Michal; Lam, Kit S.; Salmon, Sydney E.; Krchnak, Victor; Sepetov, Nikolai; Kocis, Peter
PA Selectide Corp., USA
SO PCT Int. Appl., 301 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K017-00
ICS C12Q001-68; C12P021-00
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 9
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9428028	A1	19941208	WO 1994-US6078	19940527
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5840485	A	19981124	US 1994-249830	19940526
AU 9470486	A1	19941220	AU 1994-70486	19940527
AU 686186	B2	19980205		
EP 705279	A1	19960410	EP 1994-919294	19940527
EP 705279	B1	20030219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09501490	T2	19970210	JP 1995-501022	19940527

JP 3394777 B2 20030407
AT 232882 E 20030315 AT 1994-919294 19940527
PRAI US 1993-68327 A 19930527
US 1994-249830 A 19940526
WO 1994-US6078 W 19940527
GI

FMOC-Ala-Phe-Val
FMOC-Ala-Phe-Val-Lys
BOC-Gly-Tyr-Leu-Lys-SCAL-TG I

AB A library for identifying and analyzing ligands of acceptors of interest comprises: a multiplicity of **solid supports** to which are attached (1) a species of test compound comprised of a series of subunits, and (2) a species of coding mol. which is topol. segregated from the test compound; the sequence of subunits of the test compound attached to a particular **support** is encoded by the coding mol. attached to the same **support**. Each of the **solid phase synthesis support** beads contains a single type of synthetic test compound The synthetic test compound can have backbone structures with linkages such as amide, urea, carbamate, ester, amino, sulfide, disulfide, or carbon-carbon, such as alkane and alkene, or any combination thereof. The synthetic test compound can also be a mol. scaffold, such as derivs. of monocyclic or bicyclic carbohydrates, steroids, sugars, heterocyclic structures, polyarom. structures, etc. The coding mol. (preferably a peptide) may be segregated in the interior of the **support** and the test compound on the exterior, accessible to a macromol. acceptor mol. of interest. Thus, BOC-Lys(FMOC)-OH was coupled to safety catch amide linker (SCAL)-modified tentagel (TG) resin; the Nε-FMOC group was removed and FMOC-Lys(FMOC)-OH was coupled to the side chain of the first Lys. The FMOC groups were removed and the resin was divided into 3 parts, which were sep. coupled with FMOC-Ala-OH, FMOC-Phe-OH, and FMOC-Val-OH. Corresponding (coding) amino acids BOC-Gly-OH, BOC-Tyr-OH, and BOC-Leu-OH were then coupled to the Nα-position of Lys after BOC deprotection. Further division and peptide coupling steps gave a total of 27 tripeptide moieties such as (I), in which the FMOC-protected tripeptides represent the test compound and the BOC-protected tripeptide represents the coding mol. Replacement of the BOC protecting group with F3CCO was followed by sequencing of the coding peptide.

ST library **solid phase** encoded topol sepd; peptide coding mol **solid phase** library; combinatorial library peptide coding mol

IT Polyamides, preparation
RL: PNU (Preparation, unclassified); PREP (Preparation)

IT Antibodies
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(binding of **supported** peptides to anti-β-endorphin antibodies; preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT Edman degradation
(edman degradation of coding peptides for determination of test compds.; preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT Polymers, preparation
RL: PNU (Preparation, unclassified); PREP (Preparation)
(poly(di)sulfide; preparation of **solid phase** libraries

of test compds. and their topol. separated coding mols.)

IT **Combinatorial library**
Merrifield synthesis
(preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT Peptides, preparation
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT Alkanes, preparation
Polyamines
Polycarbonates, preparation
Polyesters, preparation
Polyureas
Urethane polymers, preparation
RL: PNU (Preparation, unclassified); PREP (Preparation)
(preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT Alcohols, preparation
RL: PNU (Preparation, unclassified); PREP (Preparation)
(polyhydric, preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT Alkenes, preparation
RL: PNU (Preparation, unclassified); PREP (Preparation)
(polymers, preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT 9013-20-1, Streptavidin
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(binding of **supported** peptides to streptavidin; preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT 167017-79-0DP, resin bound
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(detection of anti-β-endorphin antibodies; preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT 58822-25-6DP, resin bound 140897-59-2DP, resin bound 167017-78-9DP, resin bound
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT 51-67-2, TyrAmine 66-99-9, β-Naphthaldehyde 75-04-7, Ethanamine, reactions 75-31-0, IsopropylAmine, reactions 78-81-9, IsobutylAmine 78-96-6, 1-Amino-2-propanol 79-08-3, Bromoacetic acid 86-87-3, 1-Naphthylaceticacid 89-00-9, 2,3-Pyridinedicarboxylic Acid 89-01-0, 2,3-Pyrazinedicarboxylic Acid 90-02-8, reactions 96-17-3, 2-Methylbutyraldehyde 97-96-1, 2-Ethylbutyraldehyde 98-03-3, 2-Thiophenecarboxaldehyde 98-97-5, 2-Pyrazinecarboxylic Acid 99-96-7, reactions 100-46-9, BenzylAmine, reactions 100-52-7, Benzaldehyde, reactions 107-15-3, 1,2-Ethanediamine, reactions 108-91-8, Cyclohexanamine, reactions 109-73-9, ButylAmine, reactions 109-85-3, 2-MethoxyethylAmine 117-34-0, Diphenylaceticacid 121-33-5, Vanillin 122-59-8, Phenoxyacetic acid 123-08-0 123-11-5, 4-Methoxybenzaldehyde, reactions 123-15-9, 2-Methylvaleraldehyde 141-43-5, reactions 156-38-7, 4-Hydroxyphenylacetic acid 156-87-6 447-61-0, α,α,α-Trifluoro-o-tolualdehyde 455-24-3, 4-Trifluoromethylbenzoic acid 463-00-3, γ-Guanidinobutyric acid 555-16-8, 4-Nitrobenzaldehyde, reactions 584-93-0, α-Bromovaleric acid 619-66-9, 4-Carboxybenzaldehyde 619-84-1, 4-Dimethylaminobenzoic

Acid 630-19-3, Trimethylacetaldehyde 638-32-4, Succinamicacid 645-65-8, 4-Imidazoleacetic Acid 653-21-4, Pentafluorophenylaceticacid 872-85-5, Pyridine-4-carboxaldehyde 1003-03-8, CyclopentylAmine 1877-73-2, 3-Nitrophenylacetic acid 1912-43-2, 2-Methyl-3-indoleaceticAcid 2043-61-0, Cyclohexanecarboxaldehyde 2124-55-2, Indole-4-carboxylic Acid 2393-23-9, 4-MethoxybenzylAmine 3218-36-8, 4-Phenylbenzaldehyde 3300-51-4, 4-TrifluoromethylbenzylAmine 3641-13-2 3978-80-1 4530-20-5 4998-07-6, 2-Nitro-4,5-dimethoxybenzoic acid 5292-21-7, Cyclohexylacetic acid 6232-88-8 6928-85-4, 4-Methyl-1-aminopiperazine **7568-93-6**, 2-Amino-1-phenylethanol 10351-19-6, 4-Pyridylthioacetic acid 13139-15-6 15231-41-1 15761-38-3 16060-65-4, 4-Guanidinobenzoic Acid 16136-58-6, 1-Methylindole-2-carboxylic Acid 16935-04-9 19293-58-4, 4-DimethylaminobenzylAmine 22948-94-3, 1-Acetylindole-3-carboxaldehyde 25173-72-2, 3-(3,4,5-Trimethoxyphenyl)propionic acid 29022-11-5, FMOC-Gly-OH 34967-24-3, 3,5-DimethoxybenzylAmine 35661-39-3 35661-40-6 35661-60-0 35737-15-6, FMOC-Trp-OH 39508-04-8D, resin bound 39515-51-0, 3-Phenoxybenzaldehyde 47373-14-8 47458-79-7 51317-25-0, Biphenylacetic acid 51387-90-7 57260-73-8 60875-16-3, 4-(3-Methyl-5-oxo-2-pyrazolin-1-yl)benzoic Acid 68858-20-8 71989-20-3 71989-31-6 74141-18-7 77285-08-6 78081-87-5 79410-20-1 84624-27-1 90159-87-8D, resin bound 91000-69-0 92954-90-0 109850-54-6, Naphthalenemethanamine 112772-46-0 116611-64-4, FMOC-His-OH 121343-82-6 152835-00-2 167017-73-4 167017-74-5D, resin bound 167017-75-6 167017-76-7 167017-77-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT 107271-36-3P 152768-11-1P 152835-01-3P 153838-40-5P 166410-28-2P 166410-33-9P 167017-70-1P 167017-71-2P 167017-80-3DP, resin bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT 167017-81-4P 167017-82-5P 167017-83-6P 167017-84-7P 167017-85-8P 167017-86-9P 167017-87-0P 167017-88-1P 167017-89-2P 167017-90-5P 167017-91-6P 167017-92-7P 167017-93-8P 167017-94-9P 167017-95-0P 167017-96-1P 167017-97-2P 167017-98-3P 167017-99-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT 167017-72-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(scaffolding; preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT 9004-07-3D, Chymotrypsin, resin bound
RL: CAT (Catalyst use); USES (Uses)
(selective cleavage/deprotection of peptide from resin surface; preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

IT **7568-93-6**, 2-Amino-1-phenylethanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of **solid phase** libraries of test compds. and their topol. separated coding mols.)

RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 19 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1960:39189 HCAPLUS
DN 54:39189
OREF 54:7757g-i,7758a-d
ED Entered STN: 22 Apr 2001
TI Examination of the rutaceae of Hong Kong. IV. Synthesis of dihydronitidine
AU Arthur, H. R.; Ng, Y. L.
CS Univ. Hong Kong
SO Journal of the Chemical Society, Abstracts (1959) 4010-12
CODEN: JCSAAZ; ISSN: 0590-9791
DT Journal
LA Unavailable
CC 10H (Organic Chemistry: Alkaloids)
AB Dihydronitidine (I) was synthesized and the structures for nitidine (II) and oxynitidine (III) proposed in the earlier work confirmed. Acetopiperone (25 g.) and 30 g. veratraldehyde treated with 150 ml. alc. with 30 ml. 10% aqueous NaOH gave 30 g. 3,4-dimethoxy-3',4'-methylenedioxychalcone (IV), m. 135° (alc.). IV (30 g.) in 110 ml. EtOCH2CH2OH containing 6.5 ml. AcOH treated 3 min. at 100° with 12.5 g. KCN in 45 ml. H2O, heating continued 10 min., 150 ml. H2O added, and the mixture cooled gave 30 g. α-(3,4-dimethoxyphenyl)-γ-(3,4-methylenedioxyphenyl)-α-oxobutyronitrile (V), yellow needles, m. 146° (alc.). V (30 g.) in 200 ml. AcOH treated gradually with 30 ml. concentrated H2SO4 gave 25 g. α-(3,4-dimethoxyphenyl)-γ-(3,4-methylenedioxyphenyl)-γ-oxobutyramide (VI), m. 177° (alc.). VI (25 g.) in 350 ml. 7% aqueous NaOH and 200 ml. alc. refluxed 10 hrs. and then acidified gave 22 g. α-(3,4-dimethoxyphenyl)-γ-(3,4-methylenedioxyphenyl)-γ-oxobutyric acid (VII), needles, m. 172° (alc.). VII (11 g.) in 110 ml. AcOH containing 2 ml. 70% HClO4 hydrogenated during 2 hrs. at 60°/1 atmospheric over 2 g. 5% Pd-C, most of the solvent removed, H2O added, the oily product extracted with C6H6, the 8 g. brown oil [α-(3,4-dimethoxyphenyl)-γ-(3,4-methylenedioxyphenyl)-butyric acid] refluxed 4 min. with 20 ml. POCl3, the mixture poured on ice, the **solid** dissolved in CHCl3, washed with aqueous NaOH, H2O, dried, and evaporated gave 6.5 g. 2-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-6,7-methylenedioxy-1-oxonaphthalene (VIII), m. 165° (alc.). VIII(6 g.) in 15 ml. HCONH2 and 0.8 ml. HCO2H heated 3 hrs. at 180° with 0.8 g. (NH4)2SO4, 0.8 ml. HCO2H added hourly, the mixture cooled, diluted with H2O, extracted with CHCl3, washed, and evaporated gave 3.5 g. 2-(3,4-dimethoxyphenyl)-1-formamido-1,2,3,4-tetrahydro-6,7-methylenedioxynaphthalene (IX), m. 178° (dioxane-alc.). IX (1.5 g.) refluxed 15 min. with 3 ml. POCl3 in 10 ml. PhMe gave a **solid** which suspended in MeOH and basified gave 1 g. 3,4,11,12-tetrahydro-6,7-dimethoxy-2',3'-methylenedioxy-1,2-benzophenanthridine (X), m. 188-9° (MeOH). X (0.9 g.) heated 0.5 hr. at 240° with 0.2 g. 30% Pd-C and extracted with CHCl3 gave 0.6 g. 6,7-dimethoxy-2',3'-methylenedioxy-1,2-benzophenanthridine (XI), m. 273° (C5H5N). XI (0.5 g.) in 5 ml. xylene and 10 ml. PhNO2 refluxed a few min. with 1 ml. Me2SO4 gave the methosulfate of XI, m. 306-7° (decomposition) (aqueous alc.). XI methosulfate (0.4 g.) in 60 ml. H2O and 4 ml. concentrated HCl refluxed 5 hrs. with 8 g. Zn powder under argon, 3 ml. more HCl added after each hr., the solution cooled to 0-5°, sealed 12 hrs. under argon, the **solid** washed, shaken with CHCl3 and NH3, the extract washed, dried, and evaporated gave 0.2 g. I, prisms, m. 208-11° (alc.). Simple transformations used for I led to **syntheses** of II and III.
IT Formamide, N-[6-(3,4-dimethoxyphenyl)-7,8-dihydronaphtho[2,3-d]-1,3-dioxol-5-yl]-
[1,3]Benzodioxolo[5,6-c]phenanthridine, 12,13-dihydro-2,3-dimethoxy-12-methyl-, dihydronitidine

[1,3]Benzodioxolo[5,6-c]phenanthridinium compounds, 2,3-dimethoxy-12-methyl-, methyl sulfate
IT **7568-93-6**, Benzyl alcohol, α-(aminomethyl)-
(derivs.)
IT 548-31-2, Oxynitidine 6872-57-7, Nitidine 18034-03-2, [1,3]Benzodioxolo[5,6-c]phenanthridine, 2,3-dimethoxy- 41303-46-2, Naphtho[2,3-d]-1,3-dioxol-5(6H)-one, 6-(3,4-dimethoxyphenyl)-7,8-dihydro- 41303-67-7, Chalcone, 3,4-dimethoxy-3',4'-methylenedioxy- 41303-68-8, Hydratropic acid, 3,4-dimethoxy-β-piperonyloyl- 41303-71-3, [1,3]Benzodioxolo[5,6-c]phenanthridine, 4b,5,6,11b-tetrahydro-2,3-dimethoxy- 54022-58-1, Hydratroponitrile, 3,4-dimethoxy-β-piperonyloyl- 88775-39-7, Hydratropamide, 3,4-dimethoxy-β-piperonyloyl-
(preparation of)
IT 456-12-2, Egeline 13063-06-4, Nitidine, dihydro-
(synthesis of)
IT **7568-93-6**, Benzyl alcohol, α-(aminomethyl)-
(derivs.)
RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 20 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1959:62377 HCAPLUS
DN 53:62377
OREF 53:11276b-i,11277a-g
ED Entered STN: 22 Apr 2001
TI Psychopharmacological activity of ring- and side chainsubstituted β-phenethylamines
AU Benington, F.; Morin, R. D.; Clark, Leland C., Jr.; Fox, R. Phyllis
CS Battelle Mem. Inst., Columbus, O.
SO Journal of Organic Chemistry (1958), 23, 1979-84
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA Unavailable
CC 10E (Organic Chemistry: Benzene Derivatives)
AB **Synthesis** of a number of ring substituted β-phenethylamines containing alkyl, halogen, and alkoxy substituents by various methods is described. The influence of these ring substituents on the psychotomimetic activity of substituted β-phenethylamines was examined by observing the effect of these compds. on cat behavior. Addnl. information was thus required on the influence of both the nature and position of substituents on the psychotomimetic activity. The procedure developed for the **synthesis** of 4-ethyl-β-phenethylamine (I) is representative of that used to obtain related compds. Method 1. PhEt was chloromethylated with paraformaldehyde and HCl in the presence of ZnCl2 to give 72% 4-EtC6H4CH2Cl (II), b17 99-102°. II with NaCN in aqueous alc. gave 80% 4-ethylphenylacetonitrile (III), b15 134-6°. III (36 g.) added slowly to 19 g. LiAlH4 in 600 ml. Et2O, refluxed 0.5 hr., hydrolyzed slowly with H2O, and the Et2O filtrate treated with dry HCl gave 23.3 g. I.HCl, m. 208-9° (alc. or alc.-EtOAc). Yields were similar for other compds. synthesized by this method. 4-BrC6H4CH2Br and 4-IC6H4CH2Br were prepared by bromination of p-BrC6H4Me and p-IC6H4Me. All the required substituted benzyl chlorides were prepared by the chloromethylation reaction. Method 2. m-Toluic acid (25 g.) and 30 ml. SOCl2 refluxed 3 hrs., excess SOCl2 removed, and the residue distilled in vacuo gave 26.7 g. m-toluyl chloride (IV), b30 115-16°. IV in Et2O

added to cold Et2O solution containing 17.6 g. CH2N2, left at room temperature overnight, the Et2O removed, and the residual material crystallized gave 19.6 g. diazoketone, m. 69-70°. The diazoketone refluxed overnight with 50 ml. dioxane, 280 ml. 28% NH4OH, 28 ml. 10% AgNO3, and the hot solution treated with C gave 14.6 g. 3-methylphenylacetamide (V), m. 147-8°. V in 325 ml. refluxing C6H6 added dropwise to 11.6 g. LiAlH4 in 250 ml. Et2O, the mixture refluxed 0.5 hr., cooled, hydrolyzed, extracted, and the extract treated with dry HCl gave 13.7 g. 3-methyl-β-phenethylamine, m. 170-1° (alc.-EtOAc). Method 3. 3,4-Methylenedioxy-β-nitrostyrene (m. 160-1°, obtained in 86% yield from piperonal and MeNO2 in the presence of alkali) (32 g.) in 400 ml. refluxing C6H6 added portionwise to 23 g. LiAlH4 in 400 ml. Et2O, the mixture refluxed 1 hr., cooled, hydrolyzed, and the filtrate treated with dry HCl gave 20.5 g. 3,4-methylenedioxy-β-phenethylamine-HCl, m. 213-14° (alc.-EtOAc). The following ring substituted β-phenethylamines were thus prepared (substituent, method, and m.p. of the HCl salt given): 2-Me, 2, 226°; 4-Et, 1, 208-9°; 4-iso-Pr, 1, 266-8°; 4-tert-Bu, 1, 258-60° (decomposition); 4-hexyl, 1, 175-7°; 4-Ph, 1, 293-5°; 4-F, 1, 212-13°; 4-Cl, 1, 218-18.5°; 4-I, 1, 294-6° (decomposition); 4-Br, 1, 240-3° (decomposition); 3,5-di-MeO, 2, 155-7°; DL-3,4,5-trimethoxy-β-methyl, 3, 220-1°; DL-3,4,5-trimethyl-β-methyl, 3, 265-6°; DL-3,4-methylenedioxy-β-methyl, 3, 191-2°. Tyramine (13.7 g.) in 85 ml. AcOH treated portionwise with 32 g. Br in 90 ml. AcOH and cooled gave 31.2 g. 3,5-dibromo-4-hydroxy-β-phenylethylamine-HCl (VI), m. 269-70° (decomposition). VI (28.2 g.) in 600 ml. H2O at 70° treated with 18 g. NaOAc in 50 ml. H2O, the separated oil extracted with Et2O, and distilled gave 15.2 g. N-acetyl-3,5-dibromo-4-hydroxy-β-phenethylamine (VII), m. 147-8°. VII (15.2 g.) in 3 g. NaOH and 80 ml. H2O treated with 3 portions of Me2SO4 and kept several hrs. gave 13.7 g. N-acetyl-3,5-dibromo-4-methoxy-β-phenethylamine (VIII), m. 121-2° (alc.). Crude VIII (12 g.) and 70 ml. 1:1 HCl refluxed 1 hr. gave 8.9 g. 3,5-dibromo-4-methoxy-β-phenethylamine-HCl, m. 233-4° (alc.-EtOAc). 2,6-Dimethylphenol (100 g.) and 150 ml. Ac2O refluxed 3.5 hrs. and distilled gave 108 g. 2,6-dimethylphenyl acetate, b0.6 83-5°. A mixture of this product and 93 g. anhydrous AlCl3 warmed on a steam bath to initiate reaction, left 2 hrs. at room temperature, heated an addnl. hr., poured on ice and HCl, and the crude **solid** product collected gave 76.5 g. 3,5-dimethyl-4-hydroxyacetophenone (IX), m. 154-4.5° (MeOH-H2O). IX (75 g.) in 100 ml. MeOH and 100 ml. Me2SO4 refluxed 15 min. with 80 g. NaOH in 90 ml. H2O, diluted to 1200 ml. with H2O, and extracted gave 66 g. 3,5-dimethyl-4-methoxyacetophenone (X), m. 47-8° (Et2O). X (65.4 g.), 47 g. morpholine, and 17 g. S refluxed 7 hrs. and poured into 200 ml. hot alc. gave 65 g. 3,5-dimethyl-4-methoxyphenyl-thioacetomorpholide (XI), m. 86-7° (Et2O-ligroine). XI (56.7 g.), 110 ml. AcOH, 25 ml. H2O, and 15 ml. concentrated H2SO4 refluxed 7.5 hrs., cooled, poured into 800 ml. H2O, extracted with Et2O, then with dilute NaOH, and acidified gave 34.5 g. 3,5-dimethyl-4-methoxyphenylacetic acid (XI), m. 77-8° (Et2O-ligroine). XI (18 g.), 14 ml. SOCl2, and 60 ml. CHCl3 refluxed 3 hrs., stripped of solvent and excess SOCl2, and added slowly to excess NH4OH gave 14 g. 3,5-dimethyl-4-methoxyphenylacetamide (XII), m. 109-10° (C6H6-ligroine). XII (14 g.) in 200 ml. C6H6 refluxed 1 hr. with 8.3 g. LiAlH4 in 300 ml. Et2O and dry HCl added to the crude material gave 15.7 g. 3,5-dimethyl-4-methoxy-β-phenyl-ethylamine-HCl, m. 226-7° (alc.-EtOAc). 3,4,5-(EtO)3C6H2CH2CO2H (16 g.), 10 ml. SOCl2, and 20 ml. CHCl3 refluxed 1 hr. and the crude acid chloride added to NH4OH gave 10.2 g. 3,4,5-triethoxy-β-phenethylacetamide (XIII), m. 137-8° (C6H6-ligroine). XIII (8 g.) in 100 ml. C6H6 stirred 2 hrs. with 3.8 g. LiAlH4 in Et2O, hydrolyzed, and treated with dry HCl gave 5.4 g. 3,4,5-triethoxy-β-phenethylamine-

HCl, m. 172-3°. 3,4-Dimethyl-ω-chloroacetophenone (84% yield from o-xylene, ClCH2COCl, and AlCl3, m. 76-7°) (36.5 g.) added portionwise to 150 ml. alc., 25 g. N-methylbenzylamine, and 25 g. anhydrous Na2CO3, the mixture refluxed 6 hrs., filtered, evaporated, the residue treated with H2O, extracted with Et2O, and distilled gave 33.6 g. crude product, b0.4 170-5°, treated with HCl to give 29.3 g. 3,4-dimethyl-N-benzyl-N-methylaminoacetophenone-HCl (XIV), m. 197-8° (decomposition). XIV (27.5 g.) in 200 ml. MeOH hydrogenated at room temperature and 3 atmospheric H over 1 g. 10% Pd-C gave 12.5 g. dl-3,4-dimethyl-α-hydroxy-N-methyl-β-phenethylamine-HCl, m. 137-8° (alc.-Et2O). 3,4,5-Trimethylacetophenone (60 g.) in 150 ml. AcOH treated at room temperature with 59 g. Br gave 47.6 g. 3,4,5-trimethyl-ω-bromoacetophenone (XV), m. 77.5-8.0° (alc.). XV (40 g.) treated as above with 20.8 g. PhCH2NHMe and 22 g. anhydrous Na2CO3 in 125 ml. alc. gave after treatment with dry HCl 31.6 g. 3,4,5-trimethyl-N-benzyl-N-methylaminoacetophenone-HCl (XVI), m. 178.5-9.0° (alc.-Et2O). XVI (26.2 g.) in 150 ml. MeOH hydrogenated at 3 atmospheric H over 1 g. 10% Pd-C with simultaneous debenzylation and reduction of the CO group gave 14.5 g. dl-3,4,5-trimethyl-α-hydroxy-N-methyl-β-phenethylamine-HCl, m. 186-7°. The above compds. were tested on the cat for pilomotor, pupil dilation, growl, hiss, aggressive behavior, withdrawing, and salivation and the results tabulated. It was noted that nearly all these derivs. exhibited an analeptic activity in the nembutalized cat at a low level of anesthesia.

IT Psychotomimetic agents
(chemical constitution and)

IT Pharmacology
(of phenethylamines)

IT Analeptics
(phenethylamine derivs. as)

IT Phenethyl alcohol, 3,4-dimethyl-α-methylamino-, dl-, hydrochloride
Phenethylamine, 3,4,5-trimethoxy-β-methyl-, DL-, hydrochloride
Phenethylamine, 3,5-dioromo-4-methoxy-, hydrochloride
Phenethylamine, 4-methoxy-3,5-dimethyl-, hydrochloride
Phenethylamine, β,3,4,5-tetramethyl-, DL, hydrochloride
Phenethylamine, β-methyl-3,4-methylenedioxy-, DL, hydrochloride

IT Phenylephrine
(basicity of)

IT Phenethylamine, m-methyl-
Phenethylamine, o-methyl-
Phenethylamine, p-methyl-
(hydrochlorides)

IT 51-41-2, Arterenol 51-43-4, Adrenaline 51-61-6, Pyrocatechol, 4-(2-aminoethyl)- 51-67-2, Tyramine 94-07-5, Synephrine 104-14-3, Benzyl alcohol, α-(aminomethyl)-p-hydroxy- 370-98-9, Phenol, p-(2-methylaminoethyl)- 501-15-5, Pyrocatechol, 4-(2-methylaminoethyl)- 536-21-0, Benzyl alcohol, α-(aminomethyl)-m-hydroxy- 589-08-2, Phenethylamine, N-methyl- 6589-55-5, Benzyl alcohol, α-(methylaminomethyl)- **7568-93-6**, Benzyl alcohol, α-(aminomethyl)-
(basicity of)

IT 64-04-0, Phenethylamine
(derivs., preparation and pharmacology of)

IT 459-19-8, Phenethylamine, p-fluoro-, hydrochloride 637-26-3, Phenethylamine, 3,5-dimethoxy-, hydrochloride 876-98-2, 2,6-Xylenol, acetate 1467-05-6, Toluene, α-chloro-p-ethyl- 1485-00-3, Styrene, 3,4-methylenedioxy-β-nitro- 1653-64-1, Phenethylamine, 3,4-methylenedioxy-, hydrochloride 1711-06-4, m-Toluoyl chloride 2492-83-3, Phenethylamine, p-chloro-, hydrochloride 3166-81-2, Phenethylamine, 3,4,5-triethoxy-, hydrochloride 3166-88-9,

Phenethylamine, p-ethyl-, hydrochloride 5325-04-2, Acetophenone, 4'-hydroxy-3',5'-dimethyl- 13062-88-9, Phenol, 4-(2-aminoethyl)-2,6-dibromo-, hydrochloride 17027-69-9, Phenethylamine, p-phenyl-, hydrochloride 17263-64-8, Acetophenone, 2-diazo-4'-methyl- 39260-89-4, Phenethylamine, p-bromo-, hydrochloride 39260-90-7, Phenethylamine, p-iodo-, hydrochloride 50690-08-9, Acetophenone, 2-chloro-3',4'-dimethyl- 51632-28-1, Acetonitrile, (p-ethylphenyl)- 60609-65-6, Acetophenone, 4'-methoxy-3',5'-dimethyl- 61035-87-8, Phenethylamine, p-isopropyl-, hydrochloride 90765-38-1, Acetamide, 2-m-tolyl- 99070-34-5, Acetamide, N-(3,5-dibromo-4-hydroxyphenethyl)- 99985-50-9, Acetamide, 2-(4-methoxy-3,5-xylyl)- 100126-17-8, Acetamide, N-(3,5-dibromo-4-methoxyphenethyl)- 100251-59-0, Phenethylamine, p-tert-butyl-, hydrochloride 100251-87-4, Phenethyl alcohol, 3,4,5-trimethyl-α-methylamino-, hydrochloride 100874-90-6, Phenethylamine, p-hexyl-, hydrochloride 101717-59-3, Acetophenone, 2-(benzylmethylamino)-3',4'-dimethyl-, hydrochloride 101777-15-5, Acetamide, 2-(3,4,5-triethoxyphenyl)- 102005-30-1, Morpholine, 4-[(4-methoxy-3,5-xylyl)thioacetyl]- 102009-75-6, Acetophenone, 2-(benzylmethylamino)-3',4',5'-trimethyl-, hydrochloride 104216-50-4, Acetic acid, (4-methoxy-3,5-xylyl)- 105906-41-0, Acetophenone, 2-bromo-3',4',5'-trimethyl-
(preparation of)

IT **7568-93-6**, Benzyl alcohol, α-(aminomethyl)-
(basicity of)

RN 7568-93-6 HCAPLUS

CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 21 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1950:19985 HCAPLUS

DN 44:19985

OREF 44:3939h-i,3940a-i,3941a-c

ED Entered STN: 22 Apr 2001

TI A new synthesis of α-amino-p-hydroxyacetophenones and their reduction to the corresponding aminoethanols

AU Asscher, M.

CS N. V. Philips-Roxane, Weesp, Neth.

SO Recueil des Travaux Chimiques des Pays-Bas et de la Belgique (1949), 68, 960-8
CODEN: RTCPB4; ISSN: 0370-7539

DT Journal

LA English

CC 10 (Organic Chemistry)

OS CASREACT 44:19985

GI For diagram(s), see printed CA Issue.

AB cf. C.A. 27, 2681. A new **synthesis** is described for compds. of the type p-HOC6H4COCH2N by the condensation of phenol or its derivs. with aminoacetonitriles, with the help of gaseous HCl, ZnCl2, or AlCl3. The corresponding alcs. were prepared by catalytic reduction of the ketones obtained. To 73 g. iso-PrNH2.HCl in 98 g. 40% HCHO, cooled with EtOH-**solid** CO2, 36.5 g. NaCN in 75 ml. H2O was added dropwise with stirring at a rate to maintain a temperature of -4° to 0°; after 1 hr. at room temperature, the mixture was diluted, extracted with C6H6, the C6H6 extract
dried with anhydrous Na2SO4, and distilled under a vacuum to remove the C6H6, producing 67 g. of residue, iso-PrNHCH2CN.HCl (I), light yellow viscous oil, unstable above 70°. To 67 g. I in 30 ml. absolute alc. was added

25 g. dry HCl in 60 g. absolute alc. dropwise while cooling externally with ice and NaCl to keep the temperature below 8°, and then 200 ml. dry Et2O; on standing there separated 58 g. I.HCl, m. 166-7°; recrystd. from EtOH-MeCOEt it formed glittering needles, m. 168-9°. I.HCl (13.5 g.) and 14 g. PhOH were added to 33 g. anhydrous AlCl3 in 60 ml. PhNO2, dry HCl introduced for 3 hrs. at 30-40° the mixture cooled, poured into 100 ml. H2O, and the precipitated p-HOC6H4COCH2NHCHMe2 (II), filtered after 1 hr.
and washed with Me2CO, recrystd. from H2O, m. 258-60° (decomposition). Anhydrous AlCl3 (30 g.), 14 g. PhOH, and 11 g. MeNHCH2CN.HCl (III) were added to 60 g. PhNO2 with shaking and cooling, dry HCl passed in for 3 hrs. at 20-30°, the mixture poured into 70 ml. H2O, cooled, allowed to stand for 1 hr., the precipitate of crude p-HOC6H4COCH2NHMe.HCl (IV) dissolved in 300 ml. H2O, 30 g. of 50% Na lactate added to remove the Al, then charcoal added, the mixture filtered, cooled, and NH3 added to pH 8; the 12.5 g. precipitate
of the free base of IV, filtered and washed with H2O and Me2CO, m. 142-4° (decomposition). Treatment with dilute HCl gave 83% IV, m. 242-4° (decomposition). A similar preparation with H2SO4 in alc. instead of HCl gave a 45% yield. Prolonged treatment with dry HCl and standing gave only 75% IV. With no HCl the yield of free base of IV dropped to 25%. PhCl as solvent gave inferior yields of IV. The N-Ac compound, obtained by boiling IV with Ac2O, m. 191.5-2.5°. p-HOC6H4COCH2NH2.HCl (V), prepared in 51% yield by condensing PhOH and H2NCH2CN.HCl, m. 249-51°. BzOPh was condensed with III by methods similar to those for the preparation of IV except that dry HCl was admitted for 8 hrs. (final temperature at 60°), the mixture poured into H2O, cooled, and Na lactate added; addition of NH3, to the neutral point precipitated p-PhCO2C6H4COCH2NHMe.HCl
(VI), which, crystallized from 30% alc. HCl, MeCOEt, and alc.-MeCOEt, gave a small yield of VI, m. 243-5° (decomposition). PhOMe (64 g.) and 44 g. III were added to 108 g. anhydrous AlCl3 in 240 g. PhNO2, dry HCl passed in during 6 hrs. at 20-30°, and the mixture poured into 250 ml. H2O and cooled to 0°, precipitating p-MeOC6H4COCHMe.HCl (VII), which, dried with Me2CO, extracted with absolute alc., and crystallized from absolute alc. yielded 38 g. pure
VII, m. 211-14°. Heating VII with 2 ml. 48% HBr at 150° for 2 hrs. and addition of NH3 yielded 50% free base of VII. PhOH (9.3 g.) and 131 g. MePhNCH2CN.HCl were similarly condensed with 22 g. AlCl3 in 40 g. PhNO2 by adding dry HCl, using 50% Na lactate and charcoal, and adding NH3, which precipitated 4.5 g. crude p-HOC6H4COCH2NMePh (VIII), m. 102-10°, after 2 crystns. from dilute EtOH. VIII.HCl m. 223-5°. PhOMe (20 g.) and 15 g. Et2NCH2CN.HCl (IX) were added to 33 g. AlCl3 in 60 g. PhNO2, dry HCl passed in for 4 hrs. at 35°, the mixture poured into 120 ml. H2O, cooled, the aqueous layer separated, extracted
twice with CCl4 with charcoal, the solution made alkaline with strong NaOH with cooling until the precipitated Al redissolved, the oil extracted, dissolved in AcOEt,
dried with anhydrous Na2SO4, and 22 g. picric acid in warm AcOEt added, precipitating
after 6 hrs. 12 g. yellow needles of MeOC6H4COCH2NEt2 picrate (X), m. 142-5°. The AcOEt solution of X above was extracted with dilute HCl and evaporated under a vacuum to a sirup which, heated with concentrated HCl for 3 hrs.
at 150° in a sealed tube, evaporated to dryness in vacuo, and recrystd. from EtOH-MeCOEt, gave p-HOC6H4COCH2NEt2.HCl (XI), m. 187-9°. This method proved superior to direct **synthesis** from PhOH and IX. Under comparable conditions to those used for IV, PhOH failed to condense with H2NCH2CHMeCN, H2NCH2CHMeCH2CN, Me2CHCH(NH2)CN, EtCPh(NH2)CN, and BzNMeCH2CN [cf. Ber. 36, 1646(1903)], which is soluble in C6H6 and m. 75-6° (from petr. ether). H2NCH2CHMeCN.HCl (XII) was prepared by condensation of 30% AcH, MeNH3Cl, and NaCN solution, Et2O-extracted, the solution

evaporated to dryness, and the product converted by alc. HCl to XII, m. 124-5.5° (decomposition). IV (20.5 g.) suspended in 100 ml. H2O and 10 ml. 36% HCl, was treated with H and 5 g. Raney Ni at room temperature and pressure, the solution filtered after shaking for 12 hrs., and 13 ml. of 25% NH3 added, precipitating 14.3 g. small white needles of p-HOC6H4CH(OH)CH2NHMe (XIII), m. 186-7° (decomposition). XIII can also be prepared from IV by reduction with a mixture of PdO and PtO2. Reduction of 25 g. of IV tartrate, m. 193-5°, in H2O with Raney Ni gave 22 g. (88%) XIII tartrate, m. 188-9° (decomposition). Reduction of V, by methods similar to those for IV, gave 80% p-HOC6H4CH(OH)CH2NH2.HCl, m. 177-9° (decomposition). A similar reduction of III and subsequent addition of NH3 gave
75% p-HOC6H4CH(OH)CH2NHCHMe2, m. 136-8°. Combustion analyses of the several compds. agreed well with theory.

IT Ethers
(cyclic, α-keto derivs.)
IT Ketones
(epoxy)
IT Reduction
(of α-amino-p-hydroxyacetophenone derivs.)
IT Phenols
(reactions with aminoacetonitriles)
IT Acetamide, N-(p-hydroxyphenacyl)-N-methyl-
Acetophenone, 2-(benzylmethylamino)-4'-hydroxy-
Acetophenone, 2-(benzylmethylamino)-4'-hydroxy-, hydrochloride
Acetophenone, 2-diethylamino-4'-hydroxy-, hydrochloride
Acetophenone, 2-diethylamino-4'-methoxy-, picrate
Acetophenone, 4'-hydroxy-2-isopropylamino-, hydrochloride
Acetophenone, 4'-methoxy-2-methylamino-
Benzyl alcohol, α-(aminomethyl)-p-hydroxy-, hydrochloride
Glycinonitrile, N-isopropyl-, hydrochloride
Propionitrile, 2-methylamino-, hydrochloride
IT 21213-89-8, Acetophenone, 4'-hydroxy-2-methylamino-
(and derivs.)
IT **7568-93-6**, Benzyl alcohol, α-(aminomethyl)-
(derivs.)
IT 540-61-4, Glycinonitrile
(derivs., reaction with PhOH and its derivs.)
IT 94-07-5, Synephrine 7376-66-1, Benzyl alcohol, p-hydroxy-α-(isopropylaminomethyl)- 19745-72-3, Acetophenone, 2-amino-4'-hydroxy-, hydrochloride 29705-80-4, Acetophenone, 4'-methoxy-2-methylamino-, hydrochloride
(preparation of)
IT 108-95-2, Phenol
(reaction with glycinonitrie derivs.)
IT **7568-93-6**, Benzyl alcohol, α-(aminomethyl)-
(derivs.)
RN 7568-93-6 HCAPLUS
CN Benzenemethanol, α-(aminomethyl)- (9CI) (CA INDEX NAME)



=>

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 19:21:18 ON 01 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 1 Feb 2004  VOL 140 ISS 6
FILE LAST UPDATED: 30 Jan 2004  (20040130/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=>
=>

=> d stat que
L1               STR

        5
       Cy
       /
      /
NH~G1~~C~~O
1   2   3   4

REP G1=(1-10) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   5

STEREO ATTRIBUTES: NONE
L3               SCR 2043
L5          1913 SEA FILE=REGISTRY SSS FUL L1 AND L3
L9          1022 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L5
L12        94197 SEA FILE=HCAPLUS ABB=ON  PLU=ON  SOLID(W)PHASE
L13           25 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 AND L12


=>
=>

=> d ibib abs hitrn l13 1-25

L13  ANSWER 1 OF 25  HCAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2001:785205  HCAPLUS
DOCUMENT NUMBER:          137:20594
TITLE:                    .DELTA.Tt-mechanism in the design of self-assembling
                          structures
```

AUTHOR(S): Urry, Dan W.; Hayes, Larry; Luan, Chixiang; Gowda, D. Channe; McPherson, David; Xu, Jie; Parker, Timothy
CORPORATE SOURCE: OADI Technology Center, Bioelastics Research, Ltd., Birmingham, AL, 35211-6918, USA
SOURCE: Self-Assembling Peptide Systems in Biology, Medicine and Engineering, [Workshop], Crete, Greece, July 1-6, 1999 (2001), Meeting Date 1999, 323-342. Editor(s): Aggeli, Amalia; Boden, Neville; Zhang, Shuguang. Kluwer Academic Publishers: Dordrecht, Neth.
CODEN: 69BYXZ
DOCUMENT TYPE: Conference
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:20594

AB Protein-based polymers can be designed in which self-assembly occurs as the temp. is raised above the onset temp., Tt, of an inverse temp. transition for hydrophobic folding and assembly. Instead of changing the temp., however, by many means the value of Tt can be lowered from above to below an operating temp. to drive hydrophobic folding and assembly. This is the .DELTA.Tt-mechanism. Modulation of charges on the polymer provides the most dramatic means of controlling Tt and therefore becomes the most effective means for controlling self-assembly. The formation of charge raises the value of Tt and causes disassembly, whereas neutralization of charge by lowering degree of ionization or by increasing ion-pairing drives self-assembly. For example, a polymer with one Asp(COO-) or Glu(COO-) per 30 residues can be in soln. with its Tt above 100.degree.C. Titrn. with a cationic drug lowers Tt to below 25.degree.C and results in self-assembly into a drug delivery vehicle capable of a const. release profile for a const. surface area, and the vehicle simply disperses as the drug is released. Similarly an anionic drug can induce self-assembly of a cationic, e.g., Lys(NH3+)-contg., protein-based polymer. Two solns. of protein-based polymers, one polymer with neg. charges, e.g., COO-, and the other with pos. charges, e.g., NH3+ and both with hydrophobic residues sufficient to shift the pKa values of their resp. functional groups, can exhibit their individual inverse temp. transitions at temps. much higher than body temp., even greater than 100.degree.C. On combining the two solns., the polymers self-assemble with a Tt below room temp. Each polymer by ion pairing with the other dramatically lowers the temp. of the inverse temp. transition for polymer self-assembly. The effectiveness of this self-assembly of two oppositely charged protein-based polymers increases as the individual hydrophobic-induced pKa shifts are larger and as steric matching occurs in the ion-pairing between the pair of polymers. Furthermore, the same protein-based polymer can contain both pos. and neg. charges with hydrophobically shifted pKa values to become locked in self-assembled structures. In summary, ion-pairing within properly designed protein-based polymers results in self-assembling materials and structures by means of the .DELTA.Tt-mechanism.

IT **170742-70-8P**
RL: BPN (Biosynthetic preparation); CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation); PROC (Process)
(inverse temp. transition mechanism for hydrophobic folding and self-assembly of protein-based polymers)

IT **434956-82-8 434956-86-2**
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)
(inverse temp. transition mechanism for hydrophobic folding and self-assembly of protein-based polymers)

IT **157932-32-6P**
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(inverse temp. transition mechanism for hydrophobic folding and self-assembly of protein-based polymers)

IT **434956-70-4P 434956-75-9P**
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(inverse temp. transition mechanism for hydrophobic folding and self-assembly of protein-based polymers)
IT **434956-38-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(inverse temp. transition mechanism for hydrophobic folding and self-assembly of protein-based polymers)
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:423029 HCAPLUS
DOCUMENT NUMBER: 136:217046
TITLE: Synthesis and properties of peptide fragments of the S-region of the surface protein of the hepatitis B virus
AUTHOR(S): Kuranova, I. L.; Churkina, S. I.; Os'mak, A. V.; Filonova, E. B.; Lyudmirova, V. L.; Noskova, O. V.
CORPORATE SOURCE: Leningrad State Univ., Russia
SOURCE: Khimiya Prirodnykh Soedinenii (1992), (3,4), 406-413
CODEN: KPSUAR; ISSN: 0023-1150
PUBLISHER: Izdatel'stvo Fan
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A peptide fragment with the 140-146 sequence of the main component of the surface protein of the hepatitis B virus (HBsAG) and a no. of its structural analogs have been synthesized by the classical method in soln. Conjugates of the peptides synthesized with bovine serum albumin and with a synthetic polypeptide analog of polytuftsin have been obtained. The ability of the prepns. to bind antibodies from the blood sera of hepatitis B patients has been studied. The possibility has been shown of their use for revealing antibodies to the hepatitis B virus in **solid-phase** enzyme-mediated immunoassay.
IT **112592-90-2D**, Polytuftsin, analog **112710-32-4D**, Polytuftsin, analog
RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(prepn. of conjugates of polytuftsin analog and peptides of surface protein of hepatitis B virus and their ability to bind antibodies from blood serum of hepatitis B patients)

L13 ANSWER 3 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:284222 HCAPLUS
DOCUMENT NUMBER: 134:307611
TITLE: Conjugated polymer tag complexes and their preparation and use in assays
INVENTOR(S): Leif, Robert C.; Franson, Richard C.; Vallarino, Lidia
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027625	A1	20010419	WO 2000-US27787	20001007
W: CA, CH, DE, FI, GB, JP, US				

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
EP 1221052 A1 20020710 EP 2000-968871 20001007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY
PRIORITY APPLN. INFO.: US 1999-158718P P 19991008
WO 2000-US27787 W 20001007

AB Processes are described for: (1) the sequential **solid phase** synthesis of polymers with at least one tag, which can be a light emitting and/or absorbing mol. species (optical-label), a paramagnetic or radioactive label, or a tag that permits the phys. sepn. of particles including cells. When multiple optical-labels are suitably arranged in three-dimensional space, the energy transfer from one mol. species to another can be maximized and the radiationless loss between members of the same mol. species can be minimized; (2) the coupling of these polymers to biol. active and/or biol. compatible mols. through peripheral pendant substituents having at least one reactive site; and (3) the specific cleavage of the coupled polymer from a **solid phase** support. The tagged-peptide or polymers produced by these processes and their conjugates with an analyte-binding species, such as a monoclonal antibody or a polynucleotide probe are described. When functionalized europium macrocyclic complexes, as taught in our U.S. patents 5,373,093 and 5,696,240, are bound to polylysine and other peptides, the emitted light increases linearly with the amt. of bound macrocyclic complex. Similar linearity will also result for multiple luminescent macrocyclic complexes of other lanthanide ions, such as samarium, terbium, and dysprosium, when they are bound to a polymer or mol.

IT **335196-10-6**
RL: ARU (Analytical role, unclassified); BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); ANST (Analytical study); BIOL (Biological study); PROC (Process); RACT (Reactant or reagent)
(conjugated polymer tag complexes and prepn. and use in assays)

IT **335196-11-7P**
RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(conjugated polymer tag complexes and prepn. and use in assays)

IT **335196-10-6DP**, conjugates with europium macrocyclic compds.
RL: ARU (Analytical role, unclassified); PRP (Properties); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)
(conjugated polymer tag complexes and prepn. and use in assays)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:464984 HCAPLUS
DOCUMENT NUMBER: 133:89802
TITLE: Preparation of poly(ethylene glycol)-peptides conjugates having long-lasting effect for stimulating digestive tract motility
INVENTOR(S): Suzawa, Toshiyuki; Yamazaki, Motoo; Kishibayashi, Nobuyuki; Karasawa, Hiroshi
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

JP 2000191700 A2 20000711 JP 1998-372373 19981228
PRIORITY APPLN. INFO.: JP 1998-372373 19981228
GI



I

AB Peptides having activity for stimulating digestive tract motility linked to at least one polyalkylene glycol(s) directly or through a spacer or pharmacol. acceptable salts thereof, which are useful as enhancers of digestive tract motility or remedies for disorders of digestive tract motility, are prepd. Thus, motilin-Cys-NH2, i.e. H-Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Met-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln-Cys-NH2 (I), was prepd. by the **solid phase** method using **solid phase** peptide synthesizer PSSM-8 (Shimazu Seisakusho Ltd., Japan) and Rink amide MBHA resin and conjugated with 2,4-bis[methoxy(polyethylene glycol)]-6-[(3-maleimidopropyl)amino]-s-triazine (prepn. given) to give branched polyethylene glycol-conjugated peptide deriv. (II; R = H-Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Met-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln-). II and the latter compd. in vitro increased contractility of rabbit duodenum sample with AC50 of 1.2.+-.0.4 and 6.9.+-.3.3, resp.

IT **280766-88-3P 280766-89-4P 280766-90-7P**
280766-91-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of poly(ethylene glycol)-peptides conjugates having long-lasting effect for stimulating digestive tract motility)

L13 ANSWER 5 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:753256 HCAPLUS
DOCUMENT NUMBER: 132:3555
TITLE: Prepn. of labeled peptide analogs contg. glutamine and lysine as substrates for Factor XIIIa
INVENTOR(S): Storey, Anthony Eamon; Mendizabal, Marivi; Champion, Susan; Gibson, Alex; Guilbert, Benedicte; Wilson, Ian Andrew; Knox, Peter
PATENT ASSIGNEE(S): Nycomed Amersham Plc, UK
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9960018	A1	19991125	WO 1999-GB1550	19990514

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,

MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2332277	AA	19991125	CA 1999-2332277	19990514
AU 9939428	A1	19991206	AU 1999-39428	19990514
AU 762736	B2	20030703		
BR 9910468	A	20010109	BR 1999-10468	19990514
EP 1077998	A1	20010228	EP 1999-922325	19990514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002515510	T2	20020528	JP 2000-549636	19990514
RU 2205186	C2	20030527	RU 2000-131699	19990514
ZA 2000006313	A	20020717	ZA 2000-6313	20001103
NO 2000005751	A	20010108	NO 2000-5751	20001114
PRIORITY APPLN. INFO.:			EP 1998-303872 A	19980515
			WO 1999-GB1550 W	19990514

OTHER SOURCE(S): MARPAT 132:3555

AB Compds. Y-(CR2)n-X-NHJ [X = CO or CR2; n = 1-6; Y = L(A)m or R1R2CR; L is a metal complexing agent; A = CR2, CR:CR, C.tplbond.C, NRCO, CONR, SO2NR, NRSO2, CR2OCR2, CR2SCR2, CR2NRCR2, a cycloheteroalkylene, cycloalkylene, arylene, or heteroarylene group or a polyalkylene glycol, polylactic acid, or polyglycolic acid moiety; m = 0-10; one of R1 and R2 is NH(B)qZ1 and the other is CO(B)qZ2, where p and q = 0-45 (total no. of amino acid residues does not exceed 45); B is a cyclic peptide or an amino acid, Z1 and Z2 are protecting groups; J and each R group = H, alkyl, alkenyl, alkynyl, alkoxyalkyl, or hydroxyalkyl] were prepd. as substrates for the fibrin-stabilizing enzyme Factor XIIIa even when labeled with a detectable moiety. Thus, Ac-NQEQVSPYTLLKG-Pn216 [pn216 is NHCH2CH2N(CH2CH2NHCMe2CMe:NOH)2] was prepd. by the **solid phase** method and its technetium-99m complex used for imaging with a rat jugular vein clot model.

IT **250786-78-8DP**, technetium-99m-labeled **250786-79-9DP**, technetium-99m-labeled
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of labeled peptide analogs contg. glutamine and lysine as substrates for Factor XIIIa)

IT **250786-78-8P 250786-79-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of labeled peptide analogs contg. glutamine and lysine as substrates for Factor XIIIa)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:176272 HCAPLUS
DOCUMENT NUMBER: 130:352449
TITLE: A Novel Linking-Protecting Group Strategy for **Solid-Phase** Organic Chemistry with Configurationally Stable .alpha.-[N-(Phenylfluorenyl)]amino Carbonyl Compounds: Synthesis of Enantiopure Norephedrines on Solid Support
AUTHOR(S): Gosselin, Francis; Van Betsbrugge, Jo; Hatam, Mostafa; Lubell, William D.
CORPORATE SOURCE: Departement de chimie, Universite de Montreal, Montreal, QC, H3C 3J7, Can.
SOURCE: Journal of Organic Chemistry (1999), 64(7), 2486-2493 CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 130:352449
GI



I

AB A novel linking strategy has been developed for synthesizing configurationally stable .alpha.-amino aldehyde on polymeric supports. Alkylation of L-alanine Me ester with 9-bromo-9-p-bromophenylfluorenene, followed by ester hydrolysis and coupling to isoxazolidine, provided N-(9-p-bromophenylfluoren-9-yl)alanine isoxazolidide I (R = Br, R1 = 2-isoxazolidinylcarbonyl), which was transformed into its corresponding boronate I (R = 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-1-yl, R1 = 2-isoxazolidinylcarbonyl) by a palladium-catalyzed cross-coupling reaction with diboron pinacol ester. The boronate was anchored to four different polymeric aryl halides derived from MeO-PEG-5000, Merrifield resin, Wang resin, and non-cross-linked-polystyrene (NCPS). Treatment of the polymer bound alaninal I (R = NCPS with 3-phenyloxy linker, R1 = CHO), which resulted from LiAlH4 redn. of polymer bound I (R = NCPS with 3-phenyloxy linker, R1 = 2-isoxazolidinylcarbonyl), with phenylmagnesium bromide, cleavage of the resulting amino alc. I (R = NCPS with 3-phenyloxy linker, R1 = CH(OH)Ph) and subsequent N-protection with di-tert-Bu dicarbonate, furnished (1R,2S)-N-(tert-butyloxycarbonyl)norephedrine as the major diastereomer. Thus, a process was demonstrated by which the 9-phenylfluoren-9-yl protecting group was converted into a new linker for the **solid-phase** synthesis and manipulation of .alpha.-amino carbonyl compds.

IT **225098-26-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(enantioselective synthesis of norephedrines on solid support via a novel linking-protecting group strategy for the **solid phase** chem. which uses configurationally stable .alpha.-[N-(phenylfluorenyl)]aminocarbonyl compds.)

REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:251193 HCAPLUS
DOCUMENT NUMBER: 128:321939
TITLE: Preparation of chiral peptide nucleic acids derived from hydroxyproline
INVENTOR(S): Lowe, Gordon
PATENT ASSIGNEE(S): Isis Innovation Limited, UK; Lowe, Gordon
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9816550	A1	19980423	WO 1997-GB2820	19971013	
W: JP, US					
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
EP 956297	A1	19991117	EP 1997-945009	19971013	
R: DE, ES, FR, GB, IT, NL					
JP 2001502673	T2	20010227	JP 1998-518106	19971013	
US 6403763	B1	20020611	US 1999-284179	19990409	
US 2002072586	A1	20020613	US 2001-932862	20010817	

PRIORITY APPLN. INFO.: GB 1996-21367 A 19961014
WO 1997-GB2820 W 19971013
US 1999-284179 A3 19990409

OTHER SOURCE(S): MARPAT 128:321939

GI



AB Chiral peptide nucleic acids are provided which hybridize strongly with complementary nucleic acids and have potential as antigene and antisense agents and as tools in mol. biol. Compds. with cis-stereochem. and based on proline and a spacer amino acid have structures I and II [n = 1-200; B = protected or unprotected nucleobase; R = H,optionally substituted alkyl, aralkyl, or heteroaryl; X = e.g. OH; Y = e.g. H]. Thus, peptide nucleic acid oligomer I (n = 10, B = thymin-1-yl, R = H, Y = H, X = Lys-NH2), prepd. from a protected dipeptide monomer by **solid-phase** methods, complexed with poly(rA) (Tm = 72.degree., 45% hypochromicity), poly(dA) (Tm = 70.degree., 28% hypochromicity), and dA10 (Tm = 61.degree.).

IT **206760-06-7P 206760-16-9P 206760-17-0P**
206760-19-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and complexation of proline-derived peptide nucleic acids with oligonucleotides)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:127114 HCAPLUS
DOCUMENT NUMBER: 126:118183
TITLE: Polymerization of Unprotected Synthetic Peptides: A View toward Synthetic Peptide Vaccines
AUTHOR(S): O'Brien-Simpson, Neil M.; Ede, Nicholas J.; Brown, Lorena E.; Swan, John; Jackson, David C.
CORPORATE SOURCE: Cooperative Research Centre for Vaccine Technology, University of Melbourne, Parkville, 3052, Australia
SOURCE: Journal of the American Chemical Society (1997), 119(6), 1183-1188
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal

LANGUAGE: English

AB A generic method is reported for the assembly of multi-peptide polymers in which peptides are synthesized in the **solid phase**, the N-terminal residue acryloylated, and the derivatized peptides cleaved, purified and finally polymd. by free radical induced polymn. The high mol. wt. polymers generated in this way have individual peptides pendant from a backbone support. Incorporation of 6-aminohexanoyl or other residue(s) at the N-terminus of the peptide prior to acryloylation allows the peptide to be distanced from the polymer backbone and incorporation of acryloylated reagents into the polymn. mixt. also permits distancing of pendant peptides along the length of the backbone support. The polymn. process results in highly antigenic artificial proteins as measured by ELISA. Because this approach allows the incorporation of the same or combinations of different purified peptides into polymers, it lends itself to the assembly of potential vaccine candidates contg. epitopes from single or multiple pathogens into a single covalent structure.

IT **186085-48-3P 186085-51-8P 186085-54-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and polymn. of acryloyl peptides as synthetic peptide vaccines)

IT **186085-52-9P 186085-55-2P 186085-56-3P**
186085-57-4P 186085-64-3P 186085-65-4P
186085-67-6P 186085-68-7P 186085-69-8P
186085-70-1P 186085-71-2P 186085-72-3P
186085-77-8P 186085-78-9P 186085-79-0P
186085-80-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and polymn. of acryloyl peptides as synthetic peptide vaccines)

L13 ANSWER 9 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:24259 HCAPLUS
DOCUMENT NUMBER: 126:199813
TITLE: Amino acids and peptides. XXIX. Synthesis and antimetastatic effects of peptides and peptide-poly(ethylene glycol) hybrids related to the core sequence of the type III connecting segment domain of fibronectin
AUTHOR(S): Kawasaki, Koichi; Maeda, Mitsuko; Inoue, Sachiye; Yamashiro, Yuko; Kaneda, Yoshihisa; Mu, Yu; Tsutsumi, Yasuo; Nakagawa, Shinsaku; Mayumi, Tadanori
CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, 651-21, Japan
SOURCE: Biological & Pharmaceutical Bulletin (1996), 19(12), 1574-1579
CODEN: BPBLEO; ISSN: 0918-6158
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Peptides H-Glu-Ile-Leu-Asp-Val-NH2, H-Glu-Ile-Leu-Asp-Val-Pro-Ser-Thr-NH2, H-Arg-Glu-Asp-Val-NH2 and their poly(ethylene glycol) (PEG) hybrids related to the core sequence of the type III connecting segment domain of fibronectin A chain were prepd. by the soln. method or the **solid phase** method. Their inhibitory effects on the adhesion and migration of B16-BL6 melanoma cells to fibronectin were assessed in vitro and their therapeutic potency against tumor metastasis were also examd. Anti-adhesive and anti-migrative effects of the synthetic fibronectin-related peptides were superior to those of their PEG hybrids, so we found that the in vitro bioactivity of peptides decreased by PEGylation. In the in vivo assay, we found that the synthetic peptides contg. Glu-Ile-Leu-Asp-Val and Arg-Glu-Asp-Val sequences exhibited an inhibitory effect on the exptl. metastasis of B16-BL6 melanoma. Of the synthetic peptides, H-Glu-Ile-Leu-Asp-Val-NH2 exhibited the most potent

inhibitory effect. Hybrid formation of Arg-Glu-Asp-Val with poly(ethylene glycol) resulted in potentiation of the inhibitory effect of the parent peptides. A mixt. composed of PEG hybrids of Glu-Ile-Leu-Asp-Val, Arg-Glu-Asp-Val and Tyr-Ile-Gly-Ser-Arg dramatically inhibited tumor metastasis.

IT **186887-21-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and antimetastatic effects of peptides and peptide-poly(ethylene glycol) hybrids)

L13 ANSWER 10 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:526776 HCAPLUS
DOCUMENT NUMBER: 122:266020
TITLE: Site specific synthesis of conjugated peptides
INVENTOR(S): Mensi-Fattohi, Nahla; Molineaux, Christopher J.; Shorr, Robert G. L.
PATENT ASSIGNEE(S): Enzone, Inc., USA
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9500162	A1	19950105	WO 1994-US6953	19940621
W: AU, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SE, SK, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9471135	A1	19950117	AU 1994-71135	19940621
US 5428128	A	19950627	US 1994-313547	19940927
PRIORITY APPLN. INFO.:			US 1993-80457	19930621
			WO 1994-US6953	19940621

AB A process for synthesizing a polypeptide contg. a substantially non-antigenic polymer, preferably poly(alkylene glycols) such as poly(ethylene glycol) (PEG) at a specifically predetd. site comprises (1) initiating synthesis of the polypeptide and (2) introducing a substantially non-antigenic polymer at a point in the synthesis which corresponds to the pre-detd. site. Said polymer is conjugated to a facilitator moiety, preferably an amino acid, prior to said introducing step (2) to form a facilitator-polymer conjugate such as N.alpha.-Fmoc-N.epsilon.-PEG-Lys and N-.alpha.-Fmoc-N-.epsilon.-PEG-.beta.-Ala-Lys. Thereby, said process more preferably comprises (a) initiating synthesis of the polypeptide, (b) introducing a blocked facilitator moiety at that point in the synthesis that corresponds to the predetd. site, (c) completing the synthesis, and (d) deblocking and conjugating the facilitator moiety with said non-antigenic polymer. Thus, 60 g methoxy poly(ethylene glycol) (mol. wt. 5,000) was treated with a toluene soln. of 57 mmol COCl2 overnight, evapd. to dryness for removing excess COCl2, redissolved in toluene/CH2Cl2, and treated with 2.1 g N-hydroxysuccinimide and 1.7 mL Et3N to give, after workup, methoxy poly(ethylene glycol) succinimidyl carbonate. The latter compd. (34 mg) was condensed with 4.3 mg [N.alpha.-Fmoc-Glu1]-phospholipase A2 activating peptide (PLAP) (Fmoc-Glu-Ser-Pro-Leu-Ile-Ala-Lys-Val-Leu-Thr-Thr-Glu-Pro-Pro-Ile-Thr-Pro-Val-Arg-Arg-OH, prepd. by the **solid phase** method) in a borate buffer (pH 9.0) and the peglylated product was purified on a semipreparative C18 column and lyophilized dryness to give [N.alpha.-Fmoc-Glu1-N.epsilon.-PEG-Lys7]-PLAP, which was treated with 30% piperidine in DMF for 15 min to give [N.epsilon.-PEG-Lys7]-PLAP.

IT **162784-40-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(Phospholipase lipase A2 activating peptide; site specific synthesis of polymer-conjugated peptides)

IT **162784-42-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(dynorphin A; site specific synthesis of polymer-conjugated peptides)

IT **162784-37-4P 162784-38-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate for site specific synthesis of polymer-conjugated peptides)

IT **162784-43-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(.alpha.-Neoendorphin; site specific synthesis of polymer-conjugated peptides)

IT **162784-41-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(.beta.-Neoendorphin; site specific synthesis of polymer-conjugated peptides)

L13 ANSWER 11 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:21746 HCAPLUS
DOCUMENT NUMBER: 122:81979
TITLE: Pegylated peptides. III. **Solid-phase** synthesis with pegylating reagents of varying molecular weight: synthesis of multiply pegylated peptides
AUTHOR(S): Lu, Yi-An; Felix, Arthur M.
CORPORATE SOURCE: Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ, 07110, USA
SOURCE: Reactive Polymers (1994), 22(3), 221-9
CODEN: REPLEN; ISSN: 0923-1137
DOCUMENT TYPE: Journal
LANGUAGE: English

AB N.alpha.-Terminal **solid-phase** pegylation studies were carried out by coupling PEGn-CH2CO2H [I; PEG = monomethoxypoly(ethylene glycol); n = 750, 2000, 5000, 10,000] to either N-terminally hindered (Ile) or unhindered (Gly) model peptide-resin to study the effect of the mol. wt. of the pegylating reagent on the efficiency of coupling. The coupling proceeded to completion (quant. ninhydrin detn.) with hindered peptide-resin within 8 h using I (n = 750) and proceeded almost as rapidly using I (n = 2000). However, acylations with I (n = 5000, 10,000) were much slower and did not proceed to completion even after 72 h. N.alpha.-Pegylation of unhindered peptide-resin proceeded to completion more rapidly (within 4 h) and was successfully carried out with I (n = 750, 2000, 5000). However, pegylation of unhindered peptide-resin did not proceed to completion with I (n = 10,000) even after 72 h. The feasibility of multiply pegylating peptides by the 9-fluorenylmethyloxycarbonyl (Fmoc)/tert-Bu **solid-phase** procedure was also examd. Dipegylation, in which PEG2000 was inserted at the N-terminal and C-terminal positions, or at the side-chain and C-terminal positions, were successfully achieved by this method. Two model dipegylated peptides, PEG2000-CH2CO-Nle-Gly-Ile-Asn-Asn-Tyr-Lys-Asn-Pro-Lys-Leu-Orn(PEG2000-CH2CO)-NH2 and H-Ile-Leu-Asn-Gly-Ile-Asn-Asn-Tyr-Lys(PEG2000-CH2CO-Nle)-Asn-Pro-Lys-Leu-Orn(PEG2000-CH2CO)-NH2, were synthesized by the Fmoc/tert-Bu **solid-phase** procedure. The model peptides, fragments of interleukin-2, were chosen since they possess several trifunctional amino acids and offer various sites for multiple pegylation. The synthesis of the dipegylated peptides was achieved through the initial attachment of Fmoc-Orn(PEG-CH2CO)-OH to the solid support, followed by Fmoc/tert-Bu **solid-phase** peptide synthesis. N-Terminal pegylation was carried out by coupling PEG-CH2CO-Nle-OH to the pegylated undecapeptide resin. The side-chain

pegylation of Lys was achieved by coupling Fmoc-Lys(PEG-CH2CO-Nle)-OH to the CO2H-pegylated pentapeptide resin, followed by Fmoc/tert-Bu **solid-phase** assemblage of the dipegylated peptide-resin. Following cleavage by trifluoroacetic acid and purifn. by reversed-phase HPLC, the dipegylated peptides were fully characterized by amino acid anal., anal. HPLC, 1H NMR and laser desorption ionization mass spectrometry. Attempts to synthesize the corresponding dipegylated peptides using functionalized PEG5000 were unsuccessful due to a combination of steric hindrance and the high-mol.-wt. PEG that was employed. In addn., attempts to carry out a second pegylation in which the N-terminus residue is sterically hindered (e.g. Ile) failed to couple using functionalized PEG2000. These studies demonstrate that **solid-phase** pegylation proceeds more efficiently with functionalized poly(ethylene glycol) of lower mol. wt. and that coupling is less efficient to sterically hindered residues.

IT **160262-40-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, via **solid-phase** methods, polyethylene glycol-derivatized building blocks for)

IT **160298-41-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, via **solid-phase** methods, polyethylene glycol-derivatized building blocks for and on-resin polyethylene glycol functionalization in)

L13 ANSWER 12 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:656270 HCAPLUS
DOCUMENT NUMBER: 121:256270
TITLE: Pegylated peptides. II. **Solid-phase** synthesis of amino-, carboxy- and side-chain pegylated peptides
AUTHOR(S): Lu, Yi An; Felix, Arthur M.
CORPORATE SOURCE: Roche Res. Cent., Hoffmann-La Roch Inc., Nutley, NJ, USA
SOURCE: International Journal of Peptide & Protein Research (1994), 43(2), 127-38
CODEN: IJPPC3; ISSN: 0367-8377
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB General procedures are presented for the site-specific pegylation of peptides at the NH2-terminus, side-chain positions (Lys or Asp/Glu) or COOH-terminus using **solid-phase** Fmoc/tert-Bu methodologies. A model tridecapeptide fragment of interleukin-2, IL-2(44-56)-NH2, was chosen for this study since it possesses several trifunctional amino acids which serve as potential sites for pegylation. The pegylation reagents were designed to contain either Nle or Orn, which served as diagnostic amino acids for confirming the presence of 1 PEG unit per mol of peptide. NH2-terminal pegylation was carried out by coupling PEG-CH2CO-Nle-OH to the free NH2-terminus of the peptide-resin. Side-chain pegylation of Lys or Asp was achieved by one of two pathways. Direct side-chain pegylation was accomplished by coupling with Fmoc-Lys(PEG-CH2CO-Nle)-OH or Fmoc-Asp(Nle-NH-CH2CH2-PEG)-OH, followed by **solid-phase** assemblage of the pegylated peptide-resin and TFA cleavage. Alternatively, allylic protective groups were introduced via Fmoc-Lys(Alloc)-OH or Fmoc-Asp(O-Allyl)-OH, and selectively removed by palladium-catalyzed deprotection after assemblage of the peptide-resin. **Solid-phase** pegylation of the side-chain of Lys or Asp was then carried out in the final stage with PEG-CH2CO-Nle-OH or H-Nle-NH-(CH2)2-PEG, resp. COOH-Terminal pegylation was achieved through the initial attachment of Fmoc-Orn(PEG-CH2CO)-OH to the solid support, followed by **solid-phase** peptide synthesis using the Fmoc/tBu strategy. The pegylated peptides I, II, III, and IV were purified by dialysis and preparative HPLC and were fully characterized by anal. HPLC, amino acid anal., 1H-NMR spectroscopy and laser desorption mass spectrometry.

IT **158598-91-5DP**, amide with [p-(.alpha.-amino-2,4-dimethoxybenzyl)phenoxy]acetamide resin **158598-92-6DP**, amide with [p-(.alpha.-amino-2,4-dimethoxybenzyl)phenoxy]acetamide resin **158598-94-8DP**, amide with [p-(.alpha.-amino-2,4-dimethoxybenzyl)phenoxy]acetamide resin **158621-98-8DP**, amide with [p-(.alpha.-amino-2,4-dimethoxybenzyl)phenoxy]acetamide resin
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate in **solid-phase** synthesis of pegylated peptide)

IT **158598-88-0P 158598-89-1P 158598-90-4P**

158598-93-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, by **solid-phase** method)

L13 ANSWER 13 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:671693 HCAPLUS
DOCUMENT NUMBER: 119:271693
TITLE: Pegylated peptides. I: **Solid-phase** synthesis of N.alpha.-pegylated peptides using Fmoc strategy
AUTHOR(S): Lu, Yi An; Felix, Arthur M.
CORPORATE SOURCE: Pept. Res. Dep., Hoffmann-La Roche Inc., Nutley, NJ, 07110, USA
SOURCE: Peptide Research (1993), 6(3), 140-6
CODEN: PEREEO; ISSN: 1040-5704
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The feasibility of coupling carboxymethyl(polyethylene glycol) to peptides ("pegylating") by the **solid-phase** procedure was examd. Although poly(ethylene glycol) (PEG) was partially degraded by HF, the use of CF3CO2H was fully compatible with the PEG system. Therefore, the 9-fluorenylmethoxycarbonyl (Fmoc)/tert-Bu **solid-phase** strategy was utilized for the synthesis of a series of model tetra-, octa-, and dodecapeptides, and the corresponding N.alpha.-pegylated peptides, which were prepd. from common peptide-resin intermediates. PEG-OCH2-CO-Nle-OH (I) proved to be an ideal reagent for N-terminal pegylation. I served as a diagnostic for the detn. of the no. of PEG units/mol of peptide. **Solid-phase** coupling reactions proceeded by std. procedures using BOP-activation. The authentic pegylated peptides (readily purified by conventional methods of preparative HPLC) were fully characterized by amino acid anal., 1H-NMR, anal. HPLC, and laser desorption ionization mass spectrometry, leading to the values that are identical with the expected structures.
IT **151492-76-1P 151492-77-2P 151492-78-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, via **solid-phase** methods, and characterization of)

L13 ANSWER 14 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:546582 HCAPLUS
DOCUMENT NUMBER: 117:146582
TITLE: Synthesis, analysis, and immunodiagnostic applications of polypyrrole latex and its derivatives
AUTHOR(S): Tarcha, P. J.; Misun, D.; Finley, D.; Wong, M.; Donovan, J. J.
CORPORATE SOURCE: Diagn. Div., Abbott Lab., North Chicago, IL, 60064-3500, USA
SOURCE: ACS Symposium Series (1992), 492(Polym. Latexes), 347-67
CODEN: ACSMC8; ISSN: 0097-6156
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Poly(pyrrole) latex particles possess several unique properties in regard to their use as **solid phase** supports for immunoassays. Firstly, they are intensely colored black presumably due to their free radical nature, which is delocalized throughout the extensively conjugated chain. The particles, with immobilized protein on their surfaces, serve not only as a support, but as an easily visualized protein label. Secondly, the surface can be modified with reactive groups, which provide for covalent linkage of the appropriate biomols. Chromatog.-based immunoassays were demonstrated in the useful clin. ranges for hepatitis B surface antigen, AIDS antibody, and the pregnancy marker human chorionic gonadotropin.

IT **143501-83-1P**
RL: PREP (Preparation)
(prepn. and antibody protein immobilization of)

L13 ANSWER 15 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:236154 HCAPLUS
DOCUMENT NUMBER: 116:236154
TITLE: Solubilizing protecting groups in peptide synthesis. Effect of side-chain-attached polyethylene glycol derivatives upon .beta.-sheet formation of model peptides
AUTHOR(S): Mutter, Manfred; Oppliger, Hans; Zier, Andreas
CORPORATE SOURCE: Sect. Chim., Univ. Lausanne, Lausanne, CH-1005, Switz.
SOURCE: Makromolekulare Chemie, Rapid Communications (1992), 13(3), 151-7
CODEN: MCRCD4; ISSN: 0173-2803
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The solubilizing power of poly(ethylene glycol) for side chain protection of trifunctional amino acid residues for the synthesis of hydrophobic peptides was investigated. A series of potentially .beta.-sheet-forming and hydrophobic model peptides Ac-[Lys(P)-Val]m-NH2 [m = 5, 6, P = -COCH2(OCH2CH2)nMe], Ac-Lys(P)-Val-[Lys(Ac)-Val]3-Lys(P)-Val-NH2, Ac-[Lys(Ac)-Val]2-Lys(P)-Val-[Lys(Ac)-Val]2-NH2, Ac-[Lys(Ac)-Val]4-NH2, and H-[Glu(R)-Lys(Boc)-Pro-Gly-Lys(Boc)]2-OH (R = p-OCH2C6H4NHCOCH2-P; Boc = Me3CO2C) carrying poly(ethylene glycol) derivs. at different positions in the side chains were prepd. The disruption or destabilization of conformations detd. by CD were used as a qual. measure of for the solubilizing power of the attached poly(ethylene glycol).
IT **141405-42-7P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and conformation of, by CD)

L13 ANSWER 16 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:656614 HCAPLUS
DOCUMENT NUMBER: 115:256614
TITLE: Synthesis of N.alpha.-(tert-butoxycarbonyl)-N.epsilon.-[N-(bromoacetyl)-.beta.-alanyl]-L-lysine: Its use in peptide synthesis for placing a bromoacetyl cross-linking function at any desired sequence position
AUTHOR(S): Inman, John K.; Highet, Patricia F.; Kolodny, Nelly; Robey, Frank A.
CORPORATE SOURCE: Lab. Immunol., Natl. Inst. Allergy and Infect. Dis., Bethesda, MD, 20892, USA
SOURCE: Bioconjugate Chemistry (1991), 2(6), 458-63
CODEN: BCCHES; ISSN: 1043-1802
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The title amino acid deriv. Boc-Lys(COCH2CH2NHCOCH2Br)-OH (I; Boc = Me3CO2C) has been synthesized as a reagent to be used in **solid-phase** peptide synthesis for introducing a side-chain bromoacetyl group at any desired position in a peptide sequence. I is synthesized by condensation of BrCH2CONHCH2CH2CO2H with Boc-Lys-OH and is a white powder which is readily stored, weighed, and used with a peptide synthesizer, programmed for N.alpha.-Boc amino acids derivs. Residues contg. I are stable to final HF deprotection/cleavage. I-contg. peptides can be directly coupled to other mols. or surfaces which possess free sulfhydryl groups by forming stable thioether linkages. Peptides contg. both I and cysteine residues can be self-coupled to produce either cyclic mols. or linear peptide polymers, also linked through thioether bonds. Products made with I-contg. peptides may be characterized by amino acid anal. of acid hydrolyzates by quantification of .beta.-alanine, which separates

from natural amino acids in suitable anal. systems. Where sulfhydryl groups on coupling partners arise from cysteine residues, S-(carboxymethyl)cysteine in acid hydrolyzates may also be assayed for this purpose. Examples are given of the use of I in prepg. peptide polymers and a peptide conjugate with bovine albumin to serve as immunogens or model vaccine components.

IT **137255-84-6P 137255-85-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L13 ANSWER 17 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:650891 HCAPLUS
DOCUMENT NUMBER: 115:250891
TITLE: Hydrolysis of oligoribonucleotides by .alpha.-helical basic peptides
AUTHOR(S): Perello, Margarita; Barbier, Bernard; Brack, Andre
CORPORATE SOURCE: Cent. Mol. Biophys., CNRS, Orleans, 45071, Fr.
SOURCE: International Journal of Peptide & Protein Research (1991), 38(2), 154-60
CODEN: IJPPC3; ISSN: 0367-8377
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Poly(Leu-Lys-Lys-Leu) increases markedly the rate of hydrolysis of oligoribonucleotides. The polypeptide adopts an .alpha.-helical conformation in water in the presence of salt. Non-helical poly(Pro-Lys-Lys-Leu) is much less active. Ac-Leu-Lys-Lys-Leu-NHEt has no hydrolytic activity. Oligotetrapeptides Ac-(Leu-Lys-Lys-Leu)n-NHEt with increasing chain-length have been prepd. by **solid phase** synthesis to evaluate the crit. chain-length required for the hydrolytic activity. It is possible to correlate the activity to the propensity to form .alpha.-helices.

IT **137307-89-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(deprotection of)

IT **137285-82-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oligoribonucleotide hydrolysis by, .alpha.-helical conformation effect on)

L13 ANSWER 18 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:35375 HCAPLUS
DOCUMENT NUMBER: 112:35375
TITLE: New **solid-phase** catalysts for asymmetric synthesis: cross-linked polymers containing a chiral Schiff base-zinc complex
AUTHOR(S): Itsuno, Shinichi; Sakurai, Yoshiki; Ito, Koichi; Maruyama, Toshihiro; Nakahama, Seiichi; Frechet, J. M. J.
CORPORATE SOURCE: Sch. Mater. Sci., Toyohashi Univ. Technol., Toyohashi, 440, Japan
SOURCE: Journal of Organic Chemistry (1990), 55(1), 304-10
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 112:35375

AB A cross-linked polystyrene resin contg. chiral primary amino alc. moieties bound through the ether linkage to some of its p-methylene-substituted arom. rings is a useful regenerable chiral auxiliary in the enantioselective catalytic alkylation of aldehydes. The primary amino groups of the chiral amino alcs. reacts with the aldehydes to form Schiff bases, which catalyze the addn. of dialkylzinc to aldehydes leading to optically active secondary alcs. having enantiomeric purity of up to 99%. A series of polymeric amino alcs. were synthesized by two methods

involving either attachment of a chiral moiety as a side chain onto a reactive cross-linked polystyrene, or the terpolymn. of a chiral monomer with styrene and a crosslinking agent. New crosslinking agents affording more flexibility to the chiral catalysts were used in the prepn. of the chiral polymers and found to provide excellent performance. An interesting extension of the method is its adaptation to a continuous-flow system where diethylzinc and aldehyde are supplied continuously to a column filled with the chiral polymeric catalyst. Large amts. of chiral products and high turnovers may be obtained by this method.

IT **109826-97-3P 109826-98-4P 124176-02-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as chiral auxiliary for asym. alkylation of aldehydes)

L13 ANSWER 19 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1989:633578 HCAPLUS
DOCUMENT NUMBER: 111:233578
TITLE: Synthesis of bioadhesives
AUTHOR(S): Berenbaum, M. B.; Williams, J. I.; Bhattacharjee, H. R.; Goldberg, I.; Swerdloff, M. D.; Salerno, A. J.; Unger, P. D.
CORPORATE SOURCE: Allied-Signal Inc., Morristown, NJ, 07960, USA
SOURCE: Polymer Preprints (American Chemical Society, Division of Polymer Chemistry) (1989), 30(1), 350-1
CODEN: ACPPAY; ISSN: 0032-3934
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Decapeptide H-Lys(COCF3)-Pro-Ser-Tyr-4Hyp-4Hyp-Thr-Tyr-Lys(COCF3)-Ala-OH (4Hyp = 4-hydroxyproline) was prepd. by the **solid-phase** method and polymd. with diphenylphosphoryl azide to give polymers with av. mol. wts. as high as 65,000. The trifluoroacetyl groups were removed with piperidine, and the resulting water-sol. polymer was tested as an adhesive in aluminum lap joint shear tests and a shear strength of 2.6 was obsd. Addn. of mushroom tyrosinase resulted in a lap shear strength of 5.6. A com. epoxy adhesive gave a value of 17.5 in this test.

IT **123893-92-5P 123908-20-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn., oxidn., and adhesive properties of)

L13 ANSWER 20 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1989:8695 HCAPLUS
DOCUMENT NUMBER: 110:8695
TITLE: Preparation and testing of protein fragments for use in preparation of malaria vaccines
INVENTOR(S): Bernardi, Adriano; Bonelli, Fabio; Pessi, Antonello; Verdini, Antonio Silvio
PATENT ASSIGNEE(S): Eniricerche S.p.A., Italy
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3723583	A1	19880128	DE 1987-3723583	19870716
DE 3723583	C2	19910613		
SE 8702698	A	19880117	SE 1987-2698	19870630
SE 468393	B	19930111		
SE 468393	C	19930506		
ZA 8704778	A	19880224	ZA 1987-4778	19870701
CH 673461	A	19900315	CH 1987-2506	19870702

GB 2193215	A1	19880203	GB 1987-15737	19870703
GB 2193215	B2	19900307		
BE 1000729	A4	19890321	BE 1987-769	19870713
ES 2008151	A6	19890716	ES 1987-2234	19870714
FR 2601590	A1	19880122	FR 1987-9960	19870715
FR 2601590	B1	19900518		
AT 8701790	A	19960715	AT 1987-1790	19870715
NL 8701686	A	19880216	NL 1987-1686	19870716
US 5225530	A	19930706	US 1991-803483	19911204

PRIORITY APPLN. INFO.: IT 1986-21144 19860716
US 1987-68121 19870629

AB H-Lys-Pro-Lys-His-Lys-Lys-Leu-Lys-Gly-Pro-Gly-Asp-Gly-Asn-Pro-(Asn-Ala-Asn-Pro)n-Asn-Ala-OH (I) (n = 3-40), useful in prepn. of malaria vaccines and in detection of antibodies to sporozoites, were prepd. I (n = 3), prepd. by the **solid-phase** method on polyacrylamide resin, together with Freud's complete adjuvant, raised NANP antibodies in mice and increased the rate of replication of mouse lymph gland cells.

IT **117736-25-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, in prepn. of malaria vaccine)

L13 ANSWER 21 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1988:92736 HCAPLUS
DOCUMENT NUMBER: 108:92736
TITLE: Synthesis of a new carrier for immunization: polytuftsin. Two examples of its use with peptides selected in the hepatitis B surface antigen
AUTHOR(S): Trudelle, Y.; Brack, A.; Delmas, A.; Pedoussaut, S.; Rivaille, P.
CORPORATE SOURCE: Cent. Mol. Biophys., C.N.R.S., Orleans, Fr.
SOURCE: International Journal of Peptide & Protein Research (1987), 30(1), 54-60
CODEN: IJPPC3; ISSN: 0367-8377
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Sequential poly(Arg-Thr-Lys-Pro) consisting mainly of the repeat of tuftsin Thr-Lys-Pro-Arg was synthesized by condensing the p-nitrophenyl ester of Arg(HCl)-Thr-Lys-(2-Cl-Z)-Pro in the presence of 1-hydroxybenzotriazole. Two haptenic sequences of the Pre-S region of hepatitis B virus antigen (10-26 and 39-55) were prepd. by **solid phase** and coupled to polytuftsin via glutaraldehyde. The peptides, either free or coupled to polytuftsin, were administered to mice and the antisera were assayed by ELISA. Coupling the peptides to the polypeptide improved the antipeptide antibody titer in Freund complete adjuvant or in NaCl 0.9%. Cross-reaction between antibodies induced by the peptides and the native protein was also improved. Polytuftsin alone is very poorly immunogenic.

IT **112592-90-2P**, Polytuftsin **112710-32-4P**
RL: PREP (Preparation)
(prepn. of, as immunization carrier)

IT **112592-90-2DP**, reaction products with hepatitis B virus antigen peptides **112710-32-4DP**, reaction products with hepatitis B virus antigen peptides
RL: PREP (Preparation)
(prepn. of, as immunization carriers)

IT **112617-61-5P 112963-39-0P**
RL: PREP (Preparation)
(prepn. of, for immunization carriers)

L13 ANSWER 22 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1984:79993 HCAPLUS
DOCUMENT NUMBER: 100:79993
TITLE: A cyclic angiotensin antagonist: [1,8-

cysteine)angiotensin II
AUTHOR(S): Matsoukas, John M.; Scanlon, Martin N.; Moore, Graham J.
CORPORATE SOURCE: Dep. Med. Biochem., Univ. Calgary, Calgary, AB, T2N 1N4, Can.
SOURCE: Journal of Medicinal Chemistry (1984), 27(3), 404-6
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB [Cys1,8]angiotensin II (I) [87937-69-7] a cyclic analog of angiotensin II (II) [4474-91-3] in which the C-terminal CO2H group remains free, by substituting cysteine for the N-terminal and C-terminal amino acids of the mol., was prepd by the **solid-phase** method and evaluated for antagonistic activity on uterus from DES-primed female rat. Antagonistic potencies were detd. as the min. concn. of antagonist required to completely block the response to an ED75 dose II. The results showed that replacement of the N- and C-terminal residues of II with S-(acetamidomethyl)cysteine resulted in a compd. having 10% of the antagonistic activity of the most potent known antagonist in this tissue, [Sar1,Ile8]angiotensin II, and when the acetamidomethyl groups were removed and the peptide cyclized by formation of an S-S bond, the antagonistic activity of the resulting compd. decreased by 10% of that of its open-chain synthetic precursor. The decrease in activity may be interpreted as manifestations of changes in peptide conformation. The antagonistic potencies of the peptide could be attributed to the length of the side chain in position 8.
IT **87937-71-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and angiotensin II-inhibiting activity of)

L13 ANSWER 23 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1977:568380 HCAPLUS
DOCUMENT NUMBER: 87:168380
TITLE: Alternating liquid-**solid phase** peptide synthesis
AUTHOR(S): Frank, Hartmut; Meyer, Helmut; Hagenmaier, Hanspaul
CORPORATE SOURCE: Inst. Org. Chem., Univ. Tuebingen, Tuebingen, Fed. Rep. Ger.
SOURCE: Chemiker-Zeitung (1977), 101(4), 188-93
CODEN: CMKZAT; ISSN: 0009-2894
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The title method of peptide synthesis involved coupling solid polymer-bound benzhydryloxycarbonyl amino acids to liq. polymer-bound CO2H-protected amino acids or peptides by dicyclohexylcarbodiimide/1-hydroxybenzotriazene and cleaving and deprotecting the resulting peptide resin with CF3CO2H to give liq. phase peptide ester. The reacted and unreacted compds. can be sepd. by filtration; consequently, this method avoids the necessity for 100% yields in every reaction step. H-Gly-Val-Gly-Ala-Pro-OH, the 28-32-sequence of calcitonin M, was prepd. by this method.
IT **64543-85-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and deblocking of)
IT **64543-92-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and **solid-phase** peptide coupling of)

L13 ANSWER 24 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1975:606534 HCAPLUS

DOCUMENT NUMBER: 83:206534
TITLE: Conformational studies on sequential polypeptides. V. Synthesis and characterization of (Pro-Leu-Gly)10, (Pro-Leu-Gly)n, and (Leu-Pro-Gly)n
AUTHOR(S): Scatturin, A.; Tamburro, A. M.; Vidali, G.; Bordignon, E.
CORPORATE SOURCE: Ist. Chim. Org., Univ. Padova, Padua, Italy
SOURCE: International Journal of Peptide & Protein Research (1975), 7(3), 221-8
CODEN: IJPPC3; ISSN: 0367-8377
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Polypeptides (Pro-Leu-Gly)n and (Leu-Pro-Gly)n, of the non-polar regions of collagen, were obtained via the corresponding tripeptide P-O2NC6H4 esters. The sequential polypeptide (Pro-Leu-Gly)10 was also obtained by **solid-phase** synthesis.
IT **25734-29-6P 57283-49-5P 57655-17-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L13 ANSWER 25 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:155096 HCAPLUS
DOCUMENT NUMBER: 76:155096
TITLE: Benzyl styrene-divinylbenzene copolymer useful as an ester-forming C-protecting group in **solid-phase** peptide synthesis
INVENTOR(S): Southard, George L.
PATENT ASSIGNEE(S): Eli Lilly and Co.
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3645996	A	19720229	US 1969-805884	19690310

PRIORITY APPLN. INFO.: US 1969-805884 19690310
AB An .alpha.-hydroxybenzylated styrene-divinylbenzene copolymer [9003-70-7] or an .alpha.-chlorobenzylated styrene-divinylbenzene copolymer (I) were prepd. and used as an ester-forming C-protecting group in **solid-phase** peptide synthesis. For example, a styrene-divinylbenzene copolymer in nitrobenzene was treated with PhCOCl and AlCl3 to give a benzoyl polymer, which was washed, dispersed in diethylene glycol dimethyl ether, and reduced with NaBH4 to give the .alpha.-hydroxybenzyl polymer, which was treated with CH2Cl2 and dry HCl to give I. Alanine, leucine, valine, and glycine were introduced onto the resin by way of their enamine-dicyclohexylamine salts. The Leu-Ala-Gly-Val-I. HCl was shaken with 50% F3CCO2H in CHCl3 to sep. 76% purified cryst. Leu-Ala-Gly-Val. HCl.
IT **9074-73-1P**
RL: PREP (Preparation)
(manuf. of, protective groups for, chlorobenzylated divinylbenzene copolymers as)

=> select hit rn l13 1-25
E1 THROUGH E82 ASSIGNED

=> fil reg
FILE 'REGISTRY' ENTERED AT 19:21:42 ON 01 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JAN 2004 HIGHEST RN 644468-14-4
DICTIONARY FILE UPDATES: 30 JAN 2004 HIGHEST RN 644468-14-4

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
=>

=> d reg 114 1-82

1	RN	434956-86-2	REGISTRY
2	RN	434956-82-8	REGISTRY
3	RN	434956-75-9	REGISTRY
4	RN	434956-70-4	REGISTRY
5	RN	434956-38-4	REGISTRY
6	RN	335196-11-7	REGISTRY
7	RN	335196-10-6	REGISTRY
8	RN	280766-91-8	REGISTRY
9	RN	280766-90-7	REGISTRY
10	RN	280766-89-4	REGISTRY
11	RN	280766-88-3	REGISTRY
12	RN	250786-79-9	REGISTRY
13	RN	250786-78-8	REGISTRY
14	RN	225098-26-0	REGISTRY
15	RN	206760-19-2	REGISTRY
16	RN	206760-17-0	REGISTRY
17	RN	206760-16-9	REGISTRY
18	RN	206760-06-7	REGISTRY
19	RN	186887-21-8	REGISTRY
20	RN	186085-80-3	REGISTRY
21	RN	186085-79-0	REGISTRY
22	RN	186085-78-9	REGISTRY
23	RN	186085-77-8	REGISTRY
24	RN	186085-72-3	REGISTRY
25	RN	186085-71-2	REGISTRY
26	RN	186085-70-1	REGISTRY
27	RN	186085-69-8	REGISTRY
28	RN	186085-68-7	REGISTRY
29	RN	186085-67-6	REGISTRY
30	RN	186085-65-4	REGISTRY
31	RN	186085-64-3	REGISTRY
32	RN	186085-57-4	REGISTRY
33	RN	186085-56-3	REGISTRY
34	RN	186085-55-2	REGISTRY
35	RN	186085-54-1	REGISTRY
36	RN	186085-52-9	REGISTRY
37	RN	186085-51-8	REGISTRY
38	RN	186085-48-3	REGISTRY

39	RN	170742-70-8	REGISTRY
40	RN	162784-43-2	REGISTRY
41	RN	162784-42-1	REGISTRY
42	RN	162784-41-0	REGISTRY
43	RN	162784-40-9	REGISTRY
44	RN	162784-38-5	REGISTRY
45	RN	162784-37-4	REGISTRY
46	RN	160298-41-9	REGISTRY
47	RN	160262-40-8	REGISTRY
48	RN	158621-98-8	REGISTRY
49	RN	158598-94-8	REGISTRY
50	RN	158598-93-7	REGISTRY
51	RN	158598-92-6	REGISTRY
52	RN	158598-91-5	REGISTRY
53	RN	158598-90-4	REGISTRY
54	RN	158598-89-1	REGISTRY
55	RN	158598-88-0	REGISTRY
56	RN	157932-32-6	REGISTRY
57	RN	151492-78-3	REGISTRY
58	RN	151492-77-2	REGISTRY
59	RN	151492-76-1	REGISTRY
60	RN	143501-83-1	REGISTRY
61	RN	141405-42-7	REGISTRY
62	RN	137307-89-2	REGISTRY
63	RN	137285-82-6	REGISTRY
64	RN	137255-85-7	REGISTRY
65	RN	137255-84-6	REGISTRY
66	RN	124176-02-9	REGISTRY
67	RN	123908-20-3	REGISTRY
68	RN	123893-92-5	REGISTRY
69	RN	117736-25-1	REGISTRY
70	RN	112963-39-0	REGISTRY
71	RN	112710-32-4	REGISTRY
72	RN	112617-61-5	REGISTRY
73	RN	112592-90-2	REGISTRY
74	RN	109826-98-4	REGISTRY
75	RN	109826-97-3	REGISTRY
76	RN	87937-71-1	REGISTRY
77	RN	64543-92-6	REGISTRY
78	RN	64543-85-7	REGISTRY
79	RN	57655-17-1	REGISTRY
80	RN	57283-49-5	REGISTRY
81	RN	25734-29-6	REGISTRY
82	RN	9074-73-1	REGISTRY

=> d ide can 1 6 8 12 14 15 19 20 39 40 46 47 48 49 56 57 60 61 62 63 64 66 67 68 82

L14 ANSWER 1 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **434956-86-2** REGISTRY
CN L-Proline, glycyl-L-valylglycyl-L-valyl-L-prolylglycyl-L-valylglycyl-L-phenylalanyl-L-prolylglycyl-L-.alpha.-glutamylglycyl-L-phenylalanyl-L-prolylglycyl-L-valylglycyl-L-valyl-L-prolylglycyl-L-valylglycyl-L-phenylalanyl-L-prolylglycyl-L-lysylglycyl-L-valyl-, homopolymer (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF (C127 H189 N31 O33)x
CI PMS
PCT Polyamide, Polyamide formed
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

CM 1

CRN 434956-85-1
CMF C127 H189 N31 O33

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20594

L14 ANSWER 6 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **335196-11-7** REGISTRY
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, monoester with L-alanyl-L-tryptophyl-L-alanyl-L-lysyl-L-alanyl-L-lysyl-L-alanyl-L-lysyl-L-alanyl-L-lysyl-L-alanyl-L-lysyl-L-prolyl-L-alanyl-L-prolyl-L-phenylalanyl-L-alanyl-L-alanyl-L-alanine (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF (C2 H4 O)n C90 H145 N25 O20
CI PMS
PCT Polyether
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A



PAGE 1-B





PAGE 1-C



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:307611

L14 ANSWER 8 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **280766-91-8** REGISTRY
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-methoxy-, 23,23-diether with L-phenylalanyl-L-valyl-L-prolyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-tyrosylglycyl-L-.alpha.-glutamyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-glutaminyl-L-.alpha.-glutamyl-L-lysyl-L-.alpha.-glutamyl-L-arginyl-L-asparaginyl-L-lysylglycyl-L-glutaminyl-S-[1-[3-[(4,6-dihydroxy-1,3,5-triazin-2-yl)amino]propyl]-2,5-dioxo-3-pyrrolidinyl]-L-cysteinamide (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF (C2 H4 O)n (C2 H4 O)n C136 H211 N41 O39 S
CI PMS
PCT Polyether
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 1-E



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 133:89802

L14 ANSWER 12 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **250786-79-9** REGISTRY
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-[2-[[2-[bis[2-[[2-(hydroxyimino)-1,1-dimethylpropyl]amino]ethyl]amino]ethyl]amino]ethoxy]-, 13-ester with N2-acetyl-L-asparaginyl-L-glutaminyl-L-.alpha.-glutamyl-L-glutaminyl-L-valyl-L-seryl-L-prolyl-L-tyrosyl-L-threonyl-L-leucyl-L-leucyl-L-lysylglycine (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF (C2 H4 O)n C85 H145 N23 O25
CI PMS
PCT Polyether
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A





PAGE 2-A



PAGE 2-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:3555

L14 ANSWER 14 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **225098-26-0** REGISTRY
CN Poly(oxy-1,2-ethanediyl), .alpha.-[[4'-[9-[[(1S)-2-(2-isoxazolidinyl)-1-methyl-2-oxoethyl]amino]-9H-fluoren-9-yl][1,1'-biphenyl]-4-yl]methyl]-.omega.-methoxy- (9CI) (CA INDEX NAME)
MF (C2 H4 O)n C33 H32 N2 O3
CI PMS
PCT Polyether
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352449

L14 ANSWER 15 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **206760-19-2** REGISTRY
CN 5'-Adenylic acid, 2'-deoxy-, homopolymer, compd. with glycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolyl-L-lysinamide (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Lysinamide, glycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolylglycyl-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-L-prolyl-, compd. with 2'-deoxy-5'-adenylic acid homopolymer (1:1) (9CI)
FS STEREOSEARCH
MF C126 H155 N43 O41 . (C10 H14 N5 O6 P)x
PCT Polyamine, Polyamine formed, Polyether, Polyether formed
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 189164-05-4
CMF C126 H155 N43 O41

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-B

PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A



CM 2

CRN 25191-20-2
CMF (C10 H14 N5 O6 P)x
CCI PMS

CM 3

CRN 653-63-4
CMF C10 H14 N5 O6 P

Absolute stereochemistry. Rotation (+).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 128:321939

L14 ANSWER 19 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **186887-21-8** REGISTRY
CN L-Threoninamide, hydroxyacetyl-L-.alpha.-glutamyl-L-isoleucyl-L-leucyl-L-

.alpha.-aspartyl-L-valyl-L-prolyl-L-seryl-, 1-ether with .alpha.-methyl-.omega.-hydroxypoly(oxy-1,2-ethanediyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF (C2 H4 O)n C41 H69 N9 O16
CI PMS
PCT Polyether
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 126:199813

L14 ANSWER 20 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **186085-80-3** REGISTRY
CN L-Prolinamide, N2-[1-oxo-6-[(1-oxo-2-propenyl)amino]hexyl]-L-asparaginyl-L-alanyl-L-asparaginyl-L-prolyl-L-asparaginyl-L-alanyl-L-asparaginyl-L-prolyl-L-asparaginyl-L-alanyl-L-asparaginyl-L-prolyl-L-asparaginyl-L-alanyl-L-asparaginyl-L-prolyl-L-asparaginyl-L-alanyl-L-asparaginyl-, homopolymer (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF (C89 H136 N32 O32)x
CI PMS

PCT Polyacrylic, Polyamide, Polyamide formed
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

CM 1

CRN 186085-40-5
CMF C89 H136 N32 O32

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

PAGE 2-B



PAGE 2-C



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 126:118183

L14 ANSWER 39 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **170742-70-8** REGISTRY
CN L-Proline, glycyl-L-.alpha.-aspartylglycyl-L-phenylalanyl-L-prolylglycyl-L-valylglycyl-L-valyl-L-prolylglycyl-L-valylglycyl-L-phenylalanyl-L-prolylglycyl-L-phenylalanylglycyl-L-phenylalanyl-L-prolylglycyl-L-valylglycyl-L-valyl-L-prolylglycyl-L-valylglycyl-L-phenylalanyl-, homopolymer (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF (C133 H184 N30 O33)x
CI PMS
PCT Polyamide, Polyamide formed
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

CM 1

CRN 170742-69-5
CMF C133 H184 N30 O33

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20594

REFERENCE 2: 123:340850

L14 ANSWER 40 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **162784-43-2** REGISTRY
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 7-ester with 7-(N6-carboxy-L-lysine)-.alpha.-neoendorphin (swine) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN .alpha.-Neoendorphin (swine), 7-(N6-carboxy-L-lysine)-, poly(oxy-1,2-ethanediyl) deriv.
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 7-ester with 7-(N6-carboxy-L-lysine)-.alpha.-neoendorphin (pig)
FS PROTEIN SEQUENCE
MF (C2 H4 O)n C62 H91 N15 O15
CI PMS
PCT Polyether

SR CA
LC STN Files: CA, CAPLUS, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A



PAGE 2-A



PAGE 3-A



PAGE 3-B

— NH_2

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 122:266020

L14 ANSWER 46 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **160298-41-9** REGISTRY
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1,12-diether with N-(hydroxyacetyl)-L-norleucylglycyl-L-isoleucyl-L-asparaginyl-L-asparaginyl-L-tyrosyl-L-lysyl-L-asparaginyl-L-prolyl-L-lysyl-L-leucyl-N5-(hydroxyacetyl)-L-ornithinamide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Ornithinamide, N-(hydroxyacetyl)-L-norleucylglycyl-L-isoleucyl-L-asparaginyl-L-asparaginyl-L-tyrosyl-L-lysyl-L-asparaginyl-L-prolyl-L-lysyl-L-leucyl-N5-(hydroxyacetyl)-, poly(oxy-1,2-ethanediyl) deriv.
FS PROTEIN SEQUENCE
MF (C2 H4 O)n (C2 H4 O)n C69 H115 N19 O20
CI PMS
PCT Polyether
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 122:81979

L14 ANSWER 47 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **160262-40-8** REGISTRY
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 9,14-diether with L-isoleucyl-L-leucyl-L-asparaginylglycyl-L-isoleucyl-L-asparaginyl-L-asparaginyl-L-tyrosyl-N6-[N-(hydroxyacetyl)-L-norleucyl]-L-lysyl-L-asparaginyl-L-prolyl-L-lysyl-L-leucyl-N5-(hydroxyacetyl)-L-ornithinamide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Ornithinamide, L-isoleucyl-L-leucyl-L-asparaginylglycyl-L-isoleucyl-L-asparaginyl-L-asparaginyl-L-tyrosyl-N6-[N-(hydroxyacetyl)-L-norleucyl]-L-lysyl-L-asparaginyl-L-prolyl-L-lysyl-L-leucyl-N5-(hydroxyacetyl)-, poly(oxy-1,2-ethanediyl) deriv.
FS PROTEIN SEQUENCE
MF (C2 H4 O)n (C2 H4 O)n C85 H143 N23 O24
CI PMS
PCT Polyether
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 2-A



PAGE 2-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 122:81979

L14 ANSWER 48 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **158621-98-8** REGISTRY
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, ether with N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-isoleucyl-L-leucyl-N-(triphenylmethyl)-L-asparaginylglycyl-L-isoleucyl-N-(triphenylmethyl)-L-asparaginyl-N-(triphenylmethyl)-L-asparaginyl-O-(1,1-dimethylethyl)-L-tyrosyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N-[1-[[(2-hydroxyethyl)amino]carbonyl]pentyl]-L-asparaginyl-L-prolyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-L-leucine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-isoleucyl-L-leucyl-N-(triphenylmethyl)-L-asparaginylglycyl-L-isoleucyl-N-(triphenylmethyl)-L-asparaginyl-N-(triphenylmethyl)-L-asparaginyl-O-(1,1-dimethylethyl)-L-tyrosyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N-[1-[[(2-hydroxyethyl)amino]carbonyl]pentyl]-L-asparaginyl-L-prolyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-, poly(oxy-1,2-ethanediyl) deriv.
MF (C2 H4 O)n C163 H206 N20 O27
CI PMS
PCT Polyether
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A



PAGE 4-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 121:256270

L14 ANSWER 49 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **158598-94-8** REGISTRY
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, ether with N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-isoleucyl-L-leucyl-N-(triphenylmethyl)-L-asparaginylglycyl-L-isoleucyl-N-(triphenylmethyl)-L-asparaginyl-N-(triphenylmethyl)-L-asparaginyl-O-(1,1-dimethylethyl)-L-tyrosyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N-(triphenylmethyl)-L-asparaginyl-L-prolyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-L-leucyl-N5-(hydroxyacetyl)-L-ornithine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Ornithine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-isoleucyl-L-leucyl-N-(triphenylmethyl)-L-asparaginylglycyl-L-isoleucyl-N-(triphenylmethyl)-L-asparaginyl-N-(triphenylmethyl)-L-asparaginyl-O-(1,1-dimethylethyl)-L-tyrosyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N-(triphenylmethyl)-L-asparaginyl-L-prolyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-L-leucyl-N5-(hydroxyacetyl)-, poly(oxy-1,2-ethanediyl) deriv.
FS PROTEIN SEQUENCE
MF (C2 H4 O)n C181 H217 N21 O28
CI PMS
PCT Polyether
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A



PAGE 2-A



PAGE 3-A



PAGE 4-A







1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 121:256270

L14 ANSWER 56 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **157932-32-6** REGISTRY
CN L-Proline, glycyl-L-lysylglycyl-L-isoleucyl-, polymer with glycyl-L-valylglycyl-L-isoleucyl-L-proline (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Proline, 1-[N-[N-(N-glycyl-L-valyl)glycyl]-L-isoleucyl]-, polymer with 1-[N-[N-(N2-glycyl-L-lysyl)glycyl]-L-isoleucyl]-L-proline
CN L-Proline, 1-[N-[N-(N2-glycyl-L-lysyl)glycyl]-L-isoleucyl]-, polymer with 1-[N-[N-(N-glycyl-L-valyl)glycyl]-L-isoleucyl]-L-proline
CN L-Proline, glycyl-L-valylglycyl-L-isoleucyl-, polymer with glycyl-L-lysylglycyl-L-isoleucyl-L-proline (9CI)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF (C21 H38 N6 O6 . C20 H35 N5 O6)x
CI PMS
PCT Polyamide, Polyamide formed
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

CM 1

CRN 157932-31-5
CMF C21 H38 N6 O6

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



CM 2

CRN 106871-64-1
CMF C20 H35 N5 O6

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20594

REFERENCE 2: 134:71874

REFERENCE 3: 121:205998

L14 ANSWER 57 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **151492-78-3** REGISTRY
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, ether with N-(hydroxyacetyl)-L-norleucyl-L-asparaginyl-L-alanyl-L-asparaginyl-L-prolyl-L-asparaginyl-L-alanyl-L-asparaginyl-L-prolyl-L-asparaginyl-L-alanyl-L-asparaginyl-L-prolinamide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Prolinamide, N-(hydroxyacetyl)-L-norleucyl-L-asparaginyl-L-alanyl-L-asparaginyl-L-prolyl-L-asparaginyl-L-alanyl-L-asparaginyl-L-prolyl-L-

asparaginyl-L-alanyl-L-asparaginyl-, poly(oxy-1,2-ethanediyl) deriv.
FS PROTEIN SEQUENCE
MF (C2 H4 O)n C57 H90 N20 O21
CI PMS
PCT Polyether
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PAGE 2-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 119:271693

L14 ANSWER 60 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **143501-83-1** REGISTRY
CN 1H-Pyrrole, 1-[[[[[[(aminomethyl)amino]methyl]amino]methyl]amino]acetyl]-, monohydrobromide, homopolymer (9CI) (CA INDEX NAME)
MF (C9 H17 N5 O . Br H)x
CI PMS
PCT Polyother, Polyother only
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 143501-82-0
CMF C9 H17 N5 O . Br H



● HBr

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 117:146582

L14 ANSWER 61 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **141405-42-7** REGISTRY
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[4-(hydroxymethyl)phenyl]amino]-2-oxoethyl]-.omega.-methoxy-, 5,5'-diester with N6-[(1,1-dimethylethoxy)carbonyl]-N2-[N-[1-[N6-[(1,1-dimethylethoxy)carbonyl]-N2-[N-[N6-[(1,1-dimethylethoxy)carbonyl]-N2-[N-[1-[N6-[(1,1-dimethylethoxy)carbonyl]-N2-L-.alpha.-glutamyl-L-lysyl]-L-prolyl]glycyl]-L-lysyl]-L-.alpha.-glutamyl]-L-lysyl]-L-prolyl]glycyl]-L-lysine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:

CN L-Lysine, N6-[(1,1-dimethylethoxy)carbonyl]-N2-[N-[1-[N6-[(1,1-dimethylethoxy)carbonyl]-N2-[N-[N6-[(1,1-dimethylethoxy)carbonyl]-N2-[N-[1-[N6-[(1,1-dimethylethoxy)carbonyl]-N2-L-.alpha.-glutamyl-L-lysyl]-L-prolyl]glycyl]-L-lysyl]-L-.alpha.-glutamyl]-L-lysyl]-L-prolyl]glycyl]-, poly(oxy-1,2-ethanediyl) deriv.
FS PROTEIN SEQUENCE
MF (C2 H4 O)n (C2 H4 O)n C88 H138 N16 O27
CI PMS
PCT Polyether
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 2-C



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 116:236154

L14 ANSWER 62 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **137307-89-2** REGISTRY
CN Poly[1,2-pyrrolidinediylcarbonylimino[2-oxo-1-[4-[[(phenylmethoxy)carbonyl]amino]butyl]-1,2-ethanediyl]imino[2-oxo-1-[4-[[(phenylmethoxy)carbonyl]amino]butyl]-1,2-ethanediyl]imino[1-(2-methylpropyl)-2-oxo-1,2-ethanediyl]], (all-S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF (C39 H54 N6 O8)n
CI PMS
PCT Polyamide
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK





1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 115:250891

L14 ANSWER 63 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **137285-82-6** REGISTRY
CN Poly[1,2-pyrrolidinediylcarbonylimino[1-(4-aminobutyl)-2-oxo-1,2-ethanediyl]imino[1-(4-aminobutyl)-2-oxo-1,2-ethanediyl]imino[1-(2-methylpropyl)-2-oxo-1,2-ethanediyl]], [(S),(S),(S)]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF (C23 H42 N6 O4)n
CI PMS
PCT Polyamide
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 116:194836

REFERENCE 2: 115:250891

L14 ANSWER 64 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **137255-85-7** REGISTRY
CN Poly[imino(3-oxo-1,3-propanediyl)imino[5-(aminocarbonyl)-1,5-

pentanediyl]imino[2-[(L-lysyl-L-seryl-L-isoleucyl-L-arginyl-L-isoleucyl-L-glutaminyl-L-arginylglycyl-L-prolylglycyl-L-arginyl-L-valyl-L-isoleucyl-L-tyrosyl)amino]-1-oxo-1,3-propanediyl]thio(2-oxo-1,2-ethanediyl)], [(S),(R)]- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE
MF (C87 H150 N30 O21 S)n
CI PMS
PCT Polyamide, Polythioether
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A





PAGE 1-B



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 115:256614

L14 ANSWER 66 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **124176-02-9** REGISTRY
CN Benzenepropanol, .beta.-amino-4-[(4-ethenylphenyl)methoxy]-.alpha.,.alpha.-diphenyl-, (S)-, polymer with 1,15-bis(4-ethenylphenyl)-2,5,8,11,14-pentaoxapentadecane and ethenylbenzene (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,5,8,11,14-Pentaoxapentadecane, 1,15-bis(4-ethenylphenyl)-, polymer with (S)-.beta.-amino-4-[(4-ethenylphenyl)methoxy]-.alpha.,.alpha.-diphenylbenzenepropanol and ethenylbenzene (9CI)
CN Benzene, ethenyl-, polymer with (S)-.beta.-amino-4-[(4-ethenylphenyl)methoxy]-.alpha.,.alpha.-diphenylbenzenepropanol and 1,15-bis(4-ethenylphenyl)-2,5,8,11,14-pentaoxapentadecane (9CI)
FS STEREOSEARCH
MF (C30 H29 N O2 . C26 H34 O5 . C8 H8)x
CI PMS
PCT Polystyrene
SR CA
LC STN Files: CA, CAPLUS, CASREACT

CM 1

CRN 122247-24-9
CMF C26 H34 O5

PAGE 1-A





CM 2

CRN 109826-69-9
CMF C30 H29 N O2

Absolute stereochemistry.



CM 3

CRN 100-42-5
CMF C8 H8

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 112:35375

L14 ANSWER 67 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **123908-20-3** REGISTRY
CN L-Alanine, N-[N2-[N-[N-[trans-4-hydroxy-1-[trans-4-hydroxy-1-[N-[N-[1-[N6-(trifluoroacetyl)-L-lysyl]-L-prolyl]-L-seryl]-L-tyrosyl]-L-prolyl]-L-prolyl]-L-threonyl]-L-tyrosyl]-N6-(trifluoroacetyl)-L-lysyl]-, homopolymer (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF (C59 H80 F6 N12 O19)x
CI PMS
PCT Polyamide, Polyamide formed
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

CM 1

CRN 123908-19-0
CMF C59 H80 F6 N12 O19

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 111:233578

L14 ANSWER 68 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **123893-92-5** REGISTRY
CN Poly[(4-hydroxy-1,2-pyrrolidinediyl)carbonyl(4-hydroxy-1,2-pyrrolidinediyl)carbonylimino[1-(1-hydroxyethyl)-2-oxo-1,2-ethanediyl]imino[1-[(4-hydroxyphenyl)methyl]-2-oxo-1,2-ethanediyl]imino[2-oxo-1-[4-[(trifluoroacetyl)amino]butyl]-1,2-ethanediyl]imino(1-methyl-2-oxo-1,2-ethanediyl)imino[2-oxo-1-[4-[(trifluoroacetyl)amino]butyl]-1,2-ethanediyl]-1,2-pyrrolidinediylcarbonylimino[1-(hydroxymethyl)-2-oxo-1,2-ethanediyl]imino[1-[(4-hydroxyphenyl)methyl]-2-oxo-1,2-ethanediyl]], stereoisomer (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF (C59 H78 F6 N12 O18)n

CI PMS
PCT Polyamide
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A



PAGE 2-A



PAGE 3-A





1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 111:233578

L14 ANSWER 82 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN **9074-73-1** REGISTRY
CN L-Valine, N-(2-methyl-1-oxo-3-phenyl-1-propenyl)-, compd. with N-cyclohexylcyclohexanamine (1:1), polymer with N-(2-methyl-1-oxo-3-phenyl-1-propenyl)glycine compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glycine, N-(2-methyl-1-oxo-3-phenyl-1-propenyl)-, compd. with N-cyclohexylcyclohexanamine (1:1), polymer with N-(2-methyl-1-oxo-3-phenyl-1-propenyl)-L-valine compd. with N-cyclohexylcyclohexanamine (1:1) (9CI)
FS STEREOSEARCH
MF (C15 H19 N O3 . C12 H23 N . C12 H23 N . C12 H13 N O3)x
CI PMS
PCT Polyamide, Polyamide formed, Polyother, Polyvinyl
LC STN Files: CA, CAPLUS

CM 1

CRN 50853-11-7
CMF C12 H23 N . C12 H13 N O3

CM 2

CRN 50853-09-3
CMF C12 H13 N O3



CM 3

CRN 101-83-7

CMF C12 H23 N



CM 4

CRN 50853-10-6
CMF C15 H19 N O3 . C12 H23 N

CM 5

CRN 50853-08-2
CMF C15 H19 N O3

Absolute stereochemistry.
Double bond geometry unknown.



CM 6

CRN 101-83-7
CMF C12 H23 N



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 76:155096